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Simone Sharma Abstract 
Mutations in LRRK2 have been established as a common genetic cause of Parkinson’s 
disease  (PD).  Variation  in  gene  expression  of  PARK  loci  has  previously  been 
demonstrated in PD pathogenesis, although it has not been described in detail for 
LRRK2  expression  in  the  human  brain.  This  study  further  elucidates  the  role  of 
LRRK2 in development of PD by describing an investigation into the role of LRRK2 
genetics and expression in the human brain.  
The  G2019S  mutation  is  a  common  LRRK2  mutation  that  exhibits  a  clinical  and 
pathological  phenotype  indistinguishable  from  idiopathic  PD.  Thus,  the  study  of 
G2019S mutation is a recurrent theme. The frequency of G2019S was estimated in 
unaffected subjects that lived or shared a cultural heritage to the predicted founding 
populations of the mutation, and was found not to be common in these populations.  
Morphological  analysis  revealed  a  ubiquitous  expression  for  LRRK2  mRNA  and 
protein in the human brain. In-situ hybridisation data suggests that LRRK2 mRNA is 
present  as  a  low  copy  number  mRNA  in  the  human  brain.  A  semi-quantitative 
analysis of LRRK2 immunohistochemistry revealed extensive regional variation in 
the LRRK2 protein levels, although the weakest immunoreactivity was consistently 
identified in the nigrostriatal dopamine region. No difference was observed in the 
morphological  localisation  of  LRRK2  mRNA  and  protein  in  unaffected,  IPD  or 
G2019S positive PD subjects.  
Dysregulation of LRRK2 mRNA expression and the effects of cis- acting genetic 
variation  on  these  levels  were  demonstrated.  A  widespread  decrease  of  LRRK2 
mRNA  was  observed  in IPD  and  G2019S  positive PD  subjects  in  comparison  to 
unaffected  controls.  Furthermore,  non-coding  genetic  variation  was  also 
demonstrated to have an effect on the LRRK2 transcriptional activity in PD subjects. 
Collectively, these findings suggest that LRRK2 has an important physiological role, 
and a dysregulation in its levels could affect auxiliary mechanisms that contribute to 
PD  pathogenesis.  This  data  also  supports  the  possibility  of  a  shared  mechanism 
contributing to the identical phenotype of IPD and G2019S linked PD.  [2] 
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1  Introduction 
1.1  Parkinson’s Disease 
Parkinson’s  Disease  (PD)  is  an  insidious  and  a  progressive  disease  that  affects 
approximately 1% of the population over the age of 65 years. It has a broad clinical 
spectrum which is usually defined by a combination of any of the following six motor 
features: rest tremor, bradykinesia, rigidity, loss of postural reflexes, flexed posture, 
and  freezing  of  gait  (Lees  et  al.  2009).  At  least  two  of these  cardinal  symptoms 
should be present before a clinical diagnosis of PD can be  made. The  symptoms 
usually  present  themselves  asymmetrically,  and  levodopa  (L-DOPA)  replacement 
therapy offers relief to the initial clinical symptoms of resting tremor, bradykinesia 
and rigidity, but this does not halt the progression of the disease. 
Age is the biggest risk factor for the disease, and majority of PD cases are idiopathic 
(IPD) with less than 10% reporting a family history (Lees et al. 2009). Despite the 
rarity of monogenic inheritance in PD, mendelian genes collectively known as the 
PARK loci have been shown to be associated with familial inheritance. Some PARK 
loci have also been implicated in the idiopathic forms of the disease, suggesting that 
shared  mechanistic  pathways  might  contribute  to  familial  and  idiopathic  disease 
pathogenesis.  
1.2  Clinical phenotype 
The clinical diagnosis published by James Parkinson in 1817 entitled ‘An essay on 
the shaking palsy’, set the precedent for further investigation into this debilitating 
disease. He identified the progressive nature of the disease along with the cardinal 
symptoms  of  akinesia  (impaired  muscle  movement),  resting  tremor,  bradykinesia 
(slow  movement)  and  postural  instability,  and  referred  to  the  disease  as  Shaking 
Palsy or Paralysis Agitans (Lees 2007).  
The clinical signs were expanded upon by Charcot in 1881 who observed that “You 
easily  recognise  how  difficult  it  is  for  them  to  do  things  even  though  rigidity  or [19] 
 
tremor is not the limiting factor. Instead even a cursory exam demonstrates that their 
problem  relates  more  to  slowness  in  execution  of  movement  rather  than  to  real 
weakness.” (translation of Charcot, 1881 (Goetz 2002)). Based on his extensive and 
detailed observations of the tremor associated with the disease, he added rigidity to 
the  characteristic  features  of  the  Paralysis  Agitans.  However,  as  Charcot  did  not 
consistently observe rest tremor, he argued that Paralysis Agitans was an inaccurate 
description, and suggested that the disease be referred to as ‘Parkinson’s Disease’ 
(PD).   
The cardinal features based on the motor symptoms as described by Parkinson and 
Charcot still remain essential for the clinical diagnosis of PD. However, it has long 
been  acknowledged  that  there  are  various  non-motor  symptoms  that  include 
autonomic and neuropsychiatric symptoms. Some of the disturbance of autonomic 
functions  precede  the  motor  symptoms  and  can  include  sleep  disturbances, 
constipation, sexual dysfunction, and hyposmia (impairment of smell) (Bohnen et al. 
2007; Lim et al. 2009). The neuropsychiatric symptoms appear later in the course of 
disease  and  include  depression  and  anxiety,  followed  by  cognitive  decline  (Emre 
2003;  Lim  et  al.  2009).  The  complexity  presented  by  the  broad  spectrum  of  PD 
symptoms  has  made  it  necessary  to  include  the  non-motor  symptoms  in  clinical 
diagnosis of the disease. As a result, the unified Parkinson’s diseases rating scale was 
revised by the UK movement disorder society to incorporate these symptoms as well 
as the cardinal motor symptoms (Litvan et al. 2003). This combination of motor and 
non-motor symptoms has resulted in PD being described as a highly complex disease, 
and  poses  a  tough  challenge  to  the  scientists  studying  PD  pathogenesis  and  the 
relevant therapeutics. [20] 
 
1.3  Pathological phenotype 
1.3.1  Nigral cell loss  
The pathology of PD is frequently characterised by the pallor of specific subnuclei of 
the  substantia  nigra  pars  compacta.  The  dopaminergic  (DAergic)  neurons  of  the 
substantia nigra (SN) contain cytoplasmic neuromelanin, a pigment which gives these 
nuclei  a  macroscopical  black  appearance  (Forno  1996).  A  loss  of  this  pigment 
correlates with severe degeneration (approximately ~50%) of the DAergic neurons in 
SN of PD subjects (see Figure 1.1). 
The neuronal cell loss in SN is not uniform in PD.  The ventrolateral tier of neurons 
in the pars compacta (A9) are the most vulnerable to PD, degenerating earlier and 
more  severely  than  the  dorsal  medial  regions  (Fearnley  &  Lees  1991).  Differing 
amounts of neuromelanin in DAergic neurons of the ventrolateral versus the dorsal 
medial regions have been suggested to be a cause of the selective vulnerability of the 
nigral neurons (Gibb & Lees 1991). This is interesting in terms of PD pathogenesis as 
the  ventrolateral  tier  of  the  nigra  projects  to  the  dorsal  putamen  which  is 
predominantly involved in motor co-ordination, and the relatively spared areas of the 
medial and ventral tegmental areas (VTA) project to the caudate which is involved in 
cognition (Fearnley & Lees 1991). 
The  DAergic  neurons  of  the  ventral  tier  contain  a  smaller  amount  of 
neuromelanin than those in the dorsal medial areas, but whether neuromelanin is 
protective  or  toxic  remains  undecided  (Zecca  et  al.  2003).  Furthermore,  the 
DAergic  neurons  within  the  red  nucleus,  are  relatively  protected  from 
degeneration despite having similar levels of neuromelanin to the neurons in the 
ventrolateral nigra (Gibb 1992). These observations along with weak expression 
of neurotrophic factors, such as brain derived neurotrophic factor (BDNF) in SN 
has led to the suggestions that weakened trophic support plays a central role in 
the regional vulnerability of dopamine neurons (Howells et al. 2000). Higher cell 
density of midbrain DAergic neurons have also been suggested to add to their [21] 
 
vulnerability  (Gibb  1992).  Cells  with  disproportionately  large  axons  in 
comparison to the somata, or with long thin-caliber axons that are un- or poorly 
myelinated have also been suggested to be susceptible to PD degeneration (Braak 
et  al.  2004).  In  contrast,  local  circuit  neurons  and  projection  cells  with  short 
axons  (e.g.,  the  small  pyramidal  cells  of  neocortical  layers  II  and  IV  and  the 
granule cells of dentate fascia) remain relatively resistant (Braak et al. 2004). 
    
Figure 1.1: Degeneration of dopaminergic neurons in substantia nigra of PD patients. 
Loss of pigment is evident in PD when compared to the substantia nigra in the normal brain. 
This image was obtained from- http://www.gwc.maricopa.edu/class/bio201/parkn/parkn1.jpg. 
1.3.2  Lewy body inclusions 
In the early 1900’s, Friederich H. Lewy examined PD brains and described spherical 
pathological inclusions in  the  dorsal  motor nucleus  of  the  vagus  nerve  (DMVN), 
nucleus  basalis  of  Meynert,  paraventricular  nucleus  and  lateral  thalamic  nucleus. 
Further  examination  led  him  to  conclude  that  this  inclusion  body  pathology  was 
predominantly observed, but not limited to the brainstem and basal ganglia structures. 
Lewy  described  these  pathological  inclusions  as  having  a  ‘dense  core’  with  a 
‘transparent and lighter-stained cytoplasmic sheath’. The lesions in the SN were first 
identified by Tŕetiakoff in patients with PD and in those with encephalitis lethargica, 
leading him to coin the term “corps de Lewy” or Lewy bodies (LB) (Lees 2007). [22] 
 
Later confirmed in all pigmented neurons of the brainstem including locus coeruleus 
(LC), the most consistent lesions were observed in SN, securing their position as the 
pathological  hallmark  of  PD  (Forno  1996).  The  principle  component  of  these 
inclusions was identified as α-synuclein, (a protein expressed in presynaptic nerve 
terminals) in 1997 (Spillantini et al. 1997). 
In PD, these pathological inclusions develop either as globular LBs in the neuronal 
perikarya, or as spindle- or thread like  Lewy neurites (LNs) in cellular processes 
(Braak et al. 2003). Classical brainstem or intraneuritic LBs are usually presented as 
spherical  and  weakly  acidophilic  inclusion  bodies  with  a  smooth  halo.  LBs  are 
typically located within the deposits of lipofuscin or neuromelanin granules of the 
cells vulnerable to degeneration. The selective pattern of nigral cell death is mirrored 
by the initial appearance of LBs in ventrolateral regions, followed by the presence in 
more medial and dorsal regions of the SN
 (Gibb & Lees 1991). LNs are thought to 
ante-date the appearance of LBs, and are only visible using immunohistochemical 
methods,  whereas  LBs  can  be  observed  using  routine  histological  staining  (e.g. 
haemotoxylin and eosin) (Braak et al. 2003). 
Unlike  brainstem  LBs,  cortical  LBs  lack  the  typical  well  defined  halo.  In  PD 
pathology, cortical LBs and LNs are predominantly found in areas containing non-
pigmented and less vulnerable neurons that typically display weak immunoreactivity 
for α-synuclein. These inclusions can be seen in hippocampus amygdala, neocortex, 
and olfactory bulb (Braak et al. 2003). Cortical LBs are distinct from another pale 
staining cytoplasmic inclusion which is found in the pigmented neurons of SN and 
LC, and is termed the ‘pale body’. It has been suggested that cortical LBs and pale 
bodies are early lesions that precede the classical LBs (Braak et al. 2003).  
1.3.3  Extra-nigral pathology 
As first noted by Lewy, PD pathology is not limited to the nigrostriatal system but 
instead involves various extranigral regions that include the mesocortical DAergic 
system,  noradrenergic,  serotonergic,  cholinergic  brainstem  nuclei,  and  the  limbic [23] 
 
system (Jellinger 1999). In cases with severe damage, lesions can also be observed in 
various regions of the neocortex (Braak et al. 2003). 
1.3.3.1 Sub- cortical pathology 
Apart from severe degeneration and lesions in SN, neuronal loss can also occur in 
other  regions  of  the  brainstem  (although  not  as  severe  as  in  SN).  These  include 
noradrenergic  nuclei  of  dorsal  motor  nucleus  of  the  glossopharyngeal  and  vagal 
nerves (dorsal IX/X motor nucleus, respectively) of the medulla oblongata, and the 
locus coeruleus (LC) (Jellinger 1999). The melanised noradrenergic neurons of the 
LC  project  bilaterally  to  various  locations  including  the  cerebral  cortex,  limbic 
system  and  spinal  cord.  Like  the  loss  of  nigral  neurons  in  SN,  a  complete 
degeneration of the LC complex can also be seen in PD subjects with long duration of 
illness. Lesions are frequently observed in these nuclei in addition to the anterior 
olfactory nucleus (Braak et al. 2004).  
The other regions affected in midbrain, although not to the same extent as the nigral 
neurons (A9 cell group) are the DAergic neurons of VTA (A10 cell group, origin of 
DAergic cell bodies) which are involved in the mesocorticolimbic dopamine system 
and the red nucleus which is involved in motor coordination (German et al. 1989). 
The  dorsal  raphè  which  is  the  largest  serotonergic  nucleus  in  the  brainstem  also 
undergoes degeneration in PD, and a deficit of neurons in the mesocorticolimbic and 
noradrenergic systems has been suggested to contribute to the cognitive symptoms 
associated with PD (Jellinger 1999).  
1.3.3.2 Limbic and Cortical pathology 
PD-related LB inclusions can be frequently and consistently observed in the nucleus 
basalis of Meynert (nbM), and this group of cholinergic nerve cells in the substantia 
innominata  have  wide  projections  to  the  neocortex  and  limbic  areas,  such  as 
hippocampus and amygdala, both of which are known to have PD pathology (Braak 
et al. 2003). The limbic areas of anterior cingulate gyrus and temporal cortex are 
more severely affected than the frontal and parietal cortices with the occipital areas 
being relatively spared (Braak & Braak 2000). Pathology within limbic structures [24] 
 
(amygdaloid nucleus, CA2/3 neurons of the hippocampal formation, limbic thalamic 
nuclei  with  prefrontal  projections)  has  been  correlated  with  dementia  and  other 
cognitive related symptoms in PD (Jellinger 2004; Junqué et al. 2005). 
1.3.4  Neuropathological stages associated with PD progression  
Despite the extensive degeneration of DAergic neurons of the SN in PD, it has been 
shown  that  the  pathology  in  nigral  and  extranigral  system  does  not  evolve 
simultaneously, but instead follows a coherent sequence of disease related alterations 
(Braak et al. 2003). Braak and colleagues investigated the assumption that the lesions 
in PD appear prior to the somato-motor dysfunctions, and were able to produce a 
detailed topographical map of how the progression of PD lesions can be used to stage 
the pathological process. As such, they were able to demonstrate the extent to which 
extranigral  impairment  contributes  to  the  somato-motor  dysfunctions  in  PD 
pathogenesis (Braak & Braak 2000; Braak et al. 2003).  
Braak and colleagues detail that in the course of PD, major components of somato-
motor and emotional motor systems suffer a gradually evolving deterioration as a 
result of LB pathology which develops in 6 different stages (Braak et al. 2003; Braak 
et al. 2004). They were able to demonstrate that the LB pathology in PD begins in the 
lower brainstem nuclei and assumes an upward course, eventually extending into the 
cerebral cortex (see Figure 1.2). Stages 1 and 2, involve and remain virtually confined 
to the medulla oblongata, whereas in stage 3 the lower and upper brainstem is also 
involved.  By  stage  4,  LB  lesions  can  be  observed  in  anteromedial  temporal 
mesocortex. At stage 5, the olfactory areas are severely affected along with the limbic 
areas of the allocortex. By stage 6, the LB pathology is conspicuous in nearly all of 
the neocortex (Braak et al. 2003; Braak et al. 2004). Mesocortical and neocortical 
areas that undergo late myelination have been suggested to develop lesions earlier 
and  at  higher  densities  than  those  that  begin  to  myelinate  earlier,  thereby 
recapitulating  the  process  of  cortical  myelination  in  reverse  order  (Braak  &  Del 
Tredici 2004). [25] 
 
                               
Figure 1.2: Braak staging related to PD pathology. The six stages of PD progression are illustrated. The thick white arrows identify the 
anatomical progression of LB pathology with medulla oblongata being the first to be affected followed by pontine tegmentum, midbrain and finally 
the neocortex. This image was adapted and modified from (Braak et al. 2003).  [26] 
 
The Braak PD staging system has also been investigated in other disorders that are 
associated with LBs, and although the system fits most cases, there are exceptions. 
For  example,  the  staging  system  does  not  have  relevance  to  LBs  that  occur  in 
Alzheimer’s disease, where many of these inclusions are confined to the amygdala 
(Uchikado et al. 2006). LBs have also been demonstrated in brains of asymptomatic 
subjects, thought to represent the early disease stages and is known as incidental LB 
disease (Parkkinen et al. 2003). As a result, the dementia with Lewy bodies (DLB) 
Consortium proposed a new scheme for the pathologic assessment of LBs and LNs, 
taking into account both Lewy-related and Alzheimer-type pathology (McKeith et al. 
2005). Under this scheme, the lesion density is graded semi-quantitatively, but the 
pattern of regional involvement is deemed more important than total LB count, and 
can be divided into predominantly brainstem (IX-X cranial nerve nucleus, LC and 
SN),  transitional  (nbM,  amygdala,  transentorhinal,  cingulate  gyrus)  or  diffuse 
neocortical pathology (temporal, frontal and parietal cortices). A probability of the 
clinical DLB syndrome can be assigned based on this assessment.  
 
 
Figure  1.3:  Staging  of  α-synuclein  pathology  according  to  the  dementia  with  Lewy 
bodies (DLB) consortium. This image presents the grading criteria of LB pathology in 
cerebral cortex of DLB cases as defined by the DLB consortium. The LB pathology is scored 
as stages 1 to 4: Stage 1 = sparse LBs and LNs; Stage 2 = >1 LB per high power field and 
sparse LNs; Stage 3 =  4 LBs and scattered LNs in low power field; Stage 4 = numerous LBs 
and LNs. This image was obtained from (McKeith et al. 2005). [27] 
 
1.3.5  PD pathology and autonomic symptoms 
The involvement of non-motor autonomic symptoms has been suggested to predate 
the PD-associated motor symptoms by many years. Extensive LB pathology in PD 
subjects has been reported in the regions central to the autonomic functions, such as 
lower  brainstem  autonomic  nuclei,  hypothalamus,  spinal  cord  and  enteric  plexus 
(Braak  et  al.  2006).  The  DMVN  is  involved  in  oesophageal  motility,  and  the 
pathology of this nucleus has been suggested to lead to gastrointestinal dysfunctions, 
such  as  drooling,  dysphagia  (swallowing  difficulties)  and  gastroesophageal  reflux 
(Wolters & Braak 2006). Most PD patients also have an impaired sense of smell 
which has been attributed to severe degeneration of olfactory bulbs in PD patients 
(Del Tredici et al. 2002). Neuronal cell loss of serotonergic neurons of the dorsal 
raphè nuclei, and cholinergic neurons of the pedunculopontine tegmental nucleus are 
thought to be involved in the sleep disturbances associated with the PD phenotype 
(Jellinger  1999).  Constipation  and  sexual  dysfunction  are  the  other  autonomic 
symptoms  that  often  precede  the  motor  symptoms  of  PD,  thereby  supporting  the 
notion that the PD pathology might begin in the peripheral nervous system, and not 
the central nervous system (Micieli et al. 2003). 
1.3.6  Glial cell loss 
Glial  cells  have  been  suggested  to  have  varying  degrees  of  involvement  in  PD 
pathology, and can be involved either by reacting to, or by directly being affected by 
the  existing  pathology  (Croisier  &  Graeber  2006).  Microglia  and  astrocytes  are 
sensitive to changes in cellular environment, and can be activated upon reaction to 
toxins  and  pathological  conditions,  resulting  in  an  immune  response  and 
inflammation. However, the role of inflammation (neuroprotective or toxic), and the 
little  reactive  astrocytosis  observed  in  PD  brains  makes  their  role  in  the  disease 
pathogenesis debatable (reviewed in (Teismann & Schulz 2004).  
Although  α-synuclein  immunoreactivity  in  PD  is  mostly  limited  to  the  neuronal 
populations, instances of glia (oligodendroglia and astrocytes) immunoreactive for α-
synuclein in midbrain, basal ganglia, cerebral cortex, cerebellum and spinal cord have [28] 
 
been described (Arai et al. 1999; Wakabayashi et al. 2000; Hishikawa et al. 2001). 
Fibrillary glial inclusions composed of α-synuclein, however, remain characteristic of 
multiple system atrophy (MSA). Therefore, the significance of glial pathology in PD 
is still unknown and requires further elucidation. 
1.4  Basal ganglia circuitry  
The progressive degeneration of the SN is associated with the DAergic denervation of 
the striatum. This positive correlation between dopamine deficiency in the striatum 
and nigral cell loss in PD patients led Hornykiewicz to describe PD as a ‘striatal 
dopamine  deficiency  syndrome’  (Hornykiewicz  2008).  The  loss  of  SN  DAergic 
neurons that project towards the striatum results in a dopamine deficiency causing the 
earliest PD symptom in posterior putamen. As such, most symptomatic therapies are 
aimed at replacing dopamine.  
There is no diagnostic laboratory test for PD, and the diagnosis relies on clinical 
features.  Neuroimaging  techniques  such  as  positron  emission  tomography  (PET) 
using fluorodopa ([
18F]-DOPA) are used to measure levodopa uptake into dopamine 
nerve terminals. In PD subjects a decline in striatal dopamine uptake of up to 5% per 
year  can  be  observed  (Fearnley  &  Lees  1991).  Loss  of  dopamine  causes  a 
downstream  dysfunction  in  the  circuit  anatomy  of  basal  ganglia,  resulting  in  the 
motor fluctuations observed in PD.  
The basal ganglia encompasses the striatum (putamen and caudate), globus pallidus 
which contains external and internal segments (GPe and GPi, respectively), SN pars 
compacta  and pars  reticulata  (SNpc  and  SNpr,  respectively), and the  subthalamic 
nucleus (STN) (see Figure 1.4a). Information from all parts of the cerebral cortex is 
received by the basal ganglia which projects back through frontal cortex via partially 
closed loops. The striatum and the STN are the two main entry points for receiving 
input for the basal ganglia. 
The  intrinsic  circuitry  of  the  basal  ganglia  is  described  as  having  two  projection 
systems:  a  ‘direct’  pathway  extending  between  striatum  and  GPi/SNpr,  and  an [29] 
 
‘indirect’  pathway  with  excitatory  projections  between  striatum  to  GPe  to  STN. 
These pathways differ in their functionality as the corticostriatal afferents primarily 
act to facilitate or excite the ‘direct’ pathway, but inhibit the ‘indirect pathway’. In 
the  direct  pathway,  cortical  activity  excites  the  inhibitory  GABAergic  neurons  in 
striatum, leading to inhibition of GPi and SNpr, which in turn removes their tonic 
inhibition from the thalamus. In contrast, cortical activity that excites glutamatergic 
neurons in the striatum in the indirect pathway, performs an overall inhibition of the 
thalamus. It does this by using inhibitory GABAergic projections between striatum-
GPe-STN, and excitatory (glutamatergic) between STN-GPi/SNpr (see Figure 1.4b).  
Dopamine from the SN stimulates dopamine receptors, and modulates glutamatergic 
(excitatory) effects on corticostriatal inputs by exerting a dual effect on the striatal 
neurons: exciting D1 receptors in the direct pathway and inhibiting D2 receptors in 
the  indirect  pathway.  Dopamine  depletion  in  PD  disrupts  this  fine  corticostriatal 
balance leading to decreased activity in the direct circuit and an increased activity in 
the indirect circuit. The tonic inhibition on the thalamus needs to be removed for the 
purpose  of  voluntary  movement.  During  PD,  a  lack  of  dopamine  results  in  D1 
receptors (in the direct pathway) not being able to exert their excitatory effect on 
striatum resulting in a removal of subsequent inhibition from GPi/STN. This means 
the tonic inhibition on the thalamus cannot be removed and the afferent signals are 
sent to the cortex for movement to continue. In the indirect pathway, a depletion of 
dopamine results in the D2 receptors not being able to exert an inhibition on the 
striatum which means the subsequent inhibition on the GPe and STN is removed, 
resulting  in  excitatory  signals  from  STN  increasing  the  inhibitory  output  from 
GPi/SNpr.  Replacing  dopamine  in  the  form  of  its  precursor  levodopa  (L-DOPA) 
addresses this imbalance and allows for basal ganglia to function normally. Although 
this  is  by  no  means  a  definitive  cure,  L-DOPA  in  combination  with  a  dopa- 
decarboxylase  inhibitor  is  an  effective  therapy  that  improves  the  quality  and 
functional capacity of PD subjects (Lees et al. 2009). 
 [30] 
 
 
     
Figure 1.4: Basal ganglia components and circuitry. (A) Anatomical components that form the basal ganglia circuitry. The image was obtained 
from http://www.dana.org/uploadedImages/Images/Spotlight_Images/BW_JanFeb07_basal_ganglia_spot.jpg. (B) A simplified schematic of direct 
and indirect pathways of basal ganglia. Arrows in green show excitatory effect and in red show an inhibition. Dopamine serves to activate the 
direct pathway over the indirect pathway, and thus increase the signal to the thalamus by removing the inhibition from GPi/SNpr, whereas in the 
indirect pathway, the STN increases the tonic inhibition on thalamus via GPi/SNpr.  
    (A)                         (B) [31] 
 
1.5  Disease Aetiology 
1.5.1  Environmental factors 
Up until the late 20
th century, PD was thought to mainly result from environmental 
insults, and there is some clinical  and  epidemiological evidence that supports the 
notion of PD occurring as a result of a neuronal infection, for example, neuro-virulent 
strains of influenza A virus (Takahashi & Yamada 1999). The enteric system has 
been  shown  to  be  affected  in  the  earlier  stages  of  PD  pathogenesis,  leading  the 
authors to speculate that a viral pathogen could infect the CNS via the postganglionic 
enteric  neurons  (Braak  et  al.  2003).  A  variety  of  other  mechanisms,  including 
inhibition  of  complex  I  of  the  mitochondrial  respiratory  chain,  displacement  of 
dopamine from vesicular stores, and formation of mitochondrial or cytosolic reactive 
oxygen species (ROS) have also been proposed as the means for harmful agents to 
exert their neurotoxic effects (Richardson et al. 2007). Cellular and animal models 
have  been  created  to  mimic  parkinsonian  symptoms  following  exposure  to 
neurotoxins, thereby emphasising the role of environmental toxins in PD aetiology.  
6-hydroxydopamine  (6-  OHDA)  was  one  of  the  first  neurotoxins  to  be  isolated 
(Schober 2004). It was found to selectively degenerate catecholaminergic neurons, as 
a result of decreased mitochondrial complex I function and increased production of 
reactive oxygen species (ROS) (Betarbet et al. 2002). Another neurotoxin found to 
mimic parkinsonian symptoms in animal models is the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP). It was discovered in 1982, when a group of young heroin 
addicts were diagnosed with parkinsonian symptoms after injecting a synthetic drug, 
a  major  contaminate  of  which  was  the  neurotoxin  MPTP  (Langston  et  al.  1983). 
MPTP has since been successfully used to develop cellular and animal models of PD. 
In the brain, MPTP crosses the blood brain barrier and is metabolised by monoamine 
oxidase  B  into  1-methyl-4-phenylpyridinium  (MPP+),  a  potent  mitochondrial 
complex I inhibitor. MPP+ displays a selective toxicity for DAergic neurons in SN, 
thereby replicating PD symptoms (Richardson et al. 2005). MPTP is now widely used 
to disrupt the nigrostriatal dopamine pathway in non-human primate models. Another [32] 
 
mitochondrial  complex  I  inhibitor  that  successfully  mimics  PD  symptoms  and 
neuropathology  in  rodent animal  models is the  pesticide rotenone  (Betarbet et al. 
2002). Rotenone is administered systemically, and can inhibit mitochondrial complex 
I uniformly, as opposed to 6-OHDA and MPTP, both of which display a selectivity 
for  catecholaminergic  neurons.  Despite  the  widespread  mitochondrial  complex  I 
inhibition by rotenone, it results in degeneration of nigral-striatal DAergic neurons 
(Betarbet et al. 2002). The specific degeneration of these neurons by a wide range of 
neurotoxins that display complex I inhibition, and thus inhibit the respiratory chain 
suggests an important role for mitochondrial dysfunction in PD pathogenesis. 
Exposure to agricultural products has also been suggested to increase sensitivity of 
DAergic neurons to toxins later in life (Richardson et al. 2006). Paraquat or 1,1’-
dimethyl-4, 4’-bipyridinium is a herbicide that is structurally similar to MPP+ and 
crosses the blood brain barrier to cause degeneration of DAergic neurons, and cause 
locomotor  dysfunction  in  mice  (Brooks  et  al.  1999).  Unlike  MPTP  or  rotenone, 
paraquat  does  not  require  dopamine  transporter  nor  does  it  inhibit  mitochondrial 
complex I. Paraquat exerts its effects by oxidising the cytosolic form of thioredoxin 
and  activating  Jun  N-terminal  kinase  (JNK),  followed  by  caspase-3  activation, 
whereas MPTP and rotenone oxidize the mitochondrial form of thioredoxin and do 
not activate JNK-mitogen-activated protein kinase and caspase-3 (Ramachandiran et 
al. 2007). When administered together with manganese ethylenebisdithiocarbamate 
(maneb), a fungicide that enhances the neurotoxic effects of MPTP on locomotion in 
mice, a greater toxicity towards the nigral dopamine system was observed, than when 
either of them were administered individually to the rodent model (Thiruchelvam et 
al. 2000). 
Apart from the ATP depletion, complex I inhibition can increase cellular levels of 
mitochondrial reactive oxygen species (ROS) (Adam-Vizi 2005). Increase in ROS 
production and subsequent respiratory inhibition, leading to oxidative stress has been 
suggested as a possible mechanism for nigral cell death (Kushnareva et al. 2002). The 
relevance of PD models (cellular and animal) that recapitulate PD symptoms resultant 
from mitochondrial dysfunction was further emphasised by the identification of point [33] 
 
mutations  in  mitochondrial  transfer  RNA  (tRNA)  genes  in  the  SN  of  PD  cases 
(neuropathologically confirmed) (Kösel et al. 1998; Grasbon-Frodl et al. 1999). The 
knowledge  obtained  from  these  PD  models  is  instrumental  in  understanding  the 
impact of oxidative stress and complex I inhibition on mitochondrial dysfunction, and 
is fast becoming a major contribution to the explanation of PD pathogenesis.  
1.5.2  Genetics of PD  
Identification of PD causing toxins and the low concordance rate in monozygotic and 
dizygotic  twin  studies  perpetuated  the  idea  that  PD  was  not  caused  by  genetic 
elements. However, PET studies utilising F-DOPA uptake have shown reduced levels 
of striatal dopamine in unaffected twins and relatives of PD patients when compared 
to  controls,  suggesting  a  familial  component  to  PD  aetiology  (Brooks  1991). 
Moreover, in the last two decades several genes linked to familial PD have been 
reported. Linkage mapping using positional cloning in large kindreds or autozygosity 
mapping in small families have been used to identify dominant and recessive genes 
for PD, respectively. These mendelian genes have collectively come to be known as 
the PARK loci.  
Many  genes  associated  with  PD  have  also  been  identified  by  candidate  gene 
association  studies  and  are  continuously  being  updated  at  PD  Gene 
(http://www.pdgene.org). Majority of these genes were investigated either due to their 
functional relevance in a mechanistic pathway, or for their role in other diseases that 
displayed  parkinsonian  symptoms.  Investigations  into  recessive  disorders  such  as 
Gaucher’s disease, or diseases with LBs but complex phenotypes such as Neimann-
Pick Type C (NPC), infantile neuroaxonal dystrophy (INAD) and neurodegeneration 
with brain iron accumulation (NBIA) have provided many new candidates for PD 
research (Hardy et al. 2009).  
 
 [34] 
 
Locus  Chromosome  Gene  Mode of inheritance and phenotype 
PARK1  4q21-q23  SNCA  AD, Mid-late with DLB features 
PARK2  6q25.2-q27  PRKN  AR, EO, slow progression, no LBs 
PARK3  2p13  Unknown  AD, Classic PD with LBs 
PARK4  4q21  SNCA 
(triplication) 
AD, EO with DLB features 
PARK5  4q14  UCH-L1  Unclear transmission, Classic PD 
PARK6  1p35-p36  PINK1  AR, EO, slow progression with LBs 
PARK7  1p36  DJ1  AR, EO, slow progression 
PARK8  12p11.2-q13.1  LRRK2  AD, Classic PD with heterogenous pathology 
PARK9  1p36  ATP13A2  AR, Atypical -Kufor-Rakeb syndrome 
PARK10  1p32  Unknown  Unclear transmission, Classic PD  
PARK11  2q36-q37  GIGYF2   AD, Classic PD 
PARK12  Xq21-q25  Unknown  Classic PD 
PARK13  2p12  HTRA2/OMI  Classic PD 
PARK14  22q13.1  PLAG26  AR,  parkinsonism-dystonia  phenotype,  NBIA-type2, 
with LBs 
PARK15  22q12-q13  FBXO7  AR, parkinsonian pallidal syndrome 
-  17q21.1  MAPT  Frontotemporal dementia with parkinsonism linked to 
chromosome- 17. 
-  1q21  GBA  Parkinsonism with LBs 
-  5q23.1-q23.3  Synphilin-1  Classic PD 
-  2q22-q23  NR4A2/Nurr1  Classic PD 
Table 1.1: Autosomal dominant and recessive genes linked to PD. This table describes the 
familial PARK loci (1-15), and genes shown to be associated to PD in non-familial forms. 
AD: autosomal dominant, AR: autosomal recessive, EO: early onset, LB: Lewy body. Classic 
PD refers to the late- onset clinical IPD phenotype unless otherwise stated. [35] 
 
1.5.2.1 PARK loci and familial PD 
1.5.2.1.1  PARK 1/4 (SNCA) 
A genome wide linkage analysis mapped an Italian family (Contrusi kindred) with 
autosomal dominant form of PD, to a locus on chromosome 4q21 (PARK1) in 1996 
(Polymeropoulos et al. 1996). This locus contained SNCA, which became the first 
gene  to  be  implicated  in  familial  PD  (FPD).  The  SNCA  gene  spans  117  kb  and 
contains 6 exons that encode for a 140 amino acid protein known as α-synuclein. 
Three missense mutations, A53T, A30P and G46L were identified in the original 
Italian  (Contrusi  kindred),  German  and  Spanish  families,  respectively 
(Polymeropoulos et al. 1997; Krüger et al. 1998; Zarranz et al. 2004). The protein 
encoded by this locus (α-synuclein) was also demonstrated as a principal component 
of the LBs (Spillantini et al. 1997; Spillantini et al. 1998).  
Various studies have reported multiplications of the wild-type SNCA locus in families 
with parkinsonism. Initially, designated the PARK4 locus, duplications of the SNCA 
gene have been reported in two French (Chartier-Harlin et al. 2004; Ibáñez et al. 
2004a), an Italian, a Swedish (Fuchs et al. 2007), and two Japanese (Nishioka et al. 
2006) families. SNCA triplications have also been identified in American (Singleton 
et al. 2003) and Swedish-American kindreds (Farrer et al. 2004). However, screening 
of large cohorts of patients has suggested that missense mutations and multiplications 
of the wild-type SNCA are a rare cause of parkinsonism (Hope et al. 2004; Johnson et 
al. 2004; Lockhart et al. 2004). 
The clinical phenotype resulting from a duplication of the wild-type gene has a mid- 
late onset with a slow progression that is clinically similar to IPD (Chartier-Harlin et 
al. 2004; Ibáñez et al. 2004a; Nishioka et al. 2006). In contrast, SNCA triplications 
result  in  an  earlier  age  of  onset  with  a  faster  progression,  and  a  more  severe 
presentation of the phenotype that includes dementia, autonomic dysfunction, and a 
reduced lifespan (although this varies in different cases) (Singleton et al. 2003; Farrer 
et al. 2004; Fuchs et al. 2007). This pathologic gain of function demonstrates the 
importance of a critical dosage of the SNCA locus, and how alterations in the gene [36] 
 
copy number can impact on the severity of the clinical phenotype. The role of SNCA 
mRNA  upregulation  was  further  supported  by  the  identification  of  NACP-Rep1 
polymorphism in the promoter region of the SNCA gene. Consistently, identified as a 
risk factor in various populations, an in-vitro increase in transcription is associated 
with the risk allele of NACP-Rep1 (Chiba-Falek & Nussbaum 2001; Maraganore et 
al. 2006). Therefore, the importance of gene dosage effects of SNCA can be observed 
in both the familial and idiopathic forms of PD. 
The physiological role of α-synuclein remains unclear but it has been implicated in 
synaptic plasticity, vesicle recycling, chaperone mechanisms, storage and regulation 
of neurotransmitters (Schiesling et al. 2008).
 As mentioned previously, wild-type α-
synuclein has been identified as the principal component of LBs and LNs, and as 
such plays a crucial role in PD. Phosphorylation of wild-type α-synuclein results in 
increased oligomerisation and eventual accumulation as the major insoluble fibrillar 
component of the LBs (Goldberg & Lansbury 2000). An overexpression model using 
Drosophila  melanogaster  showed  an  adult-loss  of  DAergic  neurons,  α-synuclein 
positive intraneuronal inclusions and a loss of locomotor activity (Feany & Bender 
2000).  Whether  aggregation  of  wild-type  α-synuclein  or  toxic  oligomeric 
intermediates  cause  cell  death  is  debatable,  but  the  processes  leading  to  the 
fibrillisation of the protein seems to form a strong link to the pathology.  
1.5.2.1.2  PARK2 (PRKN) 
A  locus  mapping  to  chromosome  6q25.2-27,  designated  PARK2  was  linked  to 
autosomal recessive forms of juvenile parkinsonism (AR-JP), with a typical age of 
onset  of  40  years  of  age  (Matsumine  et  al.  1997).  The  causative  gene  was  later 
identified as parkin (PRKN), and shown to contain 12 exons that span 1.53 Mb and 
encode a 465 amino acid (52 kDa) protein (Kitada et al. 1998). 
Homozygous deletions of exons 1 and 5 were identified in Japanese families with 
AR-JP (Kitada et al. 1998), and deletion of exons 5, 6 and 7 were also confirmed in a 
two individuals from a Greek pedigree with early onset parkinsonism (Leroy et al. 
1998a).  Since  then  a  multitude  of  mutations  in  PRKN  including  deletions,  exon [37] 
 
multiplications, point and frameshift mutations have been identified as a cause for 
early onset parkinsonism (<50 years of age) (reviewed in (Schiesling et al. 2008)). 
PRKN mutation carriers display typical signs of IPD with a slower progression of the 
disease, a more symmetric onset, and dystonia as a possible initial sign (Lohmann et 
al. 2003). To date over 100 mutations in early onset PD cases (< 45 years of age) 
have been identified in PRKN, accounting for about 50% of familial and 20% of PD 
cases with no family history (Abbas et al. 1999; Lücking et al. 2000). Heterozygous 
mutations in PRKN have been shown to be present at a similar frequency in PD 
patients and controls (Lincoln et al. 2003; Kay et al. 2007). However, functional brain 
imaging  studies  have  shown  alterations  of  nigrostriatal  DAergic  projections  in 
asymptomatic  heterozygous  PRKN  mutation  carriers,  leading  to  suggestions  that 
heterozygosity  might  constitute  a  risk factor  by  causing  haploinsufficiency  of  the 
PRKN gene in PD (Hilker et al. 2001).  
Parkin is an ubiquitin E3 ligase that is responsible for the addition of ubiquitin to 
specific substrates which are then targeted for degradation by the proteasome in the 
ubiquitin protease system (UPS). PRKN mutations lead to a loss of ligase function 
which affects the ubiquitination and degradation of the protein, thereby strengthening 
the hypothesis that protein degradation and aggregation might play a central role in 
PD pathogenesis (Shimura et al. 2000). Post-mortem analysis of PRKN brains report 
a typical  neuron loss  in  SN,  but  LBs  are  rarely  observed  in the  brains  of  PRKN 
mutation  carriers  (Farrer  et  al.  2001),  however,  parkin  has  been  shown  to  be  a 
component of LBs in PD and DLB brains (Schlossmacher et al. 2002).  
1.5.2.1.3  PARK3 
The  third  PARK  locus  was  mapped  to  chromosome  2p13  in  1998,  and  indicates 
association  with  autosomal  dominant  PD  with  a  late  onset  and  a  pathological 
phenotype that includes LBs (Gasser et al. 1998). Many genes in this region have 
been  excluded  as potential  candidates,  although  polymorphisms in  the  sepiapterin 
reductase gene in the PARK3 region have been suggested to modulate the onset or 
risk of PD (Sharma et al. 2006).  [38] 
 
1.5.2.1.4  PARK5 (UCH-L1) 
The locus for PARK5 was mapped onto chromosome 4p14, and the gene linked to 
FPD was identified as the multifunctional ubiquitin C-terminal hydrolase 1 (UCH-
L1), and a single missense mutation (I93M) was reported in affected siblings from a 
German  kindred,  presenting  typical  PD  symptoms  (Leroy  et  al.  1998b).  UCH-L1 
produces a neuron-specific enzyme that is part of the UPS pathway. Biochemical 
studies reveal a dual role for UCH-L1 protein; as a ubiquitin hydrolase and also as an 
E3 ligase. In-vitro studies have demonstrated how UCH-L1 uses these two opposing 
enzymatic  activities  to  exert  its  influence  on  α-synuclein  degradation  (Liu  et  al. 
2002).  
UCH-L1 has also been shown to be present in LBs of IPD brains (Lowe et al. 1990). 
Only a single neuropathology report has been presented on I93M mutation carriers, 
describing  LBs  in  the  affected  regions,  and  also  demonstrating  co-localisation  of 
UCH-L1 with α-synuclein in cortical LBs (reviewed in (Schiesling et al. 2008). This 
mutation has not been found in other PD families, thereby leading some to challenge 
the credibility of UCH-L1 gene as a PARK locus. 
1.5.2.1.5  PARK6 (PINK1) 
The PARK6 locus was mapped to chromosome 1p35-p36 in a large Sicilian family 
known as the ‘Marsala kindred’ with autosomal recessive PD, clinically characterised 
by  an  early  age  of  onset  (32-48  years),  and  exhibiting  a  typical  parkinsonism 
phenotype (Valente et al. 2001). Identified as the PTEN-induced putative kinase 1 
(PINK1), the gene spans 18 kb, and the 8 exons encode a 581 amino acid protein (63 
kDa) (Valente et al. 2004). Mutations in PINK1 account for 1-7% of early onset PD 
cases (depending on the ethnicity), and are therefore regarded as the second most 
common cause of early-onset PD (Tan et al. 2006). 
PINK1 variants result in a loss-of function, and include point mutations as well as 
insertions  and  deletions  that  lead  to  frameshift  and  subsequent  truncation  of  the 
protein. Typically associated with a recessive transmission, a homozygous mutation 
(W437X) in the PINK1 gene has also been shown to be associated with autosomal [39] 
 
dominant parkinsonism (Criscuolo et al. 2006). Heterozygous PINK1 mutations have 
been shown to be more frequent in IPD patients compared with controls, and have 
been suggested to act as a risk for developing PD via haploinsufficiency or even a 
dominant-negative  effect  (Abou-Sleiman  et  al.  2006).  Brain  imaging  studies 
performed  on  asymptomatic  heterozygous  carrier  of  PINK1  mutations  identified 
reduced  striatal  F-DOPA  uptake  in  PET  studies,  lending  support  to 
haploinsufficiency contributing to pathogenic influences in PD (Khan et al. 2002).   
PINK1 is a protein kinase that has been shown to have a neuroprotective effect by 
phosphorylating specific mitochondrial proteins (modulating their function), and loss 
of PINK1 function can be rescued by parkin (Clark IE et al. 2006; Park et al. 2006; 
Yang et al. 2006; Exner et al. 2007). Post-mortem analysis of PINK1 carriers present 
typical features of IPD with neuronal loss and LB inclusions in affected areas, and the 
protein has been shown to be immunoreactive in a proportion of LBs in PD and DLB 
(Gandhi  et  al.  2006;  Murakami  et  al.  2007).  The  heterozygous  nature  of  the 
mutations,  however,  makes  it  difficult  to  determine  whether  mutant  or  wild-type 
PINK1, or both forms accumulate in the neuronal inclusions.  
1.5.2.1.6  PARK7 (DJ-1) 
The  PARK7  locus  was  mapped  to  chromosome  1p36  in  a  Dutch  family  who 
presented  with  an  autosomal  recessive  form  of  PD  (van  Duijn  et  al.  2001).  The 
candidate for this locus was identified as the oncogene, DJ-1, which spans 24 kb and 
contains 8 exons that produce a 189 amino acid (20 kDa) protein (Bonifati et al. 
2003a). Patients with mutations in DJ-1 show typical PD symptoms, plus dystonic 
features and/or psychiatric signs (van Duijn et al. 2001). 
The first mutations identified were a large homozygous chromosomal deletion of 14 
kb  in  the  Dutch  kindred,  and  a  homozygous  point  mutation  in  an  Italian  family 
(Bonifati et al. 2003b). Although additional mutations in DJ-1 have been identified, 
they remain a rare cause of early-onset PD (<1%) (reviewed in (Schiesling et al. 
2008)). A decreased F-DOPA uptake in patients with homozygous DJ-1 deletions 
was reported, but asymptomatic individuals with heterozygous mutations showed no [40] 
 
alterations  in  F-DOPA  PET  imaging  (Dekker  et  al.  2004).  Even  though  DJ-1 
mutation carriers show an early-onset phenotype comparable to PINK1 and PRKN 
mediated PD, an unremarkable F-DOPA metabolism in asymptomatic heterozygous 
DJ-1 carriers is in stark contrast to the other two recessive genes.  
DJ-1 controls gene transcription and stability of mRNA regulation (Bonifati et al. 
2003), and is thought to have neuroprotective effects by acting as an oxidative stress 
sensor within cells
 (Taira et al. 2004). Histopathological studies relating to the brains 
of DJ-1 mutation carriers have not been reported, but it has been shown to have a 
mainly astrocytic expression in the brain with higher levels in subcortical areas that 
are affected in PD (Bonifati et al. 2003; Bandopadhyay et al. 2004). DJ-1 is not a 
component of LBs and LNs, but it has been identified in glial-positive inclusions and 
tangles associated with tauopathies such as Pick’s disease, progressive supranuclear 
palsy (PSP), corticobasal degeneration (CBD) and Alzheimer’s disease (Rizzu et al. 
2004).  
1.5.2.1.7  PARK8 (LRRK2) 
The PARK8 locus was originally identified in 2002 in a large Japanese family known 
as the Sagamihara kindred, after the area in which the family resides (Funayama et al. 
2002).  The  affected  members  in  the  family  presented  with  autosomal  dominant 
parkinsonism that responded to levodopa. A genome-wide linkage analysis revealed a 
novel locus for  FPD on chromosome 12p11.2-q13.1. Further analysis identified a 
disease associated haplotype shared by the affected and unaffected members of the 
family, suggesting a low disease penetrance. Linkage to the PARK8 locus was also 
identified in European families (German Canadian and Nebraskan) (Zimprich et al. 
2004a),  thereby  further  highlighting  its  importance  as  a  monogenic  cause  of  PD 
across different populations. PARK8 linked parkinsonism displays a wide spectrum 
of  clinical  and  pathological  phenotypes.  The  Sagamihara  kindred  showed  no 
dementia and pure nigral degeneration with no LB pathology whereas the European 
families  reported  by  Zimprich  and  colleagues  were  clinically  heterogenous  and 
presented with signs of dementia, PSP, or motor-neuron degeneration (Funayama et [41] 
 
al. 2002; Zimprich et al. 2004a; Wszolek et al. 2004). These European subjects were 
found to have tau and α-synuclein pathology (Wszolek et al. 2004) 
The gene responsible for PARK8 linked PD was identified as Leucine rich repeat 
kinase  2  (LRRK2)  by  two  independent  groups  in  2004  (Paisán-Ruíz  et  al.  2004; 
Zimprich et al. 2004b). LRRK2 spans 144 kb and contains 51 exons that encode a 
>250 kDa protein. Paisan-Ruiz and colleagues (2004) identified missense mutations, 
Y1654C and R1396G in LRRK2 gene in British and Spanish families, respectively. 
Since a number of families identified by them were of a Basque origin, they named 
the gene product dardarin from the Basque word dardara meaning tremor. Zimprich 
and colleagues also identified a total of four mis-sense (Y1699C; R1441C; I1122V 
and I2020T) and one putative splice site (L1114L) mutation in the families that they 
initially identified the PARK8 linkage in. Over 50 variants have since been identified 
in LRRK2, many of which are regarded as pathogenic (see (Schiesling et al. 2008; 
Lesage & Brice 2009) for review). However, the G2019S mutation identified in exon 
41 of LRRK2, has come to be regarded as the most common genetic cause of PD in 
Europeans, North African Berbers and Ashkenazi Jewish populations (Ozelius et al. 
2006; Lesage et al. 2006; Healy et al. 2008).  
An interesting feature of the LRRK2 mutations is the pleiomorphic pathology they 
display. The LRRK2 linked pathology can include not only classic nigral degeneration 
with  or  without  LB  pathology,  but  also  pathologies  associated  with  Alzheimer’s 
disease, multiple system atrophy (MSA), or PSP (Wszolek et al. 2004; Miklossy et al. 
2006;  Ross  et  al.  2006).  Both  G2019S  and  I2020T  mutations  occur  in  adjacent 
codons in the conserved activation loop of the kinase catalytic domain, and cause a 
dominant gain-of function effect which increases the protein’s kinase activity in vitro 
(West et al. 2005; Gloeckner et al. 2006; Greggio et al. 2006). However, they display 
different pathological phenotypes. The I2020T mutation in the original Sagamihara 
kindred  presents  pure  nigral  degeneration  without  α-synuclein  positive  inclusions 
(Funayama et al. 2005), whereas G2019S mutation exhibits classical IPD pathology 
which includes selective degeneration of SN and LC neurons accompanied with α-
synuclein positive LBs in the brainstem and limbic cortex (Ross et al. 2006). Ross [42] 
 
and colleagues (2006) also reported that G2019S mutation carriers can occasionally 
contain NFTs in addition to extensive LB pathology in the amygdala. However, an 
isolated case with G2019S linked PD has been reported to have nigral degeneration 
with  no  pathological  inclusions  (Gaig  et  al.  2007).  The  mutations  R1441C  and 
Y1699C also display neuronal loss and gliosis in SN, and R1441C carriers present 
classic α -synuclein pathology with LBs localised either just to the brainstem or a 
more  widespread  LB  and  LN  pathology  pattern  (Zimprich  et  al.  2004b).  Tau 
immunoreactive  neuronal  and  glial  lesions  reminiscent  of  PSP  pathology  was 
observed in Y1699C mutation carriers who displayed signs of dementia. The I1371V 
mutation,  on  the  other  hand,  shows  ubiquitin  as  well  as  α-synuclein  positive  LB 
pathology (Giordana et al. 2007). A case of the basque R1441G LRRK2 mutation has 
been shown to have mild neuronal loss without α-synuclein, tau, LRRK2, or ubiquitin 
cytoplasmic inclusions (Martí-Massó et al. 2009). LRRK2 is a large and a complex 
multidomain  protein  that  functions  as  a  kinase,  acts  as  a  mediator  in  synaptic 
endocytosis,  plays  a  role  in  the  maintenance  of  neuronal  viability  and  possibly 
functions as a scaffolding protein for cell signalling pathways, thereby suggesting that 
LRRK2 might be an important physiological protein with a central role to play in a 
variety of neurodegenerative diseases (Greggio & Cookson 2009). 
1.5.2.1.8  PARK9 (ATP13A2) 
Initially described in a Jordanian family, Kufor-Rakeb syndrome (KRS) is a rare form 
of  recessively  inherited,  juvenile  onset  parkinsonism  with  additional  symptoms 
including pyramidal degeneration, upward gaze palsy, spasticity and dementia (al-Din 
et al. 1994). The PARK9 locus linked to KRS was mapped to chromosome 1p36 
(Hampshire et al. 2001). Identification of compound heterozygous deletion and splice 
site mutation in affected members of a large Chilean family resulted in the candidate 
gene  being  identified  as  ATPase  Type  13A2  (ATP13A2)  which  spans  29  kb  and 
encodes 29 exons (Ramirez et al. 2006). The same research group also identified a 22 
bp homozygous duplication in the original Jordanian family to whom the locus was 
originally linked to. It has been suggested that the aggregation of the mutant protein 
in the endoplasmic reticulum causes proteasomal or lysosomal dysfunction (Ramirez [43] 
 
et al. 2006). Other variants in the gene, both heterozygous and homozygous have 
been reported to be associated with early-onset parkinsonism in Brazil and Italy (Di 
Fonzo  et  al.  2007).  A  knockdown  of  the  ATP13A2  ortholog  in  Caenorhabditis 
elegans enhances α-synuclein misfolding, and the yeast ortholog of ATP13A2 has 
also  been  shown  to  protect  cells  from  manganese  toxicity,  thereby  revealing  an 
interaction between PD genetics and environmental risk factors (Gitler et al. 2009). 
So far nothing has been reported on the histopathology associated with mutations in 
this gene. 
1.5.2.1.9  PARK10 
A genomic screen investigating the influence of age of onset on PD found significant 
linkage  to  chromosome  1  (Li  et  al.  2002).  Designated  PARK10,  this  locus  was 
mapped to chromosome 1p32 in an Icelandic IPD population with late-onset using 
genome wide linkage analysis (Hicks et al. 2002). Various genes have been suggested 
as possible candidates with the strongest association being observed in the CDCP2 
gene (Maraganore et al. 2005). However, this association remains to be confirmed.  
1.5.2.1.10  PARK11 
The autosomal dominant model of disease transmission associated with the PARK11 
locus was confirmed in a large number of families mapping to chromosome 2q36-q37 
(Pankratz  et  al.  2003;  Maraganore  et  al.  2005).  Heterozygous  mutations  have 
suggested that Grb10-Interacting GYF Protein-2 (GIGYF2) gene might be a possible 
candidate  for  the  PARK11  locus  (Lautier  et  al.  2008).  However,  the  presence  of 
GIGYF2 mutation (N457T) in neurologically normal controls, and a lack of genotypic 
and haplotypic association (Sutherland et al. 2009a) suggests that this gene is not 
strongly related to the development of PD. 
1.5.2.1.11  PARK12 
This FPD locus was mapped to chromosome Xq21-q25 (Pankratz et al. 2002; Hicks 
et al. 2002), but a candidate gene(s) has not yet been identified.  [44] 
 
1.5.2.1.12  PARK13 (HTRA2/OMI) 
The  candidate  gene  for  the  PARK13  locus  is  located  within  the  PARK3  linkage 
locus,  and  was  mapped  to  2p12-2p13  (Gray  et  al.  2000;  Faccio  et  al.  2000). 
Mutational screening of HTRA2/OMI in German patients with PD identified novel 
heterozygous mutations in this 3.8 kb gene (Strauss et al. 2005). The novel variants 
identified  in  the  German  case-control  cohort  by  Strauss  and  colleagues  (2005) 
interfere with the serine protease activity of the protein, and were shown to induce 
mitochondrial dysfunction in-vitro. The protein has been detected in LBs (Strauss et 
al. 2005), and has been shown to be phosphorylated by PINK1 (Plun-Favreau et al. 
2007). This led the authors to hypothesise that mitochondrial dysfunction plays an 
important role in neurodegeneration observed in a fraction of PD patients.  
1.5.2.1.13  PARK14 (PLA2G6) 
Mutations in phospholipase A2 (PLA2G6) on chromosome 22q13.1 are associated 
with INAD and NBIA-type 2 in unrelated consanguineous families (Morgan et al. 
2006;  Khateeb  et  al.  2006;  Gregory  et  al.  2008).  Linkage  analysis  in  adult-onset 
levodopa-responsive  dystonia-parkinsonism  with  pyramidal  signs  and  cognitive/ 
psychiatric features (but no iron in basal ganglia) identified PLA2G6 as the candidate 
(Paisan-Ruiz et al. 2009). The mutation R632W in PLA2G6 was shown to segregate 
with disease in a consanguineous Iranian dystonia-parkinsonism pedigree (Sina et al. 
2009). This gene is now referred to as PARK14 (Hardy et al. 2009). 
1.5.2.1.14  PARK15 (FBXO7) 
A genome wide linkage analysis on a large Iranian pedigree affected with autosomal 
recessive,  early-onset  parkinsonian-pyramidal  syndrome  (PPS)  showed  linkage  to 
chromosome  22  which  was  designated  the  PARK15  locus.  Subsequent  candidate 
gene screening revealed a disease-associated homozygous variation (R378G) in F-
Box only protein 7 (FBXO7), thought to have a role in the UPS degradation pathway 
(Shojaee et al. 2008). Mutations in FBXO7 have also been found in Italian and Dutch 
families, all of which display a complex PPS phenotype similar to ATP13A2 and 
PLA2G6 families (Hardy et al. 2009).  [45] 
 
 
Figure 1.5: A schematic view of the pathology associated with the familial PARK loci. The major molecular mechanisms involved in PD, have 
been determined from in-vitro and in-vivo studies of the proteins encoded by mutant genes implicated in PD. Histopathological findings associated 
with mutations in PARK genes are indicated. LRRK2 mutations exhibit the most heterogenous pathology. Neuropathological findings have not yet 
been reported for DJ-1 and Htra2/Omi mutations and PRKN mutation carriers are usually negative for LB pathology. α-synuclein pathology has 
been reported for rare cases with PINK1 mutations. AD= autosomal dominant, AR= autosomal recessive. [46] 
 
1.5.2.2 Common genetic variation in PD 
Genetic variation acting as a susceptibility factor forms the basis of the common 
disease –common variant (CD-CV) hypothesis. Since the identification of the first 
mendelian PD gene, many studies have focused on the basic tenets of the CD-CV 
hypothesis in order to identify common genetic variants within the population (>1%) 
that may lead to an increased risk rather than directly cause PD. The completion of 
the  ‘International  Haplotype  Map  (HapMap)  project’,  and  current  technological 
advances have allowed researchers to test genomic variation at a much larger scale 
than was previously afforded by traditional candidate gene association studies. The 
high-throughput ability of genome wide association (GWA) studies is now frequently 
used to assess the contributions of common variants in the mechanistic foundations of 
the disease. Data from GWA studies can be used not only to identify novel risk loci 
that might be potential interactors of the established PARK loci, but also to discover 
novel pathways in the disease pathogenesis.  
The first GWA PD study was used to screen ~200,000 SNPs in a cohort of discordant 
sib-pairs (Maraganore et al. 2005). To assess the influence of 3,035 SNPs identified 
in these sib-pairs, the group replicated the study in an unrelated patient-control series 
along with hypothesis-based SNPs previously selected for PD loci. Combined results 
from both the cohorts, nominated a small number of SNPs in various genes as being 
significantly associated with PD. The second PD GWA study produced around 220 
million  genotypes  in  a  case-control  cohort  of  over  500  individuals  (Fung  et  al. 
2006a).  This  information  was  publicly  released  with  the  premise  that  future 
researchers could mine these data to identify genetic variability that poses a mild or 
moderate risk of PD. The initial GWA studies reported many susceptible loci for PD, 
but  the  marker  densities,  sample  sizes,  and  population  substructures  could  have 
contributed  to  the  data  not being replicable.  The  ever  increasing  precision  of  the 
microarray technology with higher SNP density and superior data mining techniques 
have  resulted  in  better  consistency  across  GWA  studies.  Replication  for  a  SNP 
identified by Maraganore and colleagues in the Phactr2 gene was recently reported in 
a GWA study comprising IPD samples in populations from US, Canada and Ireland [47] 
 
but not in Norway (Wider et al. 2009). This emphasizes how important it is to have 
an  accurate  and  a  standardised  interpretation  of  GWA  studies,  as  an  inaccurate 
analysis could not only produce false positives but also result in true positives being 
missed in the vast amount of data generated by these platforms.  
Prior to the arrival of GWA studies, case-control associations focused on specific 
candidate genes. Conflicting results and a lack of replication are frequently reported 
as  an  observation  of  these  studies.  Nevertheless,  this  approach  has  been  highly 
influential  in  establishing  the  basis  of  identifying  common  genetic  variation  that 
could alter the risk of PD in PARK and other loci. Variants in the promoter of SNCA 
have consistently been shown to be associated with increased expression and risk of 
PD,  especially  the  dinucleotide  repeat  polymorphism,  NACP-Rep1  allele 
(Maraganore  et  al.  2006).  Associations  have  been  reported in  the  3’block around 
exons 5 and 6 of the SNCA gene (Mueller et al. 2005). Multiple SNPs in SNCA were 
identified as risk factors in a case-control cohort from Japan (Mizuta et al. 2006). The 
high level of linkage disequilibrium (LD) in the SNCA gene has been suggested to be 
one of the causes for multiple risk factors identified in this locus. Regardless of this, 
the  consistent  association  of  SNCA  variants  with  PD  risk  suggests  that  there  are 
functional  variant(s)  that  act  as  risk  modifiers.  For  example,  a  meta-analysis 
confirmed that the allele size of NACP-Rep1 is a susceptibility factor that acts by 
altering  SNCA  mRNA  expression  levels  (Maraganore  et  al.  2006),  and  a  3’  SNP 
(rs356219) is reportedly associated with SNCA mRNA levels in SN and cerebellum 
(Fuchs  et  al.  2008).  Recent  GWA  studies  have  consistently  shown  that  common 
variants in SNCA are associated with both the familial and idiopathic forms of PD 
(Pankratz et al. 2009; Sutherland et al. 2009b). 
Case-control association studies for the mis-sense polymorphism Ser18Tyr (Lincoln 
et al. 1999) in the UCH-L1 gene showed a reduced risk for IPD with this variant 
(Maraganore et al. 1999). The 50% frequency of this variant in Japanese and Chinese 
(Satoh & Kuroda 2001; Toda et al. 2003), and a meta-analysis of published studies 
further suggested a positive association for a protective risk in IPD. This association 
has  been  refuted  by  other  studies,  although  a  recent  GWA  study  reported  an [48] 
 
association  with  a  different  SNP  (rs10517002)  in  UCH-L1  and  IPD  subjects 
(Sutherland et al. 2009b). 
Certain genetic variants in LRRK2 gene have provided the strongest evidence that 
common genetic variation within the general population leads to an increased risk of 
PD. Both G2019S and G2385R mutations have been observed in a number of PD 
patients, although the association remains ethnicity dependent. On the basis of data 
from 24 different populations, the International LRRK2 Consortium concluded that 
G2019S related PD was a common cause of PD (familial and idiopathic) in European 
and certain Middle-Eastern populations (up to 40%) (Healy et al. 2008). In contrast, 
the G2385R variant is more prevalent in the far Eastern populations, and has been 
associated with an increased risk for developing PD in several independent Chinese 
(Singapore/Taiwan), Japanese and Korean populations (Tan et al. 2007a). The variant 
G2385R is not found in Europeans (Berg et al. 2005; Di Fonzo et al. 2006), and is 
also  not  common  in  Indians  or  Malays  (Tan  et  al.  2007b).  This  highlights  the 
importance of sample group choice in association studies. The variant R1682P has 
also been identified as a risk factor in certain Chinese populations 
 (Tan et al. 2008; 
Ross  et  al.  2008),  and  an  intronic  SNP  has  also  been  shown  to  be  reportedly 
associated in a Singaporean IPD cohort (Skipper et al. 2005). Apart from a strong 
association for G2019S mutation, LRRK2 association studies have not always yielded 
positive results for European IPD cases (Biskup et al. 2005; Paisán-Ruíz et al. 2005), 
but  an  association  has  been  reported  for  the  SNP  rs2723264  and  PD  in  a  Greek 
population (Paisán-Ruíz et al. 2006). A tSNP correlated to rs2723264 was recently 
shown to have a modest association with PD samples in an Australian cohort. The 
same group also identified modest associations to two other SNPs (rs10784486 and 
rs10878405) and IPD (Sutherland et al. 2009b). However, no associations for LRRK2 
were observed in a GWA study for familial PD samples (Pankratz et al. 2009).   
It  has  been  suggested  that  young  onset-PD  cases  might  have  a  stronger  genetic 
component (Tanner et al. 1999). Despite this, there is only limited information on 
association  between  common  variants  in  recessive  PARK  loci  and  PD,  although 
pathogenic  mutations  have  been  identified.  A  polymorphism  in  the  promoter  of [49] 
 
PRKN gene (-28 T/G) has been shown to be a risk factor for IPD affecting the age of 
onset  (West  et  al.  2002;  Sutherland  et  al.  2007),  but  similar  findings  were  not 
observed for other SNPs in the PRKN promoter (Mata et al. 2002; Ross et al. 2007). 
In familial PD samples, Maraganore and colleagues demonstrated common variation 
in DJ-1 as being associated with PD risk in related females, but not as a risk factor for 
overall PD (Maraganore et al. 2004). However, GWA studies have not identified any 
strong  associations  for  common  genetic  variation  in  the  recessive  genes  (PRKN, 
PINK1 and DJ-1) and PD. 
The susceptibility risk for PD is not limited to the familial PARK loci and includes 
various  other  genes,  some  of  which  are  associated  with  a  parkinsonism  plus 
phenotype. Like the NACP-Rep1 allele for SNCA, a consistent association is reported 
for  the  common  microtubule  associated  protein  tau  (MAPT)  H1  haplotype  for  an 
increased risk for familial and idiopathic PD (Skipper et al. 2004; Healy et al. 2004; 
Zhang et al. 2005; Tobin et al. 2008). Mutations in MAPT were originally identified 
in  rare  families  with  autosomal  dominant  frontotemporal  dementia  linked  to 
chromosome  17  with  parkinsonism  (FTDP-17),  and  linkage  of  PD  to  MAPT  was 
initially reported in 2001 (Hutton et al. 1998; Scott et al. 2001). Aggregation of tau is 
a pathological hallmark for several neurodegenerative disorders collectively known as 
tauopathies, and Alzheimer’s disease is the most common example. Tau pathology 
also underlies several diseases with parkinsonian features, such as PSP, CBD and 
FTDP-17. The MAPT locus is comprised of two extended LD blocks, designated H1 
and H2, and associations for the common H1 haplotype have been reported for the 
parkinsonian disorder PSP (Baker et al. 1999; Pittman et al. 2005). The region around 
MAPT has a complex linkage disequilibrium (LD) structure, and this has led to the 
suggestions that multiple susceptible genes (or alleles) could be present in this large 
LD block. For example, allele Q of saitohin gene which is contained in intron 9 of the 
MAPT  gene  is  in  complete  LD  with  H1  clade  (Levecque  et  al.  2004).  There  is 
evidence  that  the  complex  genomic  region  around  MAPT  H1  clade  acts  as  a 
susceptibility factor in PD risk, and a fine mapping of a large number of cases would 
identify the functional variant(s) modulating this risk (Zabetian et al. 2007).  [50] 
 
Homozygous mutations in glucocerebrosidase (GBA) gene cause Gaucher’s disease, a 
recessive lysosomal storage disease that is clinically recognised by liver damage, but 
can also present neurological problems, and at autopsy can reveal LBs (Hardy et al. 
2009).  The  discovery  of  GBA  as  risk  factor  for  PD  was  a  serendipitous  clinical 
observation,  where  it  was  noted  that  the  parents  and  second  degree  relatives  of 
Gaucher’s patients frequently had PD (Goker-Alpan et al. 2004). This was the first 
study  to  show  that  heterozygous  mutations  in  GBA  gene  were  a  risk  factor  for 
parkinsonism (in a familial cohort), and it was later confirmed in PD populations 
comprising  Ashkenazi  Jewish  subjects  (Aharon-Peretz  et  al.  2004;  Gan-Or  et  al. 
2008). A lack of association between GBA variants and PD in Europeans (Toft et al. 
2006; Mata et al. 2008; Sutherland, et al. 2009b)
 has been reported. However, recent 
studies  have  shown  that  GBA  mutations  confer  an  increased  risk  of  familial  and 
idiopathic PD in Europeans (Bras et al. 2009; Neumann et al. 2009; Nichols et al. 
2009).  
Search for common genetic variation and its modulation of PD risk has also been 
extended  to  PARK  interacting  partners,  transcription  factors  and  micro-RNAs 
(miRNA), although these remain to be verified. Synphilin-1, an interacting partner for 
α-synuclein  has  been  shown  to  produce  LB-  like  cytosolic  inclusions  in-vitro 
(Engelender et al. 1999). Variants in this gene have been reported in isolated PD 
cases, and the variant R621C has also been assigned a functional relevance (Marx et 
al.  2003).  A  recent  association  study  did  not  find  any  of  the  previously  reported 
synphilin-1 variants to be associated with risk for PD, although the authors did report 
a marginal association of microsatellite markers in the synphilin regions (5q21) and 
IPD (Myhre et al. 2008).  
Nuclear receptor related 1 (Nurr1/ NR4A2) functions as a transcription factor which 
has been shown to be critical for nigral DAergic cell development and differentiation 
(Martinat et al. 2006). Therefore, many studies have attempted to ascertain whether 
defects in this gene could contribute to PD. A polymorphism in intron 6 of the gene, 
(7048insG) was identified in familial and idiopathic PD patients (Xu et al. 2002; [51] 
 
Zheng et al. 2003; Hering et al. 2004), along with other heterozygous mutations (-
291delT and -245T-G) (Le et al. 2003). Subsequent studies were not able to replicate 
these findings (Zimprich et al. 2003; Ibáñez et al. 2004b; Healy et al. 2006). A recent 
investigation into PD risk-conferring polymorphism in fibroblast growth factor 20 
(FGF20), revealed a strong association with a SNP in the 3’ untranslated region of 
the  gene  (G.  Wang  et  al.  2008).  Functional  analysis  showed  that  the  risk  allele 
disrupts  a  binding  site  for  microRNA-433  (miRNA),  leading  to  an  increased 
translation  of  FGF20  both  in  vitro  and  in  vivo.  A  correlation  with  an  increased 
expression of α-synuclein in a cell-based system and in PD brains led the authors to 
suggest that common variation can alter regulation of miRNAs and could be a novel 
mechanism that modulates PD risk.  
1.6  LRRK2 – a link between familial and idiopathic PD 
Majority of PD develops as a result of complex interactions between genetic and 
environmental  agents.  Establishing  the  contribution  of  genetic  components  to  the 
development of idiopathic PD (IPD) is paramount to understanding the multifactorial 
characteristics of the disease, and the study of familial PARK loci is the first step to 
understanding these genetic contributions.  
LRRK2  was  only  identified  as  the  causative  gene  for  PARK8  linked  autosomal 
dominant PD in 2004, however, it has come to be regarded as a key player in both the 
familial and idiopathic forms of the disease. Many pathogenic variants have since 
been identified in LRRK2 (see Figure 1.6, reviewed in (Lesage & Brice 2009)). The 
pathogenic  G2019S  mutation  in  LRRK2  is  the  most  common  cause  of  hereditary 
LRRK2 associated PD, accounting for 3 per 100,000 PD cases in white population 
(based on an estimate of 200 per 100,000 with a hereditary PD rate of 15% by the 
International LRRK2 Consortium (Healy et al. 2008)). The widespread frequency of 
G2019S mutation amongst IPD cases has resulted in it being termed as a common 
risk factor for non-familial PD (see Table 1.2). The variant R1441G is frequently 
reported in Spanish PD subjects of the Basque origin (Mata et al. 2005), and the 
variants G2385R and R1628P have also been identified as risk factors in Chinese [52] 
 
populations (Tan et al. 2007a). The identification of genetic variation in LRRK2 as 
susceptibility  factors  in  IPD  subjects,  qualifies  this  mendelian  gene  as  a  major 
candidate in bridging the gap between familial and idiopathic PD.  
1.6.1  LRRK2 gene structure and function 
As previously mentioned, the LRRK2 gene contains 51 exons that span 144 kb. A 9kb 
mRNA transcript has been identified in various tissues including the brain, and is 
predicted to encode a ~250 kDa (2,482-amino acids) multi-domain protein that is 
expressed in various tissues including the brain (Zimprich et al. 2004b; Paisán-Ruíz 
et  al.  2004).  The  LRRK2  protein  belongs  to  the  ROCO  superfamily  that  contain 
functional domains of ROC (Ras of complex proteins), COR (C-terminal of ROC), 
followed  by  a  kinase  domain  belonging  to  the  mitogen-  activated  protein  kinase 
kinase kinase (MAPKKK) subfamily (see Figure 1.6), but the LRRK2 kinase domain 
has also been suggested to have structural similarities with the receptor-interacting 
protein kinases (RIPK) (Greggio & Cookson 2009). These functional domains are 
flanked by armadillo, ankyrin and 13 leucine rich repeats at the N-terminus and 7 
WD40  repeats  at  the  C-terminus  which  serve  as  modules  for  protein-protein 
interactions (Guo et al. 2006). The LRRK2 paralog LRRK1 has an identical domain 
structure, but a smaller N-terminus than LRRK2, and is also widely expressed in brain 
and  other  tissues  (reviewed  in  (Mata  et  al.  2006a)).  Both  genes  are  reportedly 
conserved in vertebrates, and may have diverged from a common ancestral LRRK 
ortholog.  
 [53] 
 
 
 
Figure 1.6: A schematic representation of the functional domains and genetic variation in the LRRK2 gene. The 51 exons of LRRK2 encode 
2527 amino acids, and the functional domains which are conserved comprise of: Armadillo (ARM), Ankyrin repeat (ANK), leucine rich repeat 
(LRR), Ras of complex proteins: GTPase (Roc), C-terminal of Roc (COR), mitogen activated kinase kinase kinase (MAPKKK) and WD-40 
domains. The exons and the variants identified in them are numbered above the gene line. The variants in red and bold represent recurrent proven 
pathogenic mutations, whereas the potentially pathogenic mutations (which display cosegregation), are highlighted in bold. Risk factors are shown 
in blue and in hatched box. Variants of unknown significance are represented in blue and in italics. This figure is adapted from (Lesage & Brice, 
2009). [54] 
 
The multi-domain complex of LRRK2 allows two distinct enzymatic activities, 
namely, GTPase and kinase. The ROC domain of LRRK2 shares homology with 
the Ras related GTPase superfamily, responsible for regulating diverse cellular 
processes, such as mitogenic signalling (Guo et al. 2006). The activation of the 
Ras related GTPase requires a conversion of the GDP-bound state to the GTP-
bound conformation. The GTPase binding domain of LRRK2 is necessary for the 
protein’s  kinase  activity  as  it  is  predicted  to  stimulate  LRRK2 
autophosphorylation. Mutations R1441C/G in the GTPase domain, disrupt GTP 
hydrolysis which subsequently alters the downstream enzymatic activity of the 
protein (Lewis et al. 2007; Li et al. 2007)
 . A crystal structure of the LRRK2 ROC 
domain (in complex with GDP-Mg
(2+)) was recently predicted to display a dimeric 
fold which is stabilised by complex interactions and extensive domain-swapping 
of two monomers (Deng et al. 2008). Pathogenic mutations (R1441 and I1371) 
disrupt  the  ROC  dimer  resulting  in  decreased  GTPase  activity.  This  led  the 
authors to conclude that the ROC domain regulates LRRK2 kinase activity as a 
dimer, possibly via the COR domain acting as a molecular hinge (Deng et al. 
2008). 
 
The  kinase  domain  of  the  protein  remains  inactive  until  a  change  in  the 
confirmation of the activation segment within the large C-terminal lobe is induced 
by  phosphorylation  (auto-  or  exogenous)  (Mata  et  al.  2006a).  This  enables 
substrate access and catalysis. The activation segment is found between conserved 
tripeptide  motifs  DF/YG  and  APE,  and  the  LRRK2  mutations,  G2019S  and 
I2020T lie at the N-terminal boundary of this segment (Mata et al. 2006a). By 
using myelin basic protein (MBP) as a test substrate, West and colleagues (2005) 
measured the activity of LRRK2 protein, and determined that it possesses mixed-
lineage kinase (MLK) activity (West et al. 2005). LRRK2 protein has also been 
demonstrated to undergo autophosphorylation, where the intrinsic GTP binding 
activity  modulates  downstream  kinase  activity  (Smith  et  al.  2006;  West  et  al. 
2007). Other regulatory sequences suggested to modulate the kinase activity of 
LRRK2,  include  the  N  and  C-termini.  The  N-terminus  of  LRRK2  has  been 
suggested to have an inhibitory effect (Greggio et al. 2008), and C-terminal tail is [55] 
 
required  for  full  kinase  activity  (Jaleel  et  al.  2007)  (reviewed  in  (Greggio  & 
Cookson 2009)). 
A knockdown of  LRRK2 in a DAergic neuroblastoma  cell line induced using 
RNA interference (RNAi), identified a transcriptional downregulation of genes 
involved  in  various  functions,  namely,  axonal  guidance,  nervous  system 
development,  cell  cycle,  cell  growth,  cell  differentiation,  cell  communication, 
MAPKKK cascade, and Ras protein signal transduction (Häbig et al. 2008). This 
suggests that LRRK2 might have an important physiological role. The presence of 
Ras/GTPase and kinase domains provide support for the LRRK2 protein being 
involved  in  upstream  regulation  of  intracellular  signalling,  such  as  the  MAP 
kinase  pathways.  These  pathways  are  evolutionary  conserved  three-tiered 
signalling cascades where each kinase activates the subsequent kinase (Mata et al. 
2006a). Activation of MAPKKK by Ras starts a chain of events, whereby, the 
extracellular  signal  from  receptor  is  relayed  to  cytosolic  kinases  by 
phosphorylation  and  subsequent  activation  of  MAPKK  (MAPK/ERK  kinase), 
which in turn phosphorylates and activates MAPK (Guo et al. 2006). Substrates of 
MAPK  activation  include  transcription  factors,  mitochondrial  and  cytosolic 
proteins  and  nuclear  substrates  for  various  cellular  functions.  Investigation  of 
LRRK2  substrates  and  interacting  partners  would  help  define  the  regulatory 
pathways it participates in. Studies have already reported on the potential LRRK2 
interactors that can be grouped into proteins that induce a chaperone-mediated 
response,  proteins  associated  with  the  cytoskeleton  and  trafficking,  and 
phosphorylation and kinase activity (Dächsel et al. 2007a). For example, LRRK2 
has been shown to phosphorylate moesin, an actin- binding ERM (ezrin, radixin 
and moesin) protein that has been implicated in neurite outgrowth (Jaleel et al. 
2007). The substrates for LRRK2 have been identified using the in-vitro kinase 
assays, and still remain to be tested for physiological relevance in in-vivo kinase 
assays. In-vivo kinase assays are technically demanding, but Imai and colleagues 
(2008) have identified what could be an authentic in-vivo substrate for LRRK2 
(Imai  et  al.  2008).  The  authors  showed  that  4E-BP,  a  repressor  of  protein 
translation  that  is  affected  by  oxidative  stress  and  other  stimuli,  is  prime [56] 
 
phosphorylated by LRRK2, and that drosophila LRRK2 (dLRRK2) modulates the 
maintenance of DAergic neurons by regulating protein synthesis in this pathway.  
1.6.2  LRRK2 and neurodegeneration 
LRRK2 protein has been shown to have a cytoplasmic localisation, and occurs in 
a  soluble  state  in  the  normal  brain  (Giasson  et  al.  2006).  Studies  have  been 
published evaluating the morphological expression of LRRK2 mRNA and protein 
in  post-mortem  human  brain  (discussed  in  later  chapters).  Differences  in  the 
transcriptional  activity  of  LRRK2  in  post-mortem  human  brains  have  been 
reported,  although  there  is  only  limited  information  available  on  this.  LRRK2 
protein has been shown to localise to LBs, however, this is heavily dependent on 
the  antibody  used  for  immunohistochemical  studies  and  currently  remains  a 
contentious issue.  
The centromeric region for PARK8 locus also mapped onto dementia with late 
onset familial Alzheimer’s disease (Scott et al. 2000). A G2019S mutation carrier 
with frontotemporal lobar degeneration (FTLD) was identified with ubiquitinated 
intranuclear  neuronal  inclusions,  but  due  to  the  reduced  penetrance  of  the 
mutation, it cannot be said whether the mutation is an underlying cause of the 
disease (as a disease modifier) or purely co-incidental (Dächsel et al. 2007b). The 
possibility  of  LRRK2  being  involved  in  other  neurodegenerative  diseases  was 
further demonstrated in the brains of frontotemporal dementia with parkinsonism-
17 (FTDP-17) and MSA diagnosed patients (Miklossy et al. 2007; Huang et al. 
2008). Miklossy and colleagues demonstrated that LRRK2 is associated with tau-
positive neuronal and oligodendroglial inclusions (coiled bodies) in the brains of 
frontotemporal dementia of the pallido-ponto-nigral degeneration type linked to 
the  chromosome  17  (FTDP-17/PPND)  (Miklossy  et  al.  2007).  As  mentioned 
previously, LRRK2 variants produce clinical and pathological features reminiscent 
of other parkinsonian entities (see section 1.5.2.1.7). This favours a possible role 
for LRRK2 in tauopathies, despite a lack of genetic variants.  
Identification  of  G2019S  mutation  in  a  patient  diagnosed  with  frontotemporal 
lobar  degeneration  with  ubiquitinated  neuronal  intranuclear  inclusions  (FTLD-
U/NII), lends support to the notion that LRRK2 might be involved in the UPS [57] 
 
system,  and  like  ubiquitin  might  play  a  central  physiological  role  in 
neurodegeneration (Dächsel et al. 2007b). LRRK2 was reportedly identified in 
glial cytoplasmic inclusions (GCIs) of MSA patients, which typically contain α-
synuclein (Huang et al. 2008). Interestingly, LRRK2 protein has been shown to 
phosphorylate  α-synuclein  in-vitro  (Qing  et  al.  2009).  The  wild-type  LRRK2 
protein  has  been  shown  to  form  cytoplasmic  aggregates  which  are  greatly 
ubiquitinated upon interaction with parkin (Smith et al. 2005a). 
The interaction of LRRK2 with other PARK loci (dominant and recessive), and its 
implication in both synucleino- as well as tauopathies, suggests that it might play 
an  important  role  in  various  pathways.  However,  the  extent  to  which  LRRK2 
might contribute to these pathways, common or otherwise, remains to be seen. 
1.6.3  LRRK2 G2019S mutation in PD  
The G2019S (6055G->A) mutation occurs in exon 41 of LRRK2 and substitutes 
glycine  to  serine.  It  accounts  for  3-6%  of  FPD  and  1-2%  of  IPD  cases  in 
Europeans (Gilks et al. 2005; Nichols et al. 2005; Di Fonzo et al. 2005). G2019S 
associated  PD  is  asymmetrical,  tremor-predominant  parkinsonism  with 
bradykinesia and rigidity that responds to dopamine replacement (Hernandez et al. 
2005; Goldwurm et al. 2006). 
1.6.3.1 LRRK2 G2019S mutation and ‘gain- of function’ 
In-vitro kinase assays using full length recombinant LRRK2 protein have shown 
an increase in the kinase activity of mutant (G2019S) LRRK2 in comparison to 
the wild-type protein (Smith et al. 2005a; West et al. 2005). G2019S mutation has 
also been shown to form inclusion bodies, and cause neuronal degeneration in 
SH-SY5Y neuroblastoma cells and mouse primary cortical neurons (Smith et al. 
2005a).  Replacing  the  kinase  domain  with  a  ‘kinase-dead’  version  blocks 
inclusion body formation and delays cell death, thereby supporting the notion that 
increased kinase activity results in neuronal toxicity (West et al. 2005; Greggio et 
al. 2006). Over-expression of wild-type and mutant (G2019S) LRRK2 has been 
shown  to  reduce  the  neurite  length  and  branching  in  primary  neuronal  cell 
cultures,  whereas  LRRK2  deficiency  results  in  increased  neurite  length  and 
branching (MacLeod et al. 2006). Neurite shortening has also been reported in [58] 
 
differentiated  SH-SY5Y  transfected  with  G2019S  mutant-  LRRK2,  which  was 
also shown to exhibit an increase in autophagic vacuoles (Plowey et al. 2008). 
This  observation  in  addition  to  the  sequence  similarity  of  LRRK2  to  receptor 
interaction  protein  kinase  (RIPK)  family,  led  the  authors  to  hypothesize  that 
LRRK2  is  involved  in  MAPK/ERK  signalling.  This  hypothesis  was  later 
confirmed in two cellular models (HEK293 and SH-SY5Y), whereby the authors 
demonstrated that wild-type LRRK2 protein is involved in the activation of the 
ERK  pathway,  and  also  confers  protection  in  response  to  hydrogen  peroxide 
mediated oxidative cellular stress (Liou et al. 2008).   
This ‘gain-of-function’ mechanism for G2019S- linked pathogenesis is not limited 
to cellular models, and has to some extent been recapitulated in an animal model 
too.  Adult-onset  loss  of  DAergic  neurons,  locomotor  dysfunction,  and  early 
mortality associated with expression of wild-type and G2019S mutant LRRK2 
protein  has  been  reported  in  transgenic  D.  melanogaster  (Liu  et  al.  2008). 
Expression  of  wild-type  and  mutant  LRRK2  protein  in  photoreceptor  cells 
resulted  in  retinal  degeneration,  and  L-dopa  treatment  improved  locomotor 
impairment but did not prevent the loss of DAergic cells in the mutant flies. The 
G2019S  mutant-LRRK2  protein  was  observed  to  cause  a  more  severe 
parkinsonism-like phenotype than the wild-type protein in the drosophila model. 
This is in contrast to the clinical findings observed by the International LRRK2 
Consortium who reported that “LRRK2 G2019S PD is less severe than IPD and 
requires dopamine replacement treatment later than IPDs, and were less prone to 
drug induced dyskinesia” (Healy et al. 2008). 
Based on the in-vitro ‘gain-of-function’ studies, LRRK2 kinase inhibitors have 
been suggested as potential therapeutics for LRRK2-linked PD. However, the core 
clinical  and  pathological  phenotypic  features  for  PD  subjects  with  G2019S 
mutation  are  indistinguishable  from  IPD,  and  there  is  no  difference  in  the 
symptoms  of  homozygous  or  heterozygous  carriers  of  the  G2019S  mutation 
(Ishihara et al. 2006). No difference was observed in striatal dopamine transporter 
binding  [
123Ioflupane]  analysis  of  G2019S  mutation  carriers  and  IPD  patients 
(Isaias  et  al.  2006).  Moreover,  no  specific  biochemical  differences  in  the 
phosphorylation  and  levels  of  signal  transduction  proteins  were  reported  in [59] 
 
leukocyte  extracts  of  G2019S  PD  versus  IPD  subjects  (White  et  al.  2007). 
However, identification of physiological substrates and interactors of LRRK2 is 
needed in order to better understand the in–vitro and in-vivo kinase activity of 
wild-type and mutant LRRK2.  
1.6.3.2 G2019S penetrance 
Typically associated with late onset PD symptoms (mean age of onset of 57.5 
years) (Healy et al. 2008), rare cases of G2019S mutation carriers with early onset 
(<50 years) PD have also been reported (Bras et al. 2005; Clark LN et al. 2006; 
Punia et al. 2006; Ferreira et al. 2007). The penetrance of G2019S mutation has 
increasingly  come  into  question  as  reports  have  identified  G2019S  mutation 
carriers who do not develop parkinsonian symptoms well into their 80s, and in 
some  instances  remain  unaffected  throughout  their  lifetimes  (Kay  et  al.  2005; 
Eblan  et  al.  2006;  Saunders-Pullman  et  al.  2006).  The  penetrance  levels  of 
G2019S mutations were initially estimated to be 17% at the age of 50, increasing 
to 85% at the age of 80 years (Kachergus et al. 2005). Another study estimated the 
G2019S penetrance in a selected autosomal dominant series from North Africa 
and Europe (probands included in the analysis) to be 33% at age 55, and 100% at 
75 (Lesage et al. 2005b). A lower estimation of G2019S penetrance (17% at 50 
years, 54% at 70 years) in a family of Italian origin has been reported (Goldwurm 
et al. 2007). This variability in penetrance (lifetime penetrance of 32% (at age 80), 
among families, albeit estimated using different study designs (including multiple 
affected  members  versus  single),  suggests  that  other  genetic  or  environmental 
factors  play  a  part  in  modifying  the  penetrance  of  G2019S  mutation  and  its 
function in PD development.  
The  International  LRRK2  Consortium  pooled  worldwide  data  to  address  many 
important clinical questions related to LRRK2 mutations but also to assess the age- 
specific cumulative risk of PD for G2019S mutation carriers in a sample size of 
19,376 unrelated PD patients from various populations (Healy et al. 2008). They 
estimated that a G0219S mutation carrier has a 28% risk of developing PD at the 
age of 59 which increases to 51% at 69 years, and 74% at the age of 79, and this 
did not differ according to gender or ethnicity (Healy et al. 2008). This revised but 
reduced penetrance explains the high prevalence of LRRK2 mutations in PD, and [60] 
 
its  occasional  occurrence  in  controls.  They  also  estimated  that  8%  of  LRRK2 
mutation  carriers  developed  PD  symptoms  before  the  age  of  40  years  but 
symptoms were rare in G2019S mutation carriers before the age of 40.  
1.6.3.3 Worldwide frequency of LRRK2 G2019S mutation 
The frequency of G2019S mutation is highly population specific but a worldwide 
carrier rate of 1% in IPDs (n=14,253), and 4% in patients with hereditary PD (n= 
5,123) has been estimated (Healy et al. 2008). The highest frequency of G2019S 
mutation  related  PD  cases  has  been  reported  in  North  African  Berbers  and 
Ashkenazi  Jews  with  proportions  of  up  to  30-40%  and  18-30%,  respectively 
(Ozelius et al. 2006; Lesage et al. 2006; Healy et al. 2008).  
Amongst European populations, low frequencies of this mutation are observed in 
FPD  patients  from  Northern  Europe  (~1%),  intermediate  frequency  (1.9%)  in 
selected  Italian  populations,  and  high  frequency  in  Southern  Europe  (2.9%  in 
Northern Spain; 3.4% in Catalonia and 4.9% in Portugal) (Aasly et al. 2005; Bras 
et al. 2005; Berg et al. 2005; Hernandez et al. 2005; Gaig et al. 2006; Mata et al. 
2006b, Goldwurm et al. 2006). This led to the suggestions that G2019S mutation 
frequency displays a European north-south gradient. However, a low frequency of 
G2019S mutation in southern European populations of Greek and Italian origins 
refutes this (Spanaki et al. 2006; Cossu et al. 2007; Xiromerisiou et al. 2007; Kay 
et al. 2006; Squillaro et al. 2007; De Rosa et al. 2009). Therefore, a north-south 
gradient  of  G2019S  mutation  in  the  Iberian  Penninsula  might  be  a  more 
appropriate term to use, excepting the already known genetically distinct Basque 
population (Cavalli-Sforza & Piazza 1993), which displays a higher frequency of 
the  R1441G  LRRK2  mutation  (Gorostidi  et  al.  2009;  Mata  et  al.  2009a).  The 
G2019S mutation has also been identified in the southern American countries of 
Chile,  Brazil,  Peru  and  Uruguay,  which  were  colonized  by  European  settlers 
mainly from the Iberian Peninsula (Perez-Pastene et al. 2007; Mata et al. 2009b; 
Pimentel et al. 2008; Munhoz et al. 2008; Santos-Rebouças et al. 2008). 
In Eastern Europe, a frequency of 5.9-7.7% has been reported amongst FPD and 
0.5-0.7% in IPD patients from Russia (Illarioshkin et al. 2007; Pchelina et al. 
2008). Although this mutation is rare in Central Asia and the far East, isolated [61] 
 
cases have been reported in Japan and India (Lu et al. 2005; Tan et al. 2005a; 
Zabetian et al. 2006b; Fung et al. 2006b; Punia et al. 2006; Tomiyama et al. 2006; 
Tan et al. 2007a; Cho et al. 2007; Shojaee et al. 2009). Homozygous carriers of 
G2019S mutation are rare in Europe, but have frequently been reported in North 
African  populations,  such  as  Tunisia  and  Algeria  where  consanguineous 
marriages are common (Lesage et al. 2006; Ishihara et al. 2007; Warren et al. 
2008; Lesage et al. 2008; Hulihan et al. 2008). Although there is no difference in 
clinical  phenotypes,  or  the  age  of  onset  of  first  PD  symptom  in  heterozygous 
(ranging  from  30  to  82  years)  or  homozygous  (ranging  from  28  to  86  years) 
carriers of the mutation, a higher penetrance for G2019S homozygous carriers has 
been  reported  (Ishihara  et  al.  2006;  Lesage  et  al.  2006;  Ishihara  et  al.  2007; 
Hulihan et al. 2008; Healy et al. 2008). 
Reports of elderly and apparently healthy G2019S mutation carriers, adds a caveat 
to the potential genetic testing, and as such appropriate framework of pre- and 
post-test counselling is required for this mutation with such a variable penetrance 
(Goldwurm et al. 2007). An accurate estimation of population specific frequency 
of G2019S mutation is essential for the correct and cost-effective use of genetic 
testing and counselling of PD patients and asymptomatic carriers.  [62] 
 
 
  Population  IPD (N)  FPD (N)  Control (N) 
North Africa  Arab Berbers  39% (56)  36% (143)  <1% (739) 
Jews  Ashkenazi Jews  10% (259)  28% (78)  1% (410) 
Iberian Peninsula  Portuguese                                               
Spanish                                                                    
Basque 
4% (317)                                 
3% (806)                                 
0% (117) 
14% (85)                                
4% (283)                                 
0% (41) 
0% (100)                                             
0% (544)                               
0% (425) 
Southern Europe  Italian and Sardinian                                   
Greek                                                                 
Cretan 
2% (2516)                   
<1% (235)               
0% (174) 
4% (633)              
0% (0)              
1% (92) 
<1% (1040)             
0% (0)                  
0% (0) 
Central and 
Northern Europe 
French                                                    
German and Austrian                                      
British                                                                                  
Irish                                                                      
Swedish                       
Norwegian 
2% (300)                        
<1%(803)                         
1% (1145)                       
<1% (236)                  
2% (200)                    
1% (371) 
3% (174)                   
1% (231)                  
2% (192)                  
3% (35)                
0% (127)                  
1% (64) 
0% (348)                     
0% (436)                   
0% (1786)                    
0% (212)                   
0% (200)                  
0% (572) 
Eastern Europe  Polish                                                                  
Serbian                                                               
Russian 
0% (153)                    
0% (47)                      
1% (157) 
0% (21)                            
4% (51)           
0% (10) 
0% (190)                       
0% (161)                       
0% (126) 
Other European  North American                                                      
South American (Chilean)                                                     
Australian 
1% (2606)                    
3% (137)                     
<1% (578) 
3% (1450)                          
3% (29)                      
2% (252) 
<1% (4934)                    
0% (153)                            
0% (0) 
Asia  Indian                    
Chinese                                                       
Japanese                                                
Korean 
<1% (718)                  
0% (1360)                 
<1% (526)                  
0% (436) 
0% (82)                   
<1% (973)                  
2% (60)                
0% (17) 
0% (1200)                            
0% (938)                      
<1% (372)                     
0% (0) 
Table 1.2: World-wide carrier rate of LRRK2 G2019S mutation in PD subjects and 
unaffected controls, according to the International LRRK2 consortium (Healy et al. 
2008). This table displays the percentage carrier rates of G2019S mutation in various 
populations. IPD= idiopathic PD; FPD= familial PD; (N) = the total number of samples 
genotyped. [63] 
 
1.7  Objectives and Principal questions addressed in the thesis 
Variation in gene expression has been demonstrated to be a major driving force of 
the phenotypic evolution. Many factors work together in cis or trans to regulate 
gene expression and as such produce the phenotypic diversity so readily observed 
amongst different species. In any study of the disease aetiology, it is essential to 
establish the effects of auxiliary mechanisms that might not necessarily be the 
primary cause of the disease, but nevertheless have an impact on the eventual 
product  of  the  gene,  and  thereby  contribute  to  the  clinical  and  pathological 
understanding of the disease. The Queen Square Brain Bank (QSBB) houses an 
excellent resource for post-mortem PD tissue with detailed clinical summaries, 
and studying a measurable phenotype such as gene expression in human tissue 
that has experienced disease pathogenesis would further our understanding of PD 
pathogenesis. 
It is widely  acknowledged that the impact of  genetic variation on quantitative 
traits such as gene expression can have an effect on the overall phenotype. As 
such,  the  effects  of  genetic  variation  (coding  and  non-coding)  on  LRRK2 
expression remains a central and primary theme of this thesis.  
The  exonic  LRRK2  mutation,  G2019S  is  reported  to  be  pathogenic,  and 
biochemical studies have proposed an in-vitro ‘gain of function’ for the mutation. 
However,  the  clinical  (and  pathological)  phenotype  displayed  by  G2019S 
mutation carriers remains indistinguishable from IPD subjects that are reportedly 
negative for this mutation. Therefore, studying the gene expression in PD brains 
that suffered from idiopathic forms of the disease versus those of the G2019S 
mutational  insult  would  allow  us  to  ascertain  potential  differences  or  identify 
overlapping pathogenic events between the two forms of PD. 
Therefore, the overall hypothesis of this thesis was that differences in the LRRK2 
expression profile between unaffected controls and PD subjects could contribute 
to the development of PD, and both the coding and non-coding genetic variation 
in the LRRK2 gene could play a major role in this.  [64] 
 
The major aims used to test the hypothesis are summarised as follows: 
·  To  estimate  the  carrier  rate  frequency  of  the  common  LRRK2  G2019S 
mutation  in  unaffected  subjects  from  populations  that  might  have 
contributed to the genetic origins of G2019S mutation. 
·  To determine the distribution of LRRK2 mRNA and protein in the human 
brain, and to assess whether there is a deviation from the normal pattern in 
cases of IPD and those with G2019S mutation. 
·  To  establish  any  potential  dysregulation  in  the  mRNA  transcriptional 
levels, and to assess how this might contribute to PD pathogenesis.  
·  To ascertain if common genetic variation in LRRK2 upstream regions can 
affect the transcriptional ability of the gene.  [65] 
 
Chapter 2 [66] 
 
2  Methods and Materials 
2.1  QSBB Tissue 
Frozen post-mortem brain tissue was obtained from the Queen Square Brain Bank 
(QSBB) after acquiring ethical approval from National Hospital of Neurology and 
Neurosurgery (NHNN), Local Research Ethics Committee (LREC) (Reference: 
06/Q0512/11) and Research and Development department of University College 
Hospital  London  (UCLH)  (Reference:  06L  306).  Informed  consent  had  been 
acquired by the QSBB. All the tissue used in this study was pathologically proven 
to be IPD.  
2.1.1  Paraffin embedded tissue 
Formalin fixed brain tissue and spinal cord were processed as shown in Table 2.1. 
The processed tissue was the embedded in paraffin wax and stored until required. 
Reagent  3 Day Time 
70% Alcohol             
90% Alcohol                     
90% Alcohol 
6.00 hours                       
6.00 hours              
6.00 hours 
Absolute Alcohol                
Absolute Alcohol              
Absolute Alcohol                 
Absolute Alcohol 
6.00 hours                       
6.00 hours                   
6.00 hours                      
6.00 hours 
Chloroform          
Chloroform 
6.00 hours                      
6.00 hours 
Wax                                   
Wax                                  
Wax 
6.00 hours                      
6.00 hours                      
6.00 hours 
Table 2.1: Reagents and times used for paraffin processing of post-mortem tissue.  
 [67] 
 
2.1.2  Frozen tissue 
In order to preserve the integrity of the post-mortem tissue, it was frozen using 
polished  brass  plates,  which  were  pre-cooled  to  -70
0C.  The  tissue  was 
subsequently stored at -70
0C prior to use. The pH value of the tissue was routinely 
recorded for each subject. 
2.2  Nucleic acid extraction 
2.2.1  DNA extraction 
Genomic  DNA  was  extracted  from  human  brain  (pathology  proven),  blood 
(clinical), or buccal swab (where specified) samples using the wizard genomic 
DNA  purification  kit  (Promega,  U.K.)  described  as  follows.  960 l  0.5M 
ethylendiaminetetraacetate (EDTA) was added to 4ml nuclei lysis solution and 
chilled  on  ice.  4.8ml  of  this  mixture  was  added  to  a  frozen  piece  of  brain 
approximately 1cm
3 in size. 140 l proteinase K (at 20 mg/ml) was then added and 
the tube incubated at 55ºC for 16 hours until the brain was completely digested. 
24 l RNAse solution was added to the nuclear lysate and mixed in by inversion. 
The tube was incubated at 37ºC for 30 minutes, and then allowed to cool to room 
temperature for 5 minutes. 200 l of protein precipitation solution was added, and 
the tube vortexed vigorously for 20 seconds. The tube was chilled on ice for 5 
minutes, and then centrifuged at 13,000 rpm at room temperature for 4 minutes. 
The supernatant was carefully transferred (leaving the protein pellet behind) to a 
tube containing 4.8ml of propan-2-ol (Sigma, UK). The tube was gently mixed by 
inversion to precipitate  the DNA and then centrifuged  at 13,000  rpm at room 
temperature for 1 minute. The supernatant was carefully decanted and 4.8ml of 
70% ethanol (Sigma, UK) added. The tube was gently mixed by inversion (to 
wash the DNA pellet) and then centrifuged at 13,000 rpm for 1 minute at room 
temperature. The ethanol was carefully aspirated and the pellet air-dried (sealed 
over  with  perforated  parafilm  to  avoid  contamination).  The  pellet  was 
resuspended  in  800 l  DNA  rehydration  solution  and  incubated  at  room 
temperature  for  16  hours.  The  DNA  solution  was  stored  at  4ºC.  The  DNA 
concentration (assayed at 260 nm) and quality was measured using the NanoDrop [68] 
 
ND-1000  (NanoDrop  Technologies,  U.S.A.),  enabling  the  identification  of 
samples contaminated with protein or other organic compounds. 
2.2.1.1 DNA samples obtained through external collaborations 
For chapter 3, DNA samples from unaffected subjects of various ethnicities were 
obtained from Dr. Neil Bradman (The Centre for Genetic Anthropology, UCL) 
and have been described in previous studies (Weale et al. 2001; Thomas et al. 
2002; Behar et al. 2003; Ingram et al. 2007; Veeramah et al. 2008). For chapter 6, 
DNA  samples  from  unaffected  subjects  were  obtained  from  Prof.  Steve 
Humphries (Rayne Institute, UCL) and have been described in a previous study 
(Miller et al. 1996). 
2.2.2  RNA isolation and extraction 
The quality and quantity of isolated RNA is essential for successful analysis of 
gene expression. The RNA must be pure and intact and free of contaminants such 
as  DNA  and  other  potential  inhibitors,  for  example,  RNAses  (released  from 
membrane bound-organelles upon cell disruption). As RNA is highly susceptible 
to degradation, it is essential that endogenous RNAse activity is rendered non-
functional  by  using  strong  denaturants  in  order  to  ensure  successful  RNA 
isolation. Therefore, a sterile technique should be employed at all times when 
handling reagents and equipment used for RNA isolation.  
The tissue was homogenised in 1ml of Trizol, a monophasic solution of phenol 
and guanidine isothiocyanate (Invitrogen, UK) in tissue grind tubes (Kontes glass 
company,  UK).  The  homogenate  was  transferred  to  sterile  eppendorf  tubes.  To 
separate  different  phases,  200 l  of  chloroform  (Sigma,  UK)  was  added  to  the 
homogenate  and  shaken  vigorously  to  mix.  The mixture  was  incubated  at  room 
temperature  for  2-3  minutes  followed  by  centrifugation  at  13,000  rpm  for  15 
minutes. The centrifugation separated the mixture into three phases, and the upper 
aqueous phase which contains that RNA was transferred to a separate tube and the 
organic phase discarded. The RNA was then precipitated using 500 l of isopropyl 
alcohol (Sigma, UK) from the aqueous phase and incubated at room temperature for 
10  minutes  followed  by  centrifugation  at  13,000  rpm  for  10  minutes.  The 
supernatant was removed. The RNA pellet was washed with at least 1ml of 75% [69] 
 
ethanol. The sample was then mixed by vortexing and centrifuging at 7,500 rpm for 
5 minutes. The ethanol was removed and the pellet air dried for up to half an hour or 
until dry (sealed over with perforated parafilm to avoid contamination).  
The RNA was then dissolved in RNAse free water (70-100 l). RNA concentration 
(assayed at 260 nm) and quality was measured using the NanoDrop ND-1000 
(NanoDrop Technologies, U.S.A.). 
2.3  Genotyping 
2.3.1  Polymerase chain reaction (PCR) 
Polymerase  chain  reaction  (PCR)  was  routinely  used  to  determine  genotypes. 
PCR was developed by Kary Mullis in 1983, and has since become a common and 
an  indispensable  technique  in  molecular  biology.  It  is  a  relatively  simple 
technique that amplifies a DNA template to produce millions of copies of specific 
DNA fragments in vitro. However, to produce such specific fragments some prior 
knowledge of the sequence is required. This information is then used to design 
oligonucleotide  primers  which  are  usually  a  stretch  of  approximately  20 
nucleotides corresponding to the sequence of interest. The primers bind to the 
complementary DNA sequence (one to the strand running from 5’ to 3’ direction 
and the other to the strand running in 3’ to 5’ direction) of the denatured template 
DNA.  In  the  presence  of  a  heat-stable  DNA  polymerase  and  the  four 
deoxynucleoside  triphosphates  (dNTPs,  namely,  dATPs;  dGTPs;  dCTPs  and 
dTTPs),  the  primers  initiate  synthesis  of  new  DNA  strands  that  are 
complementary  to  the  DNA  strands  of  the  target  DNA  segment.  Each  newly 
synthesized strand then act as a template for further DNA synthesis in subsequent 
cycles, thereby doubling the amount of template each cycle. After about 25 cycles 
of DNA synthesis, the PCR product will include up to 10
5 copies of the initial 
target sequence. 
2.3.2  PCR components 
Genomic DNA (50 ng/ l) was amplified using Taq DNA polymerase kit (Qiagen, 
UK). The PCR components included 2 l 10X buffer; 4 l Q-solution; 2 l each 
primer (100nM each); 2 l deoxynucleoside triphosphates (dNTPs; 10mM each), [70] 
 
0.16 l Taq polymerase and double distilled water (ddH2O) to make up a total 
volume of 20 l. The dNTPs were obtained from Invitrogen (UK) and the primers 
were  designed  using  online  tools  available  at  http://www.cybergene.se/.  The 
primers were blasted against NCBI database to check for specificity and were 
obtained from Sigma Genosys, UK. Standard cycling conditions were used: 94° C 
for 5 minutes; and 30 cycles of 94° C for 30 seconds, 55-65°C for 30 seconds and 
72°  C  for  45  seconds;  72°  C  for  7  minutes.  Annealing  temperatures  were 
dependent  on  the  primers.  The  thermal  cycler  used  for  the  PCR  reaction  was 
GeneAmp PCR system 9700 (Applied Biosystems, UK). 
2.3.3  Restriction Fragment length polymorphisms 
Restriction digestion of amplified genomic DNA was carried out in a total volume 
of 15 l, containing 1.5 l of appropriate reaction buffer, 10 l PCR product, 1-2 
units of the restriction enzyme, and the rest of the volume was made up with 
ddH2O. However, the volume of water was adjusted accordingly upon the addition 
of 100X bovine serum albumin (BSA) and each assay was incubated overnight 
according  to  manufacturer’s  instructions.  All  the  restriction  enzymes  were 
provided by New England Biolabs, UK. The digested product was then genotyped 
using agarose gel electrophoresis. 
2.3.4  Agarose gel Electrophoresis 
Agarose gels used for analysing and genotyping DNA fragment sizes were made 
by melting agarose powder (Roche, UK) in 1X Tris-Borate- EDTA (TBE) buffer 
(121.1g Tris, 61.8g anhydrous boric acid, 7.4g EDTA in 10 litres of ddH2O) in a 
microwave oven. The gels were routinely made between 1 to 2.5% of the volume. 
The gels were cast with the addition of 10 g/ml of ethidium bromide (EtBr). In 
order to be analysed, 5 l of digested PCR product was mixed with 1 l of Orange 
G loading dye (prepared in equal volumes of glycerol and water) and run along a 
1 kb DNA ladder. The Orange G loading dye and the 1 kb DNA ladder were 
obtained from Sigma, UK and Promega, respectively. The samples were subjected 
to electrophoresis for approximately 30 to 60 minutes at 80 to 120mV. The DNA 
samples in the gel were visualised under a UV transilluminator.    [71] 
 
2.3.5  Taqman assays 
The  taqman  assay  by  design  service  for  SNP  genotyping  assays  provided  by 
Applied Biosystems was occasionally used to design probes for specific assays. 
These probes were dye-labelled with FAM and VIC. The allelic discrimination 
PCR reaction consisted of: taqman universal PCR master mix (2.5µl), 40X assay 
mix (0.125µl), genomic DNA (5-20ng) in a total volume of 5µl made up with 
ddH2O. The reaction was run on ABI7900 (Applied Biosystems, UK)  and the 
cycling  conditions  were  optimised  to  the  specific  probe.  SDS2.1  software 
(Applied Biosystems, UK) was used for allelic discrimination. 
2.4  PCR based mRNA expression studies 
Many techniques have been developed to measure the relative and absolute levels 
of gene expression in tissue. Traditionally, gene expression levels were measured 
using northern blot analysis; RNAse protection assays or in situ hybridisation. All 
of these methods have their advantages. For example, northern blot analysis can 
provide information about mRNA size, alternative splicing and the quality of the 
RNA  samples;  RNAse  protection  assays  can  map  transcript  initiation  and 
termination sites, and intron-exon boundaries; in- situ hybridisation is a complex 
technique  but  the  only  one  that  allows  identification  of  anatomical  or  cellular 
localisation of a specific transcript. The major disadvantage common to all these 
techniques is the lack of sensitivity when measuring transcripts that are expressed 
at low levels. However, recently  more high throughput, sensitive and accurate 
methods have been developed. Microarrays and quantitative PCR based methods 
are  now  routinely  used  to  measure  gene  expression  levels.  Quantitative  PCR 
based methods are especially sensitive in detecting low level RNA expression, 
and was the technique most routinely used to measure mRNA expression levels 
for the purpose of this thesis.  
2.4.1  Reverse-Transcriptase (RT-PCR) 
DNA templates are required for thermostable DNA polymerases used in the PCR 
process, therefore in theory, limiting the technique to DNA studies. However, this 
technique could also be applied to the analyses of RNA populations by reverse 
transcribing  RNA  to  complementary  DNA  (cDNA).  This  reverse  transcription [72] 
 
provides the necessary DNA template for the thermostable DNA polymerases to 
perform the PCR. Either random primers, oligo(dT) primers or sequence specific 
primers can be used for reverse-transcription. However, the quality and purity of 
starting RNA template are essential for a successful RT-PCR reaction and any 
subsequent analysis. After the initial reverse transcription step, where the RNA 
has been converted into cDNA, basic PCR can be performed to amplify the target 
sequence many-fold. 
RNA was reverse transcribed to form cDNA using the First-Strand cDNA synthesis 
Superscript II RT (Invitrogen, UK) kit. The reaction constituted 2µg of total RNA, 
1µl random hexamers, 1µl dNTP mix (10mM each) and 8µl sterile ddH2O. The 
mixture was heated to 65° for 5 minutes, followed by a quick chill on ice. The 
contents  were  then  centrifuged  and  the  remaining  cDNA  synthesis  mixture  was 
added which included 4µl of 5X First-Strand Buffer, 2 l of 0.1 M dithiothreitol 
(DTT),  followed  by  1µl  of  RNAse  OUT.  The  contents  were  then  mixed  and 
incubated at 25°C for 2 minutes. 1µl (200 units) of SuperScript II RT was added and 
the mixture was incubated at 42°C for 50 minutes, followed by 70°C for 15 minutes 
to  inactivate  the  reaction.  The  cDNA  was  further  diluted  1  in  10  in  Diethyl 
pyrocarbonate (DEPC) treated water (Ambion, UK) to make up a working stock. 
2.4.2  Quantitative real Time PCR (qPCR) 
Quantitative  real-time  polymerase  chain  reaction  (qPCR)  is  a  technique  that 
quantitates the fluorescence emitted each PCR cycle (in real time). Methods used 
to  detect  and  quantitate  a  PCR  product,  involve  fluorescently  labelled 
oligonucleotide  probes  or  DNA-binding  fluorescent  dyes,  for  example,  SYBR 
green that intercalates with double stranded DNA as it is being synthesized. 
The  DNA  binding  fluorescent  dyes  are  easy  to  use  and  do  not  require  the 
oligonucleotide  primers  to  be  labelled,  however,  they  can  also  generate  non-
specific  products.  In  order  to  check  the  amplicon  homogeneity,  thermal  melt 
curves can be generated that allow the product to form a double-stranded DNA at 
a  lower  temperature  of  60°C  (fluorescence  is  quenched  when  the  product  is 
double-stranded). The temperature is slowly ramped up to 95°C to be denatured. 
Any potential peaks with different melting temperatures and/or broad peaks in the [73] 
 
melt curve are indicative of multiple products or non-specific amplification. This 
serves as a good quality control during routine use of this particular application of 
PCR. 
Fluorescence values are recorded during every cycle, however, the first significant 
increase in the florescent signal (above the background noise) is measured at the 
threshold cycle (Ct). The Ct values directly correlate to the initial amount of target 
template, that is, the amount of RNA in the sample. This Ct value is recorded 
during the exponential phase of amplification, and is fundamental to qPCR. It 
works on the premise that a sample with high concentrations of starting template 
will require fewer amplification cycles to cross the critical threshold cycle where 
the fluorescent will be quantitated (Bustin et al. 2005). However, if there is little 
template to start off with, then many rounds of amplification would be required to 
reach that critical threshold cycle. As the Ct value is inversely proportional to the 
initial copy number, a standard curve can be generated by plotting the Ct values 
against  the  logarithm  of  initial  copy  numbers.  The  linear  regression  of  the 
standard  curve  allows  the  target  Ct  to  be  directly  compared  to  the  Ct  of  the 
standard  calibrator,  resulting  in  the  quantitation  of  the  original  amount  of  the 
template,  which  could  be  recorded  as  having  more  or  less  mRNA  than  the 
standard.   
Factors like fluctuations in the efficiency of the reaction, small initial quantities of 
the target RNA, non-specific priming, and slow degradation of the reaction mix 
add to the disparities associated with qPCR (Bustin et al. 2005). Therefore, it is 
essential that the assay is well optimised and reproduces with same efficiency 
across  the  plates.  Multiple  Ct  values  should  be  determined  by  performing  the 
reaction in triplicates for each sample.  
The qPCR in this thesis was performed on ABI7500 (Applied Biosystems, UK) 
using  SYBR-green  dye  mix  that  releases  fluorescence  during  the  critical 
threshold,  allowing  for  an  accurate  quantitation  of  the  initial  RNA  starting 
template. The 25 l reaction required 5 l of cDNA (50ng/ l), 12.5 l SYBR-green, 
2.25 l  primers  (900nM)  and  3 l  ddH2O.  The  SYBR-green  dye  mix  and  the [74] 
 
MicroAmp  Optical  96-well  reaction  plates  were  both  supplied  by  Applied 
Biosystems. 
2.4.2.1 Primer sequences and conditions 
The cDNA primers were designed so as to have at least one of the primers on an 
exon-exon boundary. This minimises any contamination through the amplification 
of genomic DNA. They were designed so as to amplify the predicted transcripts 
for that gene. The cycling conditions, apart from the annealing temperatures were 
similar for all the target genes: 50° C for 2 minutes; 95° C for 10 minutes; and 35 
cycles of 95° C for 15 seconds, 55-65°C for 30-45  seconds and 72° C for 45 -60 
seconds. A dissociation curve was added at the end of each reaction to determine 
that a single specific PCR product was being formed by the primers: 95°C for 15 
seconds; 60°C for 1 minute and 99°C for 15 seconds. A single peak for all the 
samples at the same temperature ensures all the product is dissociating at the same 
temperature ensuring only one product. The qPCR products were also checked on 
agarose gels to ensure the presence of a single product.  
2.4.2.2 Standard curve v/s Ct 
Triplicate  reactions  were  run  for  each  sample.  The  plates  for  each  gene  were 
calibrated using the same sample to ensure that the Ct values remained consistent 
across the plates. The samples were quantitated against a standard curve generated 
from reactions containing serial dilutions of human brain for each target gene. 
Six-fold  serial  dilutions  of  a  calibrator  template  were  used  for  the  relative 
quantitation, with the highest dilution being 500 fold of the lowest. The dilutions 
were as follows: 500, 100, 20, 4, 2 and 1 fold of the lowest. The Ct values of these 
serial dilutions were used to construct the standard curve, which was generated 
using the SDS2.0 software (Applied Biosystems, UK).  
2.4.2.3 Normalisation 
The  normalisation  of  target  gene  expression  is  essential  to  account  for  any 
inherent variations between and within cDNA samples. This is achieved by the 
use of an endogenous reference gene. This reference gene should be expressed 
invariantly in all tissues of an organism. The use of reference genes corrects for 
any potential sample variations and increases the reliability of qPCR by taking [75] 
 
into  account  the  amount  of  starting  materials,  inherent  variation  in  RNA  and 
cDNA sample loading variation between the samples etc (Gutala & Reddy 2004).  
2.4.2.3.1  Endogenous reference genes and normalisation factor 
In  this  study,  four  endogenous  reference  genes  were  used  to  normalise  the 
expression  of  our  gene  of  interest,  and  are  mentioned  as  follows:  Ribosomal 
Protein L13a (RPL13A) (Jesnowski et al. 2002); Hypoxanthine Phosphoribosyl-
transferase 1 (HPRT1), (Meldgaard et al. 2006); TATA binding protein (TBP), 
and  Glucose  6  –phosphate-1-dehydrogenase  (G6PD)  (Ohl  et  al.  2005).  The 
relative  abundance  values  for  the  reference  genes  were  calculated  for  each 
experimental sample. 
2.4.2.3.2 Calculation of normalisation factor 
The data produced by qPCR can give rise to spurious results if an appropriate 
normalisation factor is not calculated. Despite using four endogenous reference 
genes it was important to determine which of these reference genes behaved in a 
dissimilar pattern in affected and unaffected tissue. It is also possible that different 
reference  genes  have  varied  expression  levels  in  different  anatomical  regions. 
Therefore, it was important to use more than one reference gene to calculate a 
normalisation factor. The software, NormFinder employs a model based approach 
to identify the reference genes that present the least amount of variation in the 
dataset (Andersen et al. 2004). The algorithm used in this software requires the 
use of a minimum of three reference genes. It then estimates the variation in the 
reference genes in cases as well as control samples, and selects the reference gene 
with  the  best  stability  value  or  a  combination  of  two  best  reference  genes.  A 
geometric mean of these two best reference genes is calculated (to account for any 
outliers) for each sample, giving rise to a virtual reference gene. Therefore, when 
affected and unaffected  subjects were compared the NormFinder software was 
used to identify the reference genes with the least amount of variation.  
In order to normalise each target gene sample, the relative value obtained for the 
target gene was divided by the value of the virtual reference gene. Since a large 
number of samples were used in the study and a triplicate for each sample was 
included, it was not possible to perform the reaction for all the samples on a single [76] 
 
plate. Therefore, in order to normalise the samples across the different plates the 
following steps were used: 
Step 1, normalisation of individual samples to its reference gene: 
 Internal normalisation of each sample, X =   Gene of interest 
                                          Virtual reference gene 
(where X is the sample) 
Step 2, calculation of a normalisation factor:  
Final normalisation factor, Nf  =     1      X1+ X2+ X3.........Xi  
       N 
(where N refers to the total number of subjects, i refers to the sample number and 
Nf  is essentially a mean of all the samples that have been normalised in step 1) 
Step 3, use of the normalisation factor from step 2 to normalise the samples 
across the different plates: 
Final normalised value for each sample =   Xi 
Nf   
 [77] 
 
 
2.5  Histochemical techniques 
2.5.1  In situ hybridisation protocol 
PCR  based  methods  are  highly  sensitive  at  detecting  low  levels  of  mRNA, 
however, these methods cannot distinguish between different cellular populations. 
Laser-capture microdissection techniques can be used to isolate single cells of 
specific  population,  and  quantitative  PCR  can  be  performed  on  RNA  isolated 
from these specific populations. The RNA yield from such a technique can be low 
and  this  limits  the  number  of  experiments  that  can  be  performed.  There  are 
various  techniques  that  can  quantitate  mRNA  expression.  However,  in  situ 
hybridisation  (ISH)  remains  the  only  method  that  enables  the  morphological 
demonstration of specific mRNA or indeed DNA sequences in tissue sections, 
individual  cells,  or  chromosomal  localisation.  Therefore,  in  situ  hybridisation 
studies were used to determine the cellular localisation of LRRK2 mRNA and to 
complement the qPCR study. 
As  ISH  can  be  used  to  identify  the  localisation  of  a  specific  RNA  or  DNA 
sequence in a hetrogenous cell population, it is possible to determine whether a 
gene is being expressed at low levels in all the cells or at a high level in a few 
cells. This is especially useful if cerebral tissue sections are being used, as many 
regions of the brain are composed of different cellular populations. ISH works on 
the principle that under appropriate conditions, stable hybrids can be formed by 
hybridising  labelled,  single-stranded  fragments  of  RNA  (or  DNA)  containing 
complementary sequences (probes) to the target RNA (or DNA) of interest. These 
stable hybrids can then be visualised using a detection system. ISH is technically 
demanding and can be complicated by non-specific binding that can increase the 
background  noise,  thereby  reducing  the  signal  to  background  ratio.  Hence,  an 
extensive optimisation of the protocol is required. 
Different methods were used to look at the expression profile of LRRK2 in post-
mortem  human  tissue.  The  oligonucleotide  probes  were  labelled  using  both 
radioactive (
35S) and non-radioactive (digoxigenin) label. Both procedures have [78] 
 
their advantages and the following sections will discuss the protocol used for the 
LRRK2 ISH study discussed in this thesis. 
ISH is a procedure that requires careful handling of tissue sections and reagents 
prior  to  hybridisation  as  any  contamination  could  have  drastic  effects  on  the 
development of the mRNA signal. The tissue sections should be handled in an 
RNAase-free environment right up until the time they have been hybridised and 
washed. It was essential that all glassware was baked at 400°C and only sterile 
plastic  was  used.  The  reagents  were  made  in  diethyl  pyrocarbonate  (DEPC)-
treated  or  sterile  water,  as  appropriate.  Any  unbaked  glassware  or  non-sterile 
plastic was rendered RNAase-free by washing in 0.1M NaOH and subsequently 
with sterile water. 
2.5.1.1 Tissue samples 
Flash  frozen  tissue  was  removed  from  -80°C  freezer  and  placed  in  a  cryostat 
(Bright) at -20°C for two hours in order for the temperatures to equilibrate prior to 
cutting. The frozen sections were cut at 12µm, and depending on the size of the 
section collected they were mounted onto either superfrost slides (BDH, UK) or 
vectabond coated slides (Vector, UK). The blade was cleaned with three changes 
of absolute alcohol to avoid any cross contamination of mRNA between different 
samples. The sections were allowed to dry on a hot plate for 30 minutes and then 
stored at -80°C until further use.  
2.5.1.2 Labelling method 
The probes used for the ISH procedure were labelled using 
35S (radioactive) and 
digoxigenin  (non-radioactive)  labelling  methods.  Appropriate  positive  controls 
were used for the study 
2.5.1.2.1  Radioactive labelling and probe purification 
Oligonucleotides were 3' end-labelled with [
35S] dATP 1000Ci/mmol (Perkin 
Elmer, UK). This was done using terminal deoxynucleotide transferase at 500- 
1000 units/ml in cacodylate buffer at 37
0C for 60 minutes, according to the  
manufacturer's protocol (Promega, UK). Reactions were stopped by addition of  
TE  buffer  (10mM  Tris,  1mM  EDTA)  at  pH  8.0  to  a  total  volume  of  100 l. 
Unincorporated bases were separated from the labelled probe on G50 sephadex [79] 
 
columns, which were equilibrated in TE pH 8.0. These columns were prepared to 
2ml by volume in 2.5ml sterile syringes and plugged with baked glass wool. The 
column was washed gently with 2 x 1ml TE pH 8.0. The radioactively labelled 
probe in TE was added to the top of the column and the column was further 
washed in 3 x 200 l TE; 2 x 400 l TE (these fractions should contain about 50-
70% of the probe), and final washes of 3 x 200 l TE. These were collected as 
separate fractions. Elution characteristics of each batch of G50 sephadex were 
determined  prior  to  the  probe  purification  by  taking  2 l  aliquots  from  each 
fraction and measuring them for radioactive peaks using scintillation counter. 
 
24 l of tRNA (8.33 mg/ml in water, from Brewer’s yeast), 42 l sodium acetate 
(3.0M, pH 5.2) was added to the fractions that gave the highest radioactive peaks. 
950  l of ethanol at -20 °C was added to the mix and incubated at -70°C for 120 
minutes or -20°C overnight. The tubes were spun at 13,000 rpm, for 30 minutes at 
4
0C. The supernatant was decanted and precipitated with cold ethanol. The tubes 
were allowed to dry and the precipitates were combined by quantitative transfer in 
100 l of 10mM Tris, 1mM EDTA, pH 7.6, 10mM dithiothreitol (DTT) and stored 
at 4°C. 
2.5.1.2.2  Digoxigenin labelling 
The probes were labelled at a total concentration using the Digoxigenenin 3’ end 
labelling kit (Roche, UK). A total of 100pmol of the probe was labelled using 4 l 
of the reaction buffer; 4 l of cacodylate buffer; 1 l of terminal transferase and 1 l 
of dATP, with the rest being made up to 20 l double distilled RNAse free water. 
The reaction was incubated at 37°C for 1 hour and 2 l of 0.8M sterile EDTA was 
added  to  stop  the  reaction.  The  labelling  efficiency  was  measured  by  blotting 
serial dilutions of the labelled probe, along with a known control probe supplied 
with  the  kit.  The  visualisation  procedure  was  carried  out  according  to  the 
manufacturer’s instructions. 
 
 [80] 
 
2.5.1.3 Tissue preparation 
The sections were prepared using the following steps in an RNAase free 
environment. The slides were allowed to thaw, flat and face-up for 10 minutes,  
and were then fixed in 4% paraformaldehyde in PBS (w/v) at room temperature 
for 5 minutes. The slides were then washed twice in PBS, 2 minutes and 1 minute 
per wash, followed by a wash in physiological saline for 1 minute. The sections 
were then dehydrated by immersion in 70%, 80% and 95% ethanol in DEPC-
treated water for 2 minutes each and allowed to air-dry for a minimum of 30 
minutes 
2.5.1.4 Hybridisation 
The  hybridisation  buffer  (Sigma,  UK)  was  warmed  to  room  temperature.  The 
radioactively labelled probe was diluted at 10 l/ml in hybridisation buffer. DTT 
was  added  to  hybridisation  buffer  to  a  final  concentration  of  1mM.  The 
digoxigenin labelled was probe was diluted at 250fmol/ l and no DTT was added 
to this. Diluted probe was evenly layered over slides and covered with parafilm 
coverslips (75-100 l per small section and 150-200 l for the larger ones). The 
slides were then incubated at 42°C overnight.  
2.5.1.5 Washing 
The water bath was heated to 55°C. All solutions for post-hybridisation steps were 
made in non-sterile distilled water. Four glass troughs were filled with about 1 
litre of 1x SSC (Sigma, UK) each and allowed to heat to 55°C in the water bath. 
The coverslips were floated off, dipped into 1 x SSC rinse solutions three times 
and then stored in 1 x SSC prior to the first 55°C wash. The coverslips that were 
used for radioactive sections were stored and dealt appropriately for radioactive 
disposal. The slides were washed 4x 15minutes in 1 x SSC at 55°C, followed by 2 
x  30  minutes  at  room  temperature.  The  sections  were  then  washed  twice  in 
distilled water (to remove remaining salts), followed by washes in 70% and 95% 
ethanol. The slides were then transferred to plastic stands and allowed to air-dry 
for 30 minutes. [81] 
 
2.5.1.6 Visualisation procedures 
2.5.1.6.1  Radioactive Autoradiography 
After  hybridisation,  film  autoradiographs  were  prepared  by  exposing  slides  to 
Hyperfilm  (Amersham,  UK)  for  15-20  days.  These  were  developed  using 
automated X-Ray film processing. Emulsion autoradiographs were prepared by 
dipping slides in K5 nuclear track emulsion (Ilford Imaging, UK) diluted 1:1.5 in 
distilled  water  and  exposing  for  4-6  weeks.  Emulsion-dipped  slides  were 
developed in phenisol (1:4 in distilled water) for 3.5 minutes at 20°C, washed in 
stop bath (diluted 1:20 in distilled water) for 1 minute and fixed in hypam (1:4 in 
distilled water) 3.5 minutes. The phenisol, stop bath and hypam were all obtained 
from Ilford Imaging, UK.  Slides were subsequently washed in distilled water (30 
minutes),  counterstained,  dehydrated  through  graded  ethanols,  cleared  and 
mounted in DPX mountant (BDH, UK). 
2.5.1.6.2  Digoxigenin 
After the appropriate washings were done with 1X SSC in order to remove any 
non-specific  hybridisation,  the  sections  were  prepared  for  a  visualisation 
procedure.  The  sections  were  first  blocked  in  10%  non-fat  milk  in  phosphate 
buffered saline (PBS) for 30 minutes, and then sections were incubated with a 
primary anti-DIG antibody (Roche, UK) at a dilution of 1:250 at 4°C overnight. 
The  sections  were  then  washed  in  1  X  PBS  several  times  before  a  secondary 
biotinylated anti-mouse antibody (Dako, UK) was added at a dilution of 1:200 for 
30 minutes at room temperature. The following steps were conducted at room 
temperature. The sections were rinsed in 1X PBS and a combination of ABC stain 
(Vector,  UK)  followed  by  biotinylated  tyramide  signal  amplification  (TSA) 
solution  (Pierce  Biotechnology,  UK)  was  applied.  The  ABC  and  TSA  were 
applied to the sections for 30 minutes each and this step was performed twice. 
This  step  increases  the  signal  amplification  and  is  instrumental  during 
visualisation procedure for low copy-number mRNAs. After this incubation the 
sections were then again rinsed with 1 X PBS and incubated in 0.1M PBS for 30 
minutes.  
 [82] 
 
2.5.1.6.2.1  Glucose oxidase nickel DAB (G.O.D) method 
The digoxigenin ISH sections were washed in 0.1M PBS for 30 minutes, rinsed in 
0.1M ammonium acetate buffer (pH 6.0) and incubated in the following reaction 
solution: 0.1 M acetate buffer (pH 6.0), 0.05% diaminobenzidine (DAB), 0.04% 
ammonium chloride, 2.5% ammonium nickel sulphate, 0.25% β- D- glucose and 
0.001% glucose oxidase. The sections were incubated in the solution for around 
15 minutes, and placed in 1X PBS to stop the reaction. If darker precipitation was 
desired the sections were returned to the G.O.D. solution for a longer period. 
2.5.1.6.3  Histological counterstaining 
To  assist  with  microscopic  examination,  tissue  sections  were  counterstained. 
Destaining  of  K5  silver  emulsion  for  radioactive  sections  was  achieved  by 
immersion  in  70%  alcohol,  for  up  to  20  minutes.  These  sections  were  then 
counterstained using toulidine blue (BDH, UK), depending on the intensity of the 
stain  required.  The  sections  for  digoxigenin  ISH  were  dipped  in  Mayers 
haemotoxylin (BDH, UK) for ~10 seconds and then washed with water to remove 
any excess staining.  
The sections were mounted by sequential dehydration in graded alcohols 70%, 
80% and 95%, followed by xylene, a non-polar solvent that is used in fixation of 
animal tissues. The sections were mounted and visualised under a microscope to 
observe cellular localisation of mRNA signal. 
2.5.2  Immunohistochemistry 
2.5.2.1 Paraffin embedded tissue 
Paraffin embedded tissue sections were cut at 8 m using a Leica microtome and 
placed onto 30% alcohol solution and floated out onto warm water. The sections 
were then picked up on vectabond coated slides (Vector, UK), and left to dry at 
37°C for at least 48 hours. The sections were then incubated at 60°C overnight, 
prior to immunohistochemistry (IHC). A minimum of two sections were cut for 
each sample, one for IHC and the other for a haemotoxylin and eosin (H & E) 
stain (BDH, UK). [83] 
 
2.5.2.2 Tissue processing 
Sections  were  de-paraffinised  using  three  changes  of  xylene  for  10  minutes, 
followed  by  rehydration  using  graded  alcohols  (100%,  90%  and  70%).  Any 
endogenous  peroxidase  activity  was  blocked  using  0.3%  hydrogen  peroxide 
(H202)  in  methanol  for  10  minutes  followed  by  washing  in  distilled  water. 
Depending on the antibody used, the sections were subjected to various treatments 
for antigen retrieval. 10% non-fat milk in PBS was used to block any non-specific 
protein binding for 30 minutes at room temperature. Primary antibodies diluted in 
1X PBS were then spread onto the section and allowed to incubate for 1 hour at 
room temperature. This was followed by three washes in PBS and the relevant 
secondary antibody was then applied onto the section. The sections were washed 
in  PBS  and  incubated  in  avidin-biotin  complex  (ABC)  (Vector,  UK)  for  30 
minutes at room temperature followed by washes in PBS.   
2.5.2.3 Visualisation procedures 
The chromogen diaminobenzidine (DAB) (Sigma, UK) was used to visualise the 
antigen-antibody  reaction.  Sections  were  placed  in  500 g/100ml  PBS  DAB 
solution that was activated using 32 l of H2O2 (30% solution, BDH, UK) for up to 
4 minutes and the colour intensity checked. The sections were replaced in the 
DAB solution if darker colour intensity was required.  
2.5.2.4 Histological counterstaining 
Sections were counterstained with Mayer’s haemotoxylin for 20-30 seconds and 
washed  in  distilled  water.  Finally,  the  sections  were  dehydrated  through  70%, 
90%  and  absolute  alcohol  and  then  cleared  in  three  changes  of  xylene  and 
permanently mounted with DPX (BDH, UK). Sections adjacent to the ones that 
had undergone tissue processing as described in 2.5.2.2 were stained for H & E, 
allowing a morphological assessment of the anatomical regions being assessed. 
2.5.2.5 Pretreatments used for paraffin embed tissue 
Tissue fixation or processing can sometimes result in antigens being obscured 
which can be retrieved by different treatments. For the purpose of antigen retrieval 
in this study, various pre-treatments were used with the different antibodies as 
appropriate and are described below:  [84] 
 
Formic Acid- sections were placed in formic acid for ten minutes, followed by 
several washes in distilled water. 
Pressure cooking- sections were placed in boiling citrate buffer (pH 6.0) for ten 
minutes after the maximum pressure had reached, followed by several washes in 
distilled water. 
Formic  Acid  +  Pressure  cooking:  sections  were  placed  in  formic  acid  for  ten 
minutes, followed by several washes in distilled water, and then placed in boiling 
citrate buffer (pH 6.0) for 10 minutes as described above. 
2.6  Western blot and immunoabsorption assay 
Post-mortem frozen tissue was homogenised in ice-cold 1X Tris-buffered saline 
(Sigma,  UK)  containing  protease  inhibitor  cocktail  (Roche,  UK)  and  spun  at 
12,000X g for 10 minutes to remove cellular debris. Protein was measured by the 
bicinchoninic acid (BCA) method (Biorad, UK). Resulting protein was solubilised 
in  Laemmli  buffer  (4%  SDS,  20%  glycerol,  10%  2-mercaptoethanol,  0.004% 
bromophenol blue and 0.125 M Tris HCL, overall pH 6.8), and loaded onto 12% 
Tris-glycine  gels  (Biorad,  UK).  The  gel  was  run  in  Tris-glycine-SDS  running 
buffer  for  3  hours  at  125V.  The  proteins  were  transferred  to  hybond-P  nylon 
membranes (GE Healthcare, UK) by electroblotting. Duplicate membranes were 
blocked with 5% marvel in 1X PBS-Tween 20 (0.1% v/v).  
For  antibody  pre-absorption,  the  primary  antibody  was  incubated  with  the 
corresponding  peptide  used  to  raise  the  antibody  at  a  molar  ratio  of  1:  200 
sequentially at 37°C for 1 hour and then overnight at 4°C. The solution was spun 
at 10,000 X g and the supernatant was used to probe the duplicate blot. Both blots 
were incubated overnight at 4°C followed by washing 3 X 5min washes in 1 X 
PBS. The blots were then probed with horseradish peroxidase (HRP)-conjugated 
anti-rabbit  secondary  antibody  (Dako,  UK)  at  1:1000  dilution.  The  blots  were 
visualised  using  enhanced  chemiluminesence  (Pierce  Biotechnology,  UK)  and 
captured onto Biomax autoradiography film (Kodak, UK). [85] 
 
2.7  Procedures testing transcriptional regulation 
Eukaryotic  transcriptional  regulation  is  a  highly  complex  procedure  where  a 
multitude  of  different  mechanisms  occur  simultaneously.  Functional 
transcriptional assays under the influence of luciferase reporter genes are a good 
way of determining the transcriptional activity of the gene. Assays that identify 
accurate DNA:protein interactions are also an important step towards determining 
the role of genetic variation on the transcriptional behaviour of the gene.  
2.7.1  SH-SY5Y cells and nuclear lysates 
The SH-SY5Y human neuroblastoma cell line was obtained from the European 
collection of cell cultures (ECACC), and seeded from a split sub-confluent culture 
at 1x1,000-1x10,000 cells/cm² as recommended by ECACC. The culture medium 
used for plating and incubating cells was DMEM High Glucose with L-glutamine 
(Sigma,  UK  containing  FBS  (Gold  Heat  inactivated  EU  approved,  PAA 
Laboratories) and penicillin/streptomycin antibiotics (Sigma, UK). The cells were 
incubated at 37°C in 100% relative humidity and 5% carbon dioxide (CO2). The 
culture medium was changed approximately every two days.  
Cells were propagated and allowed to reach a confluency of 70-80%, prior to 
being sub-cultured at a ratio of 1:5, using the following protocol. The process 
involved aspirating existing culture medium from the cells and addition of 10ml 
of warm HBSS (without Ca
2+ and Mg
2+, PAA laboratories) to each plate which 
was then aspirated after the cells had been rinsed. The cells were dislodged using 
2ml of 0.25% Trypsin EDTA solution (Sigma, UK) and incubated in 5% CO2 at 
37°C for 5 minutes. The plate was then tapped to dislodge the cells, and 5ml of 
culture medium was then added to the plate. The media was then triturated to 
break up the cell clumps and transferred to a 15ml falcon. The plate was then 
rinsed with further 5ml of culture medium which was then transferred to the 15ml 
falcon already containing the cells. The cells were then centrifuged at 1,200 rpm 
for 5 minutes and the supernatant was removed and discarded. The cells were then 
resuspended  in  5ml  of  culture  medium,  diluted  accordingly  for  seeding  and 
growth in subsequent culture flask. Alternatively, the cells were resuspended in 
lysis buffer to extract nuclear lysates. Protease inhibitors (Roche, UK) were added 
from  a  concentrated  stock  to  the  lysis  buffer  as  recommended  by  the [86] 
 
manufacturers. It should be noted that this procedure is for growing cells in a 10 
cm plate or a T75 flask. Therefore, for preparation of nuclear lysates, cells were 
propagated in 3 X T175 flasks, with appropriate scale-up of reagent volumes.  
A packed cell volume of up to 50µl (100mg) was needed to extract nuclear lysates 
using  the  NE-PER  nuclear  and  cytoplasmic  extracting  reagents  from  Pierce 
Biotechnology (UK). Please see the manufacturer’s instructions for using the kit. 
The  lysate  concentration  was  measured  using  the  BCA  assay  kit  (Pierce 
Biotechnology,  UK),  against  a  standard  curve  generated  by  serial  dilutions  of 
10mg/ml bovine serum albumin (BSA). The nuclear lysates were aliquoted and 
stored at -80°C until further use. 
2.7.2  Electrophoretic mobility shift assay (EMSA) 
Electrophoretic mobility shift assays (EMSAs) can determine the binding between 
DNA and proteins within regulatory regions. The assay is based on the premise 
that compared to unbound DNA, complexes of DNA and protein migrate through 
a gel much slowly. The migration rate of the bound DNA further slows down if an 
additional protein binds to the multi-protein complex.  
2.7.2.1 Probe annealing 
In  order  to  investigate  DNA:protein  interactions,  nuclear  proteins  (e.g. 
transcription  factors)  need  to  bind  to  double  stranded  DNA.  For  this  purpose, 
complementary  nucleic  acids  (oligonucleotide  probes)  need  to  be  annealed 
together. Stocks of oligonucleotide probes were prepared at a concentration of 1-
100 pmol/µl in a Tris buffer containing salt (10mM Tris, 1mM EDTA, 50mM 
NaCl) at pH 8.0. The oligonucleotide probes (labelled with biotin) were mixed 
and annealed in 1:1 ratio at a concentration of 1pmol/µl at 95°C for 5 minutes. A 
thermocycler was used for this procedure, and was programmed so as to gradually 
reduce the heat (-1°C/cycle), until the annealed probes reached room temperature. 
This minimises the formation of secondary structures. The annealed probes were 
aliquoted and stored at -20°C until further use. [87] 
 
2.7.2.2 EMSA procedure 
The  LightShift Chemiluminescent EMSA  Kit (Pierce Biotechnology,  UK) was 
used to detect DNA:protein interactions. The annealed probes with binding site of 
interest labelled with biotin were incubated with the SH-SY5Y nuclear extract as 
per  the  manufacturer’s  instructions.  The  reaction  was  then  subjected  to  gel 
electrophoresis  on  a  6%  TBE  gel  (Invitrogen,  UK)  in  0.5  %  TBE  buffer  and 
transferred onto a nylon membrane (BioBond plus nylon membrane, Sigma, UK) 
at 60 V over 1-2 hours, or as instructed by the manufacturer. The membrane was 
cross-linked for 10-15 minutes (face down) on a transilluminator at 6 J/cm
2. The 
biotin  end-labelled  DNA  was  detected  using  the  streptavidin-horseradish 
peroxidase conjugate and the chemiluminescent substrate. This was exposed onto 
an X-ray film for 2-5 minutes depending on the signal intensity required. 
2.8  Bioinformatics and other web based resources  
2.8.1  Ensembl, NCBI and UCSC 
The Ensembl genome browser (http://www.ensembl.org/) and the National Centre 
for  Biotechnology  information  (NCBI)  (http://www.ncbi.nlm.nih.gov)  are 
publicly  available  resources  for  genetics  and  molecular  biology.  Nucleotide 
sequences, population frequencies, and also transcript sequences are some of the 
many invaluable data that can be retrieved from these resources. They also contain 
web  based  bioinformatics  programs  such  as  basic  local  alignment  search  tool 
(BLAST), that are essential in searching and retrieving homologous sequences to 
the gene of interest.  
 
The University of California Santa Cruz genome browser (UCSC) 
(http://www.genome,ucsc.edu)  is  also  a  publicly  available  web  resource  that 
provides  the  reference  sequence  and  working  draft  assemblies  for  a  large 
collection of genomes. It is especially useful for annotating information such as 
the  locus  position,  genetic  variation,  polymorphic  repeats,  cross-species 
conservation and structural variation. [88] 
 
2.8.2  HapMap 
High-density SNP genotype data in a total of 270 individuals from four different 
populations was used to create the International HapMap project (HapMap). The 
populations include 30 CEPH (Centre Humain d'Etude du Polymorphisme) trios 
(families  from  Utah,  US  of  Western  European  origin),  45  unrelated  Chinese 
individuals,  30  trios  from  the  Yoruba  people  of  Nigeria  and  45  unrelated 
individuals from Japan. This is a web based resource (http://www.hapmap.org/) 
that allows the population genotype data to be analysed for haplotypic diversity of 
the population of interest. This resource was routinely used to identify tag SNPs 
for candidate gene association studies.  
2.8.3  Transcription factor binding site (TFBS) prediction 
TRANSFAC  is  a  repository  that  contains  data  on  transcription  factors,  their 
experimentally-proven  binding  sites,  and  regulated  genes.  The  online  tool 
PROMO  predicts  DNA:protein  interaction  using  the  TFBS  predicted  in 
TRANSFAC database to construct specific binding site weight matrices for TFBS 
prediction (Messeguer et al. 2002). The PROMO algorithm can be accessed at:  
http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promo.cgi?dirDB=TF_8.3&calledBy=alggen 
2.8.4  Image processing 
Image J is a free web-based image processing program developed by National 
Institute of Health (NIH). This program was routinely used to mark the total area 
of section in order to convert the image pixels into area per mm
2. 
2.9  Statistical analysis in population genetics studies 
2.9.1  Hardy-Weinberg Equilibrium 
Hardy-Weinberg  equilibrium  (HWE)  is  the  stable  frequency  distribution  of 
genotypes in a population if mating is assumed to be random. In the absence of 
mutation, migration, natural selection or random drift, the allelic frequencies for a 
bi-allelic polymorphism with alleles A and a, will be p and q, which equal to 1. 
The  stable  frequency  of  genotypes  will  be  p
2,  2pq  and  q
2.  In  a  case-control 
association study, the expected numbers for HWE can be calculated and compared 
to observed genotypes of the population. Deviations from HWE can be identified [89] 
 
through a chi-squared test. Determination of HWE deviations in case and control 
populations was routinely made using an online tool (FINETTI) offered by the 
Institute  of  Human  Genetics,  Technical  University  Munich,  Germany.  The 
statistical significance was set at P < 0.05 for significant deviations. The statistical 
tests Pearson chi-square (χ
2) goodness -of –fit, Log likelihood ratio chi-square 
(Llr) and an Exact test are used to test deviations from expectations (HWE) in 
FINETTI,  and  these  tests  for  association  are  adapted  from  a  previous  study 
(Sasieni  1997).  The  online  program  is  available  at  http://ihg2.helmholtz-
muenchen.de/cgi-bin/hw/hwa1.pl. 
2.9.2  Linkage disequilibrium analysis and tagging SNPs 
Linkage disequilibrium (LD) is a non random association of two or more loci in a 
haplotype block, where they segregate more frequently than would be expected by 
chance alone. Two measures have been proposed to evaluate the marker pairwise 
LD value: D’ and r
2. An association probability of D’ value 0.0 between two 
markers  shows  independent  allele  assortment  whereas  a  value  of  1.0  shows 
complete linkage between the two. Therefore, genotyping one would accurately 
predict the allelic state of the other. However, the other pairwise LD measure of r
2 
takes the allele frequency of each locus into account and to obtain a LD value of 
1.0 using r
2, the allele frequency of the two locus’ should also be the same. For 
the  purpose  of  creating  LD  maps  in  this  study,  the  more  stringent  pairwise 
measure of r
2 was used. The LD plots were routinely obtained from a Caucasian 
data  dump  available  through  the  International
  HapMap  Project  web  page 
(www.hapmap.org)  and  Ensembl  (www.ensembl.org).  The  bioinformatics 
software Haploview functions as a SNP haplotype analysis suite that can analyze 
LD patterns in genetic data and estimate haplotype frequencies. This software was 
used to select the SNPs that could ‘capture’ up to 95% of the common genetic 
variation across
 the region (r
2= 0.80), termed tag SNPs (tSNPs), and is available 
at: http://www.broadinstitute.org/haploview/haploview. 
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2.9.3  Odds ratio 
The odds ratio (OR) is a way of comparing whether the probability of a certain 
event is the same for two groups. In terms of case-control association studies, this 
is interpreted as the ratio of odds of having a particular allele (or genotype) in the 
case group divided by the odds of having the allele (or genotype) in the control 
group. The 95% confidence interval (CI) for the OR’s are always estimated as the 
OR calculation is based purely on a sample of the population. For interpretation, 
an OR of 1 implies that the allele (or genotype) is equal in both groups; an OR > 1 
(and lower bound of CI no less than 1) implies significant risk in the case group; 
whereas an OR < 1 (and upper bound of CI less than 1) implies protection of the 
allele  (or  genotype)  towards  the  case  group.  The  OR  and  95%  CI’s  were 
calculated  using  the  same  online  tool  (FINETTI)  as  was  used  for  HWE 
http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl. 
2.9.4  Statistical packages used 
2.9.4.1 Data analysis 
SPSS (version 14) and STATA
tm  10.0 (StataCorp, USA) software were routinely 
used to perform parametric, non-parametric analyses and frequency probability 
tests. Specific tests are described in the individual chapters. GraphPad PRISM 
software (USA) was also occasionally used for the production of graphs.  
2.9.4.2 Corrections for multiple comparison of tests 
During  hypothesis  testing,  the  null  hypothesis  (H0)  assumes  that  there  is  no 
difference between the factors. Any difference between the factors is attributable 
to  chance,  and  a  significance  test  will  indicate  a  ‘statistically  significant’ 
association between the factors with a probability of α, which is the cut off value 
for significance and usually placed at 0.05. Therefore, if n is the independent 
associations  (or  number  of  comparisons)  that  are  examined  for  statistical 
significance,  then  the  probability  that  at  least  one  of  them  will  be  found 
statistically significant is 1 – (1 – α)
n, if  all n of the null hypothesis  are true 
(Rothman 1990). For example, if n is 20 and α is 0.05, then the probability of 
finding at least one statistically significant comparison is 0.64.  [91] 
 
Increasing the number of comparisons also increases the number of potentially 
‘significant’ results that negate an otherwise correct null hypothesis. Therefore, 
correcting for multiple comparisons is essential to avoid false-positives or type I 
errors. Traditionally, the Bonferroni procedure has been used to correct for false-
positives in multiple comparisons. However, this procedure is considered to be 
ultra-conservative on true statistical significance. Therefore, improved procedures 
based on Bonferroni have now been introduced, and include methods such as the 
step-up Simes’ threshold (Simes 1986).  
The step- up Simes’ algorithm examines the P-values in order, from largest to 
smallest,  and  sets  a  threshold  cut  off.  Once  a  P-value  is  found  that  is  small 
according to the criterion based on α (0.05) and the P-value’s position in the list, 
then  that  P  -value  and  all  smaller  P-values  are  rejected.  The  step-  up  Simes’ 
algorithm  was  used  to  correct  for  multiple  comparisons  in  this  thesis  where 
statistical significance was observed. Chapter 3  
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3  Screening  of  G2019S  mutation  in  sub-Saharan  African, 
Middle- Eastern and Eastern European populations 
3.1  Introduction 
The LRRK2 G2019S mutation has a population specific frequency, and the highest 
carrier rates for the mutation have been reported for North African Berber subjects at 
a frequency of 34% (95% CI 25.8-42.5) for idiopathic PD (IPD) and 41% (95% CI 
21.5-64.3%) for familial PD (FPD) subjects (Lesage et al. 2005a; Lesage et al. 2006). 
This is followed by Ashkenazi Jews who report a frequency of 18.3% (95% CI 11.9 – 
26.4%) in IPD and as high as ~30% in FPD subjects (Ozelius et al. 2006). As detailed 
in Table 1.2 of chapter 1, a high frequency of the G2019S mutation is also found 
amongst populations from the Iberian Peninsula.  
The worldwide incidence rate of PD has been suggested to vary by ethnicity, and 
differences  in  the  frequency  of  PD-related  mutations  or  other  common  genetic 
variation  has  been  suggested  to  play  a  role  in  this  (Van  Den  Eeden  et  al.  2003; 
Djarmati  et  al.  2004;  Tan  et  al.  2004;  Li  et  al.  2005).  For  example,  the  G2019S 
mutation has been found to be most common in North Africa where a crude incidence 
rate of PD at 4.5 per 100,000 (Libya) is much lower in comparison to the crude 
incidence rate in Europeans which can vary from 10-26 per 100,000 (Twelves et al. 
2003) (see Table 1.2 for worldwide frequencies). This has led to the suggestions that 
“The identification of populations with low and high mutation prevalence may allow 
future clinical trials to focus on neuroprotection or possibly disease prevention in 
LRRK2  carriers”  (Papapetropoulos  et  al.  2008).  As  such,  estimating  the  precise 
frequency of G2019S mutation in unaffected subjects from populations at risk would 
permit  for  a  genetic  test  better  suited  to  the  needs  of  a  particular  ethnicity,  and 
therefore, allow for a better disease management. 
A worldwide G2019S carrier rate frequency in unaffected subjects has been estimated 
at <1% (N= 14, 886) (Healy et al. 2008) (see Table 1.2 in chapter 1), but a higher 
proportion of unaffected carriers have been reported in North African Berbers and  
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Ashkenazi Jews. Amongst the North African populations, a frequency of 1-2% has 
been reported in control subjects from Algeria (Lesage et al. 2006; Hulihan et al. 
2008).  A  more  comprehensive  screening  of  G2019S  mutation  in  various  North 
African populations identified an overall carrier rate of 2.18% (95% CI 0 - 3.35) 
amongst healthy North African Arab subjects (N= 597), in comparison to European 
populations (1 in 1550) (N= 3100) (Change et al. 2008) (see Table 3.1). The study 
also reported an elevated proportion of 3.31% (1 in 46) (95% CI 0.46- 6.17%) in 
unaffected subjects of Moroccan Berber origin whereas non- Berber Moroccans were 
identified  as  having  a  slightly  lower  proportion  at  1.96%  (95%  CI-  0-  4.65%). 
Amongst the other North African populations, the reported proportions were 2.13% 
(95% CI 0-4.51%) in Algerians, 1.57% (95% CI 0 – 3.74%) in Tunisians, and 1.32% 
(95% CI 0-3.88%) in Libyans (Change et al. 2008). See Table 3.1 for a summary of 
these G2019S mutation frequency in North African populations. 
Another population that has a high frequency of the G2019S mutation is the Jewish 
population, specifically the Ashkenazim among them. Ozelieus et al. (2006) reported 
a  frequency  of  1.3%  (95%  CI  0.34-  3.2%)  in  their  Ashkenazi  Jewish  control 
population. Subsequent studies have demonstrated a G2019S mutation frequency of 
1.4- 2.4% amongst the unaffected Ashkenazim (see  
Table 3.2), (Ozelius et al. 2006; Clark et al. 2006; Eblan et al. 2006; Orr-Urtreger et 
al. 2007; Healy et al. 2008). Amongst the non- Ashkenazi Jewish population, a lower 
carrier  rate of  0.4%-1.4%  has  been  suggested,  with no  G2019S  mutation  carriers 
being reported for Yemenite and Iraqi Jews (Orr-Urtreger et al. 2007; Change et al. 
2008). However, a relatively high frequency of 2.55-2.7% (CI 0.34 - 4.76% CI) in 
Sephardi  Jews  originating  from  Morocco  and  Djerba-Tunisia  has  been  identified, 
which is comparable to the carrier rates of Ashkenazi Jews (2.2%) and even non-
Jewish subjects of Moroccan (not Berber) and Tunisian origins (1.96% and 1.57%, 
respectively) (Eblan et al. 2006; Orr-Urtreger et al. 2007; Change et al. 2008). See  
Table  3.2  for  a  summary  of  the  G2019S  mutation  frequency  in  different  Jewish 
ethnicities.  
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Table 3.1: Summary of G2019S carrier rates in populations from North Africa. IPD: 
idiopathic PD; FPD: familial PD; (N): the total number of samples genotyped for the G2019S 
mutation in the study; N/A= not available. Unless otherwise stated all the samples used for 
the G2019S mutation frequency for controls were unaffected subjects.  
 
 
 
 
  Population  IPD (N)  FPD (N)  Controls 
(Lesage et al. 2005a; 
Lesage et al. 2006)  
North Africa  41% (49)  37% (27)   1% (151) 
(Ishihara et al. 2007)  Tunisia  N/A  42% (91)  N/A 
(Lesage et al. 2007)  Algeria  N/A  14% (6)  N/A 
(Warren et al. 2008)   Tunisia  N/A  42% (91)  N/A 
(Lesage et al. 2008)   North Africa  34% (119)   41% (17)   1.5%                      
(66, Algerians) 
(Hulihan et al. 2008)  Tunisia  30% (238)  N/A  2% (371) 
(Change et al. 2008)  Total North Africa             
(Moroccan Berbers          
Morocco                 
Algeria                   
Tunisia                           
Libya) 
N/A  N/A  2.18% (597)                        
3.31% (151)                        
1.96% (102)                                                 
2.13% (141)                   
1.57% (127)               
1.32% (76)  
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Table 3.2: Summary of G2019S carrier rates in Jewish populations. IPD: idiopathic PD; 
FPD ; familial PD; (N) :the total number of samples genotyped in the study; N/A= not 
available. Unless otherwise stated all the samples used for the G2019S mutation frequency 
for controls were unaffected subjects.
  Population  IPD (N)  FPD (N)  Controls                              
or non-PD patients 
(Ozelius et al. 
2006) 
Ashkenazi Jews  13.3% (83)   29.7% (37)   1.3% (317) 
(Saunders-Pullman 
et al. 2006)                   
Ashkenazi Jews  N/A  N/A  1.4% (143)                            
Dementia patients  
(Clark et al. 2006)  Ashkenazi Jews  7.7% (155)  26.1% (23)   2% (98) 
(Eblan et al. 2006)                    Ashkenazi Jews  N/A  N/A  2.2% (45)                         
Gaucher disease patients 
(Deng et al. 2006)  Ashkenazi Jews  10.7% (28)  N/A  N/A 
(Pchelina et al. 
2006) 
Ashkenazi Jews  0.6%  3.9%  0% 
(Orr-Urtreger et al. 
2007) 
Ashkenazi Jews                 
Total non-Ashkenazi 
Jews: (Bulgaria,  
Syria, Morocco & 
Iraq) 
14.8% (344)                                                              
2.7% (112)                           
N/A  2.2% (500)                            
0.4% (957)                
(1.6% (125 Bulgarian)                                   
0.25% (400 Morocco) 
0% (300 Iraq)) 
(Djaldetti et al. 
2008) 
Ashkenazi Jews                               
Yemenite Jews            
12.7% (96)                                     
0% (63) 
N/A  N/A 
(Change et al. 
2008) 
Sephardi Jews                               
(Morocco & Djerba-
Tunisia) 
N/A  N/A  1.4% (361)                        
2.55% (196)   
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3.1.1  Haplotypic studies and origins of G2019S mutation 
The presence of G2019S mutation in various populations over the world has resulted 
in  many  studies  attempting  to  describe  its  origins  through  haplotypic  analysis.  A 
common ancestral haplotype known as the European- Middle Eastern North African 
(MENA) has been identified in North African, Jewish and European populations, and 
has been shown to contain the G2019S mutation (Lesage et al. 2005b; Kachergus et 
al. 2005; Goldwurm et al. 2005; Warren et al. 2008; Bar-Shira et al. 2009).  
The high frequency of G2019S mutation in Ashkenazi Jews (13.3% IPD and 29.7% 
FPD), and North African Arabs (40.8% IPD and 37% FPD) has led to the hypothesis 
that the common founder originated in the Middle East (Lesage et al. 2006; Ozelius et 
al. 2006). A likelihood- based haplotype approach in the study of 6 families of North 
African and European origins identified a minimal haplotype of 60 kb, and estimated 
that the families shared a common ancestor back in the 13
th century (Lesage et al. 
2005a). However, due to a high carrier rate of G2019S mutation in Ashkenazi Jews, 
this timeframe seemed unlikely as the historical migration patterns suggest that the 
Ashkenazim and Arab populations had already separated a long time ago (Colombo 
2000b;  Niell  et  al.  2003;  Zabetian  et  al.  2006a).  Therefore,  in  order  for  these 
populations to share a common ancestor for G2019S mutation, the event must have 
taken place long before the estimated 13
th century.  
Zabetian  and  colleagues  (2006)  were  able  to  replicate  the  findings  that  G2019S 
mutation originated in a common founder of European-MENA populations, by typing 
22 families of European and Ashkenazi Jewish ancestry (Zabetian et al. 2006a). They 
also showed that the initial estimate of 60 kb (as predicted by Lesage and colleagues, 
2005b)  for  the  ancestral  haplotype  was  too  short,  and  reasoned  that  the  use  of 
unstable  marker(s)  contributed  to  this.  These  subjects  were  tested  for 25  markers 
spanning  9  Mb  across  the  LRRK2  region,  and  two  ancestral  haplotypes  were 
identified. Haplotype 1 (European-MENA haplotype) was shown spanning 243 kb, 
and a distinct haplotype 2 spanned 6Mb. Haplotype 2 could be differentiated from the  
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minimal core region of the haplotype 1 (European-MENA) by using five intragenic 
and one extragenic marker. The European-MENA haplotype 1 was predominant in 
the  Ashkenazi  Jewish  and  European  families  (total  of  19  families),  whereas  the 
geographic  origin  of  haploytpe  2  was  suggested  to  be  from  Western  Europe  (3 
families). Using the likelihood method, Zabetian and colleagues were able to estimate 
that  families  with  the  common  European-MENA  haplotype  shared  a  common 
ancestor ~2,250 (95% CI 1,375-2,600) years ago, when Jewish and Arab populations 
lived in close proximity.  
This estimated timeframe also coincides with the Jewish exile from the Middle East 
in 586 BCE to 70 CE. Warren et al., also identified a haplotype in 38 Tunisian and 2 
North  American  families  with  the  G2019S  mutation,  and  confirmed  it  as  being 
consistent with European-MENA haplotype (Warren et al. 2008). Using a 25 year 
intergenerational interval, they estimated that the families shared a common founder 
2,600  years  ago  (95%  CI-  1950-  3850).  These  timeframes  have  resulted  in  the 
speculation ‘that G2019S might be of Phoenician origin, rather than Arabic, dating 
from the founding of ancient Carthage in 814 BC’ (Farrer et al. 2008). A recent study 
estimated  that  Ashkenazi  Jewish  carriers  of  European-MENA  haplotype  share  a 
common ancestor who lived 61 generations ago (95% CI 52 - 72), and at a 25 year 
intergenerational interval this would approximate to 1,525 years (95% CI- 1,300 - 
1,800  years)  ago  (Bar-Shira  et  al.  2009).  Amongst  Jewish  peoples,  the  G2019S 
mutation has been identified in Ashkenazim and Sephardim, but so far has not been 
reported in Yemenite or Iraqi Jews. Yemenite Jews form a distinct ethnic Jewish 
group, and Iraqi Jews are descendents of the original Babylonian Jews (586 BCE) 
(Motulsky 1995). This suggests that the mutation was acquired by Sephardim and 
what  were  to  become  Ashkenazim  after  the  initial  divergence  of  Jewish  groups. 
However, the G2019S European-MENA founder haplotype has also been shown in 
non-G2019S mutation carriers of Han Chinese origins (Tan et al. 2007c). 
Another haplotype has been reported in a subset of G2019S positive PD patients in 
Russia,  suggesting  that  the  LRRK2  G2019S  mutation  in  the  Russian  subjects  had 
arisen independently on different chromosomes (Illarioshkin et al. 2007). However,  
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this haplotype differed from the European-MENA founder haplotype at one SNP only 
which is indicative of a mutational event. A distinct founding haplotype associated 
with the G2019S mutation has also been reported in a Japanese family that fails to 
share  alleles  with  the  European-MENA  haplotype,  suggesting  separate  founding 
effects for this mutation in the Japanese (Zabetian et al. 2006b). Interestingly, a recent 
study reported a G2019S affected PD patient from Turkey carrying the haplotype 
identified  in  the  Japanese  (Pirkevi  et  al.  2009).  Taking  into  account  the  long 
migrations of the Turkic people into and possibly beyond Central Asia, led the others 
to  suggest  common  ancestry  for  the  Japanese-Turkic  haplotype.  However,  only  a 
single PD Turkish patient was identified with the Japanese haplotype, and a larger 
and  genetically  heterogenous  Turkish  PD  cohort  is  needed  before  strong 
recommendations  of  common  ancestry  for  the  Japanese-Turkic  haplotype  can  be 
made. 
3.1.2  Populations chosen for this study and the rationale behind it 
The  presence  of  G2019S  mutation  with  such  varying  frequencies  in  different 
geographical  locations  would  suggest  that  the  spread  of  this  mutation  is  strongly 
associated  with  human  migration  patterns  (Tomiyama  et  al.  2006).  Despite  rare 
instances of de novo occurrence of the mutation and haplotypes associated with it, the 
current literature supports a Middle-Eastern, and more specifically a North African 
Berber origin for the LRRK2 G2019S mutation.  
North African Berbers belong to the coastal Mediterranean regions of the African 
continent,  and  modern  populations  of  Mediterranean  origins  are  the  remnants  of 
genetic and cultural impact of contact amongst different civilisations over centuries 
(e.g.  Phoenicians,  Carthaginians,  Greeks,  Romans  and  more  recently  the  Arabs) 
(Bosch et al. 2000; Bosch et al. 2001; Zalloua et al. 2008). Genetic relationships 
between populations from Africa and the Arabic sub-continent would be informative 
of population movements and its impact on the Mediterranean demography. For this 
purpose, the chapter reports an investigation into sub-Saharan African, Arabian and  
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Eastern Mediterranean populations that might have contributed to the genetic makeup 
of the G2019S founding populations.  
3.1.2.1 Sub-Saharan Africa 
Chaabani and Cox reported that the Berbers are native to North Africa and “that 
Berber  ancestors  could  have  presented  a  geographical  and  genetic  intermediate 
population  between  European  and  sub-Saharan  populations”  (Chaâbani  &  Cox 
1988). A south to north migration from sub-Saharan into Northwest Africa, and from 
North Africa into the Iberian Peninsula would have resulted in a substantial gene flow 
between the populations (Flores et al. 2000; Esteban et al. 2004). This would explain 
the relatively high frequency of G2019S mutation in the Iberian Peninsula compared 
to other European regions. The frequency of G2019S mutation has been explored in 
healthy subjects of North African Berbers, Mediterranean and many European origins 
but has not been thoroughly investigated in the sub-Saharan populations, although 
small numbers of PD samples (N= 57) and controls (N= 51) from Nigeria have been 
screened for LRRK2 mutations (Lesage et al. 2005a; Okubadejo et al. 2008a). The 
prevalence  of  PD  in  sub-Saharan Africa (Nigeria  10 per  100,000;  Ethiopia  7 per 
100,000) is much lower than in Arabs (27-43 per 100,000), and is also in contrast to 
the prevalence rates reported in North Africa (North East Libya 31.4 per 100,000) 
(Ashok et al. 1986; Osuntokun et al. 1987; al Rajeh et al. 1993; Twelves et al. 2003; 
Okubadejo et al. 2006). The prevalence rates of PD in African Americans has been 
reported as being similar to the Caucasian population (Copiah County, Mississipi), 
but almost fivefold higher than in Nigerians after adjustment for age (Schoenberg et 
al.  1988;  Okubadejo  2008b).  However,  a  meta-analysis  of  PD  prevalence  in 
populations of African ancestry identified a lower prevalence in Africans and African 
Americans compared to Caucasians, but concluded that additional work was needed 
before making any speculations on ethnic differences in PD (McInerney-Leo et al. 
2004). Since age still remains the biggest risk factor for PD, the low crude prevalence 
of  PD  in  Western  and  Eastern  African  countries  could  be  attributed  to  a  life 
expectancy of less than 57 years of age (Okubadejo et al. 2006). G2019S positive 
carriers are reportedly rare in Asia, but the identification of the common European- 
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MENA haplotype amongst Han-Chinese population, suggests that the haplotype itself 
is much older than the G2019S mutation (Tan et al. 2007c). Estimating the G2019S 
mutation frequency in sub-Saharan African populations would add to the genetic data 
associated with the Berber origins of this mutation. Additionally a high carrier rate of 
mutation in African populations would also be indicative of the mutation being more 
ancient than the current prediction of ~2,250 years by Zabetian and colleagues. 
3.1.2.2 Middle Eastern/Semitic populations 
Middle-East is a vast region that includes the Arabian sub-continent as well as the 
Arab countries of North Africa. Arabian sub-continent on the other hand, refers to the 
Arabian  Peninsula  as  well  as  the  regions  of  Eastern  Mediterranean  Basin/Asian 
Minor. Therefore, the populations mentioned in this section will be described as such.  
3.1.2.2.1  Arabian Peninsula 
Berbers  are  considered  to  be  the  original  inhabitants  of  North  Africa,  and  have 
historically  come  into  contact  with  various  other  communities  as  a  result  of 
population expansion, invasions and trade navigations. Invasions from the Arabian 
Peninsula  which  started  in  7
th  century  CE,  eventually  led  to  the  consolidation  of 
Islamic rules, religion, language and culture in North Africa around the 11
th century 
(Esteban et al. 2004). The large geographical area of Arabic countries stretches over 
two  continents,  and  ethnic  groups  such  as  Berbers,  Kurds  and  selected  African 
communities form part of the Arabic society (estimated at 315 million) (Benamer et 
al. 2008). Despite the term “Arab-Berber” used by Tunisians/North African Berbers 
to define their ethno-cultural identity, Berbers are thought to have retained their own 
languages and culture and tend to practice endogamy (Benamer 2008). Therefore, it 
would be imprudent to  assume that the  Arabs  and Berbers in North Africa  are a 
genetically homogenous population. The majority of G2019S mutation data relating 
to Arabic populations have been limited to the Arab-Berbers of the North African 
coast, and these frequencies cannot account for a vast majority of Arabic people that 
might not share an immediate genetic identity with the Berbers. Therefore, a precise 
estimate  of  the  G2019S  mutation  frequency  in  populations  from  the  Arabian  
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Peninsula  is  important  for  two  reasons.  Firstly,  it  would  allow  the  design  of 
appropriate  pre-symptomatic  genetic  testing  in  Arab  populations  which  has  a  PD 
prevalence rate of 27-43 per 100,000 (Benamer et al. 2008). Secondly, the possible 
contribution of Arabs to the origins of G2019S mutation in the Berber genetic pool, if 
any at all could be addressed. 
3.1.2.2.2  Eastern Mediterranean Basin/ Asia Minor 
Regions in Eastern Mediterranean Basin, such as Syria, Jordan, and Israel/Palestine 
are  also  included  in  the  Arabian  sub-continent,  and  various  civilisations  have 
contributed  to  the  complex  genetic  makeup  of  the  ethnicities  around  the 
Mediterranean Basin (Zalloua et al. 2008). As  mentioned previously, the G2019S 
mutation has a high carrier rate amongst Ashkenazi Jews and North African Berbers, 
with  isolated  cases  identified  amongst  Sephardi  Jews  along  the  Mediterranean 
(Morocco,  Syria,  Bulgaria  and  Turkey)  (Orr-Urtreger  et  al.  2007).  Similarly, 
mutations in the MEFV gene that cause Familial Mediterranean Fever (FMF) also 
show  a  non-uniform  distribution  around  the  Mediterranean  Sea.  This  disease  is 
prevalent amongst ethnically diverse populations of Mediterranean origins, but the 
highest incidence is reported in non-Ashkenazi Jews, Armenians, Arabs (not from the 
Peninsula) and Turks (Touitou 2001; Yilmaz et al. 2001; Papadopoulos et al. 2008). 
Incomplete penetrance of MEFV mutations has been suggested as a possible cause 
for a milder phenotype observed in other populations from the Mediterranean basin, 
such as Syrians, Ashkenazi, Iraqi and Iranian Jews (Gershoni-Baruch et al. 2001; 
Mattit et al. 2006; Papadopoulos et al. 2008). The mutation V726A shows a high 
prevalence in Ashkenazi (7.4%), Iraqi Jews (12.8%) and Arabs (7.3%) but is absent 
in  Moroccan  Jews,  and  the  mutation  M694V  is  absent  in  Ashkenazi  Jews  but  is 
present in the other ethnicities (Moroccan Jews 11.1%, Iraqi Jews 2.9% and Arab 
0.6%) (Gershoni-Baruch et al. 2001). Both these mutations, like the G2019S mutation 
in  LRRK2  are  associated  with  specific  haplotypes  in  populations  that  have  been 
separated for many centuries (Aksentijevich et al. 1999). The Jewish diaspora, the 
dispersal  of  Armenian  nation,  the  Byzantine  Empire,  Arab  conquests,  and  the 
Ottoman dominance have been suggested to have had an impact (unclarified as yet)  
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on  the  historical  background  of  MEFV  (Papadopoulos  et  al.  2008).  Taking  into 
account the geographical distribution of the G2019S mutation, it is feasible that it 
follows a pattern similar to the MEFV mutations.  
Farrer  and  colleagues  (2008),  recently  hypothesised  that  the  high  frequency  of 
G2019S mutation in populations of Mediterranean heritage is due to a Phoenician 
origin of the mutation (Farrer et al. 2008). Phoenicians or Canaanites were ancient 
coastal dwelling people, and like the Hebrews (founders of Jewish population) and 
Arabs are considered to be of ancient Semitic roots. The Phoenician civilisation was 
centred in the ancient Canaan, with its heartland along the coastal regions of Lebanon 
and Syria, and also comprising Israeli/Palestinian territories. Phoenicians had a sea-
faring and trading culture, and being the dominant sea power established many cities 
in the Mediterranean Basin (Farrer et al. 2008). For example, Carthage was an ancient 
city established by Phoenicians in Tunisia, and G2019S mutation is observed at a 
high frequency in Tunisians. Therefore, assessing the G2019S mutation carrier rate in 
other populations with Phoenician heritage would add to the current hypothesis of the 
mutation  being  Phoenician.  For  this  purpose,  populations  from  the  Eastern 
Mediterranean/Asia Minor that historically lived in close proximity, and were ethno-
culturally similar to the predicted founding populations were also included in this 
study.  
3.1.2.3 Jewish diaspora: Middle-East and Eastern Europe 
Jewish people have their origins in the Middle East, but the extensive geographical 
movement (and instances of extreme genetic isolation) associated with the Jewish 
diasporas  have  resulted  in  different  Jewish  communities.  According  to  Risch  and 
colleagues, three founder events in the Jewish population history have contributed to 
different  Jewish  ethnicities,  and  if  a  generation  is  defined  as  25  years  then  the 
ancestral Jewish population of middle-east was founded >100 generations ago; the 
second  founder  effect  resulted  in  Jewish  populations  of  Central  Europe  ~  >50 
generations ago, and the third founder effect ~12 generations ago gave rise to the  
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eastern European Jewish community, commonly termed as the Ashkenazim (Risch et 
al. 2003).  
The Jewish diaspora which refers to the settling of scattered colonies of Jews outside 
the areas of Jerusalem and vicinity, began in 6
th century BCE (563 BCE) whereupon 
the Jews of the ancient Kingdom of Judah were exiled to Babylon (modern day Iraq 
and Iran). The descendents of these Babylonian Jews and other surrounding regions 
came to be known as the Oriental Jews (Motulsky 1995). Upon conquest of Jerusalem 
in 301 BCE, Jews moved towards Egypt, and by 63 BCE Jewish communities had 
also settled in the present day areas of Syria, Turkey, Greece, Italy and North Africa. 
The destruction of the second temple in ~70 CE ensured that the Jewish diaspora 
continued, and the Bar Kokhba revolt in 135 CE led to a significant destruction of 
Jewish communities in Egypt and North Africa, resulting in Jews moving up north to 
southern Europe, and settling primarily in Spain. These Jews of Spain who came to 
be  known  as  Sephardi  Jews,  were  later  exiled  from  Spain  in  1492,  when  many 
resettled  along  the  North  African  coast,  and  in  Italy,  Egypt,  Palestine  and  Syria 
(Motulsky 1995; Colombo 2000a). Although it is not clear when Jews first arrived in 
Europe, there are records of Jews in France and Germany dating from the 4
th century 
CE,  and  it  is  only  from  10
th  century  CE  that  the  group  destined  to  become 
Ashkenazim  moved  from  Southern  Europe  into  Rhineland  (France/Germany) 
(Motulsky  1995).  These  Central  European  Jewish  ancestors  of  the  Ashkenazi 
community faced increasing persecution in Western and Central Europe, and began to 
flee to Eastern Europe in the 11
th century. By the 18
th century, most Eastern European 
Jews  were  exiled  to  particular  districts  which  became  known  as  the  ‘Pale  of 
settlement’ and included much of the present day Lithuania, Belarus, Ukraine, Poland 
and parts of Western Russia.  
Currently, 80% of the world Jewry is of Ashkenazi descent, and this community also 
reports the highest frequency of G2019S mutation amongst Jewish groups (Motulsky 
1995;  Ozelius  et  al.  2006).  Few  studies  have  investigated  the  G2019S  mutation 
frequency in Oriental Jews, and so far no carriers have been reported amongst this 
specific Jewish ethnicity (Orr-Urtreger et al. 2007; Djaldetti et al. 2008). Isolated  
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non-Ashkenazi Jewish cases have been identified in Morocco, Bulgaria, Turkey and 
Syria  (Orr-Urtreger  et  al.  2007).  This  observation  along  with  the  high  levels  in 
Northern  African  Berbers  has  led  to  the  suggestions  that  G2019S  mutation  was 
acquired  by  the  Jewish  community  after  the  split  from  the  Babylonian  Jews.  In 
comparison to Ashkenazi Jews (18-30%) fewer G2019S mutation carriers amongst 
Sephardi  Jews  (2.7%)  have  been  reported,  despite  them  having  lived  in  a  closer 
proximity  to  the  North  African  Berbers  for  a  longer  period  of  time,  than  the 
Ashkenazi ancestors.  
The  high  prevalence  of  G2019S  mutation  and  shared  haplotypic  region  in  North 
African  Berbers  and  Ashkenazi  Jews,  indicates  admixture  between  the  different 
populations.  Although  rare,  G2019S  mutation  has  been  shown  to  occur  de  novo. 
Haplotypes  distinct  from  the  common  European-MENA  ancestral  haplotype  have 
also been identified in European populations (Zabetian et al. 2006a; Zabetian et al. 
2006b;  Illarioshkin  et  al.  2007).  The  high  frequency  of  G2019S  related  PD  in 
Ashkenazi Jews compared with non-Ashkenazi Jews does raise the issue of whether 
this mutation was present in the Ashkenazi ancestral population (European Jews 9
th-
13
th century), and later spread to various European populations, or whether it was an 
original European mutation introduced into the Ashkenazi Jewish population whilst 
living in the eastern ‘Pale of Jewish settlement’.   
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3.1.3  Hypothesis and specific aims 
In this chapter, I wished to investigate the hypothesis that the G2019S mutation 
might have arisen in the neighbouring populations of North African Berber and 
Ashkenazi Jews. The specific questions addressed in this chapter were whether 
G2019S  mutation is common in: a) sub-Saharan Africa, and as such is older 
than  the  currently  predicted  estimate;  b)  populations  from  the  Arabian 
peninsula, and whether they were responsible for introducing the mutation into 
the  Berber  genetic  pool;  c)  Mediterranean/Asia  Minor  populations  with 
Phoenician  heritage  that  either  lived  in  close  proximity  or  shared  a  similar 
diaspora distribution to Jewish populations. d) Eastern European populations, 
and  whether  G2019S  mutation  in  Ashkenazim  arose  prior  to  or  after  its 
establishment as an ethnic Jewish group in Eastern Europe? 
To address these questions, healthy subjects from various populations were screened 
for  the  G2019S  mutation.  Subjects  from  sub-Saharan  African  communities  of 
Ethiopia and Bantu speaking tribes were genotyped in order to address the question 
of whether the mutation is older than the current estimates. Populations from the 
Arabian Penninsula, including Kuwaiti Arabs and Bedouins from Jordan and Saudi 
Arabia, would have had a considerable impact on the North African Arab Berber 
culture during the Islamic conquest of the region in 7
th century CE, and as such were 
included in the study. Estimating the carrier rate in a diverse spread of ethnic mixes 
around  the  Eastern  Mediterranean  Basin  and Asia Minor  such  as  Syrians,  Druze, 
Israeli  and  Arab  Palestinians,  and  Armenians  would  allow  us  to  estimate  the 
frequency  of  G2019S  mutation  in  ethnic  groups  that  lived  in  close  proximity  to 
Jewish populations prior to the diaspora and would allow us to address the question 
of  Phoenician  origin  for  the  mutation.  Screening  non-Ashkenazi  Jewish  subjects 
(Morocco, Iraq and Iran), and non-Jewish eastern European subjects (Ukraine and 
Belarus)  would  also  address  the  question  of  whether  G2019S  mutation  was 
introduced into the Ashkenazim prior to or after their establishment, respectively.   
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3.2  Methods and Materials 
3.2.1  DNA source- collaborative study 
The DNAs of a total of 2,450 healthy subjects (non- Parkinsonian when examined) 
from 13 different ethnicities were included in this study to test for the presence of 
G2019S mutation. These DNAs were obtained as part of a collaborative study with 
Dr.  Neil Bradman  (The  Centre  for  Genetic  Anthropology,  UCL).  The  individuals 
were  unrelated  at  the  paternal  grandfather  level,  and  were  involved  in  previous 
genetic and anthropological studies at The Centre for Genetic Anthropology (Thomas 
et al. 2002; Behar et al. 2003; Ingram et al. 2007; Veeramah et al. 2008). Table 3.3 
reviews the numbers in the ethnically diverse mix of populations. A total of 731 
samples from sub-Saharan Africa, with 366 samples from the Bantu speaking tribes 
(Cameroon, Ghana, Democratic Republic of Congo, Malawi and Mozambique), and 
365 from Ethiopia were genotyped for the mutation. From the Arabian Peninsula, a 
total of 214 Arabs were obtained from Kuwait, and 108 Bedouins from Jordan, Saudi 
Arabia and Israel. From the Eastern Mediterranean Basin/Asia Minor, 75 Syrians, 39 
Druzes,  141  Israeli  Arabs  and  19  Palestinian  Arabs  and  308  Armenians  were 
genotyped.  The  number  of  non-Ashkenazi  Jewish  subjects  studied  was  337  of 
Moroccan (186), Iraqi (46) and Iranian (105) Jewish origins, and were obtained from 
Sheba Medical Centre, Israel. 270 healthy subjects were genotyped from Ukraine and 
248 from Belarus. 
3.2.2  DNA extraction and Taqman genotyping 
Genomic  DNA  was  extracted  from  buccal  swab  (at  The  Centre  for  Genetic 
Anthropology) using standard DNA extraction protocols. Refer to section 2.2.1 in 
chapter 2 for DNA extraction procedure. The LRRK2 G2019S (6055G >A) mutation 
was  detected  using  a  pre-designed  Taqman  Assay  C_63498123_10  probe  (NCBI 
Reference rs34637584) (section 2.3.5). The context sequence for Taqman probes for 
wild-type (G) allele: 5’ [FAM]CAT CAT TGC AAA GAT TGC TGA CTA C[G]G CAT 
TGC TCA GTA CTG CTG TAG AAT; and mutant (A) allele 5’[VIC] CAT CAT TGC 
AAA GAT TGC TGA CTA C[A]G CAT TGC TCA GTA CTG CTG TAG AAT  
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Figure 3.1: A schematic representation of the populations used in this study.   
Non-Ashkenazi Jews  ; Arabian Peninsula  ; Asia Minor  ; Eastern Europe  ;             
Africa- Sub-Saharan  and Bantu speaking tribes .  
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3.2.3  Statistical analysis 
The  P-value  of  a  hypothesis  test  is  the  probability  (calculated  assuming  null 
hypothesis is true) of observing any outcome as extreme or more extreme than the 
observed outcome, with extreme being the direction of the alternative hypothesis. An 
exact hypothesis test (for binomial random variables) was performed to estimate the 
true probability of success using a one-sided test of null hypothesis (H0) versus the 
alternative hypothesis (HA): p< 0.01. In other words, the probability of the observed 
frequency given the assumed frequency under the null hypothesis (H0) is 0.01 (at 1% 
level).  
The 95% confidence intervals (CIs) for the observed proportions were estimated, and 
Fisher’s exact test was also performed to examine any significant association between 
the populations and the number of G2019S mutation carriers identified in them. All 
these tests were performed using the STATA
tm  10.0 (StataCorp, USA) software for 
statistical analysis.   
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3.3  Results 
The results in this chapter demonstrate that LRRK2 G2019S mutation carriers are rare 
amongst  selected  populations  of  sub-Saharan  African,  non-Jewish  Middle  Eastern 
(Arabian Peninsula, Eastern Mediterranean Basin and Asia Minor), non-Ashkenazi 
Jewish and Eastern European ancestry. Only 2 positive G2019S heterozygous carriers 
were identified out of a sample of 2,485 subjects from these populations (see Table 
3.3). No G2019S mutation carriers were observed in over 700 subjects from the sub-
Saharan  Africa,  thereby  indicating  that  the  mutation  might  have  arisen  after  the 
human  migrations  out  of  Africa.  The  mutation  was  also  not  identified  in  379 
unaffected  subjects  from  the  Arabian  Peninsula,  but  the  two  positive  G2019S 
mutation carriers are of Middle Eastern origin. This observation along with a lack of 
G2019S mutation in over 500 subjects from Eastern Europe, remains neutral on the 
Middle-Eastern origin for the mutation as has been previously predicted.  
3.3.1  Proportion of G2019S positive carriers in the Middle- East 
3.3.1.1 Non-Jewish Middle East 
A G2019S positive heterozygote carrier was observed in the Syrian population (1 in 
75),  and  a  proportion  of  .0133  (exact  binomial  95%  CI  .00033-  .07206)  was 
calculated.  A  one-sided  exact  hypothesis  test  was  performed  to  test  whether  the 
observed sample proportion is different to a hypothesised proportion of 1% (0.01).  
N  Observed k  Expected k  Assumed p  Observed p 
75  1  0.75  0.01  0.01333 
(N = number of observations, K= events, p = frequency) 
Pr (k <= 1) = 0.827092 (one-sided test).  
Under  an  exact  hypothesis  test,  (H0)  is  p  =  0.01  versus  (HA):  p  <  0.01,  i.e.  the 
probability of observing one or fewer events assuming the H0 is true (i.e. p = 0.01). 
The P - value for this proportion is 0.827. Therefore, the null hypothesis cannot be  
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rejected, and implies that the observed proportion (p = 0.01333) is either similar to 
the assumed proportion of 0.01, or the sample size is too small.  
When the other two other populations in the Eastern Mediterranean Basin (Druze and 
Israeli/Palestinians Arabs) are also taken into account (n = 271), the proportion of 
G2019S  positives  is  calculated  at  .00369  (exact  binomial  95%  CIs  0.0000934  - 
0.0203870). This proportion is not different from the hypothesised proportion of 0.01 
(HA: p < 0.01; P value 0.245, one sided test), indicating that frequency of G2019S 
mutation in Eastern Mediterranean Basin could be 1%. However, when all the non-
Jewish Middle Eastern populations are taken into account (n = 901), the proportion of 
0.0011093; (exact binomial 95% CIs: 0.0000281- 0.0061682) under the hypothesis 
testing is significantly different to 1% (HA: p < 0.01; P value 0.0012, one sided test).  
3.3.1.2 Non- Ashkenazi Jewish Middle East 
Amongst the non-Ashkenazi Jewish population, only one subject from Morocco (N= 
186)  was  identified  as  being  heterozygous  for  the  G2019S  mutation.  Using  the 
hypothesis  test  for  a  sample  size  of  186  (Moroccan  Jews),  the  proportion  is 
0.0053763 (exact binomial 95% CIs 00013 - .02959). This proportion was similar to 
the hypothesised proportion at the 1% level (HA: p < 0.01; P value 0.444, one sided 
test). When the Iraqi and Iranian Jews were included in the analysis (total n = 335), 
similar results were obtained for the observed proportion (.0029851; exact binomial 
95% CIs .0000756 - .0165187; HA: p < 0.01; P value 0.151, one sided test).  
Fisher’s exact test for comparisons between non-Ashkenazi Jewish (n = 335) and 
Eastern Mediterranean Basin/Asia Minor (n = 582) identified no major difference 
between these two Middle-Eastern sub-populations (P -value- 0.597, one sided). 
3.3.1.3 Middle – East 
The other populations from the Middle-East included in this study were from Arabian 
Peninsula (n = 322) and Armenia (n = 308). For the populations from the Peninsula 
no  G2019S  mutation  carriers  were  observed,  and  under  the  hypothesis  test,  this 
proportion (0-.0113908- one sided, 97.5% CI) was found to be significantly different  
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from the assumed frequency of 1% (HA: p < 0.01; P value 0.0039, one sided test). A 
similar result was observed for the population from Armenia (0 - 0119054- one sided, 
97.5% CI; HA: p < 0.01; P value 0.0045, one sided test).  
The  proportion  of  G2019S  mutation  carriers  in  all  Middle-  Eastern  populations 
genotyped in this study (2 in 1,236) was calculated at .00162 (exact binomial 95% CI 
0.000196 - 0.0058329). This proportion (p <0.01) was significantly different from 1% 
(HA: p < 0.01; P value 0.00368, one sided test). A small sample size of the two 
populations with G2019S positive carriers in comparison to the sample size of other 
Middle-Eastern populations could have contributed to the observed frequency of < 
1%.  
3.3.2  No  G2019S  mutation  carriers  in  sub-Saharan  African  and  Eastern 
European populations 
No  G2019S  mutation  carriers  were  observed  in  sub-Saharan  African  and  Eastern 
European populations either, and the proportions (p <0.01) tested significant at P -
values of 0.0006 and 0.0055, respectively, indicating that G2019S is not common in 
either of these populations. Fisher’s exact test to compare all the sub-populations of 
Middle-Eastern origins (n = 1,236) to the sub-Saharan African populations (n = 731), 
also indicated no differences between these populations either.  Since the G2019S 
mutation  is  only  occasionally  observed  in  the  Middle-Eastern  populations 
investigated in this study, a larger sample size would be needed for a conclusive 
result.  
The  rarity  of  this  mutation  demonstrates  that  LRRK2  G2019S  mutation  is  not 
common  in  selected  Middle  Eastern  populations  amongst  whom  North  African 
Berbers and Jews have lived. The lack of this mutation in sub-Saharan Africa and 
Arabian Peninsula also suggests that the mutation was not acquired by the Berbers 
from the sub-Saharan African or the Arabian genetic pool. It is also not prevalent in 
selected Eastern European populations amongst whom Ashkenazi Jews lived.  
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  Population  Country  Sample 
numbers 
(n) 
G2019S 
mutation 
carriers 
Sub-Saharan Africa  1                                                  
2                                          
Total 
Bantu speaking                        
Ethiopia 
366                          
365                            
731 
0                                       
0 
Middle- East                       
Arabian Peninsula 
 
Eastern Mediterranean 
Basin                            
                                                           
                                                       
Asia Minor 
 Non-Ashkenazi Jewish 
 
                                 
3                                                  
4                                           
Total 
5                                     
6                                                        
7                           
Total 
8 
9                                                  
10                                                 
11                                        
Total 
                               
Kuwait                                    
Bedouin 
                            
Syrians                                       
Druze                        
Israeli/Palestinian 
                       
Armenia 
Morocco               
Iraq                                                 
Iran 
                           
214                           
108                           
322 
75                         
36                             
160                                           
271 
308                                        
186                              
46                            
103                           
335 
                                        
0                                
0 
                                           
1                                       
0                                      
0 
                     
0 
1                                           
0                                       
0              
Eastern Europe 
 
12                                                   
13                                         
Total 
Ukraine                                      
Belarus 
270                   
248              
518 
0                                      
0 
Table 3.3: The LRRK2 G2019S mutation is not common in selected populations used in 
this study. The table represents the number of G2019S positive healthy heterozygous carriers 
identified in 2,485 samples in over 13 populations representing sub-Saharan Africa, Middle-
East, and Eastern Europe.   
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3.4  Discussion 
The  G2019S  mutation  has  been  identified  as  a  major  genetic cause of  autosomal 
dominant PD in Europeans, Ashkenazi Jews and populations of North African Berber 
origins (Healy et al. 2008). The highest frequency of this mutation has been reported 
in  North  African  Berbers  and  Ashkenazi  Jews.  The  coastal  geographical  location 
inhabited by the North  African Berbers,  and the extended diaspora  of  the Jewish 
people has meant that both these groups have come into contact with various other 
ethnicities, and as such have developed a rich genetic and cultural legacy. For this 
purpose,  the  main  objectives  of  this  chapter  were  to  estimate  the  carrier  rate 
frequency of G2019S mutation in populations that have contributed to the genetic 
makeup of Berbers or Ashkenazi Jews either through having lived in close proximity, 
or being ethno-culturally similar. The G2019S carrier rate frequency was estimated in 
the  populations  to  address  the  specific  questions  of  whether  this  mutation  a)  is 
associated with sub-Saharan African population, b) or whether it is associated with 
Semitic  populations  from  the  Arabian  sub-continent  (Peninsula  and  Eastern 
Mediterranean Basin/Asia Minor), c) whether the mutation in Ashkenazim arose prior 
to or after its establishment in Eastern Europe?  
A  total  of  2,485  samples  were  screened  for  G2019S  mutation  from  populations 
obtained from sub-Saharan Africa (Ethiopia and Bantu speaking), Arabian Peninsula 
(Kuwait and Bedouins), Eastern Mediterranean Basin/ Asia Minor (Israel/Palestine, 
Jordan,  Syria  and  Armenia),  non-Ashkenazi  Jews  (Morocco,  Iraq  and  Iran),  and 
Eastern Europe (Ukraine and Belarus).  
The lack of G2019S positive carriers in a relatively large sample size of sub-Saharan 
African (n = 731), is indicative of the mutation (in North African Berbers) not being 
acquired from sub-Saharan Africa, and suggests that it arose after the earlier human 
migrations out of Africa. G2019S mutation was also not observed in subjects from 
the Arabian Peninsula (n = 322) either, although two heterozygote carriers of Middle 
Eastern ancestry were identified. One of the positive samples was of Syrian descent 
and the other sample was identified as Moroccan Jewish. Based on such few positive  
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samples, it cannot be conclusively said whether the mutation was brought over to the 
West (North Africa) by invading Arabs, and as such we cannot dispute the proposed 
North African Berber origins for G2019S mutation in the literature. This study also 
demonstrates  that  G2019S  mutation  is  not  common  in  selected  Eastern  European 
populations amongst which the ancestors of modern day Ashkenazim lived, nor is it 
prevalent  in  selected  non-  Jewish  groups  that  followed  a  similar  diaspora  to  the 
Jewish population (Armenia, n = 307). The identification of G2019S mutation in a 
Moroccan Jew, indicates that the mutation was present in the ancestral Ashkenazi 
community, prior to settlement in the ‘Pale’. The study demonstrates that G2019S 
mutation is not common amongst healthy subjects in these selected populations but 
the  two  positive  subjects  lend  support  to  the  published  data  of  a  Middle-Eastern 
origin for  G2019S  mutation, and it being  acquired by Jewish communities whilst 
living amongst other Middle Eastern populations. Unfortunately, a lack of parental 
DNA for these two G2019S positive subjects meant that the haplotype phase could 
not be resolved. Therefore, no haplotype analysis could be performed to determine 
whether these subjects contained the common European-MENA haplotype.  
Semitic origins of G2019S mutation 
Orr-Urtreger  and  colleagues,  screened  PD  patients  (n  =  23)  of  Moroccan  Jewish 
origin and did not identify any G2019S positive carriers. However, a recent study 
looking at the spread of G2019S mutation in healthy subjects from Sephardic Jewish 
population reported a proportion of 1/37 amongst Moroccan Jews (total n = 147). The 
higher proportion of G2019S mutation carriers in the Sephardi Jewish populations as 
reported  by  Change  and  colleagues  could  be  due  to  an  unidentified  Ashkenazi 
ancestry  of  those  samples.  Only  one  Moroccan  Jew  was  identified  as  having  the 
mutation in this study, and in such a small sample set (n = 186), it is not unlikely that 
this positive could be due to statistical fluctuation. Regardless of this, the presence of 
G2019S mutation in healthy carriers amongst Sephardi Jewish populations supports a 
Middle-Eastern origin for the mutation. No G2019S positive carriers were identified 
in healthy Jewish subjects from Iraq and Iran. This is in agreement with a previous  
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study that also did not observe G2019S mutation in PD (n = 19), or in healthy Jewish 
subjects of Iraqi origin (n =300) (Orr-Urtreger et al. 2007). This is not surprising as 
the Iraqi and Iranian Jews are thought to be descendents of the original Babylonian 
Jews who settled in Iraq and Iran after the destruction of first temple, and therefore, 
could represent a different gene pool to the Jewish communities that settled in the 
Iberian  Peninsula  and  North  Africa  (Sephardi)  or  Eastern  Europe  (Ashkenazi) 
(Motulsky 1995; Colombo 2000a).  
The other G2019S positive samples reported in this study is of Syrian origin and a 
previous study identified a PD affected Syrian Jew who was also positive for G2019S 
mutation (Orr-Urtreger et al. 2007). Therefore, it cannot be discounted that the one 
positive Syrian subject in this study is a migrant into the general Syrian population 
and does indeed have Jewish heritage. However, a lack of information regarding the 
ancestral heritage of the positive Syrian sample in this study does not allow us to 
address this question. The G2019S mutation has recently been hypothesised to be of 
Phoenician origin, and for that purpose populations around the Eastern Mediterranean 
Basin (Syrians, Israeli/Palestinians, and Druze), were screened for the mutation. Even 
though one positive carrier was identified amongst Syrians, due to the overall low 
number of Syrians (n = 75), the data presented in this chapter remains inconclusive 
on this matter. 
The  two  samples  identified  in  this  chapter  both  belong  to  coastal  Mediterranean 
regions  that  were  probably  frequented  by  Phoenician  navigators  and  traders.  The 
observed proportion of positive samples was identified as not being different from 
1% for their respective ethnicities, (Syrian and Moroccan Jews). However, the small 
sample size (Syrian, n = 75; Moroccan Jews, n = 186) should be taken into account. 
In contrast, these proportions were found to be < 1% when other populations from the 
Middle-Eastern  group  were  included.  Also  no  difference  was  observed  in  the 
proportions  of  G2019S  mutation  carriers  in  either  of  these  sub-groups  using  a 
Fisher’s exact test. Estimating the G2019S carrier rate in a larger sample set in Syrian 
and  Moroccan  Jews  would  address  the  questions  of  the  true  proportion  in  these 
ethnicities, and also the differences between the two groups. Screening samples from  
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Lebanon and Palestine for G2019S mutation would also add to the genetic data of the 
Phoenician origin for this mutation.  
Amongst European populations, the highest carrier rate of G2019S mutation has been 
reported in the regions of Iberian Peninsula (excluding Ashkenazi). However, nothing 
has so far been reported in the Southern Spanish regions (Andalusia) or in Gibraltar. 
These  regions  were  under  North  African  Moroccan  dominion  for  a  considerable 
amount of time and a bidirectional genetic admixture between these populations has 
been demonstrated (Bosch et al. 2001). Therefore, it is feasible that the mutation 
could have arrived in the Iberian Peninsula prior to the invasion by North Africans in 
711 CE. The coastal surroundings of these regions make it likely that they presented 
important trading routes across the Mediterranean coast for sea-faring peoples like the 
Phoenicians. In order to achieve an accurate carrier rate of G2019S mutation in the 
Iberian Peninsula, and to further provide evidence for the Phoenician origins of the 
mutation, populations from Andalusia and Strait of Gibraltar, and other populations 
with Phoenician heritage, (for example, Syrians, Lebanese and Palestinians) should 
be screened for the G2019S mutation 
G2019S  mutation  in  Ashkenazi  versus  non-Ashkenazi  Jews:  selective 
heterozygotic advantage or founder effect? 
The G2019S carrier rates in various Jewish ethnicities have been described as high in 
the  Ashkenazim,  followed  by  Sephardim.  So  far  no  incidences  for  the  G2019S 
mutation  have  been  reported  in  Yemenite  or  Iraqi/Iranian  Jews.  The  highest 
frequency  of  G2019S  mutation  amongst  unaffected  Ashkenazi  Jews  has  been 
reported at 2.4%, and an overall carrier rate of 1.4% was reported for unaffected 
Sephardim,  but  a  frequency  comparable  to  Ashkenazi  was  reported  in  Sephardi 
subjects specifically from Djerba Tunisia (2.55%) (Change et al. 2008).  
There has been some debate as to the stability of certain microsatellite makers used in 
the estimation of the common ancestral haplotype (Zabetian et al. 2006a). However, 
current data in the literature suggests an ancient founder for the G2019S mutation in  
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the Middle-East, a result of which has been the identification of this mutation in 
various ethnicities of the Middle-East.  
Founder effects can either result from the establishment of a new population from 
individuals  derived  from  a  much  larger  population  (true  founder  event),  or  a 
population bottleneck which is an extreme reduction in size. In either case, certain 
alleles maybe found at a higher frequency than they were originally present at prior to 
the founder event or bottleneck, and small population sizes under strong genetic drift 
can  also  result  in  these  alleles  achieving  an  even  higher  frequency.  One  way  of 
achieving high frequency by chance (genetic drift) is the rapid growth of a population 
from  a  limited  group  of  founders,  and  Ashkenazi  Jewish  populations  have  gone 
through severe bottlenecks and growth periods in its history (Risch et al. 1995). The 
demographic  history,  extreme  population  contractions  and  rapid  expansions,  (and 
endogamous culture) have resulted in many genetic diseases that are unique to the 
Ashkenazi Jewish population. For example, Tay-Sachs; Niemann-Pick type C (NPC); 
mucolipidosis type IV and Gaucher disease are all common to the Ashkenazim, and 
result from a defect in sphingolipid storage (Zlotogora et al. 1988). Initially the high 
frequency  of  these  autosomal  recessive  diseases  was  attributed  to  selective 
heterozygote  advantage,  where  selection  was  considered  to  have  favoured 
heterozygous  carriers  of  alleles  affecting  lipid  metabolism  and  storage  (possibly 
protecting or atleast providing resistance to tuberculosis) (Motulsky 1995). However, 
founder effects and genetic drift on the alleles rather than heterozygote advantage 
have  now  been  shown to  account  for the  lipid  storage  diseases  in  the  Ashkenazi 
population  (Risch  et  al.  1995;  Risch  et  al.  2003).  LRRK2  related  PD  results  in 
autosomal dominant form of the disease like idiopathic torsion dystonia, breast cancer 
type 1 and 2 in Ashkenazi Jews, and the heterozygote advantage applied for recessive 
disorders is not applicable here (Risch et al. 1995; Risch et al. 2003; Slatkin 2004). 
Therefore,  specific  founder  effects  resulting  from  the  dynamics  of  population 
contractions and growth in the Eastern European Jewish population, could explain the 
high  frequency  of  this  mutation  in  the  Ashkenazim  versus  the  other  Jewish  
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ethnicities,  and  future  studies  investigating  specific  founder-effect  hypothesis  in 
Ashkenazi Jews needs to be performed (Slatkin 2004).  
Furthermore,  the  G2019S  mutation  has  been  identified  in  Jewish  subjects  with 
dementia and Gaucher’s disease (Saunders-Pullman et al. 2006; Eblan et al. 2006). In 
addition to the kinase, GTPase and multi-protein complex activities, LRRK2 protein 
may also have an affinity for lipids or lipid-associated proteins, and has been recently 
to regulate synaptic vesicle endocytosis (Biskup et al. 2006; Hatano et al. 2007; Shin 
et al. 2008). This has led to the suggestion that LRRK2 protein may play a role in the 
regulation of membranous intracellular structures. Even though the LRRK2 G2019S 
has shown not to be associated with Gaucher disease patients (Eblan et al. 2006), it 
would nevertheless be interesting to investigate whether this mutation plays a role in 
other  neurological  lipid  associated  disorders  that  might  be  common  among  the 
Ashkenazi Jews. 
Conclusion 
This report shows that G2019S mutation is not present in selected populations of sub-
Saharan Africa, and Arabian Peninsula. Therefore, this data remains neutral on the 
predicted North African Berber origin for G2019S mutation. The data also suggests 
that  G2019S  mutation  in  Ashkenazi  Jews  has  not  been  acquired  from  the  local 
populations  amongst  whom  the  ancestors  of  modern  day  Ashkenazim  lived,  but 
supports the published data of the mutation being acquired prior to the beginning of 
Jewish  diaspora.  The  identification  of  two  positive  G2019S  mutation  carriers:  a 
Moroccan Jew and non-Jewish Syrian also support the published data of Middle-
Eastern  origin  for  the  mutation.  However,  it  should  be  noted  that  both  of  these 
samples  are  from  the  coastal  regions  of  the  Mediterranean  Basin,  therefore,  a 
Phoenician or a Carthaginian origin of the mutation cannot be conclusively ruled out 
as yet.   
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Chapter 4  
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4  A  morphological  study  of  LRRK2  mRNA  and  protein 
expression in the human brain 
4.1  Introduction 
In order to understand the effects of LRRK2 dysfunction on PD pathogenesis, it is 
necessary to establish its cellular expression (both transcriptional and translational). 
LRRK2 mRNA and protein expression in CNS, lungs, kidney, spleen and leucocytes, 
has  led  to  the  suggestion  that  this  gene  plays  an  important  physiological  role 
(Zimprich  et  al.  2004b;  Giasson  et  al.  2006,  Biskup  et  al.  2006;  Li  et  al.  2007; 
Westerlund et al. 2008a). Mouse embryonic development studies have suggested that 
LRRK2  is  not  an  essential  gene  for  development,  and  in-situ  hybridisation  (ISH) 
studies  have  shown  that  LRRK2  mRNA  in  the  mouse  embryonic  brain  is  first 
detected at postnatal day 8 (P8), and is expressed in striatum at constant levels during 
aging (Westerlund et al. 2008a). However, immunoblot assays have shown that the 
LRRK2  protein  is  detectable  at  E17  (Biskup  et  al.  2007),  rises  continuously  and 
eventually  peaks  at  the  post-natal  age  of  P60  (Li  et  al.  2007).  This  apparent 
discrepancy in the time course of the detection of mRNA and protein has led to the 
suggestions that LRRK2 mRNA is present in low quantities in the brain. 
4.1.1  LRRK2 mRNA expression 
The  mRNA  expression  of  LRRK2  was  initially  suggested  to  have  a  specific 
localisation to the dopamine innervated areas in the nigrostriatal dopamine system 
with a definitive distribution in the medium spiny neurons of striatum (Galter et al. 
2006; Melrose et al. 2006). Lack of mRNA in dopaminergic (DAergic) neurons of the 
substantia nigra (SN) led the authors to conclude that the gene was expressed in the 
dopamine  innervated  neurons  as  opposed  to  dopamine  synthesising  neurons. 
However, a comprehensive regional study investigating the cellular localisation of 
LRRK2 mRNA in rodent brain found that it did indeed localise to the SN in addition 
to various other regions in the brain (Simón-Sánchez et al. 2006). The localisation of 
LRRK2 mRNA to the SN and cortex was confirmed in post-mortem human brain and  
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also in subsequent mouse studies (Taymans et al. 2006; Higashi et al. 2007a; Higashi 
et  al.  2007b).  Studies  examining  the  cellular  expression  of  LRRK2  mRNA  are 
summarised in Table 4.1.  
The use of oligonucleotide probes versus riboprobes for ISH studies could be the 
major  cause  in  the  discrepant  results  observed  in  relation  to  LRRK2  mRNA 
distribution  (Galter  et  al.  2006;  Melrose  et  al.  2006;  Simón-Sánchez  et  al.  2006; 
Taymans et al. 2006; Higashi et al. 2007a; Higashi et al. 2007b). Owing to the length 
of the riboprobes (up to 200 bp), a stronger and a more specific hybridisation to 
mRNA molecules is formed in comparison to the oligonucleotide probes which are 
traditionally less than 50 bp. Initial studies that used oligonucleotide probes did not 
identify  LRRK2  mRNA  in  SN,  whereas  the  studies  that  used  riboprobes 
demonstrated  LRRK2  mRNA  presence  in  dopamine  synthesising  and  innervated 
areas (Galter et al. 2006; Melrose et al. 2006; Simón-Sánchez et al. 2006; Taymans et 
al. 2006). Subsequent studies identified LRRK2 mRNA in SN and striatal regions 
using radioactive oligonucleotide probes in rodents and post-mortem human brain 
(Higashi et al. 2007a; Higashi et al. 2007b). However, an exposure time of 10 weeks 
was  needed  to identify  LRRK2  mRNA signal,  further  indicating  that  it  might be 
present as a low copy number mRNA in the post-mortem human brain (Higashi et al. 
2007b).   
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Table 4.1: Summary of studies investigating LRRK2 mRNA localisation in the brain. AMG: amygdala, BTM: brainstem, CBM: cerebellum, CTX: 
cortex, GP: globus pallidus, HIP: hippocampus, HT: hypothalamus, LC: locus coeruleus, MB: midbrain, OT: olfactory tubercle, ON: olfactory nuclei, 
SBM: subiculum, PrN: Purkinje neurons, SN: substantia nigra, STR: striatum, THA: thalamus. 
Study reference  Tissue 
Type 
mRNA 
quantitation 
Regional mRNA expression established 
(Galter et al. 2006)  Rat            
Human 
Radioactive 
oligonucleotide 
High expression in medium spiny neurons of STR (none in cholinergic); moderate to 
weak in CTX and negative in SN. 
(Melrose et al. 2006)  Mouse  Radioactive 
oligonucleotide 
and qRT-PCR 
High expression in STR, CTX and OT, moderate in CBM and ON; weak in HIP and 
SBM; negative in the MB and BTM (but qRT-PCR revealed low mRNA expression in 
these regions). 
(Simón-Sánchez et al. 2006)  Mouse  Digoxigenin 
riboprobe 
High expression in STR, CTX, HIP, AMG, SN; moderate to low in OT, THA, brainstem, 
granule cell layer (CBM); negative in GP and PrN (CBM). 
(Taymans et al. 2006)  Rat  and 
mouse 
Digoxigenin 
riboprobe 
High expression in STR, CTX, OT, HIP, AMG, PrN, moderate in THA, HT and BTM; 
weak in SN, GP, LC and granule cell layer (CBM). 
(Miklossy et al. 2006)  Human 
cells 
qRT-PCR  Primary cultured human oligodendrocytes, astrocytes and microglia. LRRK2 expression 
was also found in human neuroblastoma cell lines. 
(Higashi et al. 2007a)  Mouse  Radioactive 
oligonucleotide 
High expression in CTX and STR; moderate in HIP and CBM; weak in HT, THA and 
SN. 
(Westerlund et al. 2008a)  Mouse                
Human 
Radioactive 
oligonucleotide 
Expression  in  STR,  HIP  and  CTX.  In  mice,  LRRK2  mRNA  was  also  identified  in 
sensory and sympathetic ganglia. SN not included in study. 
(Higashi et al. 2007b)  Human  Radioactive 
oligonucleotide 
High expression levels detected in SN, STR and CTX.  
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Such contradictions in the literature could be attributed to the inherently sensitive and 
fragile nature of mRNA molecules. In addition, post-mortem studies performed on 
human  tissue  may  be  compromised  by  the  peri-mortem  changes  that  affect  the 
integrity of mRNA expression. Post-mortem delay has been shown not to critically 
affect the quality  and preservation of mRNA for long term storage (Barton et al. 
1993; Kingsbury et al. 1995; Ervin et al. 2007). Ante-mortem events, on the other 
hand, can have a huge impact on mRNA preservation in the tissue, and agonal state 
has been reported to be influential in post-mortem preservation of mRNA molecules 
(Kingsbury  et  al.  1995).  Hypoxia  caused  due  to  respiratory  distress  (or  longer 
terminal  phase),  results  in  anaerobic  glycolysis  within  the  brain,  leading  to  an 
increasing lactate concentration in the tissue (Harrison et al. 1991). This lowers the 
pH of the tissue leading to a detrimental effect on mRNA preservation. Tissue pH has 
therefore, come to be regarded to as an important marker for terminal hypoxia in the 
absence of detailed clinical information for agonal state (Kingsbury et al. 1995). A 
combination  of  degraded  post-mortem  tissue  and  possible  insensitive  ISH  probes 
could have contributed to the previous discrepancies reported in cellular localisation 
of LRRK2 mRNA in the human brain, thereby warranting further investigation.  
4.1.2  LRRK2 protein expression 
LRRK2 protein has consistently been demonstrated to have a constitutive neuronal 
expression  in  the  mammalian  brain.  Regional  quantitative  differences  in  LRRK2 
protein levels using immunoblot assays have been demonstrated in the rodent brain 
(Biskup et al. 2006; Taymans et al. 2006; Melrose et al. 2007). Immunohistochemical 
studies  have  corroborated  regional  variation  in  the  LRRK2  protein  levels  in  the 
human brain too (Miklossy et al. 2006; Higashi et al. 2007b; Alegre-Abarrategui et al. 
2008). LRRK2 protein has been shown to localise not only to neuronal populations in 
the brain, but also weakly to astrocytes and microglia (Miklossy et al. 2006). The 
presence  of  LRRK2  in  Lewy  bodies  (LBs)  has  also  been  frequently  described, 
although the inconsistencies in the reports have made LRRK2 localisation to LBs a 
controversial issue (reviewed in (Santpere & Ferrer 2009)).   
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Just as the inconsistencies relating to LRRK2 mRNA localisation can be attributed to 
the type of hybridisation probe and the quality of tissue used, the discrepancies in 
LRRK2 localisation to LBs can also be attributed to the antibody used in the study. 
Polyclonal antibodies have been produced that recognise the LRRK2 protein, and 
despite  recognising  a  ~250  kDa  band  for  the  protein  in  mammalian  brain 
homogenates  (Biskup  et  al.  2007),  variations  have  been  reported  in  LRRK2 
immunoreactivity between the antibodies (reviewed in (Santpere & Ferrer 2009)). It 
has been widely reported that for identifying the presence of LRRK2 in LBs, the best 
results are achieved with the antibodies raised against the C- and N- termini, and 
antibodies raised against the central domains of LRRK2 do not detect the protein in 
LBs (see Table 4.2 for a summary on the antibodies that have been used to localise 
LRRK2 in LBs). The possibility of LRRK2 functional domains folding in a complex 
manner in LBs could result in antigen retrieval treatments not being able to expose 
the epitopes sufficiently enough to be recognised by the antibodies raised against the 
core functional domains. Zhu et al (2006) used four antibodies to identify LRRK2 in 
LBs  and  reported  immunoreactivity  with  all  of  them  (some  better  than  others), 
whereas  Melrose  and  colleagues,  used  six  different  antibodies  and  did  not  find 
consistent immunoreactivity in LBs or Lewy neurites (apart from with NB300-268) 
(Zhu et al. 2006a; Zhu et al. 2006b; Melrose et al. 2007). Recent investigations have 
established  that  only  NB300-268  antibody  stains  the  core  of  perikaryal  LBs,  and 
others  recognise  the  halo region of  about  10%  of  LBs  (Alegre-Abarrategui  et  al. 
2008; Santpere & Ferrer 2009). Despite the fact that the presence of LRRK2 as a 
major  component  of  LBs  remains  a  contentious  issue,  a  new  C-terminal  raised 
antibody (EB06550) has been shown to produce robust immunohistochemical results 
in post-mortem human brain (Alegre-Abarrategui et al. 2008).  
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Table 4.2: Summary of antibodies used for determining LRRK2 in Lewy bodies.  
Antibody  Epitope  Immunolabelling of α-synuclein-positive inclusions 
Ab7099b, 
Abgent        
1246-1265 
Rabbit 
No immunolabelling of α-synuclein immunoreactive inclusions identified 
in G2019S positive PD cases; sporadic PD, DLB and MSA cases (Giasson 
et al. 2006; Zhu et al. 2006a; Zhu et al. 2006b; Covy et al. 2006; Santpere 
& Ferrer 2009).  
NB300-
267, 
Novus 
Biological 
900-1000  
Rabbit 
Immunolabels the halo around a proportion of LBs in sporadic PD, DLB, 
MSA and DLBD cases. No lewy neurites or cortical LBs observed (Zhu, 
Babar et al. 2006; Zhu, Siedlak et al. 2006; Covy et al. 2006; Miklossy et 
al.  2006;  Higashi,  Biskup  et  al.  2007;  Melrose  et  al.  2007;  Alegre-
Abarrategui et al. 2008; Santpere & Ferrer 2009).  
NB300-
268,  
Novus 
Biological 
2500-2527,  
Rabbit; 
Immunolabels  intraneuritic  and  perikaryal  brainstem,  limbic  and 
neocortical  LBs  in  sporadic  PD,  DLB,  MSA  and  DLBD  cases.  Lewy 
neurites were also strongly stained (Zhu, Babar et al. 2006; Zhu, Siedlak et 
al. 2006; Covy et al. 2006; Miklossy et al. 2006; Higashi, Biskup et al. 
2007;  Melrose  et  al.  2007; Alegre-Abarrategui  et  al.  2008;  Santpere  & 
Ferrer 2009). 
AT106, 
Alexis  
1838-2133 
Rabbit 
No immunoreactivity to LBs or LNs in sporadic PD, DLB and MSA cases 
(Covy et al. 2006). 
Ab04/11        
PA0362-  
2507-2527  
Rabbit 
No robust or consistent immunoreactivity to LBs or LNs in DLBD brains 
(Melrose et al. 2007). Antibody developed in- house. 
AB9704       
AB9682                   
Chemicon 
*Rabbit                      
*Sheep                    
No robust or consistent immunoreactivity to LBs or LNs in DLBD brains 
(Melrose et al. 2007).                                                                                         
*Epitope sequences are proprietary. 
 JH5514  
JH5517 
JH5518  
2500-2515 
334-347 
527-537   
all rabbit 
JH5517 stains the halo structure of brainstem LBs but is not associated 
with cortical LBs or LNs in sporadic PD and DLB cases (Higashi et al. 
2007b). Antibody developed in-house. 
EB06550,    
Everest 
Biotech 
2015- 2026  
Goat   
Stained the halo of a minority of perikaryal and intraneuritic LBs in PD 
and DLB cases. (Alegre-Abarrategui et al. 2008)  
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As  described  in  chapter  1,  LRRK2  mutations  exhibit  a  highly  complex 
neuropathological phenotype, and as such this protein has been suggested to play 
a role in synucleopathies as well as tauopathies. The prevalent G2019S mutation 
occurs in the kinase domain, and is associated with pure nigral degeneration and 
classic  LB  pathology  (in  the  brainstem).  Autopsy  of  three  G2019S  mutation 
carriers revealed nigral degeneration accompanied with nigral LBs, leading to the 
question of selective vulnerability of catchecolaminergic neurons to degeneration 
in  LRRK2  mutation  carriers  despite  the  widespread  expression  of  the  protein 
(Giasson et al. 2006). Two of these patients showed LBs in limbic cortex, and the 
third  had  neocortical  senile  plaques  and  occasional  NFTs  which  could  be 
associated with the pathology of normal aging. 
The G2109S mutation has been shown to increase the kinase activity of LRRK2 
and enhance autophosphorylation and phosphorylation of generic substrates in in-
vitro kinase  assays,  although the in-vivo effects of this  mutation remain to be 
established. Even though the clinical and pathological phenotype associated with 
the G2019S mutation is indistinguishable from the idiopathic PD, reports have not 
been published detailing the expression profile of LRRK2 mRNA or protein in 
G2019S mutation carriers. If as the in-vitro data suggests that G2019S mutation 
increases LRRK2 autophosphorylation, it would be interesting to assess whether 
the mutation has a qualitative or quantitative effect on the expression profile of 
IPD and G2019S positive PD subjects. Any differences, subtle or otherwise in the 
brains of these subjects would not only highlight the mechanistic pathways but 
also  allow  for  a  better  interpretation  of  the  in-vitro  and  in  future  in-vivo  data 
relating to this protein.   
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4.1.3  Hypothesis and specific aims  
In  this  chapter,  I  wished  to  investigate  the  hypothesis  that  a  disease 
phenotype could result in an anatomical and cellular expression profile of 
LRRK2 that is different in control and PD subjects. The specific questions 
addressed  in  this  chapter  were:  a)  what  is  the  anatomical  distribution  of 
LRRK2 mRNA and protein in human brain; b) are there any differences in 
the morphological distribution of LRRK2 mRNA and protein expression in 
control, IPD and G2019S positive PD subjects; c) is LRRK2 protein a major 
component of LBs? 
To address these questions, a morphological expression profile of LRRK2 mRNA 
and  protein  was  determined  using  in-situ  hybridisation  (ISH)  and 
immunohistochemistry  (IHC),  respectively.  The  anatomical  distribution  was 
determined  using  post-mortem  tissue  from  medulla,  brainstem,  basal  ganglia 
(deep  grey  nuclei),  cerebellum,  medial  temporal  lobe,  and  neocortical  regions 
obtained from QSBB. Radioactive and non-radioactive methods were employed 
for  the  ISH  procedure.  A  recently  reported  antibody  EB06550  was  used  to 
determine  LRRK2  immunoreactivity  in  post-mortem  human  brain,  and  also  to 
establish the presence of LRRK2 in LBs.   
[129] 
 
4.2  Methods and materials 
4.2.1  Tissue used 
Following  removal  at  autopsy,  samples  of  brain  tissue  which  had  been  flash 
frozen and stored at -80ºC or formalin fixed and paraffin embedded were obtained 
for  in-situ  hybridisation  (ISH)  and  immunohistochemical  (IHC)  studies, 
respectively. The tissue was obtained from the Queen Square Brain Bank (QSBB) 
archive. All tissue at the QSBB is collected using ethically approved protocols, 
and is stored under a licence issued by the Human Tissue Authority. See Table 4.3 
for a summary of subjects used in the study.  
4.2.2  In-situ hybridisation 
Frozen tissue sections from 2 controls, 1 IPD and 3 G2019S positive PD cases are 
summarised in Table 4.4. The tissue sections were cut at 12µm as per instructions 
in  section  2.5.1.1  of  chapter  2.  Both  the  radioactive  and  digoxigenin  labelled 
probes were prepared as described in section 2.5.1.2 (of chapter 2). The tissue 
preparation, hybridisation, washing and visualisation procedures are described in 
sections 2.5.1.3 to 2.5.1.6 of chapter 2.  
Table 4.5 summarises the oligonucleotide probes used in this study. During the 
optimisations probes 1-4 were used for both the radioactive and non-radioactive 
ISH, but the digoxigenin labelled probe 3 which binds to the kinase domain of the 
LRRK2 gene produced the best results, and was therefore used to produce non-
radioactive ISH data. Previously published oligonucleotide probes for aldolase- C 
and BRI2 (Kingsbury et al. 2001; Lashley et al. 2008) were labelled using 
35S and 
digoxigenin, respectively to be used as positive controls for the ISH method being 
used.  A  dot  blot  was  performed  according  to  the  manufacturer’s  instructions 
(Roche,  UK)  to  determine  the  labelling  efficiency  of  the  digoxigenin  labelled 
probes.  
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  Sex 
 
Age 
 
PM delay 
(hours) 
pH 
 
Cause of death 
 
Pathological 
diagnosis 
ISH              
study 
 
IHC               
study 
 
Con1  M  76  39.5  N/A  Cancer  Control  √  N/A 
Con2  M  93  89  N/A  Old age  Control  √  N/A 
Con3  F  78  23.3  6.07  N/A  Control  N/A  √ 
Con4  F  84  28.5  6.13  Cancer  Control  N/A  √ 
Con5  F  91  98.5  6.41  Old age  Control  N/A  √ 
Con6  F  88  11.1  5.67  Myocardial infarct  Control  N/A  √ 
IPD1  F  77  80  6.53  Congestive heart failure  IPD  √  N/A 
IPD2  F  62  46.8  5.88  Gradual deterioration  IPD  N/A  √ 
IPD3  F  81  24.25  N/A  Congestive heart failure  IPD  N/A  √ 
G2019S-1  F  81  15.00  6.53  Bronchopneumonia  IPD (G2019S)  N/A  √ 
G2019S-2  F  84  32.3  5.79  Congestive heart failure  IPD (G2019S)  √  √ 
G2019S-3  F  80  44.4  6  Advanced PD  IPD (G2019S)  √  √ 
G2019S-4  F  72  24.55  N/A  Pulmonary embolism  IPD (G2019S)  √  √ 
 
Table 4.3: Summary of subjects used for in-situ hybridisation (ISH) and immunohistochemical (IHC) studies. This tissue was obtained from QSBB. 
Con- control, M- male, F-female, PM delay- post-mortem delay. N/A: not available. 
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    Con 
1 
Con 
2 
IPD 
1 
G2019S 
2 
G2019S 
3 
G2019S 
4 
Medulla  X nerve nucleus  √  N/A  N/A  N/A  N/A  N/A 
  XII nerve nucleus  √  N/A  N/A  N/A  N/A  N/A 
  Inferior olive  √  √  √  N/A  N/A  √ 
Pons  Locus coeruleus  N/A  N/A  N/A  N/A  √  √ 
  Pontine base  √  √  √  √  √  √ 
  Tegmentum  √  N/A  N/A  N/A  √  √ 
Midbrain  Substantia nigra  √  √  √  √  N/A  √ 
  IIIrd nerve nucleus  √  N/A  N/A  √  N/A  √ 
  Red nucleus / 
tegmentum 
√  √  √  √  N/A  √ 
  Tectum  √  √  N/A  √  N/A  √ 
Deep grey 
nuclei 
Caudate  √  √  √  N/A  √  √ 
  Putamen  √  √  √  N/A  √  √ 
  Globus pallidus  √  N/A  √  N/A  N/A  √ 
  Thalamus  N/A  N/A  √  N/A  N/A  N/A 
Medial 
temporal 
Dentate fascia  √  √  N/A  N/A  N/A  √ 
lobe  CA1-4  √  √  N/A  N/A  N/A  √ 
  Subiculum  √  √  N/A  N/A  N/A  √ 
  Entorhinal cortex  N/A  √  N/A  N/A  N/A  √ 
  Transentorhinal  √  √  N/A  N/A  N/A  √ 
Cerebellum  Dentate nucleus  √  N/A  √  N/A  √  N/A 
  Purkinje cells  √  √  √  √  √  √ 
  Granule cells  √  √  √  √  √  √ 
Neocortices  Frontal  √  √  √  √  √  √ 
  Parietal  √  √  √  √  √  N/A 
  Temporal  √  √  N/A  √  N/A  √ 
  Fusiform gyrus  √  √  N/A  N/A  N/A  N/A 
  Insular cortex  √  N/A  N/A  N/A  N/A  √ 
  Cingulate gyrus  √  N/A  N/A  N/A  √  N/A 
Table 4.4: Summary of anatomical regions obtained from controls, IPD and G2019S 
positive subjects for in-situ hybridisation. This tissue was obtained from QSBB. N/A: 
not available. 
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Table 4.5: Oligonucleotide probes used for radioactive and non-radioactive ISH. 
ISH 
Probes 
Sequence 5’to 3’  Corresponding 
nucleotides 
LRRK2 
Probe 1 
GTTGATAGTCAGGCTGAACAATGTCCAG                                   
LRRK2 cDNA BLAST accession: AY792511 
54 –81                                 
N-terminal 
LRRK2 
Probe 2 
CAGGCTGTTAAGACAAGAGCTTGTGGTGCTTTGCCACCTC                                                                                     
LRRK2 cDNA BLAST accession: AY792511 
5742-5781                    
Kinase domain 
LRRK2 
Probe 3 
CCGCTGATGGCAAGTTAGCAATTTTTGAAGATAAGACT                                                                                       
LRRK2 cDNA BLAST accession: AY792511 
6800 – 6838                  
WD40 domain 
LRRK2 
Probe 4 
TTGTCAGTGATTGGACTGAAGACCTTAGATCTCC 
LRRK2 cDNA BLAST accession: AY792511.                           
Previously published probe (Higashi et al. 2007b) 
133- 144                              
N-terminal 
Aldolase-
C 
CGACGCAGGGCAGTGACAGTTGCCATGGC                            
cDNA BLAST accession: AK296053 
(Kingsbury et al. 2001) 
2837-2866              
Positive control for 
radioactive ISH 
BRI2   CCGCTCTTGGGCTCGTCCTTCTTGGCCTCCTTCTGGGCCAC 
cDNA BLAST accession: BF941808.1                                                          
(Lashley et al. 2008) 
28 – 68                        
Positive control for 
nonradioactive ISH  
[133] 
 
4.2.3  Immunohistochemistry 
Immunohistochemistry was performed on paraffin embedded tissue sections from 4 
controls, 2 IPD and 4 PD cases positive for the G2019S mutation (see Table 4.3). The 
antibody and pre-treatments used in this study are listed in Table 4.6. The anatomical 
regions cut are summarised in Table 4.7. The sections were cut at 8µm and processed 
as described in section 2.5.2 of chapter 2.  
The anti-LRRK2/PARK8 antibody- EB06550 obtained from Everest Biotech (UK) 
was raised against the peptide with sequence CELAEKMRRTSV in goat. The peptide 
sequence of this polyclonal antibody corresponds to a region near the C terminus of 
the LRRK2 protein sequence according to NP_940980.2. Immunoabsorption of this 
antibody has  been reported  previously  in  an  immunohistochemical  study  (Alegre-
Abarrategui et al. 2008). The visualisation procedure was carried out as described in 
section 2.5.2.3 of chapter 2 using goat immunoglobulins (Dako, UK) at a dilution of 
1:200 and choromogen diaminobenzidine. 
Antibody  Source  Host  Dilution 
for IHC 
Pre-treatments 
required 
Anti-LRRK2/ 
PARK8-  
EB06550 
Everest Biotech, 
Oxfordshire, 
UK 
Goat  1 : 150  pressure cooking  
chapter2: section 
2.5.2.5 
Table  4.6:  Dilution  and  pre-treatments  used  for  LRRK2  EB06550  antibody  in  this 
study.  
4.2.4  Western blot analysis and antigen absorption assay  
In order to confirm the specificity of the EB06550 antibody, a western blot analysis 
using an antigen absorption assay was conducted as described in section 2.5.3 of 
chapter 2. Post-mortem frozen tissue from medulla was homogenised, and 10µg and 
20µg of the homogenised protein was used for the assay.  
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Table 4.7: Summary of anatomical regions obtained from control (con), IPD and G2019S PD subjects for LRRK2 immunohistochemistry. 
This tissue was obtained from QSBB. N/A: not available.  
    Con 
3 
Con 
4 
Con 
5 
Con 
6 
IPD 
2 
IPD 
3 
G2019S 
1 
G2019S 
2 
G2019S 
3 
G2019S 
4 
Medulla  X nerve nucleus  √  √  √  √  √  √  √  N/A  √  √ 
   XII nerve nucleus  √  √  √  √  √  √  √  N/A  √  N/A  
   Inferior olive  √  √  √  √  √  √  √  √  √  √ 
Pons  Locus coeruleus  √  √  √  √  √  √  √  √  N/A  √ 
   Pontine base  √  √  √  √  √  √  √  √  √  √ 
   Tegmentum  √  √  √  √  √  √  √  √  √  √ 
Midbrain  Substantia nigra  √  √  √  √  √  √  √  √  √  √ 
   IIIrd nerve nucleus  √  √  √  √  N/A  √  N/A  √  √  √ 
   Red nucleus/ tegmentum  √  √  √  √  √  √  N/A  √  √  √ 
   Tectum  √  √  N/A  √  √  √  N/A  √  N/A  √ 
Deep grey  
nuclei 
Caudate  √  √  √  √  √  √  N/A  √  √  √ 
Putamen  √  √  √  √  √  √  √  √  √  √ 
   Globus pallidus  N/A  √  √  √  √  √  √  √  N/A  √ 
   Thalamus  N/A  N/A  √  √  N/A  √  √  √  N/A  N/A 
   Subthalamic nucleus  N/A  N/A  √  √  N/A  √  N/A  √  √  N/A 
Medial 
temporal  
Dentate fascia  √  √  √  √  √  √  √  √  √  √ 
CA1-4  √  √  √  √  √  √  √  √  √  √ 
lobe  Subiculum  √  √  √  √  √  √  √  √  √  √ 
   Entorhinal cortex  √  √  √  √  √  √  √  √  √  √ 
   Transentorhinal  √  √  √  √  √  √  N/A  √  √  √ 
   Amygdala  √  √  √  √  √  √  √  √  √  √ 
Cerebellum  Dentate nucleus  √  √  √  √  √  √  √  √  √  √ 
   Purkinje cells  √  √  √  √  √  √  √  √  √  √ 
   Granule cells  √  √  √  √  √  √  √  √  √  √ 
Neocortical   Frontal  √  √  √  √  √  √  √  √  √  √ 
regions  Parietal  √  √  √  √  √  √  N/A  √  √  √ 
   Temporal  √  √  √  √  √  √  √  √  √  √ 
   Fusiform gyrus  √  √  √  √  √  √  √  √  √  √ 
   Insular cortex  √  √  √  √  √  √  √  √  √  √ 
   Cingulate gyrus  √  √  √  √  √  √  √  √  N/A  N/A  
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4.3  Results 
4.3.1  LRRK2 mRNA expression 
4.3.1.1 Radioactive ISH 
During the course of the study, two different ISH methods were used to construct 
an  anatomical  profile  of  LRRK2  mRNA  expression  in  human  brain.  The 
radioactive ISH technique was initially employed to detect the mRNA levels in 
this study. Emulsion autoradiography using silver stain emulsion was used for the 
assessment  of  cellular  localisation  of  LRRK2  mRNA  in  post-mortem  human 
tissue.  The  preliminary  experiments  conducted  using  radioactively  labelled 
LRRK2  oligonucleotide  probes  produced  high  levels  of  background  labelling. 
However, the aldolase-C (ALD-C) probes which served as the positive control for 
radioactive ISH consistently demonstrated robust ALD-C mRNA localisation (see 
Figure 4.1). After numerous attempts, radioactive emulsion autoradiography was 
rendered unfeasible to reliably detect the LRRK2 mRNA signal in post-mortem 
human brain tissue. Therefore, in order to generate LRRK2 mRNA expression 
profile a non-radioactive approach using a digoxigenin labelled oligonucleotide 
probe was employed for the ISH study.  
 
Figure 4.1: Radioactive ISH demonstrating the localisation for the positive control 
in the human brain. The arrows in the figure represent the localisation of radioactively 
labelled  aldolase C (ALD-C)  probe  to  the  Purkinje  neurons  of the cerebellum  in  the 
human brain. The robust signal intensity was consistently observed for the ALD-C probe, 
whereas  this  level  of  intensity  could  not  be  achieved  for  any  of  the  LRRK2  probes 
without significantly increasing the background levels. The scale bar represents 39µm.  
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4.3.1.2 Non-radioactive ISH 
The findings related to the LRRK2 mRNA distribution were similar in control, 
IPD and G2019S positive PD subjects, and are therefore described collectively. 
LRRK2 mRNA was identified as having a widespread expression in a number of 
neuronal populations in the brain regions examined (Table 4.8). LRRK2 mRNA 
was found to be expressed, but not limited to the brainstem nuclei affected by α-
synuclein  pathology  in  early  stages  of  PD  progression  which  include  the  Xth 
nerve nucleus, locus coeruleus (LC) and DAergic neurons of the SN (see images 
A-D in Figure 4.2). The other brainstem nuclei where LRRK2 mRNA was shown 
to  be  localised,  include  the  XIIth  nerve  nucleus  and  the  inferior  olive  of  the 
medulla oblongata, the pontine base and tegmentum, and the IIIrd nerve nucleus 
(Figure 4.2G), tegmentum and tectum of the midbrain (summarised in Table 4.8). 
The dopamine-innervated regions of caudate nucleus (Figure 4.2E) and putamen 
stained for LRRK2 mRNA, which was also identified in the globus pallidus and 
thalamus.  Neurons in all regions of the hippocampal  formation were found to 
express LRRK2 mRNA (Figure 4.2H and K), and the neuronal populations of the 
cortical  regions  examined  in  this  study  also  demonstrated  LRRK2  mRNA 
localisation (Figure 4.2F and summarised in Table 4.8). In the cerebellum, granule 
cell layer did not express LRRK2 mRNA, whilst clear mRNA expression was 
identified in the cytoplasm of Purkinje neurons (Figure 4.2I) and in the dentate 
nucleus (Figure 4.2J). LRRK2 mRNA expression was consistently observed in the 
vascular smooth muscle of blood vessels of different sizes (Figure 4.2L). LRRK2 
mRNA  hybridisation  signal  was  successfully  reduced  by  diluting  the  labelled 
probe with unlabelled excess at different concentrations (Figure 4.2N), thereby 
confirming the specificity of the oligonucleotide probe used in this study. The 
positive control for the BRI2 mRNA also allowed us to check the integrity of 
mRNA preservation for each subject (Figure 4.2M).   
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Figure  4.2:  Anatomical  localisation  of  LRRK2  mRNA  using  non-radioactive  ISH. 
Neuronal  expression  of  LRRK2  mRNA  in  controls  and  G2019S  positive  PD  cases  is 
represented. Regions particularly vulnerable to α-synuclein pathology and neurodegeneration 
in PD are represented in images A- E; A) Xth nerve nucleus of the medulla (control), B) and 
C) neurons of the LC (G2019S), and D) melanised DAergic neurons of the SN (control) E) 
caudate  nucleus  (G2019S).  LRRK2  mRNA  was  also  detected  in  F)  neocortical  regions 
(represented by parietal cortex) (control), G) III
rd nerve nucleus of the midbrain (and inset) 
(control), H) dentate fascia (G2019S), I) Purkinje neurons (control), and J) dentate nucleus of 
the cerebellum (control) and K) CA4 neurons of the hippocampal formation (G2019S). In 
addition,  LRRK2  mRNA  expression  was  observed  in  L)  smooth  muscle  (G2019S).  M) 
Neuronal localisation of BRI2 mRNA was treated as positive control. N) Negative control for 
the LRRK2 mRNA. The scale bar in A represents 20µm in images A, B –D, E, F, inset in G, 
I, J, L and M; 39µm in images H, K and N; 78µm in G.  
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4.3.2  Distribution of LRRK2 protein in the brain 
The distribution of the LRRK2 protein was demonstrated using the commercially 
available  polyclonal  antibody  EB05660  (raised  against  the  c-terminus  of  the 
protein). Prior to the IHC, the specificity of the antibody was investigated using 
an antigen absorption assay (Figure 4.3).  
 
Figure 4.3: Western blot analysis showing specificity of LRRK2 EB06550 antibody 
and antigen absorption by >10 fold molar ratio of the peptide. Lysates were prepared 
from  post-mortem  human  tissue  from  the  (medulla).  The  first  panel  shows  EB06550 
accurately identifying ~ 250 kDa LRRK2 protein at 10 µg and 20µg of protein loading. 
This signal is obliterated when a molar excess of the antigen is added to the antibody 
prior to incubation with the blot. 
 
An IHC study was performed on four controls, two IPD cases and four PD cases 
with the LRRK2 G2019S mutation. The LRRK2 protein like the mRNA was also 
found to be expressed in anatomical regions of the brain examined in this study 
(summarised  in  Table  4.8).  Since  no  difference  was  observed  in  the 
morphological distribution of the LRRK2 protein amongst the three groups, the 
results are therefore described collectively.   
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Table 4.8: Summary of LRRK2 mRNA and protein distribution in post-mortem 
human brain tissue. LRRK2 mRNA was not identified in the granule cell layer of the 
cerebellum, however, LRRK2 protein localisation was observed in this region. N/A: not 
available. 
Region  Sub- Regions  LRRK2 
mRNA 
LRRK2 
protein 
Medulla 
 
Xth nerve nucleus          
XIIth nerve nucleus         
Inferior olive 
√                   
√                      
√ 
√                   
√                      
√ 
Pons  Locus coeruleus        
Pontine base         
Tegmentum 
√                   
√                      
√ 
√                   
√                      
√ 
Midbrain  Substantia nigra               
IIIrd nerve nucleus             
Red nucleus/ Tegmentum        
Tectum 
√                   
√                      
√                             
√ 
√                   
√             
√                       
√ 
Deep grey nuclei  Caudate nucleus         
Putamen                       
Globus pallidus          
Thalamus                         
Subthalamic nucleus 
√                   
√                      
√                           
√                          
N/A 
√                   
√                      
√                             
√                     
√ 
Medial temporal 
lobe 
Dentate fascia             
CA2/3/4 neurons                        
CA1 neurons           
Subiculum               
Entorhinal cortex 
Transentorhinal cortex           
Amygdala 
√                   
√                      
√                             
√                     
√                     
√                      
N/A 
√                   
√                      
√                             
√                     
√                     
√                      
√ 
Cerebellum  Dentate nucleus          
Purkinje neurons         
Granule cell layer 
√                   
√                      
X 
√                   
√           
√ 
Neocortical 
regions 
Frontal cortex                   
Parietal cortex                    
Temporal cortex           
Insular cortex             
Fusiform gyrus          
Cingulate gyrus 
√                   
√                      
√                 
√                     
√                
√ 
√                   
√                      
√                             
√                     
√                
√  
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The protein displayed a cytoplasmic localisation in the neurons often extending 
into  the  apical  dendrites.  Localisation  in  the  nuclear  envelope  was  not  clearly 
identified as a consistent finding. The strongest staining for LRRK2 was found in 
the medulla with particularly strong staining in the Xth nerve nucleus, the XIIth 
nerve  nucleus  and  the  inferior  olive  (Figure  4.4A-C).  In  the  pons,  the 
noradrenergic pigmented neurons of the LC (Figure 4.4D) showed weak LRRK2 
staining  compared  to  the  neurons  of  the  pontine  base  (Figure  4.4E).  The 
melanised DAergic neurons of the SN (Figure 4.4F) also showed weaker LRRK2 
protein expression in comparison to other midbrain regions (Figure 4.4G). The 
weakest neuronal staining for LRRK2 was consistently recorded in the caudate 
and  putamen  (Figure  4.4H)  with  only  occasional  neurons  showing  weak 
immunoreactivity.  However,  diffuse  neuropil  staining  was  observed  in  the 
striatum.  Moderate  to  high  LRRK2  levels  were  observed  in  the  subthalamic 
nucleus (Figure 4.4I), globus pallidus (Figure 4.4J) and thalamus. Strong staining 
of the LRRK2 protein was routinely identified in the white matter tracts of the 
internal  capsule  (Figure  4.4K  and  L).  Vascular  smooth  muscle  also  expressed 
LRRK2 protein (Figure 4.4M).  
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Figure  4.4:  LRRK2  immunoreactivity  in  brainstem  and  basal  ganglia.  LRRK2 
protein localises to neurons in the medulla which are represented in A) Xth nerve nucleus 
(control), B) XIIth nerve nucleus (control), C) inferior olive (IPD). LRRK2 was detected 
in the pons as represented in D) locus coeruleus (IPD) and E) pontine neurons (IPD). 
LRRK2  immunoreactivity  was  weak  in  the  DAergic  neurons  of  F)  substantia  nigra 
(control), but stronger staining was detected in other midbrain regions, such as G) the 
IIIrd  nerve  nucleus  (G2019S).  H)  Neurons  in  the  putamen  (control),  consistently 
demonstrated weak LRRK2 immunoreactivity, whereas strong staining was observed in 
the neurons of I) subthalamic nucleus (control), and J) globus pallidus (G2019S). LRRK2 
immunoreactivity  was  observed  in the  white  matter  tracts in the  internal  capsule, K) 
(control) and L) (G2019S), and M) smooth vasculature staining with LRRK2 (arrow). 
The scale bar in A represents 20µm in image A, C-F, J, M and inset in H; 39µm in B, G, 
H, L and inset in I; 78µm in I and K.   
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The regions of the medial temporal lobe also displayed varying levels of LRRK2 
protein immunoreactivity (see Figure 4.5). LRRK2 staining of the hippocampal 
formation highlighting the regions of CA1-4 of Ammon’s horn, and the granule 
cell layer of the dentate fascia are represented in  Figure 4.5A. The pyramidal 
neurons of CA2-4 (Figure 4.5B) showed moderate to strong staining for LRRK2 
while  the  CA1  neurons  showed  only  weak  staining.  A  consistently  weak  to 
moderate LRRK2 immunoreactivity was observed in the amygdala (Figure 4.5C), 
whereas the neurons in subiculum, entorhinal (Figure 4.5D) and transentorhinal 
cortex  displayed  moderate  staining.  Neurons  in  the  neocortical  regions  also 
exhibited moderate to strong immunoreactivity for the LRRK2 protein (Figure 
4.5E and F), with pyramidal and stellate neurons in the molecular layers III-V 
showing the strongest LRRK2 immunoreactivity. Within the pyramidal neurons of 
the  hippocampal  formation  and  neocortical  regions,  LRRK2  immunoreactivity 
was  observed  in  the  neuronal  perikarya  and  also  axonal  fibers  and  dendrites. 
Strong labelling of LRRK2 protein was observed within the neurons of the dentate 
nucleus and in Purkinje neurons (Figure 4.5G), where staining clearly extended 
into the dendritic tree of the cerebellum. Golgi cells in the cerebellar granule layer 
also  showed  moderate  staining  although  this  varied  from  case  to  case  (Figure 
4.5H).  LRRK2  was  also  observed  in  glial  cells  that  displayed  astrocytic 
morphology (Figure 4.5I).   
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Figure  4.5:  LRRK2  immunohistochemistry  in  medial  temporal  lobe  and  cortical 
regions. IHC staining demonstrated that LRRK2 immunoreactivity varied in intensity in 
medial temporal lobe structures. In the hippocampal formation, neurons of the A) dentate 
fascia (G2019S) and B) CA2-1 (G2019S) were positively stained. Neurons in the C) 
amygdala consistently showed low to moderate staining for LRRK2 (IPD). Moderate 
staining for LRRK2 was observed in the neurons of neocortical regions D) entorhinal 
cortex (G2019S), E) temporal cortex (G2019S) F) cingulate gyrus (control). G) Purkinje 
neurons of the cerebellum were consistently found to have moderate to strong staining for 
LRRK2 protein which also extended into the dendritic tree (control), (inset–IPD). H) 
Golgi cells (see arrow) of the cerebellum also showed weak LRRK2 immunoreactivity 
(IPD). LRRK2 protein distribution was not limited to neurons and the protein was also 
detected in I) reactive astrocytes (IPD). The scale bar in A represents 410µm in image A; 
78µm in image E, 39µm in the inset in G; 20µm in the inset in A and images B – D and 
F-I.  
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4.3.3  A  semi-quantitative  analysis  of  LRRK2  protein  expression  in 
control, IPD and G2019S positive PD subjects 
In  order  to  ascertain  whether  a  difference  in  LRRK2  protein  levels  could 
contribute  to  the  PD  pathogenesis,  we  decided  to  perform  a  semi-quantitative 
analysis on the regional LRRK2 protein variation in control, IPD and G2019S 
positive PD subjects. The four tiered grading system included: 0 - no staining, + -
weak staining, ++ - moderate staining and +++ - strong staining. The regional 
levels of LRRK2 protein in the control, IPD and G2019S positive PD subjects are 
summarised in Table 4.9.  
There was no quantitative difference in the immunoreactivity for LRRK2 protein 
between  control,  IPD  and  G2019S  positive  PD  subjects,  although  a  consistent 
variation  in  regional  expression  was  recorded  across  the  groups.  Regions 
implicated in PD pathogenesis showed extensive variability in the LRRK2 protein 
staining. The Xth nerve nucleus of the medulla (Figure 4.6A-C) was identified as 
having some of the highest levels of LRRK2, while the melanised neurons of LC 
(Figure 4.6D-F) and SN (Figure 4.6G-I), displayed low to moderate levels of the 
protein in all three groups. The dopamine-innervated areas of caudate nucleus and 
putamen were consistently found to have the lowest LRRK2 protein levels of all 
the regions examined (Figure 4.6J-L). However, other regions in midbrain (IIIrd 
nerve  nucleus,  red  nucleus/tegmentum  and  tectum)  and  basal  ganglia  (globus 
pallidus, thalamus and subthalamic nucleus) were demonstrated as having much 
higher  levels  of  LRRK2  protein  in  comparison  to  the  nigrostriatal  dopamine 
system (see Table 4.9). 
Overall some of the highest LRRK2 protein levels were recorded in medulla, and 
some of the lowest in striatum and amygdala (irrespective of the disease status). 
Similarly,  in  the  medial  temporal  lobe,  moderate  LRRK2  protein  levels  were 
observed in the dentate fascia and the CA2-4 neurons, while the CA1 neurons 
consistently showed weak staining in the three groups of subjects. The dentate 
nuclei and Purkinje neurons of the cerebellum were consistently found to have 
high and moderate LRRK2 immunoreactivity, respectively. This was found to be 
consistently similar in control, IPD and G2019S positive PD subjects (Table 4.9). 
The moderate staining for  LRRK2 in the neocortical regions examined  in this  
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study was also comparable in the subjects, irrespective of the disease status (Table 
4.9). Therefore, taking into account all the regions and subjects examined in this 
study,  a  marked  difference  in  LRRK2  protein  levels  was  not  found  between 
control, IPD and G2019S positive PD subjects, but consistent regional differences 
were recorded within the groups.   
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Table 4.9: A semi-quantitative analysis of LRRK2 protein in post-mortem control, 
IPD and G2019S positive PD brain tissue. The four tiered grading system includes: 0- 
no staining, +- weak staining, ++- moderate staining and +++ strong staining. This data 
was collected using four control, two IPD and four G2019S positive PD subjects, and 
indicates the range of staining intensity observed in each region.  
Region  Sub- Regions  Control  IPD  G2019S 
Medulla  Xth nerve nucleus          
XIIth nerve nucleus         
Inferior olive 
++ - +++     
+++                    
++ - +++ 
++ - +++     
+++                    
++ - +++ 
++ - +++        
++ -  +++               
++ - +++ 
Pons  Locus coeruleus        
Pontine base         
Tegmentum 
+                                         
++ - +++                 
++ 
+ - ++          
+++             
++ - +++ 
++             
+ - ++               
+ - ++ 
Midbrain  Substantia nigra               
IIIrd nerve nucleus             
Red nucleus/ Tegmentum        
Tectum 
+                    
++ - +++        
+ - +++          
+ - ++ 
+ - ++              
+++              
++ - +++         
+ 
+                   
++ - +++            
+ - ++               
+ 
Basal Ganglia  Caudate nucleus         
Putamen                       
Globus pallidus          
Thalamus                         
Subthalamic nucleus 
0 - +                 
0 - +               
+ - ++             
+++         
+ - +++ 
0 - +                
0 - +                 
++              
+++                
+++ 
0 - +                 
0 - +               
+ - ++             
++ - +++             
+ - +++ 
Medial temporal 
lobe 
Dentate fascia             
CA2/3/4 neurons                        
CA1 neurons           
Subiculum               
Entorhinal cortex 
Transentorhinal cortex           
Amygdala 
++                   
+ - ++             
0 - +               
+ - +++                
+ - ++               
+ - ++               
+ 
++                   
+ - ++             
0 - +               
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Figure  4.6:  Morphological  distribution  of  LRRK2  protein  in  control,  IPD  and 
G2019S  positive  PD  subjects.  Neurons  of  the  Xth  nerve  nucleus  do  not  show  a 
significant difference in the intensity of LRRK2 immunoreactivity of A) control, B) IPD, 
and C) G2019S positive PD subjects. LRRK2 staining intensity was also similar in the 
noradrenergic neurons of LC of all three groups (D-F). Similarly, the melanised DAergic 
neurons  of  the  SN  showed  no  difference  in  the  three  groups  (G–I).  LRRK2 
immunoreactivity was consistently recorded as being the weakest in striatal neurons (see 
arrows), irrespective of the disease status (J–L, putamen). The scale bar in A represents 
20µm in images A – C and E – I, and insets in D and K; 39µm in images D and J – L. 
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4.3.4  LRRK2 in Lewy bodies 
LRRK2 protein was found in the halo of a small proportion of LBs (around the 
periphery). The LRRK2 immunoreactive LB inclusions were identified in nigral 
neurons (Figure 4.7A- E), neurons of the locus coeruleus (Figure 4.7F), and also 
in  the  amygdala  (Figure  4.7G).  Cortical  LBs  were  not  immunoreactive  for 
LRRK2.  Lewy  neurites  also  stained  for  LRRK2  protein  (Figure  4.7C).  The 
staining of LBs with LRRK2 remained very selective with some LBs showing 
extensive staining (Figure 4.7F), whilst others demonstrating pale staining (Figure 
4.7A). 
 
Figure 4.7: LRRK2 protein is present in a proportion of Lewy bodies. This figure 
illustrates LRRK2 staining the halo of a small proportion of LBs in the brainstem and 
also in the amygdala. Panels A –E display varying intensities of LRRK2 staining in nigral 
LBs. C) Lewy neurites were also shown to contain LRRK2 (arrows). F) Strongly stained 
LBs in locus coeruleus, G) a small proportion of LBs were also stained in amygdala. The 
scale bar in A represents 8µm in A and F; 20µm in C, D, E, G and inset in BG; 39µm in 
B.  
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4.4  Discussion 
This  study  demonstrates  that  LRRK2  mRNA  and  protein  have  a  ubiquitous 
neuronal  expression  in  the  human  brain  that  was  not  limited  to  the 
neuroanatomical regions most severely affected by α-synuclein pathology in PD 
pathogenesis. LRRK2 mRNA and protein was identified in the melanised neurons 
of the Xth nerve nucleus, LC, SN and the dopamine-innervated areas of striatum. 
However,  the  lowest  LRRK2  protein  levels  were  consistently  recorded  in  the 
nigrostriatal dopamine system. IHC studies confirmed the previously described 
neuronal cytoplasmic distribution of the LRRK2 protein, and also identified the 
protein  in  the  apical  dendrites,  axonal  fibers  and  the  neuropil  of  the  striatum 
(Biskup et al. 2006; Higashi et al. 2007a; Higashi et al. 2007b; Melrose et al. 
2007). This study also demonstrates that LRRK2 localises to a small proportion of 
LBs and Lewy neurites in the brainstem and amygdala. 
LRRK2 mRNA has a ubiquitous neuronal expression in the human brain 
The ISH study in this chapter was designed with a view to addressing the major 
inconsistencies that have been reported in the distribution of LRRK2 mRNA in 
the brain. As described in section 4.1.1, the original studies reported low levels of 
LRRK2 mRNA in the SN but high levels in the striatum. These were subsequently 
contradicted when widespread LRRK2 mRNA expression was demonstrated in 
the mammalian brain using modified ISH techniques. The ISH data presented in 
this chapter demonstrates that LRRK2 mRNA is localised not only throughout the 
nigrostriatal dopamine system but is also present in a number of other anatomical 
regions in the brain. These findings contradict the original studies that did not 
detect  LRRK2  mRNA  in  dopamine-synthesising  areas  in  rodents  and  humans 
(Galter  et  al.  2006;  Melrose  et  al.  2006),  but  instead  supports  the  subsequent 
studies that demonstrated widespread expression of LRRK2 mRNA in the human 
brain (Simón-Sánchez et al. 2006; Higashi et al. 2007b). 
Dependent on the type of hybridisation probe, labelling methods, and quality of 
tissue used, different regional distribution and levels of LRRK2 mRNA signals 
have  previously  been  reported  (summarised  in  Table  4.1).  Even  though  a 
ubiquitous  expression  for  the  LRRK2  mRNA  in  human  brain  has  been  
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demonstrated  in  this  study  using  a  digoxigenin  labelled  probe,  multiple 
amplification steps were needed to detect the LRRK2 mRNA signal. These low 
levels of LRRK2 mRNA in the human brain did not enable us to use radioactively 
(
35S)  labelled  oligonucleotide  probes  to  perform  emulsion  autoradiography 
without  producing  significant  background  staining.  Therefore,  quantitation  of 
LRRK2 mRNA in the human brain could not be undertaken by counting silver 
emulsion grains, and was instead achieved by a PCR based technique described in 
chapter 5 of this thesis.  
The results presented in this study concur with those of others suggesting a low 
copy number of LRRK2 mRNA in the mammalian brain (Simón-Sánchez et al. 
2006; Higashi et al. 2007b). Such an expression profile could be due to the fact 
that  the  LRRK2  mRNA  is  either  a)  unstable,  b)  has  a  short  half-life,  c)  is 
transported to distal sites where local translation occurs in response to external 
stimuli or, d) or has an efficient translational machinery that allows for a low copy 
number of LRRK2 mRNA molecules to produce enough protein for the region. 
The stability of LRRK2 mRNA has not been explored, and future experiments 
assessing the half-life of LRRK2 mRNA could provide valuable insight into its 
stability and also shed light on any potential regional variation. Overall this study 
supports a widespread but a low copy number expression of LRRK2 mRNA in the 
human brain that is not limited to the nigrostriatal system. 
LRRK2 protein has a ubiquitous but a variable regional expression in the 
human brain 
In  this  chapter,  I  present  data  demonstrating  widespread  LRRK2 
immunoreactivity in neuronal cell bodies, apical dendrites and axons. Like the 
mRNA, LRRK2 protein was also found to have a ubiquitous expression in the 
anatomical  regions  examined.  The  highest  levels  of  the  LRRK2  protein  were 
consistently  recorded  in  the  neurons  of  the  medulla,  and  the  nigrostriatal 
dopamine system consistently displayed low levels of the protein, irrespective of 
the disease status. The pigmented neurons in the SN showed weak to moderate 
immunoreactivity  for  LRRK2 protein, but the  neuronal populations of caudate 
nucleus and putamen exhibited the lowest immunoreactivity with occasional small  
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numbers of labelled neurons being identified, although there was strong LRRK2 
immunoreactivity in striatal neuropil confirming previous reports (Higashi et al. 
2007b; Melrose et al. 2007). Higashi and colleagues showed extensive LRRK2 
immunoreactivity in the striatal neurons (Higashi et al. 2007b), but a previous 
study  that  also  used  EB06550  antibody  reported  low  to  moderate  staining  of 
LRRK2 in striatal neurons, thereby demonstrating the reproducibility of EB06550 
antibody used in this study (Alegre-Abarrategui et al. 2008). These variations in 
LRRK2  immunoreactivity  between  studies  could  be  attributed  to  disparities  in 
tissue fixation. However, the variations are more likely to be due to the difference 
between  the  antibodies  used,  as  we  demonstrated  an  extensive  and  consistent 
neuropil staining of  LRRK2 and weak neuronal staining in striatum of all the 
subjects used in this study with the EB06550 antibody. Western blot assays have 
suggested high LRRK2 levels in mammalian striatum (rodents), but crude tissue 
lysates  cannot  distinguish  between  different  cellular  compartments,  and  may 
therefore be compatible with our findings (Biskup et al. 2006; Taymans et al. 
2006;  Melrose  et  al.  2007).  This  data  demonstrates  that  neuronal  perikaryal 
expression of LRRK2 is weakest in striatum when EB6550 antibody is used. 
It is interesting that in both the midbrain and basal ganglia, regions such as the 
IIIrd nerve nucleus, red nucleus/tegmentum and tectum (in midbrain), and globus 
pallidus, thalamus and subthalamic nucleus (in basal  ganglia), that are  not the 
primary targets of degeneration in PD pathogenesis have much higher levels of 
LRRK2 protein compared to the nigrostriatal dopamine system (see Table 4.9). 
This could suggest a possible high turnover, and an important role for the LRRK2 
protein  in  regions  critical  to  PD  pathogenesis.  Extensive  LRRK2 
immunoreactivity was especially evident in the thalamus, a region which receives 
modulatory input from the motor nuclei in the cerebellum and relays excitatory 
sensory signals to the cortex (Melrose et al. 2007). The presence of LRRK2 in a 
region such as thalamus which is essential to the basal ganglia circuitry, further 
establishes the importance of this protein in ensuring normal neuronal function to 
execute  movement.  LRRK2  was  also  shown  to  be  present  in  numerous  brain 
regions such as the hippocampus, and amygdala which are key structures of the 
limbic system. This suggests that LRRK2 may play a physiological role in not  
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only  the  motor  but  also  in  certain  cognitive  elements  associated  with  the  PD 
pathogenesis, or perhaps even normal aging. LRRK2 has also been reported in 
neurofibrillary tangles (NFTs) and the pleomorphic pathology related to LRRK2 
mutations  certainly  suggest  an  important  upstream  role  for  this  gene  in  other 
neurodegenerative disorders associated with cognitive decline (Giasson et al. 2006; 
Miklossy et al. 2006). Overall, the findings demonstrate that the LRRK2 protein, 
like the mRNA is ubiquitously present in neuronal populations of the brain and is 
not limited to the regions susceptible to α-synuclein pathology in PD. The IHC 
findings presented here also corroborate well with a previous study investigating 
LRRK2  protein  levels  (western  blot)  in  distinct  regions  of  rat  brain,  and 
confirmed the presence of high levels of LRRK2 in the hippocampus, followed by 
cortex and the least amount in putamen (Biskup et al. 2006).  
Melrose  and  colleagues  previously  reported  a  lack  of  LRRK2  mRNA,  but  a 
considerable immunoreactivity for the LRRK2 protein in the thalamus. (Melrose 
et al. 2007). This chapter demonstrates the presence of both the LRRK2 mRNA 
and  protein  in  the  thalamus  of  the  human  brain.  However,  I  was  able  to 
demonstrate regions that did not have LRRK2 mRNA signal but were positive for 
LRRK2  immunoreactivity.  LRRK2  mRNA  signal  was  not  identified  in  the 
cerebellar granule cell layer (Figure 4.1I), but golgi cells in this layer displayed 
moderate LRRK2 immunoreactivity (Figure 4.5H). The lack of LRRK2 mRNA 
expression in the granule cells could be due to small quantities of cytoplasm in 
these cells. Alternatively, LRRK2 mRNA could be present as a low copy number 
mRNA  which  cannot  be  detected  using  the  digoxigenin  labelled  probe  in  the 
granule cells of cerebellum.  
Similarly, we were not able to identify LRRK2 mRNA in the glial population, 
despite a previous report showing LRRK2 mRNA in cultured glial cells using a 
sensitive PCR based method (Miklossy et al. 2006). A low copy number of the 
LRRK2  mRNA  or  differences  between  physiological  and  cultured  glial  cells 
could  have  prevented  the  result  being  replicated  using  the  digoxigenin  ISH 
method reported in this chapter. LRRK2 immunoreactivity has previously been 
documented in human glial cells, (Miklossy et al. 2006; Melrose et al. 2007), but 
not in mouse glial population (Biskup et al. 2006; Higashi et al. 2007b). Although  
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we were able to confirm LRRK2 immunoreactivity in the reactive astrocytes, this 
was not a common occurrence.  
The localisation of LRRK2 to axons, apical dendrites and the neuropil network 
lends further support to LRRK2 being involved in axonal transport or vesicular 
trafficking system (reviewed in (Greggio & Cookson 2009). For example, LRRK2 
has  been  suggested  to  bind  to  lipid  rafts  in  synaptic  terminals  which  play  an 
important  role  in  signal  transduction,  cytoskeletal  organisation  (Hatano  et  al. 
2007), and was recently shown to regulate synaptic membrane trafficking (Shin et 
al. 2008). Furthermore, immunoblots have previously demonstrated the presence 
of LRRK2 in lung, kidney, liver, heart, skeletal muscle, and spleen of rodents 
(Giasson et al. 2006; Biskup et al. 2006), and a previous IHC study also showed 
vasculature  staining  with  LRRK2  protein  (Zhu  et  al.  2006a).  I  confirm  the 
presence  of  LRRK2  mRNA  and  protein  expression  in  smooth  muscle  which 
supports a wider role for the protein involvement in the physiology.  
No  difference  in  the  LRRK2  mRNA  and  protein  expression  profile  in 
control, IPD and G2019S positive PD subjects 
This chapter demonstrated a similar morphological distribution of LRRK2 mRNA 
and  protein  expression  in  control,  IPD  and  G2019S  positive  PD  subjects. 
Although the semi-quantitative analysis on the LRRK2 immunoreactivity showed 
no quantitative regional differences in the protein levels between the three groups, 
the  only  region  where  variable  intensity  of  LRRK2  immunoreactivity  was 
recorded in the three subject groups was the CA1 sub-region of the hippocampus. 
These neurons have been given a higher score in the G2019S positive PD subjects 
in  comparison  to  control  and  IPD  cases,  and  this  is  most  likely  due  to  the 
vulnerability of these cells to hypoxic damage immediately prior to death.  
Stronger labelling of LRRK2 protein in neuronal cell bodies and axons of PD 
subjects  has  previously  been  reported  (Zhu  et  al.  2006a),  and  another  report 
recorded  a  decrease  in  LRRK2  immunoreactivity  in  the  SN  of  PD  brains 
compared to controls (Higashi et al. 2007b). These apparent contradictions in the 
literature and our findings could be attributed to the use of different antibodies 
(see Table 4.2 for the antibodies used by these authors). The issue of quantitative  
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differences between unaffected and diseased subjects could be further addressed 
by the development of a sensitive ELISA technique.  
The overall low intensity of LRRK2 immunoreactivity in dopamine producing 
and  dopamine  innervated  regions  (irrespective  of  the  disease  status)  could  be 
indicative  of  a  high  turnover  of  the  molecules  in  regions  critical  to  PD 
pathogenesis. There was no apparent difference in the morphological expression 
profile of LRRK2 protein in the SN and striatal neurons between control, IPD and 
G2019S positive PD subjects. Since LRRK2 has been suggested to be involved in 
neuronal maintenance of DAergic neurons (Imai et al. 2008), it is possible that the 
disease pathogenesis results in increased LRRK2 protein in the surviving neurons. 
This could result in similar intensity of LRRK2 immunoreactivity across different 
subject groups. Nigral degeneration with LBs is a pathological phenotype of both 
IPD and G2019S positive PD subjects. The G2019S mutation is supposed to alter 
the function of wild-type LRRK2, but there is a distinct lack of difference in the 
expression profile of IPD and G2019S positive PD subjects in this study. It is 
possible that an overlap in or indeed a shared auxiliary mechanism is contributing 
to the pathogenesis in PD subjects with G2019S mutant LRRK2 and PD subjects 
without the G2019S mutant LRRK2. 
It is evident from this study that LRRK2 expression is not limited to nigrostriatal 
system  and  has  a  widespread  expression  both  in  terms  of  mRNA  and  protein 
levels, but what remains to be seen is whether LRRK2 dysfunction causes nigral 
degeneration or nigral degeneration itself affects LRRK2 function at a cellular or 
systems level?  
LRRK2 is present but is not an obligate component of LBs 
My results also demonstrate the presence of LRRK2 in the halo region of the LBs 
in the brainstem and amygdala of IPD cases, confirming previous reports using C- 
terminal  LRRK2  antibodies  (see  Table  4.2).  The  labelling  of  LBs  in  the 
pigmented neurons of the SN and LC with the EB06550 antibody was variable 
and not all LBs labelled with the same intensity, also confirming previous reports 
(see  Table  4.2  for  a  summary).  Intense  staining  of  Lewy  neurites  was  also 
observed  with  the  EB06550  antibody,  in  contrast  with  other  reports  in  which  
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Lewy neurites were not labelled with LRRK2 antibodies (Miklossy et al. 2006; 
Higashi et al. 2007b). LRRK2 positive LBs were not identified in the neocortical 
regions,  confirming  the  findings  of  others  using  the  NB300-268  antibody.  In 
contrast  to  the  NB300-268  antibody  which  labels  the  core  of  LBs  as  well  as 
immunostains neocortical LBs (see Table 4.2), the EB06550 antibody used in this 
study demonstrated LRRK2 protein localisation only to the halo of the brainstem 
and amygdala LBs with varying intensities. The discrepancies between antibodies 
could  be  explained  by  differences  in  the  affinity  and  avidity  of  the  LRRK2 
antibodies, and also the possibility that routine IHC techniques are not able to 
expose  the  antigen  within  the  densely  packed  insoluble  fibrils  of  LBs. 
Conformational and post-translational modifications (truncated LRRK2 isoforms) 
of the neuronal LRRK2 protein could also prevent some LRRK2 antibodies from 
staining LBs. It should be noted that NB300-268 is the only antibody to have 
reportedly identified 60 – 80 % of LRRK2 stained LBs (Zhu et al. 2006a; Zhu et 
al. 2006b; Miklossy et al. 2006; Alegre-Abarrategui et al. 2008). Even though the 
NB300-268 antibody has been suggested to demonstrate sufficient specificity for 
detecting  endogenous  human  LRRK2  and  human  LRRK2  overexpressed  in 
(HEK-293T)  transfected  cells,  this  antibody  did  not  exhibit  specificity  for 
endogenous or overexpressed mouse LRRK2 (Biskup et al. 2007). It was also 
shown to be cross-reactive to many other species that appear near the expected 
size of LRRK2 protein in wild-type and LRRK2 deficient mouse brain lysates 
(Biskup  et  al.  2007).  Furthermore,  the  hyaline  type  LB  inclusions  have  been 
suggested to bind to  a  wide range of unrelated antibodies, in particular rabbit 
antibodies (Melrose et al. 2007). This challenges the specificity of NB300-268 
which has also been shown to localise to a wide range of other neurodegenerative 
pathologies (Giasson et al. 2006; Miklossy et al. 2006). The EB06550 antibody 
used in this study has not been tested in knockout mice but did identify a ~250 
kDa band on lysate prepared from human brain homogenate, and the specificity of 
the signal was tested by obliterating the signal using a >10 fold molar excess of 
the corresponding antigen (Figure 4.3). Our findings of variation and low fraction 
of LRRK2 staining in LBs and Lewy neurites, in addition to a distinct lack of 
LRRK2 in cortical LBs with EB06550 antibody is in agreement with previous 
studies, and suggests that LRRK2 protein is not a principal component of LBs.   
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LRRK2  has  been  shown  to  be  present  in  α-synuclein  immunopositive  glial 
cytoplasmic inclusions (GCIs) in multiple system atrophy (MSA), and LRRK2 
immunoreactivity  was  also  increased  in  the  early  stages  of  myelin  sheath 
disruption and degradation in MSA (Huang et al. 2008). α-synuclein is also a 
major  component  of  GCIs  and  was  recently  shown  to  be  phosphorylated  by 
LRRK2 in-vitro (Qing et al. 2009). An in-vivo phosphorylation of α-synuclein by 
LRRK2 remains to be determined but it has been shown to co-localise with α-
synuclein in brainstem and limbic LBs (not in cortical LBs or Lewy neurites) of 
PD and DLBD brains (Miklossy et al. 2006; Higashi et al. 2007b; Perry et al. 
2008). Recently, the mRNA for both α-synuclein and LRRK2 were suggested to 
be co-regulated in rodent striatum (Westerlund et al. 2008b). LRRK2 has been 
suggested to play an important role in signal transduction mechanisms (White et 
al. 2007; Greggio & Cookson 2009), and it is feasible that LRRK2 is involved in 
an  upstream  (possibly  regulatory)  role  in  the  initial  formation  of  LBs  either 
through  irregular  protein  phosphorylation  and  subsequent  aggregation,  and/or 
protein misfolding as has been observed in in-vitro studies (Smith et al. 2005a; 
West et al. 2005; Smith et al. 2006; Greggio et al. 2006). Even though no work 
has yet been published on the presence of LRRK2 in pale bodies, presence of 
LRRK2  in  these  inclusions  would  help  elucidate  the  potential  role  of LRRK2 
during different developmental stages of LBs.  
Conclusion  
This study describes several aspects of LRRK2 mRNA and protein expression in 
the  human  brain.  The  ubiquitous  identification  of  LRRK2  expression  in  the 
cytoplasm  of  neurons,  axons,  apical  dendrites,  neuropil  network,  and  smooth 
muscle vasculature supports an important physiological role for this protein. No 
difference was observed in the expression profile of LRRK2 mRNA and protein 
in control, IPD and G2019S positive PD subjects. However, any subtle differences 
would  have  to  be  quantitated  using  more  sensitive  assays.  One  of  the  major 
findings of this study was the consistently low immunoreactivity for the LRRK2 
protein in the nigrostriatal dopamine system, suggesting a high turnover for the 
protein in the regions critical to PD pathogenesis. If LRRK2 does indeed have a 
major  role  in  neuronal  maintenance  as  recommended  by  some,  then  any  
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dysregulation  in  its  expression,  quantitative  or  qualitative  could  have  drastic 
effects on this role and contribute to nigral degeneration that is observed in PD 
subjects. Since no apparent difference was observed in the expression profiles of 
PD subjects with wild-type or G2019S LRRK2, it does raise the possibility of a 
shared  auxiliary  mechanism  contributing  to  the  indistinguishable  phenotype  of 
IPD and G2019S positive PD subjects. This concept is investigated in the next 
chapter. The data presented here confirms that LRRK2 epitopes are present in LB 
of  three  distinct  anatomical  regions  in  the  brain  (i.e.  LC,  SN  and  amygdala). 
However, the variable intensity of LB immunoreactivity with LRRK2 suggests 
that is not an obligate component of LBs, but may play an upstream role in the 
formation of LBs as the major pathological marker of PD.  
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5  A quantitative study of LRRK2 mRNA expression in the 
human brain 
5.1  Introduction 
Like most complex diseases, PD manifests a genetic heterogeneity which is not 
easily  explained  by  a  simple  mendelian  mode  of  inheritance.  Even  though 
mutational  screening  of  the  PARK  loci  in  PD  subjects,  and  assessing  the 
functional impact of identified mutations has contributed vastly to our knowledge 
behind  the  genetic  aetiology  of  the  disease,  majority  of  PD  cases  cannot  be 
explained  by  mutational  screening.  Thereby,  indicating  that  other  mechanisms 
might contribute substantially to the PD pathogenesis. Auxiliary mechanisms that 
ensure an accurate production of the protein from a gene sequence have long been 
of interest to biologists. One such mechanism is the transcriptional activity of a 
gene, which is a carefully regulated procedure that dictates not only the accurate 
structure and production of the protein but also the levels of protein expression.  
Microarray  platforms  have  been  used  to  assess  differences  in  whole  genome 
transcription  across  the  nigrostriatal  system  in  post-mortem  tissue  of  PD  and 
control  subjects  (Grünblatt  et  al.  2004;  Miller  et  al.  2004;  Zhang  et  al.  2005; 
Mandel et al. 2005; Hauser et al. 2005; Miller et al. 2006; Vogt et al. 2006; Duke 
et al. 2006; Moran et al. 2006; Simunovic et al. 2008; Bossers et al. 2009). These 
whole genome expression studies have identified novel genes and pathways that 
include  genes  related  to  protein  processing  (degradation  -  UPS  system  and 
trafficking - chaperones), signal transduction, oxidative and mitochondrial stress, 
apoptosis, vesicle trafficking, cytoskeletal stability and maintenance, and axonal 
transport. Transcriptional profiling has also been used to describe regional and 
gender specific differences in PD (Miller et al. 2006). 
In addition to identifying novel genes that might play a role in PD pathogenesis, 
these studies have also elaborated on the role of PARK loci in PD cases (Hauser et 
al. 2005; Moran et al. 2006; Moran et al. 2007; Gründemann et al. 2008). A recent 
study has described a down- regulation for the PARK genes in the dopaminergic 
(DAergic)  neurons  of  PD  cases  (Simunovic  et  al.  2008),  but  there  is  limited  
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information as to the transcriptional profile of LRRK2. A combination of northern 
blot analysis (Paisán-Ruíz et al. 2004), in-situ hybridisation (ISH) (Simón-Sánchez 
et al. 2006; Higashi et al. 2007b), and quantitative PCR (qPCR) (Zimprich et al. 
2004b; Melrose et al. 2006; Simunovic et al. 2008) have been used to identify 
quantitative differences in the regional expression of LRRK2 mRNA, although these 
data were produced using a small number of subjects.  
Mutations in the LRRK2 gene are a common genetic cause of PD, and also exhibit 
the most heterogeneous neuropathology (Zimprich et al. 2004b, Wszolek et al. 
2004; Ross et al 2006). Establishing differences in the transcriptional activity of 
the  gene  could  highlight  shared  mechanisms  in  the  pathogenic  process(es) 
displayed by the idiopathic cases versus the PD phenotype resultant from G2019S 
mutation,  which  interestingly  exhibits  a  clinical  and  a  pathological  phenotype 
indistinguishable from IPD (Aasly et al. 2005). Ubiquitous expression of LRRK2 
mRNA in the brain is demonstrated in the previous chapter of this thesis, although 
no difference was observed in the morphological distribution of LRRK2 mRNA in 
unaffected, IPD and G2019S positive PD subjects. A more sensitive PCR based 
technique would be capable of identifying subtle differences in mRNA expression 
that  an  ad-hoc  analysis  by  chromogenic  ISH  cannot.  Quantitative  analysis 
describing regional variations in LRRK2 mRNA in not only these two forms of PD 
(IPD and G2019S mutant) but also in unaffected controls is needed to further 
elucidate the role of LRRK2 gene in contributing to the molecular pathogenesis of 
PD.  
LBs are the pathological hallmark of PD, and the presence of LRRK2 protein has 
been demonstrated in a small proportion of LBs in the previous chapter, thereby 
supporting  published  reports  in  the  current  literature.  α-synuclein  is  the  major 
component of LBs (Spillantini et al. 1997), and extensive in-vitro phosphorylation 
of α-synuclein results in its oligomerisation which has been shown to promote 
aberrant aggregation of the protein as LB inclusions in both PD and DLBD cases 
(Fujiwara et al. 2002; Iwatsubo 2003; Smith et al. 2005b). It has been suggested 
that these inclusions initially form in order to sequester toxic effects that might 
result  from  an  increased  α-synuclein  activity  in  the  DAergic  neurons,  but 
eventually become cytotoxic (reviewed in (Goldberg & Lansbury 2000)).   
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Recently, the mRNA for both α-synuclein and LRRK2 was suggested to be co-
regulated in rodent striatum (Westerlund et al. 2008b), and a co-localisation of the 
two proteins was also shown in PD brains (Perry et al. 2008). Decreased LRRK2 
mRNA levels and increased α -synuclein mRNA levels in DAergic neurons of SN 
have recently been reported (Simunovic et al. 2008; Gründemann et al. 2008). 
Even though the physiological substrates for LRRK2 still remain to be confirmed, 
α -synuclein was recently shown to be phosphorylated by LRRK2 in-vitro (Qing 
et al. 2009). As such it is feasible that LRRK2 might be involved in modulating 
upstream  phosphorylating  events  of  excessive  α-synuclein  resulting  in  the 
formation of LB inclusions. Establishing a correlation between LRRK2 mRNA 
and  LB  levels  in  brain  regions  prone  to  these  inclusions  would  elucidate  the 
mechanistic pathway that might link together two highly important PARK loci.   
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5.1.1  Hypothesis and specific aims 
In  this  chapter,  I  wished  to  investigate  the  hypothesis  that  auxiliary 
mechanisms, such as dysregulation of LRRK2 mRNA could contribute to the 
PD  pathogenesis.  The  major  aims  of  this  study  were  a)  to  provide  a 
quantitative map of the LRRK2 mRNA expression in the human brain; b) to 
investigate  regional  variations  in  the  LRRK2  mRNA  levels  between 
unaffected, IPD and G2019S positive PD subjects; and c) to investigate if 
there is a correlation between LRRK2 mRNA and the levels of LB inclusions 
observed in IPD and G2019S positive PD subjects?  
To address these questions, a quantitative expression profile of LRRK2 mRNA in 
post-mortem tissue from controls, IPD and G2019S PD subjects was determined 
using qPCR. Post-mortem tissue from selected brain regions (medulla, putamen, 
amygdala, cingulate gyrus, cerebellum, frontal, parietal and entorhinal cortices) 
was  used  to  establish  the  LRRK2  mRNA  expression  profile.  In  order  to 
investigate  a  correlation  between  LRRK2  mRNA  and  LB  levels  in  the  PD 
subjects, α-synuclein immunoreactivity was used to determine the LB levels in the 
medulla,  putamen,  amygdala,  cingulate  gyrus,  frontal,  parietal  and  entorhinal 
cortices brain regions.   
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5.2  Materials and Methods 
5.2.1  Tissue Selection 
Post-mortem  tissue  that  had  been  frozen  at  -70
°C  was  obtained  from  Queen 
Square Brain Bank (QSBB) as detailed in chapter 2 (section 2.1). A preliminary 
study  was  conducted  using  the  cerebellum  tissue  from  121  IPD  cases  and  36 
unaffected controls. A summary of these subjects is provided in the Appendix. 20 
unaffected  and  20  IPD  subjects  were  selected  from  the  tissue  used  in  the 
preliminary study, and additional tissue from four G2019S positive PD subjects 
was also obtained from QSBB. The PD subjects were identified as neocortical or 
transitional LB disease according to the McKeith criteria (McKeith et al. 2005). 
Clinical and pathological details of the subjects are described in Table 5.2, Table 
5.3 and Table 5.5. In order to investigate the anatomical expression profile of 
LRRK2 mRNA, a detailed analysis was conducted using tissues from medulla, 
putamen, amygdala, cingulate gyrus, entorhinal, frontal and parietal cortices from 
these subjects. The anatomical regions available from these subjects are described 
in Table 5.4 and Table 5.6.  
5.2.2  mRNA quantitation 
The  procedures  for  RNA  extraction,  cDNA  synthesis  and  qPCR  and 
normalization  are  described  in  detail  in  chapter  2  sections  2.2.3  and  2.4.  The 
oligonucleotides used in the study are described in Table 5.1. 
5.2.3  qPCR data analysis 
qPCR data was processed using the SDS 2.0 software (Applied Biosystems, UK) 
as  described  in  chapter  2  (section  2.4.2.2).  Four  endogenous  reference  genes 
(HPRT1, RPL13A, G6PD and TBP) were measured for all the samples, and an 
appropriate normalisation factor was calculated using the software NormFinder as 
described in chapter 2 (section 2.4.2.3).  
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Primer  Sequence 5’-3’  Tm  Fragment size 
LRRK2 Forward 
LRRK2 Reverse 
TGTTGTGGAAGTGTGGGATAA 
CATTTTTAAGGCTTCCTAGCTG 
60°C (30 sec)  295 bp 
 
RPL13A Forward 
RPL13A Reverse 
GATATAATTGACACTGGCAA 
AGCAAGCTTGCGACCTTGA 
55°C (30 sec)  89 bp 
HPRT1 Forward 
HPRT1 Reverse 
TGAACGTCTTGCTCGAGAT 
GGTCATTACAATAGCTCTTC 
55°C (30sec)  188 bp 
TBP Forward 
TBP Reverse 
TAATCCCAAGCGGTTTGCTG                                 
CTGTTCTTCACTCTTGGCTC 
60°C (45 sec)  112 bp 
G6PD Forward 
G6PD Reverse 
CCACCATCTGGTGGCTGTTC                                 
GAAGGGCTCACTCTGTTTGC 
62°C (45 sec)  113 bp 
Table 5.1: The oligonucleotide primers used for qPCR study. The primer design is described in section 2.4.2.1. Tm: annealing temperature; sec: 
seconds. The cycling conditions were 50° C for 2 minutes; 95° C for 10 minutes; and 35 cycles of 95° C for 15 seconds, 55-65°C for 30-45  
seconds and 72° C for 45 -60 seconds. With the exception of LRRK2 the extension time (72°C) for all other probes was 45 seconds and for 
LRRK2 probes was 1 minute. A dissociation curve was also added at the end of the reaction; 95°C for 15 seconds; 60°C for 1 minute and 99°C for 
15 seconds, to determine that a single specific PCR product was being formed by the primers. 
  
[165] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.2:.Summary of IPD and G2019S positive PD cases used in this study. M: male; F: female; PM delay: Post-mortem delay (hours); IPD: idiopathic 
PD; N/A: not available. Mean age at death = 75.05 years; mean PM delay= 49.48 hours, mean pH= 6.29. LB status refers to transitional or neocortical Lewy 
body status as described by the McKeith criteria. 
  Sex  Age  PM 
delay 
pH  Cause of death  Pathological diagnosis  LB status 
IPD1  M  77  77.00  6.73  Heart failure  IPD  neocortical 
IPD2  M  73  11.20  6.32  N/A  IPD  neocortical 
IPD3  F  62  46.20  5.88  Gradual deterioration  IPD   neocortical 
IPD4  F  78  75.45  6.46  Advanced PD  IPD   neocortical 
IPD5  F  87  47.45  6.62  IPD, slow deterioration  IPD  transitional 
IPD6  F  81  24.25   N/A  IPD, congestive heart disease  IPD  transitional 
IPD7  M  81  103  6.15  Bronchopneumonia  IPD  transitional 
IPD8  M  73  20.30  6.22  PD, Malignant melanoma, 2 in lung  IPD  transitional 
IPD9  F  66  125.30  6.2  Advanced PD  IPD  neocortical 
IPD10  F  77  ~80  6.53  Congestive heart failure  IPD  neocortical 
IPD11  F  88  11.30  6.38  Chest infection  IPD  transitional 
IPD12  M  70  61.20  6.29  Chest infection  IPD  transitional 
IPD13  M  55  8.00  6.37  Progressive degenerative PD disorder  IPD  neocortical 
IPD14  M  71  40.45  6.1  Chest infection  IPD  neocortical 
IPD15  M  79  27.25  5.88  Sudden death  IPD   neocortical 
IPD16  M  71  81.30  6.76  N/A  IPD  neocortical 
IPD17  M  70  71.30  6.17  Coronary artery atheroma  IPD  transitional 
IPD18  M  91  31.45  5.81  Congestive heart failure  IPD  neocortical 
IPD19  F  81  57.30  N/A   Heart failure  IPD  neocortical 
IPD20  M  70  51.20  6.29  Gradual deterioration  IPD  neocortical 
G2019S-1  F  81  15.00  6.53  Bronchopneumonia  IPD (G2019S)  N/A 
G2019S-2  F  84  32.3  5.79  Congestive heart failure  IPD (G2019S)  N/A 
G2019S-3  F  80  44.4  6  Advanced PD  IPD (G2019S)  N/A 
G2019S-4  F  72  24.55  N/A  Pulmonary embolism  IPD (G2019S)  transitional   
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Table 5.3: A clinical summary of IPD and G2019S positive PD cases used in this study. This tissue was obtained from QSBB and the data was collected 
by Dr. Sean O Sullivan at QSBB. l-dopa: levodopa; yrs: years; mths: months; N/A: not available. Only the italicised samples in bold red letters were used for 
the L-DOPA induced dyskinesia correlation analysis described in section 5.3.4. 
   Age at 
onset 
Age at 
death 
Duration 
of 
disease 
Sex  
(1M/0F) 
Duration of  
l-dopa use 
(yrs) 
Maximum dose 
l-dopa (mg/day) 
 dyskinesia after 1st 2 
years of disease onset 
mths to dyskinesia 
post l-dopa initiation 
IPD1  73.1  77.7  4.6  1  1.6  435.5  0  N/A  
IPD2  65.2  73.8  8.6  1  6.3  500  0  N/A   
IPD3  55.8  65.1  9.3  0  N/A   N/A    0  N/A   
IPD4  49.4  78.7  29.3  0  26.8  N/A    1  54 
IPD5  73.9  88.2  14.3  0  12  500  0  N/A   
IPD6  59  81.5  22.5  0  20.6  1300  1  205.2 
IPD7  64.4  81  16.6  1  12.1  N/A    1  N/A   
IPD8  58.4  73.2  14.8  1  12.8  N/A    1  N/A   
IPD9  36.5  66.5  30  0  25.2  660  1  21.6 
IPD10  53.1  77.1  24  0  23.5  580  1  222 
IPD11  77.2  89  11.8  0  11  250  0  N/A   
IPD12  45.9  70.1  24.2  1  13.4  750  0  N/A   
IPD13  56.5  65.2  8.7  1  3.4  1000  0  N/A   
IPD14  67  72.2  5.2  1  0.9  N/A    0  N/A   
IPD15  73.8  79.9  6.1  1  3.9  N/A    0  N/A   
IPD16  57.1  71.2  14.1  1  9.1  625  1  98.4 
IPD17  50.4  73.3  22.9  1  21.6  1500  1  12 
IPD18  82.4  92.1  9.7  1  4.9  750  0  N/A   
IPD19  52.9  81.1  28.2  0  24.6  770  1  55.2 
IPD20  59.5  70.5  11  1  10  870  1  54 
G2019S-1  64.6  81  16.4  0  14.9  1000  1  90 
G2019S-2  N/A   84.9  N/A   0  N/A    N/A    N/A    N/A  
G2019S-3  52  80.9  28.9  0  28  2000  1  37.2 
G2019S-4  57.1  72.9  15.8  0  14  600  1  72  
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Table 5.4: Summary of the anatomical regions collected for IPD and G2019S positive PD cases. This tissue was obtained from QSBB, and the table 
provides a detail for the frozen post-mortem tissue used for the qPCR study and the availability of the anatomical regions. Ctx: cortex; N/A: not available. 
  Cerebellum  Medulla  Putamen  Amygdala  Entorhinal 
Ctx 
Cingulate 
gyrus 
Frontal Ctx  Parietal Ctx 
IPD1  √  √  √  √  √  √  √  √ 
IPD2  √  N/A  √  √  √  √  √  √ 
IPD3  √  √  √  √  √  √  √  √ 
IPD4  √  √  √  √  √  √  √  √ 
IPD5  √  √  √  √  √  √  √  √ 
IPD6  √  N/A  √  √  √  √  √  √ 
IPD7  √  √  √  √  √  √  √  √ 
IPD8  √  √  √  √  √  √  √  √ 
IPD9  √  N/A  √  √  √  √  √  √ 
IPD10  √  √  √  √  √  √  √  √ 
IPD11  √  √  √  N/A  √  √  √  √ 
IPD12  √  √  √  √  √  √  √  √ 
IPD13  √  √  √  √  √  √  √  √ 
IPD14  √  √  √  √  √  √  √  √ 
IPD15  √  √  √  √  √  √  √  √ 
IPD16  √  √  √  √  √  √  √  √ 
IPD17  √  √  √  N/A  √  √  √  √ 
IPD18  √  √  √  √  √  √  √  √ 
IPD19  √  N/A  N/A  √  √  √  √  √ 
IPD20  √  √  √  √  √  √  √  √ 
IPD21  N/A  √  N/A  N/A  N/A  N/A  N/A  N/A 
G2019S-1  √  N/A  N/A  N/A  N/A  N/A  N/A  √ 
G2019S-2  √  N/A  N/A  √  √  √  √  √ 
G2019S-3  √  N/A  N/A  N/A  √  N/A  N/A  √ 
G2019S-4  √  N/A  N/A  √  √  √  √  √  
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Table  5.5:  Summary  of  unaffected  subjects  used  in  this  study.  This  tissue  was 
obtained from QSBB. Con: control; M: male; F: female; PM: post-mortem; N/A: not 
available. Mean age at death: 79 years, mean PM delay: 47.89 hours, mean pH: 6.38. 
.
  Sex  Age  PM delay 
(hours) 
pH  Cause of death 
Con1  F  77  23.00  5.60  Cancer (colon) 
Con2  F  86  46.50  6.17  Cancer 
Con3  F  84  81.45  6.28  Cancer, heart failure 
Con4  M  85  43.35  6.68  Cancer (Oesophagus) 
Con5  M  86  53.00  6.65  Bronchopneumonia,                   
heart failure 
Con6  M  86  23.30  6.55  Myocardial infarction 
Con7  M  81  40.00  6.48  N/A 
Con8  F  53  29.50  6.64  Intra-cerebral haemorrage 
Con9  M  91  48  6.54  Bronchopneumonia 
Con10  F  88  49.25  6.23  Chronic obstructive airway 
disease 
Con11  F  85  34.00  6.31  Cancer (breast) 
Con12  F  89  77.3  6.49  Pneumonia 
Con13  M  83  117.05  6.81  Heart attack 
Con14  M  79  56.40  6.60  Cancer (prostate) 
Con15  M  75  64.50  6.18  Pulmonary embolism 
Con16  F  81  13.50  6.39  Cancer (colon) 
Con17  M  63  42.00  6.23  Congestive heart disease 
Con18  M  57  78.5  6.03  Adenocarcinoma 
Con19  F  78  23.30  N/A  N/A 
Con20  M  71  38.5  N/A  Mesolithioma 
Con21  F  83  20.00  6.55  Bowel resection with 
complications 
Con22  F  78  51.30  6.24  Cancer (colon)  
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  Cerebellum  Medulla  Putamen  Amygdala  Entorhinal Ctx  Cingulate 
gyrus 
Frontal 
Ctx 
Parietal Ctx 
Con1  √  √  N/A  √  √  √  √  √ 
Con2  √  √  √  √  √  √  √  √ 
Con3  √  N/A  √  √  √  √  √  √ 
Con4  √  √  √  √  √  √  √  √ 
Con5  √  N/A  N/A  √  √  √  √  √ 
Con6  √  N/A  √  √  √  √  √  √ 
Con7  √  √  √  N/A  √  √  √  √ 
Con8  √  √  √  √  √  √  √  √ 
Con9  √  √  √  N/A  √  √  √  √ 
Con10  √  N/A  √  N/A  √  √  √  √ 
Con11  √  N/A  √  √  √  √  √  √ 
Con12  √  √  √  √  √  √  √  √ 
Con13  √  √  N/A  √  √  √  √  √ 
Con14  √  √  √  √  √  √  √  √ 
Con15  √  N/A  √  N/A  √  √  √  √ 
Con16  √  N/A  √  √  √  √  √  √ 
Con17  √  √  √  √  √  √  √  √ 
Con18  √  N/A  √  √  √  √  √  √ 
Con19  √  √  √  √  √  √  √  √ 
Con20  √  √  √  √  √  √  N/A  √ 
Con21  N/A  √  N/A  N/A  N/A  N/A  N/A  N/A 
Con22  N/A  √  N/A  N/A  N/A  N/A  N/A  N/A 
 
Table 5.6: Summary of anatomical regions collected from unaffected controls. This tissue was obtained from QSBB. This table provides a detail for the 
frozen post-mortem tissue used for the qPCR study and the availability of the anatomical regions. Ctx: cortex; N/A : not available.  
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5.2.4  Immunohistochemistry 
Immunohistochemistry (IHC) was performed on paraffin embedded tissue sections 
from IPD and PD cases positive for G2019S mutation as described in section 2.5.2. 
The  subjects  used  are  summarised  in  Table  5.2. The  anatomical  regions  obtained 
were: medulla, putamen, amygdala, cingulate gyrus, entorhinal, frontal and parietal 
cortices. The sections were cut at 8µm and processed as described in section 2.5.2 of 
chapter  2.  The  tissue  processing  and  visualisation  procedure  was  carried  out  as 
described in sections 2.5.2.2–2.5.2.4 of chapter 2. The widely used monoclonal α-
synuclein  antibody  (VP-A106,  Vector  Laboratories)  was  used  as  the  primary 
antibody  for  the  IHC  procedure  in  this  study.  For  visualisation  with  secondary 
antibody, mouse immunoglobulins (Dako, UK) were used at a dilution of 1:200. A 
corresponding haemotoxylin and eosin stain was performed for all the sections. The 
antibodies  and  pre-treatments  used  in  this  study  are  listed  in  Table  5.7.  The  α-
synuclein immunohistochemistry for cingulate gyrus, entorhinal, frontal and parietal 
cortices was performed by Dr. Tammaryn Lashley (QSBB). 
Antibody  Source  Host  Dilution for IHC  Pre-treatments required 
α-synuclein  DAKO  Mouse 
(monoclonal) 
1 : 75  pressure cooking and formic acid 
treatment (Chapter 2, section 
2.5.2.5) 
Table 5.7: Antibody used for expression of α-synuclein immunohistochemistry. 
5.2.5  LB counts and image processing 
Upon α-synuclein immunoreactivity, the LBs within the neurons were counted for 
medulla, putamen, amygdala, cingulate gyrus, entorhinal, frontal and parietal cortices. 
All the extra-cellular inclusions that displayed α-synuclein positive immunoreactivity 
were ignored. The area containing LB inclusions was identified under an Olympus 
BX50 microscope and a photograph of the section was taken using a Nikon Eclipse 
E800. Image J (NIH) was used to mark the total area of the section to obtain the 
pixels which were then converted into area per mm
2 (see section 2.8.4). The total 
number of LBs was then divided by area per mm
2 to obtain LBs per mm
2. The LB  
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counts for cingulate gyrus, entorhinal, frontal and parietal cortices were performed by 
Dr. Tammaryn Lashley (QSBB) 
5.2.6  Statistical analysis 
The  qPCR  data  was  analysed  using  the  statistical  package  SPSS  version  14.0. 
Parametric  tests  (student’s  t-test)  were  conducted  for  data  that  was  normally 
distributed  and  non-parametric  tests  (Kruskal-Wallis  and  Mann-Whitney  or 
Spearman’s  correlation  where  stated)  were  used  for  the  data  that  did  not  exhibit 
normal distribution.  
Outliers were identified using a box and whiskers plot, and any data point that was 
more than three standard deviations from the mean was excluded from the subsequent 
analysis. If tissue was available for all three subject groups (i.e. control, IPD and at 
least three G2019S positive PD subjects), and the data did not demonstrate normal 
distribution, then non-parametric test of Kruskal-Wallis (K-W) was used to determine 
any significant difference. Any significance observed for the K-W test was further 
refined by using a  Mann-Whitney (M-W) test  between two  groups at  a time, i.e. 
control- IPD, control- G2019S, and IPD- G2019S. This allowed us to determine the 
combination of subject groups that might contribute to the significance observed in 
the K-W test. 
The LB levels for each region were counted twice on independent occasions and an 
inter-class correlation was performed to assess the consistency between the two sets 
of LB counts. For a correlation analysis between LRRK2 mRNA levels and clinical 
data or LB levels in the brain, Spearman’s non-parametric test was used. Outliers 
were identified using a scatter plot, and a bivariate correlation was performed using 
the Spearman’s rho which was set at 0.500 for a positive correlation and -0.500 for 
negative correlation between the parameters.  
The tests were corrected using the step up Simes’ threshold algorithm for multiple 
comparisons as described in section 2.9.4.2. The graphs were plotted either in SPSS 
version 14.0 or in Graphpad PRISM (for dot blots).  
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5.3  Results 
5.3.1  LRRK2  mRNA  expression  study  in  cerebellum  of  unaffected  and 
IPD subjects 
A study was conducted using qPCR to measure the LRRK2 mRNA expression levels 
in post-mortem human brain cerebellum tissue of 121 IPD cases and 36 unaffected 
controls.  The  mRNA  expression  data  was  normalised  using  two  endogenous 
reference genes, HPRT1 and RPL13A. A geometric mean of the two reference genes 
was also used to normalise the mRNA expression data. The data was checked for 
normal distribution, and any outliers (three standard deviations from the mean) were 
excluded prior to using student’s t-test to compare any potential differences between 
control (n= 35) and IPD (n = 115) subjects.  
The analysis revealed a significant difference in mRNA expression levels of LRRK2 
in IPD cases and unaffected controls when the data was normalised individually to 
the two endogenous reference genes, HPRT1 and RPL13A, (p = 0.001 and 0.003, 
respectively), or with the geometric mean of the two reference genes (p = 0.001). For 
the purpose of simplicity, only data normalized to the geometric mean is presented in 
Figure 5.1 (control LRRK2 mRNA mean = 1.187 and IPD LRRK2 mRNA mean = 
0.847, a mean difference of 0.340 in the LRRK2 mRNA levels, 95% CI: 0.149881 
and 0.530573).  
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Figure 5.1: A preliminary study showing differences in LRRK2 mRNA levels in the 
cerebellum of unaffected controls and IPD cases. The data was checked for any outliers 
(three standard deviations from the mean) using a box and whiskers plot and removed prior to 
the statistical analysis using a t-test. The data presented here reflects the LRRK2 mRNA 
levels normalised using the geometric mean of the two endogenous reference genes (HPRT1 
and RPL13A). The dots show the mean of LRRK2 mRNA levels, and the error bars around 
them represent standard error of the mean (+/- 1 SEM). Mean LRRK2 mRNA levels for 
controls is 1.187 and for IPD subjects is 0.847. The mean difference in the LRRK2 mRNA 
values  for  controls  and  IPD  subjects  is  0.340  (95%  confidence  interval  of.  0.149881  – 
0.53057). The decrease in the cerebellum LRRK2 mRNA of IPD cases versus unaffected 
controls is significant (p = 0.001). 
Following on from the results obtained from the preliminary study in cerebellum, 
post-mortem tissue was collected from other brain regions to determine a quantitative 
regional map of LRRK2 mRNA levels in the human brain. The data in following 
sections was produced using tissue from a maximum of 20 controls, 20 IPDs and four 
G2019S positive PD subjects. Four endogenous reference genes were measured for 
all the samples, and the data was analysed using non-parametric tests.  
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5.3.2  Regional variation in LRRK2 mRNA levels in control human brain 
A quantitative regional map of LRRK2 mRNA expression levels was determined to 
complement the LRRK2 ISH results in chapter 4. The data in this particular section 
was  only  produced  using  LRRK2  mRNA  levels  from  unaffected  controls  (a 
maximum of 20 samples). These samples were also normalised using a geometric 
mean  of  the  four  endogenous  reference  genes.  Figure  5.2  represents  the  relative 
LRRK2 transcript levels and demonstrates that in this data set medulla has the highest 
mRNA levels of LRRK2, followed by entorhinal cortex, cerebellum and amygdala. 
The  cortical  regions  of  cingulate,  frontal  and  parietal  are  slightly  higher  than 
putamen, but overall Kruskal-wallis (K-W) test revealed no regional differences in 
LRRK2 mRNA levels.  
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Figure 5.2: Regional expression of LRRK2 mRNA in the normal human brain. The 
mean  LRRK2  mRNA  levels  were  normalised  to  the  geometric  mean  of  the  four 
corresponding endogenous references genes. The bars represent the standard error of the 
mean,  and  indicate  that  overall  regional  levels  of  LRRK2  mRNA  are  not  significantly 
different from each other. Although a slight decrease in LRRK2 mRNA levels is observed in 
the putamen, overall the LRRK2 mRNA levels were comparable across the regions.   
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5.3.3  Differential LRRK2 mRNA expression in multiple brain regions of 
control, IPD, and G2019S positive PD subjects 
Differences  in  LRRK2  mRNA  levels  were  investigated  in  a  maximum  of  20 
unaffected controls, 20 IPD cases and four G2019S positive cases for various regions 
across  the  brain.  Due  to  limited tissue  availability,  anatomical  regions for  all  the 
G2019S positive PD subjects were not obtained (please refer to Table 5.4 and 5.6)  
Insufficient number of G2019S positive PD subjects in medulla (n =0), putamen (n = 
0), amygdala (n = 2), cingulate gyrus (n = 2), and frontal cortex (n = 2) meant that 
only  controls  and  IPD  subjects  were  included  in  the  statistical  analysis  (Mann-
Whitney (M-W)) for these regions. However, the trend of LRRK2 mRNA levels in 
G2019S positive PD samples are represented in Figure 5.3.  
G2019S positive PD subjects were included in the statistical analysis for entorhinal 
cortex (n = 3), cerebellum and parietal cortex (both n = 4). Therefore, K-W test was 
performed for these three regions to assess differences between controls, IPDs and 
G2019S positive PD subjects. If a statistical significance was achieved with the K-W 
tests, then M-W tests were performed as described in section 5.2.6.  
A general widespread decrease was observed in the LRRK2 mRNA levels in IPD 
cases  compared  to  unaffected  controls  in  a  majority  of  the  regions.  This  was 
significant in amygdala, cingulate gyrus, frontal and parietal cortices and cerebellum 
(see  Figure  5.3).  Medulla  on  the  other  hand,  showed  an  increase  in  the  LRRK2 
mRNA  levels  in  IPD  subjects.  Figure  5.3  represents  the  box  and  whiskers  plot 
detailing the interquartile ranges and minimal and maximal points of the data. Any 
point  that  was  three  standard  deviations  away  from  the  mean  was  considered  an 
outlier and not included in the analysis. A detailed spread of the individual points, 
mean and standard error of the mean are represented in Figure 5.4, Figure 5.5, and 
Figure 5.6.  
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Figure 5.3: Differential expression in LRRK2 mRNA levels in unaffected and IPD subjects. The median in the box plot is represented by the horizontal line 
inside the box and the interquartile range (IQR) is between the 25
th and 75
th percentiles which are represented by the horizontal borders of the box. The whiskers 
show the minimal and maximal values of the main data. *P < 0.05 and **P < 0.01. Statistical tests for G2019S positive PD subjects are not shown on this graph.  
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5.3.3.1 LRRK2 mRNA levels are increased in the medulla of IPD cases but 
remain unaffected in the putamen. 
Mann-Whitney  (M-W)  tests  were  performed  for  medulla  and  putamen,  and  a 
significant increase was observed in the LRRK2 mRNA levels in the medulla of IPD 
cases when compared to the controls (p = 0.027). No difference was observed in 
LRRK2 mRNA levels in putamen of the two subjects groups, although there was a 
trend towards a decrease in the LRRK2 mRNA levels of IPD cases when compared to 
the  controls.  The  differential  expression  observed  in  medulla  and  putamen  is 
represented in Figure 5.3, and the figure below (Figure 5.4) represents the spread of 
the  individual  points  (control  and  IPD  subjects  only)  using  standard  error  of  the 
mean.  
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Figure 5.4: Mean LRRK2 mRNA levels in medulla and putamen of unaffected and IPD 
subjects. This figure represents the spread of individual points, the mean and standard error 
of the mean (SEM). The number of samples (n) used for this study were: medulla- controls, n 
= 15 and IPDs, n = 16 and for putamen- controls, n = 18 and IPDs, n = 20. A significant 
increase in the LRRK2 mRNA levels in IPD cases was observed in the medulla (p = 0.027).  
p = 0.027  
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5.3.3.2 LRRK2 mRNA levels are decreased in the medial temporal regions and 
neocortical regions of IPD cases  
No significant difference was observed in the LRRK2 mRNA levels of controls, IPD 
and G2019S positive PD subjects for entorhinal cortex, although there was a trend 
towards  a  decrease in  the  LRRK2  mRNA  levels  in PD  subjects.  Due  to the  low 
number of G2019S positive PD cases in amygdala (n = 2), only controls and IPD 
subjects  were  included  in  the  statistical  analysis  for  this  region.  The  M-W  test 
revealed a significant decrease in the LRRK2 mRNA levels of IPD cases in amygdala 
in  comparison  to  unaffected  controls  (p  =  0.014).  The  differential  expression 
observed in entorhinal cortex and amygdala is represented in Figure 5.3.  
LRRK2  mRNA  levels  were  also  obtained  for  a  maximum  of  20  IPD  and  20 
unaffected controls for the cortical regions of cingulate gyrus; frontal cortex; parietal 
cortex and cerebellum. Statistical analysis demonstrated a decrease in the LRRK2 
mRNA levels of IPD subjects in comparison to the unaffected controls in cingulate 
gyrus and frontal cortex. This was significant at the 5% level, p = 0.012 for cingulate 
gyrus, and p = 0.035 for frontal cortex (see Figure 5.3).  
The preliminary cerebellum data was only normalised using, HPRT1 and RPL13A 
(Figure 5.1). Therefore, to provide consistency the other two reference genes (G6PD 
and TBP) were also measured in cerebellum of 20 controls, 20 IPDs and 4 G2019S 
positive  PD  cases.  A  significant  decrease  in  the  LRRK2  mRNA  levels  of  IPD 
subjects was again observed in comparison to the unaffected controls in cerebellum 
(p = 0.01). However, the most significant decrease in the LRRK2 mRNA levels of 
IPD subjects was observed in the parietal cortex at a significance level of 1% (p = 
0.004) (see Figure 5.3). The spread of the individual points (control, IPD and G2019S 
positive PD subjects) using standard error of the mean is represented in Figure 5.6.  
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Figure 5.5: LRRK2 mRNA levels are decreased in the medial temporal regions and 
frontal cortices of IPD cases. This figure represents the spread of individual points, the 
mean and standard error of the mean (SEM). The number of samples (n) used for this study 
were: entorhinal cortex- control, n = 19 and IPD, n = 20; for amygdala- control, n = 18 and 
IPD, n = 20; for cingulate gyrus- control, n = 19 and IPD, n = 20; and for frontal cortex,-
control, n = 19 and IPD, n = 20.  
 
5.3.3.3  Is  there  any  difference  between  LRRK2  mRNA  levels  of  IPD  and 
G2019S positive PD cases? 
There was a trend towards a generalised decrease in the mRNA levels of LRRK2 in 
G2019S positive PD cases compared to the IPDs in the medial temporal lobe regions 
of amygdala and entorhinal cortex, and the neo-cortical regions of cingulate gyrus 
and frontal cortex (Figure 5.3). The G2019S positive PD subjects were not included 
in statistical analysis for these regions (apart from entorhinal cortex), lest their low 
number skewed the results. Despite no statistical significance, the slight increase in 
     p = 0.014                            p = 0.035 
p= 0.012                    
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the LRRK2 mRNA levels of G2019S positive PD cases in comparison to IPD cases 
for both cerebellum and parietal cortex is an interesting observation (see Figure 5.6. 
However,  when  the  individual  samples  are  plotted  (Figure  5.6),  the  increase  in 
LRRK2  mRNA  levels  of  G2019S  PD  compared  to  IPD  subjects  is  only  slightly 
evident.  However,  the  LRRK2  mRNA  levels  remain  lower  than  the  unaffected 
controls in both set of PD subjects. It should be noted that cerebellum and parietal 
cortex are the only two regions where post-mortem tissue from all the four G2019S 
cases was available. Therefore, any trends where fewer G2019S positive PD cases 
were used should be interpreted with caution.  
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Figure  5.6:  Relative  LRRK2  transcript  levels  in  cerebellum  and  parietal  cortex  of 
controls,  IPDs  and  G2019S  positive  PD  subjects.  This  figure  represents  the  spread  of 
individual points, the mean and standard error of the mean (SEM). The number of samples 
(n) used for this study were: parietal cortex - control, n = 20; IPD, n = 20 and G2019S, n = 4. 
For cerebellum: control, n = 20; IPD, n = 20 and G2019S, n = 4.  
      p = 0.004                   p = 0.01  
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5.3.3.4 Multiple test Correction 
During hypothesis testing, even if all the null hypotheses are true, there is a 1 in 20 
chance that at a significance level of α = 0.05, a statistically significant finding will 
be observed, thereby increasing the risk of false-positives (see 2.9.4.2 for details). 
Therefore,  in  order  to  avoid  spurious  results  (i.e  not  to  reject  a  correct  null 
hypothesis), it is essential that all the data is corrected for multiple comparisons.  
The  comparisons  being  carried  out  in  this  particular  study  related  to  regional 
differences in LRRK2 mRNA levels of unaffected, IPD and G2019S positive PD 
subjects. As described in section 5.3.3, K-W test was performed when samples were 
present  for  all  three  groups  (3  tests:  entorhinal  cortex,  cerebellum  and  parietal 
cortices). M-W test was performed for two groups at a time (12 tests). Taking into 
account the initial student’s t-test performed for the preliminary cerebellum data set, 
this puts the total number of comparisons up to 16. The data was corrected using the 
step-up Simes’ algorithm for multiple testing by ranking the P -values from the 16 
tests in an ascending order, and setting a threshold P-value depending on its position 
within the order. As described in section 2.9.4.2, the step-up Simes’ algorithm is an 
extension of the Bonferroni procedure, although it is a little less conservative on the 
data.  
The P -value obtained using the student’s t-test for the preliminary cerebellum (p = 
0.001)  data  survived  the  step-up  Simes’  threshold  for  multiple  testing.  Table  5.8 
shows the multiple test correction for all the regions that had 20 unaffected, 20 IPD 
and  G2019S  positive  PD  subjects.  As  can  be  seen  in  Table  5.8,  the  differences 
observed  between  IPD  and  unaffected  subjects  for  parietal  cortex,  cerebellum, 
cingulate  gyrus,  amygdala,  frontal  cortex  and  medulla  remained  significant  after 
being corrected for multiple testing with the step-up Simes’ threshold. 
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  Kruskal-Wallis 
Test for IPD-
G2019S-
Control 
step-up 
Simes’ 
threshold 
Simes’ outcome    
threshold < 0.05, 
reject H0, 
threshold > 0.05, 
accept H0 
Mann-Whitney 
Test- IPD-
Control 
step-up Simes’ 
threshold 
Simes’ outcome    
threshold< 0.05, reject 
H0, threshold > 0.05, 
accept H0 
Parietal cortex  0.012  0.022  Reject H0  0.004  0.011  Reject H0 
Cerebellum  0.031  0.044  Reject H0  0.011  0.016  Reject H0 
Cingulate gyrus  X  X  X  0.012  0.027  Reject H0 
Amygdala  X  X  X  0.014  0.03  Reject H0 
Medulla  X  X  X  0.027  0.038  Reject H0 
Frontal cortex  X  X  X  0.035  0.05  Reject H0 
Entorhinal 
cortex 
0.126  0.061  Accept H0  X  X  X 
Putamen  X  X  X  0.579  0.077  Accept H0 
Table 5.8: P- values corrected using step-up Simes' threshold. Kruskal-wallis was performed for parietal cortex, cerebellum and entorhinal 
cortex only. The preliminary cerebellum study (student’s t-test) is not represented here but was included in the overall multiple comparisons. A 
significant P-value for K-W test meant that the groups (control, IPDs and G2019S PD subjects) were then compared to each other using M-W test. 
In order for the null hypothesis to be rejected, the threshold value set up by the step-up Simes’ correction had to be < 0.05. Only the P -values for 
the M-W tests between control and IPD subjects are shown in this table. H0 : null hypothesis.  
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5.3.4  LRRK2 mRNA expression and clinical data 
LRRK2 mRNA levels were correlated with gender and duration of illness for IPD 
and G2019S positive PD subjects. Spearman’s correlation revealed no association of 
LRRK2 mRNA levels with either of the parameters.  
Subjects with clinical history reporting levodopa (L-DOPA) induced dyskinesia were 
identified amongst the IPD group (n = 8) and G2019S subjects (n = 3) (see Table 5.3 
for details on the subjects). The effects of L-DOPA induced dyskinesia on regional 
LRRK2 mRNA levels were then investigated. Spearman’s correlation was performed 
to investigate association between regional LRRK2 mRNA levels and maximum L-
DOPA dose (mg/day) or with cumulative L-DOPA dosage during the duration of the 
illness  for  these  subjects.  No  correlation  was  observed  for  maximum  dose  of  L-
DOPA and LRRK2 mRNA levels, but positive trends were observed for amygdala 
(Spearman’s rho= 0.657; p= 0.156) and medulla (Spearman’s rho= 0.800; p = 0.200). 
Weak  correlations  were  observed  for  cumulative  dose  of  L-DOPA  and  LRRK2 
mRNA levels in cingulate gyrus (Spearman’s rho 0.714, p = 0.047) and entorhinal 
cortex  (Spearman’s  rho  0.683,  p  =0.042)  of  subjects  with  L-DOPA  induced 
dyskinesia.  Even  though  the  effects  of  L-DOPA  induced  dyskinesia  on  LRRK2 
mRNA levels would have been most relevant to the putamen, no correlations were 
observed with maximum L-DOPA or cumulative dose in putamen.  
5.3.5  LRRK2 mRNA expression and LB pathology count 
A correlation between LRRK2 mRNA levels and the collective LB load described as 
transitional or neocortical (according to the McKeith criteria) was performed and no 
association was observed. The LB counts per mm
2 (see section 5.2.5) in medulla, 
putamen, amygdala, entorhinal cortex, cingulate gyrus, frontal and parietal cortices 
were also correlated to the normalised LRRK2 mRNA levels of the corresponding 
regions.  No  correlation  was  observed  between  the  number  of  LB  inclusions  and 
LRRK2 mRNA levels for any of the regions.   
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5.4  Discussion 
This study demonstrates a widespread dysregulation in the  LRRK2  mRNA levels 
between unaffected and IPD subjects in various anatomical regions across the brain. 
Trends  towards  decreased  LRRK2  mRNA  levels  were  also  observed  in  G2019S 
positive PD subjects in comparison to the unaffected subjects. This overall decrease 
in  LRRK2  mRNA  levels  in  PD  subjects  used  in  this  study  suggests  a  shared 
mechanism is contributing to the PD pathogenesis experienced by IPD and G019S 
positive PD subjects. Following on from the identification of LRRK2 protein in LBs 
(as demonstrated in chapter 4), the effects of LRRK2 mRNA on the eventual LB load 
in different anatomical regions were also investigated. 
A preliminary study comparing LRRK2 mRNA levels in the cerebellum of 115 IPD 
cases and 35 unaffected controls suggested a marked decrease in LRRK2 mRNA in 
IPD cases. This was of interest since a decrease in the mRNA levels of the PARK9 
(ATP13A2) locus in the cerebellum has previously been reported (Vilariño-Güell et 
al. 2008), despite cerebellum not being immediately affected in the PD pathogenesis 
like  the  brainstem.  Therefore,  further  quantitation  of  LRRK2  mRNA  levels  was 
performed  in  regions  more  directly  implicated  in  PD,  namely,  medulla,  putamen, 
cingulate gyrus, frontal cortex, entorhinal cortex and parietal cortex. 20 unaffected 
cases, 20 IPD cases, and where available, tissue from four G2019S positive PD cases 
were chosen for this purpose.  
A total of four endogenous reference genes were measured for each sample and for 
every  anatomical region.  Whilst performing a quantitation of the regional mRNA 
expression  of  LRRK2  in  unaffected  subjects,  the  geometric  mean  of  all  the  four 
endogenous reference genes was used to normalise LRRK2 mRNA data. However, a 
slightly different methodology was taken to normalise the data when the affected and 
unaffected were compared. This was done because the normalisation by endogenous 
reference genes works on the premise that they do not differ between the affected and 
unaffected.  However,  it  cannot  be  assumed  for  certain  that  the  reference  genes 
themselves are not affected during the disease pathogenesis. Therefore, to account for  
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this  anomaly,  the  software  NormFinder  was  used  to  select  a  combination  of  the 
reference  genes  with  the  least  amount  of  estimated  variation  in  unaffected  and 
affected subjects for each region. Once these were selected, a normalisation factor 
was calculated using the geometric mean of the reference genes recommended by 
NormFinder, and this factor was then used to normalise the LRRK2 mRNA levels for 
affected and unaffected before any further analysis could be undertaken. 
Regional expression of LRRK2 mRNA in normal human brain 
This chapter demonstrates a quantitative regional description of LRRK2 mRNA in a 
maximum of 20 unaffected subjects, which to our knowledge is the largest number of 
samples examined to estimate the LRRK2 transcript levels in post-mortem human brain. 
Overall there was no statistically significant difference in the regional levels of LRRK2 
mRNA, but as demonstrated in Figure 5.2, the highest LRRK2 mRNA levels were 
identified in medulla and cerebellum. This correlates well with the semi-quantitative 
results  for  LRRK2  protein  in  chapter  4  of  this  thesis  where  medulla  followed  by 
cerebellum was consistently shown to have high LRRK2 protein levels. Similarly, the 
medial temporal regions of amygdala and entorhinal cortex, and neocortical regions of 
cingulate gyrus, frontal and parietal cortices had slightly lower levels of LRRK2 mRNA 
compared to medulla and cerebellum which also correlates well with the LRRK2 protein 
data in chapter 4. The moderate to high LRRK2 mRNA and protein (chapter 4) levels in 
the limbic regions of amygdala, entorhinal cortex and cingulate gyrus, indicates that this 
protein might  play a  role  in  other  neurodegenerative  diseases  or  possible  late  stage 
cognitive decline associated with PD. 
The lowest LRRK2 mRNA levels in this study were recorded for putamen, however, 
these mRNA levels were still comparable to other regions, and no significant difference 
was observed as is demonstrated by the error bars in Figure 5.2. This is of interest as in 
chapter 4 the lowest LRRK2 protein levels were consistently recorded for the striatal 
neurons.  Previous  studies  have  reported  higher  LRRK2  mRNA  levels  in  striatal 
putamen as compared to substantia nigra (SN) (Zimprich et al. 2004b; Melrose et al. 
2006), but due to a lack of nigral tissue we were not able to make such a comparison,  
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and this obviously remains a limitation of our study. However, a quantitation of LRRK2 
mRNA levels in the putamen as presented in this chapter coupled with data from chapter 
4, lends further support to the recommendation that LRRK2 protein has a high turnover 
in the striatal regions, and as such could play an important role in the nigrostriatal 
dopamine system. 
Widespread reduction of LRRK2 mRNA in IPD cases 
As demonstrated in the results section (Figure 5.3), with an exception of an increase 
in the medulla, LRRK2 mRNA levels were shown to have a generalised decrease in 
all other anatomical regions of IPD cases examined in this study. Apart from putamen 
and entorhinal cortex, these trends of decrease in LRRK2 mRNA were statistically 
significant and all survived the step up Simes’ threshold for multiple comparisons.  
Taking the Braak staging into account, medulla is the first region to be vulnerable to 
α-synuclein PD pathology in comparison to the other regions examined in this study. 
The increase in the LRRK2 mRNA levels in the medulla of IPD cases is different 
from the generalised decrease observed in the other regions (Figure 5.3 and Figure 
5.4). Tissue effect on genetic control of transcript isoform variation has previously 
been reported in human osteoblasts (Kwan et al. 2009). It is feasible that the LRRK2 
mRNA increase in the medulla of IPD cases is due to an upregulation of a region 
specific isoform(s) of LRRK2 transcript as a compensatory mechanism during initial 
stages of  PD progression in the medulla. However, this is purely speculative and 
further  experiments  aimed  at  measuring  not  only  the  region  specific  isoforms  of 
LRRK2  transcripts,  but  also  their  half-lives  are  needed  before  inferring  that  this 
increase in the LRRK2 mRNA levels of medulla might be an early compensatory 
mechanism in response to PD progression. 
The  putamen  shows  no significant  change  in  LRRK2 mRNA levels  despite  there 
being a widespread decrease in all other regions. This is in agreement with previous 
studies that also reported no difference in the striatal LRRK2 levels in IPD cases and 
unaffected controls (Melrose et al. 2006; Hurley et al. 2007), although a trend in  
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decreased levels was observed in IPD cases as was recorded by Galter and colleagues 
(Galter  et  al.  2006).  The  loss  of  dopamine  depletion  in  the  striatum  results  in  a 
clinical phenotype which is treated using L-DOPA replacement therapy. L-DOPA 
replacement therapy was administered to the IPD cases (all but one) used in this study 
and L-DOPA induced dyskinesia was also reported in some IPD and G2019S positive 
PD  subjects  (see  Table  5.3).  Previously  L-DOPA  induced  dyskinesia  has  been 
suggested  to  increase  striatal  LRRK2  mRNA  levels  in  marmosets  (Hurley  et  al. 
2007). Clinical history detailing L-DOPA induced dyskinesia was only available for 
half of the cases and no correlation between LRRK2 mRNA levels with maximum L-
DOPA dose and  cumulative dose  was observed in putamen.  Although a previous 
study  that  reported  increased  LRRK2  mRNA  levels  in  marmosets  (Hurley  et  al. 
2007), it should be noted that a detailed retrospective analysis of dyskinesia levels in 
post-mortem human tissue is not possible. Moreover the clinical data for L-DOPA 
induced dyskinesia was only available for a minority of cases, therefore not allowing 
for  an  accurate  correlation  analysis  between  L  -DOPA  induced  dyskinesia  and 
putamen LRRK2 mRNA levels. 
Pallor of substantia nigra (SN) is a pathological phenotype associated with both IPD 
and G2019S positive PD cases. The absence of SN is a limitation of this study, but 
the data  resultant from  whole  nigral  tissue  that might  be  severely  degenerated  in 
affected  subjects  cannot  be  easily  interpreted.  This  is  because  a  decrease  in  the 
mRNA could be associated with extensive cell loss, and a lack of change  (or an 
increase)  could  be  due  to  compensatory  mechanisms  which  might  result  in  a 
transcriptional upregulation in the surviving neurons in a region that is critical to PD 
pathogenesis.  The  best  way  to  capture  transcriptional  profile  for  SN  is  to  obtain 
individual  DAergic  neurons  using  laser  capture  microdissection,  which  we  were 
unable to do. Thus, no whole nigral tissue was involved in this study, but a recent 
study has showed a decrease in LRRK2 mRNA levels of laser capture microdissected 
DAergic neurons from IPD patients (Simunovic et al. 2008), raising the question of 
whether LRRK2 is essential for the survival of DAergic neurons or whether reduction 
in mRNA levels is just an effect of the overall cell loss in SN?  
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LRRK2  expression  in  numerous  brain  regions  such  as  the  hippocampus  and 
amygdala which are the key structures of the limbic system has led to suggestion that 
LRRK2 plays a physiological role not only in the motor but also in certain cognitive 
elements associated with the PD pathogenesis and/or normal aging (Giasson et al. 
2006). The presence of LRRK2 has been reported in neurofibrillary tangles (NFTs) 
and  the  pleomorphic  pathology  related  to  LRRK2  mutations  certainly  suggests  an 
important upstream role for this gene in other neurodegenerative disorders (Giasson et 
al. 2006). It would have been interesting to correlate LRRK2 mRNA levels in these 
regions to mini mental state examination (MMSE) scores of the patients used in this 
study. However, a lack of detailed information of MMSE scores for these subjects used 
in  this  study,  made  a  correlation  analysis  unfeasible.  Nonetheless,  the  significant 
quantitative  difference  reported  in  the  LRRK2  transcript  levels  in  amygdala  and 
cingulate gyrus, both of which form an important part of the limbic system does lead to 
the suggestion that LRRK2 might also play a role in the cognitive related decline in PD.  
The reduction of LRRK2 mRNA in the cortical regions is also of interest, as even 
though the biggest impact of PD is felt on the functions of the nigrostriatal dopamine 
system, PD is a systemic disease of the nervous system. Whether this reduction in 
cortical regions represents an end-stage involvement remains to be determined but 
various  metabolic  defects  such  as  mitochondrial  abnormalities,  oxidative  stress, 
protein aggregation and abnormal gene regulation have been suggested to result in the 
early involvement of cerebral cortex in PD (reviewed in (Ferrer 2009)). The multi-
domains  of  LRRK2  have  been  suggested  to  play  a  role  in  signal  transduction, 
apoptosis, vesicle trafficking, neuronal maintenance, and axonal transport (reviewed 
in (Greggio & Cookson 2009)). As such a reduction in the LRRK2 mRNA levels 
could  have  drastic  effects  on  any  number  of  these  functions  resulting  in  various 
metabolic defects that might contribute to PD progression.   
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Could  dysregulation  of  a  shared  auxiliary  mechanism  contribute  to  the 
indistinguishable phenotype of IPD and G2019S positive PD subjects? 
The LRRK2 mRNA levels were also investigated in the anatomical regions for the 
four G2019S positive PD cases obtained from the QSBB archive. Despite the low 
number of G2019S positive PD subjects, there was a consistent trend towards low 
LRRK2  mRNA  levels  in  G2019S  positive  PD  subjects  in  comparison  to  the 
unaffected subjects.  This  is  interesting  as  the  dysregulation  of  LRRK2  mRNA  in 
G2019S  positive  PD  subjects  is  in  the  same  direction  as  observed  in  IPD  cases 
without the G2019S mutation.  
For  a  majority  of  the  regions  (cingulate  gyrus,  amygdala,  frontal  and  entorhinal 
cortices),  lower  levels  of  LRRK2  mRNA  were  recorded  in  G2019S  positive  PD 
subjects in comparison to IPD subjects. However, the only regions where the trends 
in LRRK2 mRNA levels of G2019S positive PD subjects were comparable to IPD 
subjects were in the cerebellum and parietal cortex. This is because cerebellum and 
parietal cortex are the only two areas where tissue was available for the maximum 
number of G2019S positive PD subjects (n = 4) in this study. It should be noted that 
the sample G2019S-2 that was available for all the regions (not including medulla 
and  putamen)  also  displayed  low  levels  of  mRNA  for  the  endogenous  reference 
genes, indicating that tissue from this subject might not be well preserved. Therefore, 
all the regions that display low mRNA levels in G2019S positive PD samples in 
comparison  to  IPD  cases  (Figure  5.3)  could  have  been  skewed  by  this  particular 
sample.  Regardless  of  this,  LRRK2  mRNA  levels  were  decreased  in  all  G2019S 
positive PD subjects when compared to the unaffected controls. 
A previous study that examined the phosphorylation activity of LRRK2 in leucocytes 
of  unaffected,  IPD  and  G2019S  positive  PD  subjects  reported  a  reduced  LRRK2 
protein activity in G2019S positive PD and IPD subjects in comparison to controls, 
but a slight increase in LRRK2 phosphorylation activity of G2019S positive PD in 
comparison to IPD subjects (White et al. 2007). There is also a slight increase in the 
LRRK2 mRNA levels of the G2019S positive PD cases compared to the IPDs in this  
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study (as presented in cerebellum and parietal cortices, Figures 5.3 and 5.6), but the 
low numbers of G2019S positive PD subjects in this study does not allow us to make 
any statistical inferences. Therefore, tissue from a larger numbers of G2019S positive 
PD subjects is needed in order to accurately assess this question. 
In addition, chapter 4 of this thesis demonstrated no difference in the morphological 
profile  of  LRRK2  mRNA  and  protein  in  IPD  and  G2019S  positive  PD  subjects. 
Collectively,  these  data  suggest  that  the  widespread  decrease  in  LRRK2  mRNA 
levels of IPD as well as G2019S positive PD cases (in comparison to unaffected 
subjects)  might  be  a  shared  auxiliary  mechanism  that  contributes  to  the  purely 
idiopathic PD as well as PD resultant from the mutational insult of G2019S. 
No correlation between LRRK2 mRNA and α-synuclein immunoreactivity to 
LBs 
In-vivo substrates of LRRK2 have not yet been identified, but it was recently shown 
that  LRRK2  phosphorylates  α  -synuclein  in-vitro  (Qing  et  al.  2009).  Moreover, 
LRRK2 has also been shown to phosphorylate ERK (Liou et al. 2008) which itself 
has  been  implicated  in  a  MAPK  pathway  phosphorylating  increased  levels  of  α-
synuclein in response to MPP+ administration in a neuroblastoma cell line (Gómez-
Santos  et  al.  2002).  Increased  levels  of  α-synuclein  have  shown  to  be  toxic  in 
DAergic neurons both in MPTP administered in-vitro and in-vivo models neurons 
(reviewed in (Goldberg & Lansbury 2000)). Increased mRNA levels of α-synuclein in 
DAergic neurons of PD patients have been identified, (Gründemann et al. 2008), and 
more recently a decrease in LRRK2 mRNA levels of DAergic neurons were also 
reported (Simunovic et al. 2008). Taking the current literature into account, one could 
make  a  conceptual  argument that  LRRK2  is  an  active  member of  the  MAPKKK 
pathway that might play a part in the modulation of α-synuclein by phosphorylation.  
The  presence  of  LRRK2  protein  in  a  small  proportion  of  LBs  was  confirmed  in 
chapter 4 of this thesis, and as such a correlation was performed to investigate the 
effect of LRRK2 mRNA levels on the number of LB inclusions, if any at all. No  
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correlation was observed between the levels of LRRK2 mRNA and LB inclusions in 
IPD or G2019S positive PD subjects. However, the number of IPD (20) and G2019S 
positive  PD  (4)  subjects  in  this  study  could  be  low  for  an  accurate  correlation 
analysis. Therefore, a higher number of samples are needed for a robust correlation 
analysis between the levels of LRRK2 mRNA levels and LB inclusions in IPD and 
G2019S positive PD subjects. 
A major contribution to this investigation would have been an accurate quantitative 
measurement of both LRRK2 and α-synuclein proteins. However, current lack of a 
robust  ELISA  assay  for  LRRK2  makes  it  hard  to  perform  accurate  quantitative 
analysis  for  the  LRRK2  protein  levels.  Alternatively,  if  LRRK2  does  indeed 
modulate phosphorylation of α-synuclein in LBs, assessing the levels of phospho-α-
synuclein  in  the  LBs  might  provide  a  better  parameter  for  a  correlation  with  the 
LRRK2 mRNA and protein levels in IPD and G2019S positive PD subjects.  
Conclusion 
This  study  describes  a  quantitative  regional  expression  of  LRRK2  mRNA  in  the 
human brain. The widespread reduction of LRRK2 mRNA levels in various limbic 
and neocortical regions across the brains of IPD and G2019S positive PD subjects in 
comparison  to  the  unaffected  controls,  suggests  that  auxiliary  mechanisms  might 
make an important contribution to PD pathogenesis.  
Although the function of LRRK2 remains debatable, the multiple domains it contains 
suggest  a  possible  involvement  in  various  upstream  signalling  events.  Subtle 
quantitative  changes  in  the  LRRK2  transcription  could  affect  its  kinase  activity 
(amongst  other  functions),  and  have  unfavourable  consequences  on  subsequent 
signalling pathways. It is feasible that the broad decrease in LRRK2 mRNA levels in 
the brains of IPD subjects is an indication of how complex interactions between many 
cells types across different regions might be affected in addition to the characteristic 
loss of nigral neurons, thereby resulting in PD progression. Alternatively, if LRRK2 
is  indeed  involved  in  neuronal  maintenance,  then  a  reduction  of  LRRK2  mRNA  
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levels in PD brains, providing that it results in a reduction of LRRK2 protein levels 
might contribute to the characteristic loss of nigral neurons in both IPD and G2019S 
positive PD subjects.   
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Chapter 6  
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6  The effects of cis-acting variation on LRRK2 mRNA levels 
6.1  Introduction 
Differences  in  interspecies  gene  (transcription)  expression  profile  suggest that  the 
regulation of the transcriptome has been an essential driving force for the phenotypic 
evolution of humans (Gilad et al. 2006). Despite sharing 98.7% of their  genomic 
sequence, marked variations in the gene expression of human and chimpanzees have 
been  reported,  especially  in  the  central  nervous  system  (Enard  et  al.  2002).  The 
human  genome  has  a  lower  number  of  protein  encoding  genes  than  previously 
expected,  and  the  precise  regulation  of  these  has  been  suggested  to  result  in  the 
physiological complexity of humans (Pastinen & Hudson 2004). 
The process of transcription, where DNA is transcribed into mRNA is a carefully 
regulated mechanism that results in a quantitative phenotype. This mechanism can be 
affected  by  cis-acting  (genetic  variation)  factors,  or  by  trans-acting  regulatory 
elements,  such  as  transcription  factors  that  regulate  gene  expression  by  inducing 
DNA-protein  interactions  (reviewed  in  (Knight  2003).  The  cis-acting  genetic 
variation can be present in regulatory regions, such as promoters and enhancers, or as 
exonic (or intronic) variants that alter transcript splicing and stability, and thereby 
produce various alternatively spliced isoforms of the mRNA. Genetic variation also 
has  the  ability  to  act  in  trans,  if  present  on  a  different  chromosome.  All  these 
regulatory factors can affect the delicate process of transcription, and result in altered 
levels of the nascent mRNA (reviewed in (Knight 2003). 
Genetic  variation  that  is  involved  in  regulation  of  gene  expression  (mRNA 
transcription) is difficult to identify, as it can be located within the promoter, the 5’ 
upstream  region  (5’-UTR),  the  transcript,  or  the  introns.  Enhancers  or  silencers, 
upstream or downstream of the transcribed region also contain regulatory sequences. 
Thus, accurate identification of putative regulatory sequences is highly dependent on 
how well the genomic sequence has been annotated. However, large scale genome 
wide  expression  studies  have  demonstrated  that  altered  gene  expression  due  to  
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genetic variation is a common phenomenon, and many linked loci work together in 
cis to exert regulatory influences (Morley et al. 2004; Buckland 2004a; Cheung et al. 
2005; Dixon et al. 2007; Göring et al. 2007; Stranger et al. 2007). Variations in gene 
expression have been extensively demonstrated in the human brain (Bray et al. 2003; 
Buckland  et  al.  2004b).  Studies  suggest  that  quantitative  trait  loci  for  expression 
(eQTL) are correlated with the transcript abundance, and could work together to have 
a cumulative effect on gene expression (Myers et al. 2007). These large scale studies 
that  correlate  global  gene  expression  levels  to  genetic  variation  have  identified  a 
regulatory role for a significant proportion of the non-coding variation.  
A popular hypothesis about risk of common, complex diseases is that the causation is 
due to a small collection of variant loci (eQTL), each of which contributes a little to 
the ultimate complexity of the disease phenotype (Myers et al. 2007). Investigation of 
common  genetic  variation  that  might  produce  a  regulatory  effect  on  the  gene 
expression  is  fast  becoming an  approach  that  can  help  with  the  understanding  of 
disease  pathogenesis  when  a  mutational  insult  is  not  always  apparent.  This 
phenomenon  has  already  been  shown  to  have  an  effect  on  the  catechol-o-methyl 
transferase  (COMT)  expression  in  schizophrenia  patients  (Bray  et  al.  2003),  and 
apolipoprotein  E  (APOE)  expression  in  Alzheimer’s  disease  (Bray  et  al.  2004). 
Therefore, the concept that gene expression differences are influenced by variants in 
regulatory  elements  has  become  increasingly  popular  in  investigation  of  complex 
disorders (Pastinen & Hudson 2004; Pastinen et al. 2006). 
Whole genome expression studies provide the most information for the transcriptome 
profile. However, the effects of cis-genetic variation on inter- and intra-individual 
differences  in  the  gene  expression  can  also  be  detected  using  technologies  that 
measure the relative abundance of mRNA transcripts containing each allele. These 
technologies include  a single base extension (SBE) method  (Yan et al. 2002), an 
oligo array method (Lo et al. 2003), RT- coupled 5’nuclease assays (Zhu et al. 2004), 
haploCHIP assays (Knight et al. 2003), or purely mathematical algorithms (Teare et 
al. 2006). However, these methods usually focus on heterozygous individuals, as it is 
assumed that in the absence of any cis-acting variation, both the alleles of a gene will  
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be equally expressed. Therefore, if an individual is heterozygous for a variant that 
regulates expression in cis then the mRNA from each allele will be differentially 
expressed. Such allelic imbalances, known as differential allelic expression (DAE) 
are a widespread occurrence and can be used to identify cis-acting factors that modify 
disease risk. These can then be functionally assessed using a variety of techniques, 
such as in-vitro promoter luciferase assays.  
The effects of cis-acting variation on mRNA levels have previously been documented 
in  PARK  loci  associated  with  autosomal  dominant  and  recessive  forms  of  PD. 
Variation in the 5’UTR regions of SNCA and PRKN have been shown to affect the 
transcriptional activity of these genes. The polymorphic microsatellite repeat NACP-
Rep1 is located 10 kb upstream of SNCA transcription start site, and its alleles have 
frequently been show to produce differing risks of PD by modulating the transcription 
of SNCA (Chiba-Falek & Nussbaum 2001; Maraganore et al. 2006). The variant -
258T/G in the core PRKN promoter has been demonstrated to affect the expression of 
the gene by binding to nuclear protein in substantia nigra (SN) in-vitro, (West et al. 
2002). The wild type allele -258T was shown to have an in-vitro increase in the 
transcriptional  activity  of  the  PRKN  gene  under  oxidative  stress  or  proteasomal 
inhibition (Tan et al. 2005b). Furthermore, the variant -258G allele was shown to be 
significantly associated with PD risk in Caucasian and Chinese populations (West et 
al. 2002; Tan et al. 2005). These results demonstrate the importance of investigating 
non-coding genetic variation and their regulatory role in PD pathogenesis.  
Thus far no reports have been published on genetic variation in 5’ UTR of LRRK2 
affecting its transcriptional activity. A widespread reduction of LRRK2 mRNA in the 
brains of IPD cases versus unaffected subjects has been demonstrated in chapter 5. 
Therefore,  the  study  described  in  this  chapter  was  designed  with  a  view  to 
investigating  whether  LRRK2 mRNA  expression,  like  the  PARK loci, SNCA  and 
PRKN, can also be regulated by genetic variation in its 5’UTR sequence.  
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6.1.1  Hypothesis and specific aims 
In  this  chapter,  I  wished  to investigate  the hypothesis  that  the  alterations  in 
LRRK2 mRNA expression between IPD cases and controls as demonstrated in 
chapter 5 of this thesis is a quantitative phenotype that can be attributed to cis-
acting genetic variation in putative regulatory elements of the LRRK2 gene.  
To  address  this  question,  a  study  was  designed  with  a  view  to  investigating  the 
regulatory variation in the regions upstream of  the LRRK2 gene. A 10 kb region 
upstream of the LRRK2 transcription start site was investigated for genetic variation 
and four tag SNPs (tSNPs) were identified. An in-silico analysis with the genotype 
information  and  the  results  of  the  qPCR  study  for  the  cerebellum  (section  5.3.1, 
chapter  5)  was  then  performed  to  identify  whether  any  of  the  four  tSNPs  were 
involved in the mRNA regulation of the LRRK2 gene. Assays were then designed to 
ascertain whether differences in DNA:protein interaction due to the variation in the 
putative  regulatory  sequence  could  modulate  LRRK2  mRNA  levels.  A  genetic 
association  study  was  also  performed  to  identify  the  risk  posed  by  the  tSNP  in 
question.  
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6.2  Methods and Materials 
6.2.1  LD analysis and tagging SNPs 
A LD map 10 kb upstream (38,895,080-38,905,350) of the LRRK2 transcription start 
site was generated to select SNPs that were representative of the common genetic 
variation in that region. Caucasian HapMap Data release 21/phase II Jul06, on NCBI 
B35,  dbSNP  b125,  available  through  International
  HapMap  Project 
(www.hapmap.org) was used to calculate the LD metrics. Haploview was used to 
select  the  SNPs  that  could  ‘capture’  up  to  95%  of  the  common  genetic variation 
across
  the  region  (r
2=  0.80).  These  are  termed  tag  SNPs  (tSNPs).  The  ‘tagger’ 
function in Haploview generated four tSNPs for the 10 kb 5’-UTR of LRRK2. The 
tSNPs identified were rs10878224, rs2708435, rs1472117 and rs7294619 (see Figure 
6.1).  All  of  these  four  tSNPs  were  shown  to  be  conserved  in  the  primates,  and 
rs1472117 and rs7294619 were also conserved in other mammals (see Figure 6.2).  
6.2.2  Genotyping 
Genomic DNA was genotyped either using standard PCR and RFLP assays or the 
taqman technology as described in section 2.3 of chapter 2. The DNA for section 
6.3.1 was obtained from tissue acquired by the QSBB (see appendix 1 for a clinical 
summary of these samples). The mean age of the IPD subjects was 77 years and for 
the control subjects was 78.4 years. The DNA for the 2800 unaffected controls in 
section  6.3.1.3  was  obtained  through  collaboration  with  Prof.  Steve  Humphries 
(Rayne Institute, UCL). These controls were all male with a mean age of 56 years and 
an age range of 49-64 years. These samples have been described in a previous study 
(Miller et al. 1996). 
6.2.2.1 Restriction fragment length polymorphism 
Following on from chapter 5, the genomic DNAs for 115 IPD cases and 35 controls 
(cerebellum tissue used in the preliminary RNA studies) was obtained as described in 
section 2.2.1 of chapter 2. The primers for the four tSNPs, annealing temperatures  
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and restriction enzymes used to genotype genomic DNA are summarised in Table 
6.1.  
 
Figure 6.1: Graphical representation of LD map for a 10 kb region upstream of 
the LRRK2 gene. The r
2 parameter is used to calculate the pairwise LD values with 
black boxes showing complete LD (r
2=1.0) between the two loci. The lighter shading 
denotes a lower LD value (r
2 < 1.0), and the numbers in the boxes represent the LD 
measure of r
2. Red arrows represent the tSNPs chosen by Haploview to represent 
95% of the common genetic variation across
 the region (r
2 > 0.80). 
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Figure 6.2: Variation in upstream regions of LRRK2 and the levels of conservation. This was obtained using UCSC Genome browser on 
Human  March  2006  assembly  of  chr12:38,900,340-38,905,940.  The  blue  arrow  indicates  tSNP1  rs10878224,  purple  arrow  indicates  tSNP2 
rs2708435, red arrow indicates tSNP3 rs1472117 and green arrow indicates tSNP4 rs7296419.  
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tSNP  Position  Primer sequence                                         
5’-3’ 
Amplicon 
size (bp) 
Tm  Alleles & 
MAF 
Restriction 
Enzyme 
Type 
tSNP1:  
rs10878224 
38,900,868  F:  CTTCCAGCCTATGGTCATC            
R:  GGAGTTATAGGTTACACTGAGC 
263  58°C  T/C  
C=0.35 
Sml1  Common variant 
cutter 
tSNP2:    
rs2708435 
38,900,923  F:  CTTCCAGCCTATGGTCATC                  
R:  GGTGGGAGGCTTACTTGAGG 
361  58°C  G/A          
A= 0.35 
HinF1  Rare variant 
cutter 
tSNP3:    
rs1472117 
38,902,484  F:  TCACTCATGTTTAGGAACAC         
R:  GAAACTAGAAGTCAAACGGC 
239  55°C  G/A                
A= 0.067 
BstN1  Common variant 
cutter 
tSNP4:     
rs7294619 
38,903,469  F:  CATATTATCTTCAACAATgA                
R:  GTTGAAATGGTTAGGATTTC' 
118  48.3°C  T/C                  
C= 0.103 
DpnII  Artificial site for 
common variant 
cutter 
 
Table 6.1: PCR primer sequences and restriction enzymes used for genotyping genomic DNA. Tm: Annealing temperature at 30 seconds; 
tSNP: tag SNP; bp: base pair; MAF = minor allele frequency. Since the tSNPs for LRRK2 were genotyped using restriction assays, an artificial 
restriction site was created for LRRK2 rs7294619 by changing a base on the forward primer (highlighted ‘g’). All the restriction enzymes were 
provided by New England Biolabs. 
  
[202] 
 
6.2.2.2 Taqman 
The  taqman  assay-by-design  service  for  SNP  genotyping  assays  (Applied 
Biosystems, UK) was used to design probes for the intronic SNP rs4567538. The 
probes were dye-labelled with FAM and VIC; 
5’AGGAGTTCAGATATATCTTTGATATACTGATGTTCTTTTTTTGGNTATAT
ACCCAG[C/T]GATGAGATTACTGGATCATATGAAAATTCTCTTTTTAGTTT
TTTAAGATACCTCCA 3’ 
The allele discrimination PCR components are described in section 2.3.5 of chapter 2 
and the PCR cycling conditions used were as follows: 
95º for 10 minutes,  
(92º for 15 seconds, 60ºfor 1 minute) X 40 cycles 
4º ∞ 
6.2.3  LRRK2 mRNA quantitation 
LRRK2 mRNA levels from section 5.3.1 of previous chapter was used to assess any 
correlations  between  the  LRRK2  tSNP  genotypes  and  mRNA  levels  in  the 
cerebellum. It should be noted that unlike chapter 5 where the NormFinder software 
was used to estimate the variation in the endogenous reference genes, the same could 
not be done to this data. NormFinder needs data from more than three reference genes 
to estimate variation, and only two reference genes were measured in this relatively 
large number of samples for cerebellum (see section 5.3.1). Therefore, the LRRK2 
mRNA  data  presented  in  this  chapter  was  either  normalised  to  two  independent 
reference genes, HPRT1 and RPL13A, or normalised to the factor calculated using a 
geometric mean of the two reference genes. 
6.2.4  Statistical analysis 
The statistical significance was set at P < 0.05, and one way ANOVA analysis was 
used to determine differences between genotypes and LRRK2 mRNA levels. Please 
refer  to  sections  2.4.2.3  and  2.4.2.4  of  chapter  2  for  data  normalisation  with  the 
endogenous  reference  genes.  Any  sample  that  was  not  within  three  standard 
deviations (SD) of the overall  mean was  regarded as  an outlier and subsequently  
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omitted  from  the  analysis.  Any  deviations  from  the  Hardy  Weinberg  equilibrium 
(HWE) in the case and control populations were tested through a chi-squared test. For 
the  genetic  association  study,  calculations  of  HWE,  genotype-specific  Odds  ratio 
(OR), and 95% CI were carried out using an online tool, FINETTI (section 2.9.1 and 
2.9.3 of chapter 2). 
6.2.5  Transcription regulation procedures 
The virtual laboratory software PROMO (refer to section 2.8.3) was used to identify 
putative transcription factor binding sites (TFBS) in a 25mer DNA sequences around 
the SNP of interest in the LRRK2 upstream region. A dissimilarity margin of less or 
equal than 5 % was indicated for the predicted factors.  
6.2.5.1 Electrophoretic mobility shift assay (EMSA) 
Please refer to section 2.7.1 for details on preparation of nuclear lysates from SH-
SY5Y  neuroblastoma  cell  line.  The  oligonucleotide  probes  used  for  EMSAs  are 
detailed in Table 6.2. The procedure for the annealing of these probes to generate 
double stranded DNA (dsDNA) as well as the EMSA protocol is described in section 
2.7.2 of chapter 2. 
SNP 
rs2708435 
 
EMSA double stranded probe sequences 
(5’ – 3’ direction)  
 
 A allele                  
 
Forward                                 
 
Reverse 
  
 
Biotin-CACAGTGGAATCAAGTGATCCACAG 
             CTGTGGATCACTTGATTCCACTGTG 
G allele 
 
Forward 
 
Reverse 
 
 
Biotin-CACAGTGGGATCAAGTGATCCACAG 
            CTGTGGATCACTTGATCCCACTGTG 
Table 6.2: Oligonucleotide sequences for EMSAs. The oligonucleotide probes representing 
the forward strands were labelled with biotin at the 5’ end. The bases highlighted in yellow 
represent the alleles A and G. Prior to the EMSA the biotinylated probes were annealed to 
their complementary strands as described in section 2.7.2.1 to generate dsDNA.  
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6.3  Results 
6.3.1  LRRK2 mRNA expression and genotypes 
The IPD and unaffected subjects were genotyped for four tSNPs. These tSNPs were 
selected from a 10 kb upstream region of the LRRK2 start site that was shown to be 
conserved  in  the  primates  (see  Figure  6.2).  The  results  for  these  genotypes  were 
checked for deviations from HWE are summarised in Table 6.3. 
tSNPs  tSNP1- 
rs1087224           
n 
tSNP2- 
rs2708435            
n 
tSNP3- 
rs1472117            
n 
tSNP4- 
rs7294619            
n 
Cases                                        
Wild-type Homozygote                                   
Heterozygote                                                 
Rare Homozygote 
                         
23                                  
70                                  
32 
                         
65                        
47                  
13 
                   
115                       
13                               
0 
                   
102                      
24                      
1 
P-value                                        
Deviation from HWE 
0.16                      
No 
0.31                   
No 
0.54               
No 
0.75                
No 
Controls                                 
Wild-type Homozygote                                           
Heterozygote                                                 
Rare Homozygote 
                          
9                                
21                              
2 
                       
12                              
18                             
2 
                      
29                           
1                           
0 
                     
18                          
9                            
3 
P-value                                   
Deviation from HWE 
0.03                     
Yes 
0.16                
No 
0.93                
No 
0.27                
No 
 
Table 6.3: Genotype information for the four tSNPs upstream of LRRK2 transcription 
start site. n represents the number of samples genotyped. IPD cases and unaffected controls 
were genotyped for the four tSNPs using restriction enzymes, and the deviation from HWE 
was assessed. Apart from the control genotype data for tSNP1 (rs1087224), all other data 
displayed HWE.   
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An  in-silico  analysis  was  then  performed  to  determine  whether  this  genotype 
information could affect the LRRK2 mRNA expression data from the cerebellum of 
IPDs (n =115) and controls (n =35) as described in section 5.3.1 of chapter 5. The 
reference genes, HPRT1 and RPL13A were measured for this large set of cerebellum 
post-mortem tissue (section 5.3.1). A significant difference was not observed for the 
LRRK2  tSNP  genotypes  and  mRNA  expression.  There  was  a  trend  (a  marginal 
significance) towards a difference in genotypes for tSNPs rs10878224 and rs2708435 
and mRNA levels (p = 0.042 and 0.057, respectively) when the data was normalised 
to the housekeeper RPL13A.  
The  mRNA  expression  levels  for  the  rare  variant  genotype  (CC)  for  tSNP1 
rs10878224  showed  a  decrease  (p=  0.042)  when  compared  to  the  wild-type 
homozygote and the heterozygote (see Table 6.4). Due to the deviation of rs1087224 
control genotype data from HWE, this result was interpreted with caution and was not 
included in further analysis. The variant genotype (AA) for tSNP2 rs2708435 showed 
a trend towards increased LRRK2 mRNA levels in comparison to the other groups 
(p=0.057).  Nothing  significant  was  observed  for  tSNP3  (rs1472117)  and  tSNP4 
(rs7294619) (see Table 6.4).   
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LRRK2 tSNPs  Genotype  n  Mean LRRK2 
mRNA levels 
Standard 
deviation 
P-value 
rs10878224_H 
 
rs10878224_R 
 
TT                         
TC        
CC 
TT                         
TC                           
CC 
26                
82                        
30 
26  
80     
29 
1.001            
0.919             
0.831 
1.110            
0.928               
0.758 
0.510           
0.517         
0.348 
0.578         
0.551            
0.278 
0.424 
 
0.042 
 
rs2708435_H 
 
rs2708435_R 
GG             
GA              
AA 
GG             
GA              
AA 
69  
58  
11 
68  
56  
12 
0.870            
0.892             
1.135 
0.859             
0.912              
1.247 
0.425            
0.522            
0.593 
0.411           
0.589           
0.642 
0.238 
 
0.057 
rs1472117_H 
                      
rs1472117_R 
 
GG              
GA               
GG             
GA 
127  
13 
124 
13 
0.909             
0.946 
0.919              
0.981 
0.473           
0.606 
0.525          
0.504 
0.794 
                     
0.682 
rs7294619_H 
 
rs7294619_R 
 
TT                
TC               
CC 
TT               
TC               
CC 
103 
30          
4 
102 
29          
4 
0.904              
0.897             
0.938 
0.911             
0.885              
1.141 
0.501           
0.437           
0.423 
0.514            
0.496             
0.494 
0.988 
 
0.642 
 
Table 6.4: Effects of LRRK2 tSNPs on mRNA levels. This table represents the effects of 
LRRK2 5’-UTR tSNPs genotypes (rs10878224, rs2708435, rs1472117 and rs7294619) on the 
mean LRRK2 mRNA levels in the post-mortem cerebellum tissue. No ‘AA’ samples were 
identified for rs1472117. These descriptive statistics were calculated using one way ANOVA. 
tSNP_H and tSNP_R refers to the LRRK2mRNA data normalised using the reference genes 
HPRT1 and RPL13A, respectively. Dissimilar genotype numbers (n) for the same tSNP are 
due to different outliers being excluded during the analysis of the LRRK2 mRNA levels.  
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The  effects  of  rs2708435  genotypes  on  the  LRRK2  mRNA  levels  were  also 
normalised using the geometric mean of the two reference genes. A similar trend as 
displayed in Table 6.4 was observed with AA genotypes displaying increased LRRK2 
mRNA levels in the subjects, and GG or GA genotypes showing decreased LRRK2 
mRNA levels.  
 
       
AA GA GG
rs2708435
2.5
2.0
1.5
1.0
0.5
0.0
LRRK2_GeoMean 
LRRK2_RPL13A
LRRK2_HPRT1
 
Figure  6.3:  The  effects  of  rs2708435  genotypes  on  LRRK2  mRNA  expression  in 
cerebellum. This figure represents a trend towards higher LRRK2 mRNA expression levels 
in subjects with the AA genotype in comparison to GG or GA genotype. The LRRK2 mRNA 
levels were normalised using the reference gene HPRT1 (blue bars), RPL13A (green bars), 
and a geometric mean of the two reference genes (yellow bars). This box and whiskers plot 
was determined using the data from the unaffected and IPD subjects. The median in the box 
plot is represented by the horizontal line inside the box and the interquartile range (IQR) is 
between the 25
th and 75
th percentiles which are represented by the horizontal borders of the 
box.  
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6.3.1.1 A 5’- UTR SNP regulating LRRK2 mRNA expression 
As can be seen in Figure 6.3, only weak trends were observed for the rs2708435 
genotypes and LRRK2 mRNA expression levels. However, this data was analysed in 
both  unaffected  and  IPD  subjects.  Therefore,  in  order  to  determine  whether  the 
disease  pathogenesis  itself  has  an  effect  on  the  rs2708435  genotypes  and 
subsequently  on  the  LRRK2  mRNA  levels,  IPD  and  unaffected  subjects  were 
analysed separately using the Mann-Whitney test. Since the genotypes GG and GA 
were showing a trend in the same direction, these subjects were combined to observe 
any potential allelic effects. 
  Reference gene 
normalisation 
Genotypes  n  Mean 
rank 
Significance 
(2-tailed) 
IPD  LRRK2_HPRT1  GG+GA                     
AA 
102                            
11 
55.81                          
68 
0.241 
  LRRK2_RPL13A  GG+GA         
AA 
98                            
11 
52.79                    
74.73 
0.029 
  LRRK2_Geometric 
Mean 
GG+GA                     
AA 
102                            
11 
54.99                        
75.64 
0.047 
Control  LRRK2_HPRT1  GG+GA                  
AA 
30                             
2 
16.50                         
16.50 
1.00 
  LRRK2_RPL13A  GG+GA                     
AA 
31                              
2 
16.61                         
23 
0.417 
  LRRK2_Geometric 
Mean 
GG+GA                     
AA 
30     
2 
16.27                       
20 
0.629 
Table 6.5: rs2708435 genotypes have an effect on the LRRK2 mRNA levels in IPD subjects. n 
refers to the number of samples, and the mean rank relates to a mean of the LRRK2 expression levels 
in these subjects as calculated by the Mann-Whitney tests. The 2-tailed significance in this test shows 
that there is a marked difference in the mean values of LRRK2 mRNA levels in subjects who have the 
GG or GA genotype versus the AA genotypes in IPD subjects when normalised according to the 
reference gene RPL13A or to the geometric mean of HPRT1 and RPL13A.  
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As can be seen in Table 6.5, the rs2708435 genotypes GG and GA are associated 
with decreased levels of LRRK2 mRNA, whereas the genotype AA increases the 
LRRK2 mRNA levels in IPD subjects. This result was significant at the 5% level 
when the mRNA data was normalised to RPL13A (p = 0.029), and also when the data 
was normalised to the geometric mean of the two reference genes (p = 0.047). The 
spread of the data is represented in Figure 6.4. However, for the purpose of clarity 
only LRRK2 mRNA data normalised to the geometric mean of the two reference 
genes is displayed.  
IPD Con
Status
3.000
2.500
2.000
1.500
1.000
0.500
0.000
L
R
R
K
2
 
m
R
N
A
 
l
e
v
e
l
s
 
(
n
o
r
m
a
l
i
s
e
d
 
t
o
 
t
h
e
 
g
e
o
m
e
t
r
i
c
 
m
e
a
n
 
o
f
 
H
P
R
T
1
 
a
n
d
 
R
P
L
1
3
A
)
AA
GG+GA
rs2708435
 
Figure 6.4: The rs2708435 variant genotype AA is associated with higher LRRK2 mRNA 
levels in the cerebellum of IPD subjects. The box and whiskers plot demonstrates the effects of 
rs2708435 genotypes on LRRK2 mRNA levels normalised to the geometric mean of the two 
reference genes. The median in the box plot is represented by the horizontal line inside the box 
and the interquartile range (IQR) is between the 25
th and 75
th percentiles which are represented by 
the horizontal borders of the box. The difference in the mRNA levels for the AA genotype versus 
the GG+GA genotype is marginally significant at the 5% level (p = 0.047).  
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6.3.1.2 Functional significance of rs2708435 
The difference in the rs2708435 genotypes and their effects on the LRRK2 mRNA 
expression in the cerebellum of IPD subjects was perceived to be an interesting result. 
Therefore, further investigations were carried out to determine what might contribute 
to this differential allelic expression.  
The SNP rs2708435 has been shown to be conserved in primates (rhesus monkey, see 
Figure 6.2). Its position in the upstream sequence of LRRK2 transcription site, in 
addition  to  the  data  in  6.3.1.1  suggests  a  possible  regulatory  role  for  this  tSNP. 
Analysis of 25mer DNA sequence around the rs2708435 predicted TFBS for this 
particular DNA sequence. The PROMO database predicted that the ‘A’ allele of the 
variant creates a putative transcription factor binding site (TFBS) that interacts with 
the transcription factor GR-beta, a glucocorticoid receptor, whereas the presence of 
the ancestral allele ‘G’ was suggested to obliterate this DNA:protein interaction.  
Allele A 
TA  TAACTCCT  GG AA  TCA  AG  TGA  TCC
    0    
    1    
    2    
 
 
Allele G 
TA  TAACTCCT  GG GA  TCA  AG  TGA  TCC
    0    
    1    
 
Figure  6.5:  Prediction  of  putative  transcription  factor  binding  sites  in  25mer  DNA 
region surrounding rs2708435 by PROMO. Using a matrix dissimilarity rate of < 5%, the 
region is predicted to bind to the transcription factors IRF-2 and C/EBPbeta. The allele ‘A’ is 
predicted  to  create  a  TFBS  for  GR-beta,  whereas  the  ‘G’  allele  lacks  this  DNA:protein 
interaction.  
0 GR-beta 1 IRF-2  2 C/EBPbeta  
0 IRF-2 1 C/EBPbeta  
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In order to establish whether rs2708435 was indeed a TFBS as predicted by PROMO, 
and as such could regulate LRRK2 mRNA levels, EMSAs were performed on nuclear 
lysates  from  SH-SY5Y  cells.  Figure  6.6  demonstrates  a  common  DNA:protein 
interaction for both ‘G’ and ‘A’, but an extra interaction can be observed for the ‘A’ 
allele as was predicted by PROMO (Figure 6.5). Although initially promising, these 
results  could  not  be  reproduced  or  tested  on  nuclear  lysates  stressed  with  PD 
mimetics.  
 
Figure 6.6: EMSA results with a set of rs2708435G/A biotinylated probes. Positive controls 
are 1) Biotin + control DNA; 2) Biotin + control DNA + control extract; 3) Biotin + control DNA 
+ control extract + 200 fold molar excess of unlabeled control DNA. The positive control 1 
demonstrates that there is no protein extract for DNA to bind and therefore no shift is observed 
whereas control 2 contains sufficient target protein for biotin-control DNA. Control 3 shows a 
shift resultant from  a  specific DNA:protein  extraction,  and  demonstrates that  the  signal  shift 
observed in control 2 can be prevented by competition from an excess of unlabeled DNA. The 
free probe at the bottom of the blot shows equal loading of the probes representing the two alleles. 
The negative controls (G- and A-) did not contain nuclear extract, and as such no shift was 
observed. The blot demonstrates that the DNA probe containing the ‘A’ allele undergoes an extra 
DNA:protein interaction compared to the ‘G’ allele in three independent reactions.   
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6.3.1.3 Is rs2708435 representing an eQTL that might be a risk factor for PD 
A genetic association study was performed to determine whether the 5’UTR SNP 
rs2708435 represents non-coding common genetic variation. An appropriate taqman 
assay was not available for rs2708435. Therefore, an assay was instead designed for a 
surrogate SNP that displayed strong LD with rs2708435 (D’ =1 and r
2= 0.98). The 
surrogate SNP was rs4567538 at position 38,908,171 (intronic) in the LRRK2 gene. 
Genotype data from 109 subjects for both rs2708435 and rs4567538 was compared to 
establish the LD pattern between the two. Haploview was used to generate the LD 
metrics, and an r
2 of 0.95 was obtained after taking into account the minor allele 
frequencies of the two SNPs (rs2708435 and ts4567538) (see Figure 6.7).  
SNP  Position  Obs. 
HET 
Pred.
HET 
HWpval  MAF  Alleles 
rs2708435  38900923  0.376  0.405  0.5471  0.282  G : A 
rs4567538  38908171  0.368  0.393    0.5897  0.269    C : T 
 
Figure 6.7: LD structure between rs2708435 and rs4567538 as constructed by Haploview. A) 
In the table, Obs.HET and Pred.HET refer to observed and predicted heterozygosities for 109 
subjects. HWpval describes deviations from HWE and MAF refers to minor allele frequency of 
the two SNPs. ‘A’ is the minor allele for rs2708435 and ‘T’ is the minor allele for rs4567538. B) 
The LD pattern between the two SNPs provides an r
2 of 0.95. The frequencies of haplotypes GC 
and AT within these dataset are established at 0.711 and 0.279, respectively.   
B) 
A)  
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The  taqman assay  for  rs4567538  was used  to  genotype  614  IPD  cases and 2800 
unaffected  controls  (collaboration  with  Prof.  Steve  Humphries,  Rayne  Institute, 
UCL). The case-control associations were assessed using FINETTI (see 6.2.4 for a 
description of the statistics used). However, in a case control association study it is 
reasonable  to  only  use  controls  when  checking  for  consistency  with  HWE 
proportions,  as  under  the  assumption  of  a  rare  disease  controls  represent  the 
population  well.  If  genotypes  are  associated  with  different  disease  risks  then 
genotypes of cases may not be in HW equilibrium. The test statistics show that the 
controls  (Pearson’s  goodness  of  chi-square  fit,  p  =  0.148),  and  cases  (Pearson’s 
goodness of chi-square fit, p = 0.058) are in HWE (see Figure 6.8).  
The odds ratio (OR) tests were performed to see whether this SNP acts as a risk factor 
to the disease. The most important OR tests in order are the allele OR; Homozygous 
OR; and Heterozygous OR (see Figure 6.8). Allele OR informs whether the SNP is a 
risk factor for disease or not (95% CI boundaries must not cross the null line of 1), 
with OR < 1 – giving protective and OR > 1- providing risk. In this instance, a P 
value  of  0.00112  would  suggest  that  the  SNP  rs4567538  is  a  risk  factor  for  the 
disease. Depending on the genetic model this value could be improved with either the 
1)  Homozygous  OR  (recessive)  or  2)  Heterozygous  OR  (dominant).  For  allele  1 
(major allele), the OR improves with the homozygous test ([22] <-> [11]), p = 0.030, 
and for allele 2 (minor allele) the OR improves with the heterozygous test ([11] <-> 
[12]),  p  =  0.0018.  In  other  words,  the  major  allele  is  acting  as  a  risk  to  disease 
recessively, or perhaps additively, and allele 2 (minor allele) is acting dominantly as a 
protective factor (OR heterozygous P = 0.00184 > OR homozygous, p = 0.03017).  
The allele positivity test is also a useful test for functional variants. An OR of < 1 
under a dominant model for allele 2 (minor  allele)  gives a significant  P-value of 
0.00063, suggesting that the minor allele for the SNP might function as a protective 
factor against IPD.  
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Tests for deviation from 
Hardy-Weinberg 
equilibrium 
Tests for association (C.I.: 95% confidence interval) 
Controls  Cases  allele freq. difference  heterozygous  Homozygous  allele positivity  Armitage's trend 
test 
n11=1310 
(1293.36) 
n12=1186 
(1219.28) 
n22=304 
(287.36) 
f_a1=0.68 +/-
0.006 
 
p=0.148662 
(Pearson) 
p=0.149699 
(Llr) 
p=inf (Exact) 
 
n11=334 
(324.69) 
n12=225 
(243.61) 
n22=55 
(45.69) 
f_a1=0.73 +/-
0.013 
 
p=0.058347 
(Pearson) 
p=0.061297 
(Llr) 
p=0.066623 
(Exact) 
Risk allele 2 ‘Minor allele’ 
[1]<->[2]  [11]<->[12]  [11+]<->[22]  [11]<->[12+22]  common odds 
ratio 
Odds_ratio=0.796  
C.I.=[0.694-0.913] 
chi2=10.61  
p=0.00112 (P) 
Odds_ratio=0.744 
C.I.=[0.618-
0.897]  
chi2=9.70  
p=0.00184 
Odds_ratio=0.710 
C.I.=[0.520-
0.969]  
chi2=4.70  
p=0.03017 
Odds_ratio=0.737  
C.I.=[0.619-0.878]  
chi2=11.69  
p=0.00063 
Odds_ratio=0.817  
 
chi2=10.24  
p=0.00138 
Risk allele 1 ‘Major allele’ 
[2]<->[1]  [22]<->[12]  [22]<->[11]  [11+12]<->[22]  common odds ratio 
Odds_ratio=1.256  
C.I.=[1.095-1.442] 
chi2=10.61  
p=0.00112 (P) 
Odds_ratio=1.049 
C.I.=[0.761-
1.445] 
chi2=0.08  
p=0.77173 
Odds_ratio=1.409 
C.I.=[1.032-
1.924] 
chi2=4.70  
p=0.03017 
Odds_ratio=1.238 
C.I.=[0.916-
1.673] 
chi2=1.93  
p=0.16466 
Odds_ratio=1.220 
 
chi2=10.24  
p=0.00138 
 
Figure 6.8: rs4567538 an LD partner of rs2708435 represents a risk factor for IPD. The statistical package FINETTI was used to assess 
deviations from HWE and also to test for case-control association for rs4567538. The package can be accessed from http://ihg2.helmholtz-
muenchen.de/cgi-bin/hw/hwa2.pl and uses association tests adapted from Sasieni PD (1997) which include the Pearson's goodness-of-fit chi-square 
(P), Log Likelihood ratio chi-square (Llr) and the Exact test. Allele 1 is major and allele 2 is minor. 11: wild-type, 12 heterozygous and 22 
homozygous rare variants and n (11), n (12) and n (22) represent the respective genotypic numbers; f_a1 is the frequency of allele 1 +/- standard 
deviation.  
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6.4  Discussion 
A widespread reduction of the LRRK2 mRNA in the brains of IPD subjects was 
previously  demonstrated  in  chapter  5  of  this  thesis.  Following  on  from  that,  this 
chapter demonstrates that a SNP in the 5’- UTR region of the LRRK2 gene could 
potentially act as a regulatory SNP for the LRRK2 mRNA levels in the cerebellum of 
IPD subjects. 
A systematic search and LD analysis revealed four tSNPs; (rs10878224, rs2708435, 
rs1471127 and rs7294619) in a 10 kb region upstream of the LRRK2 transcription 
start site. These tSNPs were genotyped in control and IPD subjects that were used to 
produce the preliminary cerebellum data for the differential expression in LRRK2 
mRNA in section 5.3.1 of chapter 5. A marginal significance (P-value = 0.042) was 
observed  for  rs10878224  (tSNP1)  variant  genotype  (CC)  and  decreased  LRRK2 
mRNA expression levels (when mRNA levels were normalised to the reference gene, 
RPL13A). However, the control genotype data for this tSNP was found to deviate 
from HWE. This could be a result of population stratification (differences in allelic 
frequencies in sub-populations). Due to the fact that it was the control population that 
deviated from HWE, this tSNP was not included in further analysis.  
A trend towards increasing mRNA levels with the variant genotype AA was observed 
for  rs2708435  (tSNP2)  (p  =  0.057).  No  significant  effect  on  LRRK2  mRNA 
expression was observed for tSNP3 (rs1472117) and tSNP4 (rs7294619). Therefore, 
no subsequent analyses were performed on these SNPs. The tSNP3 (rs1472117) has 
previously been shown to be in LD with rs2201144, a SNP in the promoter region 
that has been predicted to create a transcription binding factor site depending on its 
allelic state (Paisán-Ruíz et al. 2006). However, the minor allele frequencies (MAF) 
frequencies for rs1472117 and rs7294619 were low (0.067 and 0.103, respectively), 
and this coupled with a small sample set could mask potentially regulatory influences 
on the LRRK2 mRNA expression levels.  
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rs2708435 genotypes affect LRRK2 mRNA expression levels in IPD subjects  
The  in-silico  analysis  revealed  a  marginal  but  promising  trend  for  the  tSNP2 
(rs2708435) (P-value = 0.057). Therefore, IPD and unaffected subjects were split and 
analysed separately to determine whether the disease pathology itself could be having 
an effect on the LRRK2 mRNA levels. The GG and GA genotypes showed similar 
levels  of  LRRK2  mRNA  levels,  and  were  therefore,  pooled  together  to  identify 
potential allelic  effects  on the  whole  genotype.  As can  be  seen  in  Table  6.5  and 
Figure 6.4, there was a difference in the LRRK2 mRNA levels of GG+GA genotype 
in  comparison  to  AA  in  IPD  subjects.  This  significance  was  observed  for  the 
reference gene RPL13A (p= 0.029) but not for HPRT1 (although the trend was in the 
same direction). However, the difference was significant when the LRRK2 mRNA 
data was normalised to a geometric mean of HPRT1 and RPL13A (P- value = 0.047). 
Such  variation  in  data  further  establishes  the  need  for  a  careful  selection  of 
endogenous  reference  genes  whilst  dealing  with  mRNA  data  obtained  from  post-
mortem human tissue. 
The difference in the LRRK2 mRNA levels of GG+GA and AA subjects was more 
pronounced  in  IPD  subjects,  although  a  similar  trend  was  seen  in  the  unaffected 
controls  too.  Alternatively,  trans-acting  or  non-cis  mechanisms  (e.g.,  epigenetic 
events, chromatin condensation, or environmental factors) can also have an effect on 
the  cis-variation  (Pastinen  et  al.  2004).  Therefore,  it  is  likely  that  the  significant 
difference in the genotypic impact on LRRK2 mRNA levels in the IPD subjects and 
not in the unaffected controls is a downstream effect of the disease pathogenesis, 
which  in  combination  with  other  factors  (environmental  stresses  or  epigenetic 
events), results in decreased LRRK2 mRNA expression levels that have been well 
documented in the previous chapter. However, too few unaffected subjects, especially 
the  AA  genotypes  could  have  masked  any  potential  genotypic  influence  on  the 
LRRK2 mRNA levels in unaffected controls. It should also be noted that this in-silico 
data was produced using a small number of homozygote variant (AA) samples in 
comparison to the wild-type homozygotes (GG) and heterozygotes  (GA) samples.  
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This  could  skew  a  statistical  artefact  towards  significance  in  the  PD  subjects. 
Therefore,  further  work  testing  the  in-vitro  effects  of  rs2708435  on  LRRK2 
transcriptional activity is warranted to firmly assess whether the results observed in 
this study are due to disease pathogenesis. 
Does rs2708435 represent an eQTL that might also be a risk factor for IPD? 
Support to the notion that rs2708435 might be acting as an eQTL or regulatory SNP 
for  LRRK2  mRNA  levels  was  provided  by  the  genetic  association  study  and  the 
EMSA results. Unfortunately, a taqman assay could not be designed for rs2708435. 
Therefore, a genetic association study was carried out using a surrogate intronic SNP 
rs4567538. The study identified rs4567538 to be a risk factor for IPD cases, and 
demonstrated that the major allele (ancestral) was acting as a risk factor whereas the 
minor allele (variant) was protective against PD. Since rs4567538 displays strong LD 
with 5’- UTR SNP rs2708435 (r
2=0.95), it is not implausible that rs2708435 does 
indeed represent common genetic variation with a regulatory function.  
Furthermore, the variant ‘A’ allele for rs2708435 was predicted to be a TFBS (in-
silico  analysis,  see  Figure  6.5).  This  was  demonstrated  as  having  an  extra 
DNA:protein interaction not seen with the ‘G’ allele. This was an interesting result as 
the  IPD  subjects  with  the  ‘A’  allele  show  increased  LRRK2  mRNA  levels  in 
comparison to the IPD subjects with the ancestral ‘G’ allele. This suggests that a 
transcription factor binds to the variant ‘A’ allele and increases the LRRK2 mRNA 
levels. Although initially promising, the lack of reproducibility of the EMSA data 
was a major setback to this study. The crude sensitivity of the assay resulted in a 
number  of  technical  difficulties,  which  meant  that  a)  the  data  was  not  replicated 
consistently enough, b) could not determine the transcription factor that was actually 
responsible for the shift observed in EMSA blots, and c) could not determine whether 
the use of PD mimetics would produce an effect that was consistent with the LRRK2 
mRNA  data.  A  new  method  of  multiplexing  EMSAs  has  been  developed,  where 
assays containing different transcription factors are added to the nuclear lysates, and 
then  selectively  removed  to  determine  the  appropriate  DNA:protein  interaction(s)  
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(Smith & Humphries 2009). This is a promising approach that could be used in the 
future to determine the DNA:protein interaction(s) for the rs2708435 alleles. 
Common genetic variation in LRRK2 has been shown to increase the risk of IPD in 
the Chinese population (Skipper et al. 2005), but was found not to be associated with 
IPD  risk  in  a  German  population  (Biskup  et  al.  2005).  Another  case-control 
association study in Europeans (Finnish and Greek subjects) also did not produce any 
convincing associations for LRRK2 and IPD, and the only SNP typed by them to have 
a moderately good LD with rs2708435 displayed an r
2 of 0.838 (Paisán-Ruíz et al. 
2005). The two SNPs reported to have a mild association with IPD does not have 
strong LD with rs2708435 or to its LD partner rs4567538 (HapMap data, dbSNP 
build 125). The authors did observe that the LD distribution across the Greek and 
Finnish population varied considerably from that in the European populations used in 
the human diversity series for HapMap data (Paisán-Ruíz et al. 2005). A UK based 
cohort was genotyped in this chapter, and it is therefore likely that the result being 
observed is specific to the UK population. However, the result in this study needs to 
be  replicated  in  another  UK  based  cohort  or  possibly  even  in  other  European 
populations  before  it  can  be  conclusively  said  that  the  intronic  rs4567538  or  its 
potentially regulatory LD partner rs2708435 is a risk factor for IPD.  
Conclusion 
This chapter demonstrates that the ‘non-coding DNA’ in 5’ UTR of LRRK2 gene 
harbours important regulatory elements in the form of eQTL that might affect the 
LRRK2 mRNA levels in IPD subjects. The notion that rs270435 represents an eQTL 
was supported by the EMSA results, and its LD partner rs4567538 was shown to be a 
risk  factor  in  IPD.  This  suggests  that  rs2708435  might  play  a  role  in  the  PD 
pathogenesis. It is likely that rs2708435 is working cumulatively with other variants, 
to exert its regulatory effects on the LRRK2 mRNA levels. Future investigations into 
its role as a regulatory SNP for LRRK2 transcription are therefore warranted.  
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Chapter 7  
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7  General discussion 
Parkinson’s  disease  (PD)  is  a  progressive  neurodegenerative  disorder  that  affects 
approximately 1-2 % of the population over the age of 65 years (Lees et al. 2009). 
Mutations in LRRK2 gene, which resides in the PARK8 locus (Funayama et al. 2002; 
Zimprich et al. 2004b; Paisán-Ruíz et al. 2004) have been identified as a common 
genetic cause of familial and idiopathic PD (IPD) (Healy et al. 2008). G2019S is the 
most common LRRK2 mutation, and results in a clinical and pathological phenotype 
indistinguishable from IPD cases (Di Fonzo et al. 2005; Gilks et al. 2005; Nichols et 
al. 2005; Aasly et al. 2005; Ross et al. 2006). The G2019S mutation has consistently 
been shown to increase the kinase activity of LRRK2 protein (Jaleel et al. 2007; Imai 
et al. 2008; Parisiadou et al. 2009; Gillardon 2009; Kumar et al. 2010), and has also 
been suggested to generate inclusion bodies and cellular toxicity in vitro (West et al. 
2005; Smith et al. 2005a; Gloeckner et al. 2006; Greggio et al. 2006; Smith et al. 
2006).  Autopsy  reports  investigating  LRRK2  protein  localisation  to  pathological 
inclusions in G2019S PD cases have been published (Giasson et al. 2006), but the 
rarity of post-mortem tissue from G2019S PD cases means that the expression of 
LRRK2 mRNA and protein, both in terms of localisation and quantitation, have not 
been described in such individuals. The anatomical distribution of wild-type LRRK2 
mRNA and protein in human and rodent brain has been published, but the literature is 
still  lacking  a  broad  evaluation  of  how  LRRK2  expression  might  be  altered  in 
response to idiopathic or LRRK2 linked PD (Galter et al. 2006; Melrose et al. 2006; 
Simón-Sánchez et al. 2006; Miklossy et al. 2006; Taymans et al. 2006; Zhu et al. 
2006a; Zhu et al. 2006b; Higashi et al. 2007a; Higashi et al. 2007b; Melrose et al. 
2007;  Westerlund et al. 2008a; Alegre-Abarrategui et al. 2008; Perry  et al. 2008; 
Santpere & Ferrer 2009; Higashi et al. 2009). Hence, the central theme of this thesis 
focussed on the morphological and quantitative expression of LRRK2 mRNA and 
protein in the brains of control, IPD and G2019S affected PD cases, and on assessing 
the  influence  of  genetic  variation  on  LRRK2  expression  in  these  subjects. 
Additionally,  G2019S  mutation  was  also  screened  in  PD  unaffected  members  of 
various  populations  in  sub-Saharan  Africa,  Middle  East  and  Eastern  Europe  to  
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expand our understanding of the predicted origins of this mutation. The aim of the 
following discussion is to present a critical review of the different studies presented 
in this thesis. 
7.1 Screening of G2019S mutation 
The  LRRK2  G2019S  mutation  is  common  in  Middle  Eastern  and  European 
populations  with  the  highest  frequencies  reported  in  North  African  Berbers  and 
Ashkenazi Jews (Ozelius et al. 2006; Lesage et al. 2006; Healy et al. 2008). It has 
been  predicted  that  the  G2019S  mutation  arose  in  the  Berbers,  but  there  are 
suggestions  that  the  mutation  may  have  arisen  independently  on  more  than  one 
occasion (Lesage et al. 2005b; Kachergus et al. 2005; Zabetian et al. 2006a; Warren 
et al. 2008; Bar-Shira et al. 2009; Pirkevi et al. 2009; Lesage et al. 2010). However, 
the  carrier  rate  frequency  of  this  mutation  has  not  been  investigated  in  detail  in 
neighbouring populations, for example sub-Saharan Africa (Lesage et al. 2006). In 
chapter 3, I investigated the frequency of G2019S mutation in unaffected subjects 
from populations with a potentially higher chance of carrying the mutation, due to 
possible genetic admixture with North African Berbers and Ashkenazi Jews.  
The  G2019S  mutation  was  screened  in  a  sample  set  of  2,485  subjects  without  a 
clinical  diagnosis  of  PD.  These  subjects  were  derived  from  populations  of  sub-
Saharan  African,  Middle-Eastern,  non-Ashkenazi  Jewish,  and  Eastern  European 
origins.  Only  two  subjects  were  identified  as  positive  for  G2019S  mutation, 
suggesting  that  the  mutation  is  not  common  amongst  members  of  the  selected 
populations.  The  two  samples  that  tested  positive  for  G2019S  mutation  were  of 
Syrian  and  Moroccan  Jewish  ancestry,  respectively.  According  to  the  exact 
hypothesis  test  (for  binomial  random  variables),  the  observed  proportion  is  not 
different from the expected proportion (see 3.3.1; Syrian p = 0.827; Moroccan Jewish 
p = 0.444), but this is likely to represent a statistical fluctuation due to the small 
sample  sizes  of  these  two  populations  (Syria,  n=  75;  Moroccan  Jew,  n=  186). 
Therefore, these data do not clarify the current understanding regarding the origins of 
this  mutation.  No  examples  of  G2019S  mutation  were  observed  in  sub-Saharan  
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Africans in this study which suggests that it is not common amongst PD-unaffected 
members  of  the  Bantu  speaking  and  Ethiopian  populations  investigated,  but  the 
sample size is not large enough (n = 731) to evaluate whether the mutation arose after 
the early migrations out of Africa. Similarly, the data suggests that G2019S mutation 
is not common in Ukrainian and Belarusian populations in Eastern Europe, but does 
not allow us to comment on whether the G2019S mutation in Ashkenazi Jews could 
have been acquired from neighbouring populations.  
The worldwide frequency of G2019S mutation in PD unaffected subjects has been 
suggested to be <1% (Healy et al. 2008), and whether the sample sizes available for 
this study had enough power to detect a mutation frequency of <1% is a matter of 
concern. For example, if worldwide frequency of G2019S mutation is set at 1%, then 
using an estimated proportion of 0.00080548 (2 out of 2485) for G2019S positive 
subjects in this study, suggests that a sample size of 731 for sub-Saharan Africans and 
531  for  eastern  Europeans  has  >80%  power,  and  a  sample  size  of  335  for  non-
Ashkenazi Jews has >50% power to detect a frequency of 1% in this sample set. 
However, the negligible proportions estimated for G2019S positive subjects in this 
study (section 3.3.1), in addition to the predicted <1% worldwide G2019S mutation 
frequency  (Healy et al.  2008) results in such extreme data that any estimation of 
power for the sample sizes used in this study may not be reliable. To the best of our 
knowledge,  we  could  not  find  a  method  to  reliably  estimate  power  for  these 
proportions that are close to zero. Overall, these data suggest that G2019S mutation is 
not common amongst PD unaffected members of the populations investigated in this 
study, but we cannot make any definitive statistical inferences as to the frequency of 
G2019S  mutation  in  these  subjects.  A  substantially  large  number  of  subjects  are 
needed  before  we  can  definitively  estimate  G2019S  carrier  rate  frequency  in  PD 
unaffected subjects of these populations. Expanding the study to include PD cohorts 
from the populations presented in this study would contribute to our understanding of 
the genetic origins of the mutation, and help us to assess whether the mutation in 
North African Berbers and Ashkenazi Jews could have resulted from admixture with 
their neighbours.  
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7.2 LRRK2 mRNA and protein expression in the human brain 
Investigation of LRRK2 expression in the brain is the major focus of the investigation 
recounted  in  this  thesis,  the  hypothesis  being  that  the  anatomical  and  cellular 
expression profile of LRRK2 mRNA and protein may differ between control and PD 
cases.  A  combination  of  morphological  and  quantitative  techniques  was  used  to 
address  this.  The  strength  of  this  approach  being  that  morphological  techniques 
demonstrated the cellular expression of LRRK2 mRNA and protein in a large number 
of  brain  regions,  whereas  quantitative  mRNA  methods  provided  a  more  accurate 
indication of LRRK2 mRNA expression levels, albeit in a lower number of regions. 
LRRK2  protein  levels  were  also  compared  using  semi-quantitative 
immunohistochemistry (IHC) analysis in different brain regions. Post-mortem tissue 
from  G2019S  positive  PD  cases  is  limited;  hence  there  are  few  descriptions  of 
LRRK2 mRNA and protein localisation in such cases. In addition to investigating the 
morphological differences in LRRK2 mRNA and protein expression in control and 
IPD cases, this study took advantage of the rare resource at QSBB to describe the 
LRRK2 expression profile in G2019S positive PD cases. 
7.2.1  Morphological  findings  and  regional  quantitation  of  LRRK2 
mRNA in the human brain 
In chapter 4 of this thesis, in-situ hybridisation (ISH) study demonstrated ubiquitous 
neuronal LRRK2 mRNA expression in post-mortem brain tissue from 2 control, 1 
IPD  and  3  G2019S  positive  PD  cases.  The  localisation  of  LRRK2  mRNA  to 
dopamine  synthesising  as  well  as  dopamine  innervated  regions  of  the  brain  is  in 
contrast to the original studies performed in rodents and humans (Galter et al. 2006; 
Melrose  et  al.  2006).  Our  results  concur  with  the  subsequent  findings  of  a  more 
widespread evaluation of LRRK2 mRNA expression in the brain (Simón-Sánchez et 
al. 2006; Higashi et al. 2007a; Higashi et al. 2007b). The original findings reported by 
Galter and colleagues were based on a higher sample number (4 controls and 5 PD) 
than  the  6  cases  we  have  used,  but  PCR  studies  examining  LRRK2  mRNA  in 
dopaminergic  (DAergic)  neurons  (Han  et  al.  2008;  Simunovic  et  al.  2009)  and  
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striatum (Zimprich et al. 2004b; Melrose et al. 2006; Dachsel et al. 2010) support the 
morphological findings in this study. ISH is a technically demanding procedure that 
is sensitive to various factors such as tissue preparation, tissue pH, probe labelling 
method  (radioactive  versus  non-radioactive;  choice  of  radioactive  isotope)  and 
hybridisation  protocols,  all  of  which  can  contribute  to  discrepant  results  between 
studies (Harrison et al. 1991; Barton et al. 1993; Kingsbury et al. 1995). For example, 
the original studies that investigated LRRK2 mRNA localisation using 
33P labelled 
oligonucleotide probes did not identify LRRK2 mRNA in DAergic neurons (Galter et 
al.  2006;  Melrose  et  al.  2006),  whereas  the  subsequent  studies  that  used  non-
radioactive riboprobe (Simón-Sánchez et al. 2006); or 
35S labelled oligonucleotide 
probes reported a more widespread LRRK2 mRNA localisation (Higashi et al. 2007a; 
Higashi et al. 2007b). ISH is particularly challenging on post-mortem tissue due to 
variable RNA preservation, therefore to validate the ISH procedure in this study, the 
mRNA  integrity  was  assessed  using  a  positive  control  (BRI2  mRNA),  and  the 
specificity of the LRRK2 ISH probe was demonstrated using an excess of unlabelled 
probe, as previously described (Lashley et al. 2008).  
Chromogenic digoxigenin ISH has previously been used to quantitate LRRK2 mRNA 
in the brain (Simón-Sánchez et al. 2006). However, unlike radioactive ISH where 
silver emulsion grains can be counted to provide mRNA quantitation, non-radioactive 
ISH cannot accurately measure mRNA signal. As described in section 4.3.1.1, the 
high  background  intensity  associated  with  radioactive  emulsion  autoradiography 
required the use of non-radioactive ISH for LRRK2 mRNA localisation. Therefore, 
having  demonstrated  the  distribution  of  LRRK2  mRNA  in  the  brain  using  non-
radioactive ISH, the mRNA levels were quantitated using a more sensitive qPCR 
based strategy utilising a large number of samples (Chapter 5, section 5.3.2). The 
qPCR results do not demonstrate regional variation in LRRK2 mRNA levels in control 
human brain (Figure 5.2). Although regional variations in LRRK2 mRNA levels in the 
human brain have previously been reported using a PCR based strategy, tissue from 
only one case was used to quantitate mRNA levels in these studies (Zimprich et al. 
2004b; Dachsel et al. 2010). The LRRK2 mRNA quantitation data presented in chapter  
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5 are likely to be more robust as a sample number of 15-20 cases was used (Table 5.6), 
which to our knowledge is the largest number of samples examined to estimate relative 
LRRK2 transcript levels in post-mortem human brain. Having determined the cellular 
localisation and relative regional levels of LRRK2 mRNA, a future measurement of 
mRNA expression in laser capture microdissected (LCM) neurons would refine the 
quantitation of LRRK2 mRNA in specific cellular populations of the brain. 
7.2.2  Morphological findings and regional semi-quantitation of 
LRRK2 protein in the human brain 
Analogous to the morphological findings of LRRK2 mRNA, the IHC study in chapter 
4 demonstrates a ubiquitous neuronal expression of LRRK2 protein in 4 control, 2 
IPD  and  4  G2019S  positive  PD  cases.  This  confirmed  not  only  the  cytoplasmic 
distribution  of  the  protein  but  also  its  extensive  presence  in  the  axons,  apical 
dendrites and the neuropil (Biskup et al. 2006; Higashi et al. 2007b; Melrose et al. 
2007; Alegre-Abarrategui et al. 2008). LRRK2 immunoreactivity was occasionally 
identified in reactive astrocytes (Figure 4.5I), but LRRK2 mRNA was not otherwise 
observed in glial cells, although the small amount of cytoplasm in oligodendrocytes 
could make it difficult to detect LRRK2 mRNA in these cells (Biskup et al. 2006; 
Miklossy et al. 2006). We also confirm the detection of LRRK2 mRNA and protein 
in vascular smooth muscle cells (Zhu et al. 2006a).  
Using IHC, the presence of LRRK2 protein was demonstrated in the halo of a small 
proportion of Lewy bodies (LBs). However, identification of LRRK2 protein in LBs 
has been shown to be highly dependent on the antibody used, therefore it remains 
uncertain whether LRRK2 is an obligate component of these inclusions (Miklossy et 
al. 2006; Zhu et al. 2006a; Zhu et al. 2006b; Higashi et al. 2007b; Melrose et al. 2007; 
Alegre-Abarrategui et al. 2008; Perry et al. 2008; Santpere & Ferrer 2009; Higashi et 
al. 2009). Differences in tissue fixation, protein preservation and antigen retrieval 
procedures (not all antibodies recognise protein in native conformations) can result in 
variability in immunolabelling (Williams et al. 1997). For example, the only antibody 
that  reportedly  labels  a  large  proportion  of  LBs  in  the  brainstem  and  neocortical  
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regions is the commercial antibody NB300-268 (see Table 4.2), although previous 
observation in our group suggested that NB300-268 does not label LBs (Dr. Ann 
Kingsbury,  unpublished findings),  implying  that  the  NB300-268  antibody  may be 
sensitive to tissue fixation or protein preservation.  
LRRK2  immunoreactivity  in  this  study  was  demonstrated  using  the  previously 
published  polyclonal  EB06550  antibody  (Alegre-Abarrategui  et  al.  2008).  The 
EB06550 antibody recognises LRRK2 amino acids 2015-2026 which also includes 
the site for the G2019S mutation (Santpere & Ferrer 2009). Since glycine and serine 
are  both  polar  and  hydrophilic,  the  extent  to  which  this  substitution  changes  the 
native conformation of LRRK2 in a way that might influence the antibody binding 
has  not been  documented  in  immunohistochemical  detection.  Although  antibodies 
that  recognise  specific  mutational  isoforms  have  previously  been  reported  (e.g. 
P102L substitution in the prion protein (Wadsworth et al. 2006)), they are technically 
demanding to produce,  and it is unlikely that the polyclonal EB06550 is specific 
enough to discriminate between proteins that differ at a single amino acid site. The 
specificity  of  EB06550  has  not  been  tested  on  a  LRRK2  knockout  model,  but  it 
recognises a ~250KDa band corresponding to endogenous human LRRK2 protein in 
post-mortem tissue, (Figure 4.3), biopsy material (Alegre-Abarrategui et al. 2008), 
and also labels recombinant LRRK2 protein (Dr. Patrick Lewis, unpublished data) 
which covers the LRR-WD40 domain (previously described in Anand et al. 2009). 
The specificity of the EB06550 antibody was further demonstrated in this study by 
obliterating the signal using a pre-absorption assay (Figure 4.3).  
An established 4-tiered grading method was used for semi-quantitation of regional 
LRRK2 immunoreactivity in post-mortem tissue from the 10 cases (Melrose et al. 
2007;  Alegre-Abarrategui  et  al.  2008).  Variability  in  LRRK2  immunoreactivity 
between different brain regions was a consistent finding (Table 4.9), and confirmed 
the previously reported EB06550 findings in normal adult brain (Alegre-Abarrategui 
et al. 2008). It was of note that in the nigrostriatal dopamine system the cell bodies of 
striatal  neurons  were  consistently  recorded  as  displaying  the  weakest  LRRK2 
immunoreactivity.  However,  no  difference  had  been  observed  in  striatal  LRRK2  
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mRNA levels compared to other regions (Figure 5.2). Nevertheless, the weak LRRK2 
immunoreactivity in striatal neurons (Figure 4.4H) is in contrast to the intense striatal 
neuropil  staining,  suggesting  that  LRRK2  protein  localises  to  neuronal  processes 
rather than the cell body in this region (Figure 4.4K and L). This is supported by 
western blot data indicating high LRRK2 protein levels in striatum (Biskup et al. 
2006; Taymans et al. 2006; Melrose et al. 2007) . 
The  LRRK2  immunoreactivity  data  reported  in  this  study  (Table  4.9)  do  not 
demonstrate an overall difference in LRRK2 immunoreactivity between the 4 control 
and 6 PD cases (2 IPD and 4 G2019S positive PD). Our results do not concur with a 
previous study that reported intense LRRK2 immunoreactivity in neuronal cell bodies 
and  axons of  PD cases  (n  = 6)  compared  to  controls  (n  =  4)  (Zhu  et  al  2006a). 
Additionally,  we  also  did  not observe  a  decrease  in  LRRK2  immunoreactivity  in 
nigral  neuronal  processes  in  our  PD  cases  as  has  been  previously  reported  for  a 
smaller number of PD cases (n = 2) when compared to controls (n = 2) (Higashi et al. 
2007b). Differences in tissue fixation, protein preservation, and antibodies could have 
contributed to the discrepant results between the studies. For example, a recent study 
using a different antibody reported punctate staining of LRRK2 positive structures 
within cells (Higashi et al. 2009), whereas we observed a more diffuse pattern of 
LRRK2 immunoreactivity. 
Western blots provide an alternative method to quantitate protein rather than the 4-
tiered IHC grading system presented in this study. However, western blots are semi-
quantitative  in  nature,  and  unlike  IHC  procedures,  cannot  determine  the  cellular 
localisation  of  a  protein.  It  has  been  shown  that  western  blotting  with  EB06550 
antibody produces the  best  result on  biopsy  material  compared  with  post-mortem 
tissue  likely  due  to  the  superior  protein  preservation  in  biopsy  material  (Alegre-
Abarrategui et al. 2008). A more accurate methodology to quantitate protein levels is 
an ELISA. However, lack of an available LRRK2 specific ELISA prevented the use 
of this method in my study. For this reason, a precise correlation between LRRK2 
mRNA (Figure 5.2) and protein levels could not be performed, and this remains a 
major limitation of the current study, and an area for future development. Moreover,  
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EB06550,  like  a  majority  of  other  LRRK2  antibodies,  is  polyclonal,  and  future 
replication of this morphological data using specific monoclonal LRRK2 antibodies 
is warranted.  
The  morphological  findings  in  this  study  describe  the  anatomical  distribution  of 
LRRK2 mRNA and protein in a substantial number of cases, in addition to presenting 
novel data relating to LRRK2 mRNA and protein localisation in the rarely available 
G2019S positive PD cases. The descriptive nature of the morphological data does not 
allow us to comment in detail on the physiological importance of the widespread 
LRRK2 expression, but within the limitations of the methods used, suggests that there 
is  no  major  variation  in  LRRK2  expression  resulting  from  the  G2019S  mutation. 
Future  investigations  into  accurate  quantitation  of  LRRK2  protein  levels  would 
address  whether  there  are  subtle  variations  in  LRRK2  protein  expression  in  PD 
compared to controls that cannot be assessed by the IHC technique used in this study. 
7.2.3  An investigation into LRRK2 mRNA dysregulation in IPD 
cases compared to controls 
Having quantitated LRRK2 mRNA levels in several regions of the normal human 
brain (Figure 5.2), qRT-PCR was further used to demonstrate statistically different 
LRRK2 mRNA levels in a number of cortical and subcortical regions of IPD cases 
compared to controls in chapter 5 of this thesis (Figure 5.3). The regions used in this 
study were chosen due to their selective vulnerability to α-synuclein pathology in PD 
(Braak  et  al.  2004).  In  order  to  determine  whether  changes  in  LRRK2  mRNA 
expression  could  also  be  identified  in  a  brain  region  that  is  not  vulnerable  to  α-
synuclein pathology in PD, tissue from the cerebellum was included in the study.  
Region specific expression of reference genes was taken into account by measuring 
four  endogenous  reference  genes  (HPRT1,  RPL13A,  G6PD  and  TBP1)  for  each 
sample.  Variation  in  reference  genes  in  the  dataset  was  estimated  using  the 
NormFinder software (Andersen et al. 2004), and the geometric mean of the two most 
stable reference genes as predicted by the software was used to normalise the LRRK2 
mRNA data (Bengtsson et al. 2005). The use of post-mortem tissue is associated with  
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many  confounding  factors,  e.g.  variability  in  cellular  stress  and  loss,  response  to 
disease, cause of death, and medication (Kim & Webster 2009). Cases in this series 
were collected so as to minimise these limitations by considering factors such as age, 
gender, brain pH, post-mortem delay (Tables 5.2 and 5.4). Despite this approach a 
series of 20 IPD and 20 controls may be considered too small a number to accurately 
account for many of the variables associated with the study of post-mortem brain 
tissue  (Harrison  et  al.  1991;  Barton  et  al.  1993;  Kingsbury  et  al.  1995;  Kim  & 
Webster 2009). 
7.2.3.1 LRRK2 mRNA is reduced in limbic and several neocortical regions but 
increased in medulla of IPD cases in comparison to controls 
Reductions  of  LRRK2  mRNA  in  parietal  cortex,  cerebellum,  cingulate  gyrus, 
amygdala  and  frontal  cortex,  and  increases  in  LRRK2  mRNA  in  medulla  were 
observed  in  IPD  cases  compared  to  controls  but  no  difference  was  observed  in 
entorhinal cortex or putamen (Figure 5.3). Although a difference of less than 0.5 fold 
in LRRK2 mRNA levels between IPD cases and controls is extremely modest, each 
sample was measured in triplicate and these differences in  LRRK2  mRNA levels 
remained significant after multiple test correction (Table 5.8). Additionally, this level 
of < 0.5 fold reduction was also observed in a larger number of cerebellum samples 
(IPD, n = 115; control, n = 35; Figure 5.1), suggesting that in cerebellum at least, this 
observation is robust.  
Furthermore,  we  also  observed  a  reduction  of  LRRK2  mRNA  levels  in  G2019S 
positive PD cases compared to controls (Figure 5.3) although, the small number of 
cases and restricted tissue availability of such samples does not allow us to make any 
statistical inferences. In view of the scarcity of G2019S PD cases coming to post-
mortem, a collaborative international effort between brain banks would be needed to 
make available a larger cohort of G2019S positive PD cases, to confirm the suggested 
decrease  in  LRRK2  mRNA  levels  in  G2019S  positive  PD  cases  compared  to 
unaffected  cases.  This  would  provide  an  indication  of  a  biochemical  mechanism 
common to IPD and G2019S linked PD (White et al. 2007).   
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No  change  was  observed  for  LRRK2  mRNA  levels  in  putamen  in  IPD,  and  this 
concurs with a previous ISH study which also reported no significant differences in 
the striatal LRRK2 levels between IPD cases and unaffected controls (Galter et al. 
2006).  Previously,  L-DOPA  induced  dyskinesia  has  been  suggested  to  increase 
striatal  LRRK2  mRNA  levels  in  marmosets  (Hurley  et  al.  2007).  As  clinical 
information detailing treatment, dosage and the occurrence of dyskinesia was only 
available for a small number of samples (Table 5.3), it was not possible to accurately 
correlate these data with LRRK2 mRNA levels. Recently, LRRK2 was suggested to 
be  involved  in  striatal  dopamine  transmission  (Li  et  al.  2010),  and  in  this  study 
unaltered striatal LRRK2 mRNA levels in PD brains are reported. This finding is in 
contrast to a reduction of LRRK2 mRNA in other regions of IPD brains, and may 
indicate  that  maintenance  of  LRRK2  mRNA  is  of  some  (as  yet  unidentified) 
significance in striatum where altered function plays a key role in contributing to the 
clinical symptoms in PD. LRRK2 mRNA was also reportedly reduced in DAergic 
neurons of a small number of IPD cases (Simunovic et al. 2009), however, it was not 
possible to address this in the current study as nigral tissue was unavailable. 
Whole tissue lysates were used to quantitate LRRK2  mRNA levels, therefore we 
cannot  be  sure  what  cell  type  the  observed  changes  might  be  associated  with. 
However, the findings in chapter 4 demonstrate that LRRK2 mRNA and protein is 
largely found in neurons, therefore the quantitative reduction in LRRK2 mRNA is 
likely to reflect reduced expression by neurons. The widespread reductions could be 
attributed to neuronal loss in IPD cases, however, the reduction in LRRK2 mRNA 
was also observed in cerebellum which does not display overt neuronal loss in PD. 
Although  four  endogenous  reference  genes  were  used  as  internal  controls,  laser 
capture microdissection (LCM) of neurons is a more accurate method to account for 
neuronal  loss.  Replication  of  these  data  in  a  larger  cohort  of  samples  as  well  as 
refinement  by  LCM  to  analyse  isolated  neurons,  would  clarify  how  these  results 
contribute to our knowledge of PD development. However, even the use of LCM 
cannot account for the biggest confounding factor when using diseased post-mortem 
tissue, which is the accurate interpretation of resultant data as to whether the changes  
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observed in mRNA levels contribute to the disease process or whether the disease 
itself  results  in  mRNA  expression  dysregulation.  Additionally,  we  do  not  know 
whether this LRRK2 mRNA dysregulation is specific to PD or neurodegenerative 
process  in  general.  Investigation  of  LRRK2  mRNA  in  post-mortem  tissue  from 
neurodegenerative diseases, such as other α-synucleinopathies, Alzheimer’s disease 
or  progressive  supranuclear  palsy  could  ascertain  whether  the  LRRK2  mRNA 
dysregulations observed in this study are indeed a PD specific phenomenon.  
The autosomal dominant transmission of LRRK2 mutations in familial PD cases, and 
the in-vitro mutant toxicity together suggest a ‘gain-of-function’ model for LRRK2-
linked PD (Funayama et al. 2002; Paisán-Ruíz et al. 2004; Zimprich et al. 2004b; 
Funayama et al. 2005; West et al. 2005; Gloeckner et al. 2006; Greggio et al. 2006; 
Smith  et  al. 2006;  Liu  et  al.  2008).  Additionally,  a lack  of phenotype  in  LRRK2 
knockout mouse models that report no major abnormalities, and an unaltered number 
of DAergic  neurons (L.  Wang et al.  2008;  Andres-Mateos  et  al.  2009;  Lin  et al. 
2009), further suggests that LRRK2 ‘loss of function’ does not have a marked effect 
(although it is possible that LRRK2 disruption in the developmental phase could be 
compensated  for  by  another  gene,  for  example  LRRK1,  in  constitutive  knock  out 
models (Biskup et al. 2007; Westerlund et al. 2008a)). Therefore, in light of such data 
which recommends a ‘gain of function’ model for LRRK2, and given that ablation of 
LRRK2 does not have a detectable effect, the modest reductions of LRRK2 mRNA 
levels in IPD cases observed in this study are perhaps indicative of a cellular response 
to PD as opposed to it being a causative factor.  
In  contrast  to  these  reductions,  our  findings  also  suggest  an  increase  in  LRRK2 
mRNA levels in the medulla of IPD cases (Figure 5.3). The dorsal motor nucleus of 
the vagus (DMNV) in the medulla is affected in the earlier stages of PD (Braak et al. 
2004), and the disease duration of the subjects in this study (4.6-29.3 years, Table 
5.3) suggests that we may be observing an end-stage effect in medulla. This could be 
supported by investigation of other CNS areas affected early in the disease process, 
such as olfactory bulb, locus coeruleus (Braak et al. 2004), and the intermediolateral 
nucleus of the thoracic cord (Kalaitzakis et al. 2008). The data presented are derived  
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from tissue containing various nuclear groups in medulla, such as the inferior olive 
that is not a target for α-synuclein pathology in PD. Further analysis by LCM to 
determine the contribution of different nuclei to the observed increase in LRRK2 
mRNA  is  warranted.  Interestingly,  IPD  cases  belonging  to  this  particular  sample 
series, also exhibit increased levels of DJ-1 (PARK7) mRNA levels (Dr. R. Kumaran, 
unpublished findings). DJ-1 has been shown to have a neuroprotective role (Taira et 
al. 2004; Inden et al. 2006), but its physiological interaction with LRRK2 remains to 
be confirmed (Venderova et al. 2009; Heo et al. 2010). Additionally, a protective role 
for wild-type LRRK2 in cellular (Liou et al. 2008; Milosevic et al. 2009), transgenic 
worm (Wolozin  et  al.  2008;  Saha  et  al.  2009; Ohta  et  al.  2010),  and  Drosophila 
models  (Lee  et  al.  2007;  D.  Wang  et  al.  2008)  has  been  proposed,  but  their 
contradictory  phenotypes  suggest  that  further  validation  of  the  protective  role  of 
LRRK2 is needed (Imai et al. 2008; Liu et al. 2008; Sämann et al. 2009; Venderova 
et al. 2009; Ng et al. 2009; Heo et al. 2010; Yao et al. 2010). Therefore, whether an 
increase  in  LRRK2  induces  cell  toxicity  or  a  decrease  affects  cell  protection  or 
perhaps both events contribute to PD remains to be seen in-vivo.  
LRRK2  has  been  suggested  to  be  involved  in  various  functions,  such  as  cell 
signalling, cellular stress and neuronal maintenance, cytoskeletal dynamics, vesicle 
transport, apoptosis, mitochondrial dysfunction, and cellular scaffolding (reviewed in 
(Greggio & Cookson 2009)). Although physiological substrates of LRRK2 have been 
suggested, currently the most efficiently phosphorylated substrate of LRRK2 (apart 
from the generic substrate MBP) remains LRRK2 itself (West et al. 2005; Gloeckner 
et al. 2006; Smith et al. 2006; Greggio et al. 2006; Kumar et al. 2010). However, the 
potential pathological role of LRRK2 autophosphorylation is not well understood, but 
it  is  suggested  to  regulate  LRRK2  GTPase  activity  which  in  turns  regulates  this 
protein’s kinase activity (Greggio et al. 2008; Greggio et al. 2009). A dysregulation in 
LRRK2 protein levels could affect any of the above functions, but a lack of accurate 
quantitation  of  LRRK2  protein  levels  prevents  us  from  commenting  on  how  a 
dysregulation  in  LRRK2  mRNA  might  influence  the  protein  levels.  Although  we 
present a semi-quantitation of LRRK2 protein levels in chapter 4, a more sensitive  
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technique  detecting differences  in  LRRK2 protein  levels  between  control and PD 
cases,  subtle  or  otherwise,  would  elucidate  the  significance  of  LRRK2  mRNA 
dysregulation in these IPD cases, and could potentially lead to testable hypotheses 
that can be examined in model systems. We cannot comment on whether the modest 
LRRK2 mRNA dysregulations in selected cortical and subcortical regions of IPD 
cases in this study are a contributory factor or a cellular response to the disease, but 
these data describe a novel alteration in the LRRK2 mRNA expression profile of PD 
affected versus unaffected cases. 
7.2.3.2 LRRK2 mRNA and Lewy bodies 
Similar to the findings of others, we demonstrate that LRRK2 is present in the core of 
a small proportion of LBs in chapter 4 of this thesis (Figure 4.7) (Zhu et al. 2006a; 
Zhu et al. 2006b; Miklossy et al. 2006; Higashi et al. 2007b; Melrose et al. 2007; 
Alegre-Abarrategui et al. 2008; Santpere & Ferrer 2009). The infrequent presence of 
LRRK2 in brainstem LBs and absence in cortical LBs, much like the product of the 
PARK6 locus, PINK1 (Gandhi et al. 2006), suggests that LRRK2 is not an obligate 
component of the LBs. However, if LRRK2 is present upstream of α-synuclein in the 
PD pathway as a signalling molecule (Qing et al. 2009; Carballo-Carbajal et al. 2010; 
Hsu et al. 2010; Gloeckner et al. 2009), and is not directly involved in α-synuclein 
aggregation, then the lack of detection in LBs in not surprising. Additionally, the core 
of classical LBs is mainly composed of vesicle structures (Takahashi & Wakabayashi 
2001). Electron microscopy would be required to detect whether the limited LRRK2 
immunoreactivity in LBs is a result of its localisation to vesicular structures (Biskup 
et al. 2006; Hatano et al. 2007; Shin et al. 2008; Higashi et al. 2009).   
LRRK2 has been shown to phosphorylate α-synuclein in-vitro, but the likelihood that 
there are other endogenous kinases in crude cell extracts indicates that this result 
should  be  treated  with  caution  (Qing  et  al.  2009).  Although  α-synuclein-induced 
neuropathology was recently shown to be enhanced in a double mutant transgenic 
mouse overexpressing α-synuclein and LRRK2 (Lin et al. 2009), whether α-synuclein 
is a true physiological substrate of LRRK2 remains to be seen. We did not observe  
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any correlation between LRRK2 mRNA levels and LB loads in chapter 5 of this 
thesis. LB numbers were assessed in individual regions on independent occasions, 
and  an  inter-class  correlation  was  performed  to  assess  intra-  and  inter-observer 
variability  (section 5.3.5). However, the number of cases (20  IPD and  4 G2019S 
positive  PD  cases)  in  this  study  is  likely  to  be  too  small  to  permit  an  accurate 
correlation between LRRK2 mRNA and α-synuclein positive LBs. 
7.3 Genetic  variation  in  LRRK2  5’-UTR  regions  and  its  effect  on 
LRRK2 mRNA levels 
In chapter 6 of this thesis, I hypothesised that genetic variation in the 5’UTR region 
of LRRK2 could influence LRRK2 mRNA levels. Cerebellum LRRK2 mRNA data 
(section 5.3.1) were chosen for this correlation due to the higher sample number of 
IPD (n=115) and control (n=35) subjects. The tag SNP (tSNP) rs2708435 upstream of 
LRRK2 transcription start site (Figure 6.2) exhibited weak allele specific expression 
of the cerebellar LRRK2 mRNA levels in IPD cases (Table 6.5). Based on the in-
silico data, EMSA was used to demonstrate that allele ‘A’ of rs2708435 undergoes an 
additional  DNA:protein  interaction  in  comparison  to  the  ‘G’  allele  (Figure  6.6). 
Variation at intronic tSNP rs4567538 which is in linkage disequilibrium (LD) with 
rs2708435 (r
2 = 0.95, Figure 6.7) demonstrated association with PD (Figure 6.8). 
Previous  studies  examining  LRRK2  variation  have  not  observed  this  association 
(Biskup et al. 2005; Skipper et al. 2005; Paisán-Ruíz et al. 2006; Paisán-Ruíz et al. 
2008; Sutherland et al. 2009b; Pankratz et al. 2009), and recent GWA studies have 
identified LRRK2 SNPs that might be associated with PD, none of which are in LD 
with the tSNP rs4567538 genotyped in this study (Simón-Sánchez et al. 2009; Satake 
et al. 2009). Population specific differences and sample numbers can contribute to 
differing associations, but it is most likely that the association reported in this chapter 
is a false-positive result.  
The initial statistical evidence presented for allele specific expression of rs2708435 
was extremely weak (Tables 6.4 and 6.5), and using this result as a foundation for 
subsequent experiments (EMSA and association study) is a major criticism of my  
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work. The geometric mean of the reference genes (HPRT1 and RPL13A), indicates 
that the association between variation at rs2708435 and LRRK2 mRNA levels in IPD 
cases is marginally-significant (p = 0.047, Table 6.5). However, individual analysis 
with  the  two  endogenous  reference  genes  both  of  which  give  different  statistical 
values (HPRT1, p = 0.241 and RPL13A, p = 0.029, Table 6.5) does not clarify the 
effects of the tSNP on cerebellar LRRK2 mRNA levels. Although in chapter 5, four 
reference genes were measured for a subset of cerebellum IPD (n = 20) and control (n 
=  20)  subjects,  only  two  reference  genes  were  measured  for  this  larger  set  of 
cerebellum samples (IPD, n = 115; control, n = 35), and this is a big drawback of this 
particular  study.  Furthermore,  analysis  with  ANOVA  assumes  homogeneity  of 
variance,  therefore  it  is  likely  that  the  marked  variability  in  sample  numbers  (35 
control and 115 IPD cases), may have contributed to the discrepant P-values for the 
two reference genes. Before performing the EMSA or the association study, it would 
have been preferable to confirm the weak finding of allele specific expression for 
rs2708435 (Tables 6.4 and 6.5) with a more robust assay. Although not reported in 
this thesis, various attempts were made to clone the 10kb 5’UTR region of LRRK2 
gene  to  a)  assess  whether  rs2708435  alleles  contributed  to  regulation  of  LRRK2 
transcriptional activity in-vitro; and b) to define a minimal core promoter region for 
LRRK2. However, this was unsuccessful. Although this chapter was presented last, it 
was also the first to be undertaken, and transcriptome sequencing has since become a 
robust technology to assess differential allelic expression. Overall, due to the tenuous 
statistical evidence no inferences can be made about rs2708435 and its allelic specific 
expression on LRRK2 mRNA in IPD cases. 
7.4 Future of LRRK2 and its role in PD 
It  has  become  increasingly evident  that  mitochondrial  dysfunction  may  play  a 
major role in PD pathogenesis (reviewed in (Büeler 2009)). Moreover autophagy, 
a catabolic process that results in degradation of cellular components through the 
endosomal-lysosomal  machinery,  has  also  been  implicated  in  PD (reviewed  in 
(Dagda  et  al.  2009)).  The  physiological  function  of  LRRK2  is  still  far  from 
understood, but its enzymatic activity and potential role in cell signalling events  
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has  led  to  suggestions  that  it  may  play  be  involved  in  mitochondrial  and 
autophagic dysfunction in PD (West et al. 2005; Gloeckner et al. 2006; Biskup et 
al. 2006; MacLeod et al. 2006; Iaccarino et al. 2007; Hatano et al. 2007; Shin et 
al.  2008;  Plowey  et  al.  2008;  Saha  et  al.  2009;  Higashi  et  al.  2009;  Alegre-
Abarrategui et al. 2009; Ohta et al. 2010; Mutez et al. 2010). Although LRRK2 
has been suggested to mediate mitochondrial kinase signalling via its interaction 
with extracellular signal regulated protein kinases (ERK) and c-Jun N-terminal 
kinases  (JNK),  it  remains  to  be  confirmed  whether  these  are  physiological 
substrates of LRRK2 (White et al. 2007; Plowey et al. 2008; Liou et al. 2008; 
Gloeckner et al. 2009; Carballo-Carbajal et al. 2010; Hsu et al. 2010). A lack of 
consensus  regarding  the  physiological  substrates  of  LRRK2  has  created  a 
bottleneck  in  our  understanding  of  the  true  nature  of  the  in-vitro  and  in-vivo 
effects of the intrinsic LRRK2 kinase activity (see (Yue 2009; Hu & Tong 2010) 
for  review).  Although  LRRK2  kinase  activity  has  been  the  major  focus  of 
investigation into LRRK2 linked PD, there is increasing interest in the role of the 
kinase regulating GTPase domain in  PD (West et al. 2007; Jaleel et al. 2007; 
Greggio et al. 2008; Greggio et al. 2009; Yao et al. 2010). The toxicity associated 
with mutations in other LRRK2 domains (LRR, COR and WD-40) (MacLeod et 
al.  2006;  Iaccarino  et  al.  2007;  Jaleel  et  al.  2007;  Jorgensen et  al.  2009) also 
suggests that LRRK2 mediated toxicity might not be limited to its kinase activity, 
and  perhaps  requires  dysregulation  of  the  complex  but  finely  balanced 
interactions between LRRK2 domains. Hence, before inhibition of LRRK2 kinase 
activity  can  be  confidently postulated  as  a  therapeutic  target  for  PD  (Covy  & 
Giasson  2009;  Hu  &  Tong  2010),  identification  of  LRRK2  substrates  and 
interactors, in addition to an extensive comparison of the pathogenic role of wild-
type  LRRK2  and  PD  linked  mutations  is  needed  in  mammalian  models. 
Furthermore,  confirmation of  LRRK2  interaction  with  the  encoded  proteins  of 
other  PARK  loci  that  have  been  implicated  in  mitochondrial-related  oxidative 
stress (reviewed  in  (Dagda  et  al.  2009),  such  as  PINK1,  parkin,  DJ-1,  and α-
synuclein (Smith et al. 2005a; Venderova et al. 2009; Qing et al. 2009; Lin et al.  
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2009;  Carballo-Carbajal  et  al.  2010)),  would  be  an  encouraging  step  towards 
elucidating a putative convergent pathway for different PARK loci and should 
contribute to the study of both familial and idiopathic PD.  
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Appendix 
Summary  of  IPD  and  control  subjects  used  for  the  cerebellum  study  in  chapter  5 
(section 5.3.1). Samples IPD1-IPD20 and Con1-Con22 have been previously described 
in Tables 5.2 and 5.5, respectively. M: male; F: female, PM: post-mortem delay. 
Sex  Age  PM delay  pH  Cause of death 
IPD1  M  77  46.20  6.73  Heart failure 
IPD2  M  73  11.20  6.32  CVA 
IPD3  F  62  46.20  5.88  gradual deterioration 
IPD4  F  78  75.45  6.46  Advanced PD 
IPD5  F  87  47.45  6.62  IPD, slow deterioration 
IPD6  F  81  24.25  N/A  IPD, congestive heart disease 
IPD7  M  81  103  6.15  Bronchopneumonia 
IPD8  M  73  20.30  6.22  PD, malignant melanoma, 
IPD9  F  66  125.30  6.2  Advanced PD 
IPD10  F  77  ~80  6.53  Congestive heart failure 
IPD11  F  88  11.30  6.38  Chest infection 
IPD12  M  70  61.20  6.29  Chest infection 
IPD13  M  55  8.00  6.37  progressive degenerative PD  
IPD14  M  71  40.45  6.1  Chest infection 
IPD15  M  79  27.25  5.88  Sudden death 
IPD16  M  71  81.30  6.76  N/A 
IPD17  M  70  71.30  6.17  Coronary artery atheroma 
IPD18  M  91  31.45  5.81  Congestive heart failure 
IPD19  F  81  57.30  N/A  Heart failure 
IPD20  M  70  51.20  6.29  gradual deterioration 
IPD21  M  68  39.35  N/A  N/A 
IPD22  M  69  57.20  N/A  Left ventricular failure 
IPD23  M  82  26.50  N/A  Bronchopneumonia 
IPD24  M  83  66.00  N/A  Chest infection 
IPD25  F  84  26.45  N/A  IPD 
IPD26  M  78  79.33  N/A  IPD + dementia 
IPD27  M  77  51.20  6.16 
bronchopneumonia, heart and renal 
failure 
IPD28  M  66  54.30  6.17  Cancer (prostate), chest infection 
IPD29  M  72  25.45  N/A  IPD 
IPD30  M  78  80.35  6.31  IPD + dementia 
IPD31  M  77  40.30  N/A  Bronchopneumonia  
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Sex   Age 
PM 
delay  pH  Cause of death 
IPD32  M  78  52.40  N/A  IPD 
IPD33  F  73  18.00  6.11  PSP 
IPD34  F  84  36.00  6.4  PD and trans-ischaemic disease 
IPD35  M  78  38.35  6.2  PD, dementia and chest infection 
IPD36  F  81  68.30  6.03  N/A 
IPD37  F  79  27.20  6.68  IPD 
IPD38  M  77  58.45     cardiac arrest 
IPD39  F  71  36.00  6.25  N/A 
IPD40  M  85  48.15  6.38  Chest infection 
IPD41  F  79  24.20  6.39  PD, gradual death 
IPD42  M  63  69.00  6.59  Heart failure 
IPD43  F  71  50.10  6.38  Aspiration deterioration 
IPD44  M  73  25.20  7.18  N/A 
IPD45  F  73  70.00  6.63  PD, gradual decline 
IPD46  F  79  49.30  6.07  pulmonary embolism 
IPD47  M  66  56.00  6.49  heart attack 
IPD48  F  80  27.10  5.62  PD/AD 
IPD49  F  92  45.15  6.13  gradual deterioration 
IPD50  M  76  51.15  5.77  bronchopneumonia 
IPD51  F  73  40.15  6.44  bronchopneumonia 
IPD52  M  84  47.00  6.11  bronchopneumonia 
IPD53  F  69  52.45  6.14  bronchopneumonia 
IPD54  M  87  76.10  6.01  bronchopneumonia 
IPD55  F  68  77.35  6.05  bronchopneumonia 
IPD56  M  79  22.05  6.27  bronchopneumonia 
IPD57  F  86  43.45  6.27  gradual deterioration 
IPD58  F  80  13.05  6.39  Haemo-pericardium 
IPD59  F  73  45.00  5.86  multi organ failure 
IPD60  M  76  35.3  N/A  N/A 
IPD61  M  76  71.30  6.5  Chest infection 
IPD62  M  66  21  N/A  N/A 
IPD63  M  70  46.15  6.54  bronchopneumonia 
IPD64  M  80  30  6.07  bronchopneumonia 
IPD65  F  77  48  6.98  N/A 
IPD66  M  77  23.35  6.26  bronchopneumonia 
IPD67  F  73  50  6.44  bronchopneumonia 
IPD68  F  81  29  5.59  N/A 
IPD69  M  75  44.15  6.73  bronchopneumonia 
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Sex  Age  PM 
delay 
pH  Cause of death 
IPD70  F  74  82.05  5.92  N/A 
IPD71  M  79  71.15  6.5  bronchopneumonia 
IPD72  F  74  35.05  6.11  pulmonary embolism 
IPD73  F  89  47.1  6.47  Terminal PD 
IPD74  F  77  N/A  N/A  N/A 
IPD75  F  85  22.5  N/A  N/A 
IPD76  F  71  34  6.37  N/A 
IPD77  F  66  55.3  6.27  PD 
IPD78  F  85  46.4  6.45  PD, Old age 
IPD79  F  84  18  6.64  bronchopneumonia 
IPD80  M  70  115  6.35  bronchopneumonia 
IPD81  M  66  40  6.65  coronary artery disease 
IPD82  M  69  N/A  N/A  N/A 
IPD83  M  78  45.45  N/A  N/A 
IPD84  M  76  4.5  6.32  Cancer (prostate), bronchopneumonia 
IPD85  F  81  43  N/A  N/A 
IPD86  M  71  28.5  6.23  N/A 
IPD87  M  92  17.15  N/A  N/A 
IPD88  F  69  46  N/A  N/A 
IPD89  M  80  N/A  N/A  N/A 
IPD90  M  76  38  N/A  N/A 
IPD91  M  86  49.3  N/A  N/A 
IPD92  M  74  32  N/A  N/A 
IPD93  M  73  10  N/A  N/A 
IPD94  M  71  7  N/A  N/A 
IPD95  M  73  18  N/A  N/A 
IPD96  M  75  17  6.44  lymphoma 
IPD97  M  78  7.1  6.06  CVA 
IPD98  M  79  2.55  N/A  N/A 
IPD99  M  73  70  N/A  N/A 
IPD100  M  75  4.3  N/A  N/A 
IPD101  M  66  36.45  N/A  N/A 
IPD102  M  84  6.55  N/A  N/A 
IPD103  M  94  8.43  N/A  N/A 
IPD104  M  71  N/A  N/A  N/A 
IPD105  F  79  14.15  N/A  N/A 
IPD106  F  83  1.38  N/A  N/A 
IPD107  F  76  20  N/A  N/A 
IPD108  F  81  23.3  N/A  N/A  
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Sex  Age 
PM 
delay  pH  Cause of death 
IPD109  F  81  N/A  N/A  N/A 
IPD110  F  83  73.15  N/A  N/A 
IPD111  M  70  73  N/A  N/A 
IPD112  F  79  14.15  N/A  N/A 
IPD113  F  78  6.05  N/A  N/A 
IPD114  M  62  34  N/A  N/A 
IPD115  M  77  53.15  N/A  N/A 
IPD116  F  84  24.13  N/A  N/A 
IPD117  F  77  16.15  N/A  N/A 
IPD118  F  90  26.15  N/A  N/A 
IPD119  M  84  11.3  N/A  N/A 
IPD120  M  73  55.55  N/A  N/A 
IPD121  M  86  18.4  N/A  N/A 
IPD122  M  75  23.15  N/A  N/A 
IPD123  F  77  3.3  N/A  N/A 
IPD124  M  74  12.3  N/A  N/A 
IPD125  M  83  3.3  N/A  N/A 
IPD126  F  82  24.3  N/A  N/A 
IPD127  M  79  23.55  N/A  N/A 
IPD128  M  79  28  N/A  N/A 
IPD129  M  84  17.55  N/A  N/A 
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Summary of unaffected subjects used in cerebellum study in chapter 5.  
Sex  Age 
PM 
delay  pH  Cause of death 
Con1  Female  77  23  5.6  Cancer (Colon) 
Con2  F  86  46.5  6.17  Cancer 
Con3  F  84  81.45  6.28  Cancer and heart failure 
Con4  M  85  43.35  6.68  Cancer (Oesophagus) 
Con5  M  86  53  6.65  Bronchopneumonia, heart failure 
Con6  M  86  23.3  6.55  Myocardial infarction 
Con7  M  81  40  6.48  N/A  
Con8  F  53  29.5  6.64  intra-cerebral haemorrage 
Con9  M  91  48  6.54  bronchopneumonia 
Con10  F  88  49.25  6.23  chronic obstructive airway disease 
Con11  F  85  34  6.31  Breast cancer 
Con12  F  89  77.3  6.49  Pneumonia 
Con13  M  83  117.05  6.81  Heart attack 
Con14  M  79  56.4  6.6  Cancer (prostate) 
Con15  M  75  64.5  6.18  Pulmonary embolism 
Con16  F  81  13.5  6.39  Cancer (Colon) 
Con17  M  63  42  6.23  congestive heart disease 
Con18  M  57  78.5  6.03  Adenocarcinoma 
Con19  F  78  23.3  N/A   N/A 
Con20  M  71  38.5  N/A  Mesolithioma 
Con21  F  83  20  6.55  Bowel resection with complications 
Con22  F  78  51.3  6.24  Colon cancer 
Con23  F  64  79  5.88  Bowel and liver cancer 
Con24  F  85  73.3  5.98  N/A 
Con25  F  77  79.5  6.46  chronic obstructive airway disease 
Con26  M   N/A   N/A    N/A   N/A  
Con27  F  83  22  6.25  Cancer (lung) 
Con28  M  67  22  6.55  Myocardial infarction 
Con29  F  73  28  6.38  bronchopenumonia 
Con30  F  80  28  6.08   myocardial infarction 
Con31  M  72  13  6.16  N/A 
Con32  M  74  5.5  6.51  left ventricular failure 
Con33  M  76  16  6.71  ruptured thoracic aneurysm 
Con34  F  77  18  6.7  N/A 
Con35  F  73  15  6.68  congestive heart failure 
Con36  M  71  17  6.74  ruptured thoracic aortic aneurysm 
Con37  F  85  37.1  N/A   Liver and bone cancer 
Con38  F  88  11.1  N/A   Myocardial infarction, respiratory failure  
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